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Convention for protein and gene nomenclature 
Gene names have been reported in italics and protein names referred to in standard font. 
Human proteins and genes are reported in uppercase; proteins and genes of mouse are 
reported with an uppercase first letter only. For example: XCR1, XCR1 = protein and gene 




















Background: XCR1 represents the sole member of the class C chemokine receptor family. 
In humans, this receptor has two exclusive ligands – XCL1 and XCL2. This chemokine 
signalling axis demonstrates clear conservation of sequence, structure and function 
between mice and humans. However only a single ligand, Xcl1, exists in mice. In addition, a 
lack of clarity surrounds the molecular identity of the Xcr1 protein in mice. Recent evidence 
from a rat model of peripheral nerve injury has demonstrated the expression of Xcr1 within 
the CNS and suggests this chemokine signalling axis to contribute to the inflammatory 
response to central and peripheral nerve injury. Further examination of this chemokine 
signalling axis was sought to characterise the contribution of XCR1 and XCL1 to CNS 
function.  
Aims and Objectives: 1) Determine the molecular identity of mRNA and protein produced 
by Xcr1.  2) Characterise the expression of Xcr1 and Xcl1 within the mouse CNS.  3) 
Determine the influence of a central inflammatory response on the gene and protein 
expression of Xcr1 and Xcl1 within the mouse CNS. 4) Attempt the identification of XCR1 
presence within the spinal cord of humans in the context of health and disease. 
Results: This project provides the first direct functional comparison of the two predicted 
Xcr1 isoforms and demonstrates higher β-arrestin recruitment to the Xcr1 protein 
produced from an open reading frame located entirely within exon 2. The expression of Xcr1 
and Xcl1 was observed to be low within the CNS of NTg animals. However, an increase of 
Xcl1 expression within the spinal cords of mice demonstrating prolific glial activation was 
observed, whilst the expression of Xcr1 remained unchanged. Attempts to refine the cellular 
source of Xcl1 expression identified a low expression of Xcl1 within primary microglial 
preparations from NTg, SOD1-G93A and TDP-Q331K mice. The expression of Xcl1 by these 
primary cell preparations was not influenced by LPS treatment. Detection of XCR1 within 
the spinal cord of humans by immunohistochemistry provides the first indication, to our 
knowledge, of XCR1 expression by glial cells of the white matter.  
Conclusions: Further credence has been given to the molecular identity of mouse Xcr1 to 
arise exclusively from exon 2 of Xcr1. The identity of Xcr1 mRNA however remains 
inconclusive. This has implications for future investigations of the expression of this 
chemokine receptor, as well as for the development of methodologies to achieve this. Xcr1 
and Xcl1 expression is suggested to be low within the CNS of NTg animals. The increased 
expression of Xcl1 is in accordance with this chemokine to contribute to a central 
inflammatory response, however this expression is not supported to arise from microglia. 
The presence of XCR1 within human spinal cord is indicated to localise to glial cells, 
however further investigation is required to confirm the cellular identity of this expression.  
iv 
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Chapter 1: An Overview of Chemokines and their Roles in the Central Nervous System 
This PhD project has sought to investigate the potential expression and function of the Class 
C chemokine, XCL1, and the class C chemokine receptor, XCR1, in the health and disease of 
the central nervous system (CNS). To provide a complete background to the potential 
capacity for XCR1 and XCL1 to function in the CNS, the reader is first introduced to the 
characteristics of the chemokine superfamily and the existing evidence for those members 
documented to function within the CNS, in an effort to demonstrate the possible functions 
for which the studied chemokine signalling axis may be involved. Following this, the existing 
evidence of XCR1 and XCL1 is discussed and the aim of the project is proposed. 
1.1 The Chemokine Superfamily 
1.1.1 Chemokine classification and nomenclature 
Chemokines (Chemotactic cytokines) are a superfamily of proteins which consists of 48 
members within humans. The characteristic function of chemokines is to control cellular 
migration or arrest of receptor cells and, since the initial description of CXCL8 (Walz et al., 
1989; Holmes et al., 1991; Murphy and Tiffany, 1991), represent one of the first molecular 
superfamilies in mammals to be documented to its entirety. The chemokine superfamily is 
divided in to four subfamilies- C, CC, CXC, CX3C - based on the amino acid sequence that 
separates the first to the possible second cysteine residue of the N-terminal domain. 
Chemokines may contain up to four cysteine residues in total with the disulphide bond(s) 
that exists between these also contributing to a canonical ‘chemokine fold’ structure 
(Zlotnik and Yoshie, 2012)(Figure 1.1). 
Chemokines may exist as secreted or membrane bound proteins (Cardona et al., 2006) and 
undergo significant post-translational modifications that significantly influence their 
characteristics (Mortier et al., 2011). Their chemotactic function relies upon interaction 
with their cognate receptor(s), a group of rhodopsin-like seven transmembrane proteins, 
although alternative roles for chemokines without receptor engagement have been 
demonstrated, such as antimicrobial activities (Nevins et al., 2016). A total of 23 Chemokine 
Receptors have been identified with the majority of receptors exerting their function via a 
functional intracellular coupling with a trimeric G-protein. However, 5 of these receptors, 
designated as Atypical ChemoKine Receptors (ACKRs), do not induce any intracellular 
signalling following chemokine binding and instead act to scavenge extracellular 
chemokines and modulate their signalling capacity by the internalisation of bound ligand.  
Chemokine receptors demonstrate a bias towards the class of chemokine to which they are 
activated by. The classification of chemokines and chemokine receptors is therefore based 












Figure 1.1 Structural characteristics of Chemokines. Images used with permission from (Fernandez and Lolis, 
2002). The prototypical secondary structure of chemokines is represented by CXCL8 in (A). From N’ to C’ the 
protein is composed of; a disordered N-terminal domain which exhibits the least homology, of the chemokine 
domains, between individual chemokines and is attributed with endowing the chemokine with its respective 
chemokine receptor(s) affinity; a cysteine motif which is composed of one (XC) or two (CX3C, CXC, CC) cysteine 
residues. These cysteine residues are responsible for stabilising the chemokine structure via disulphide bridges 
formed with one (XC) or two (CX3C, CXC, CC) cysteine residues found towards the C-terminus of the protein (see 
(B)); an N-loop which runs between the N-terminal and the first β-sheet; a series of three interconnected anti-
parallel β-sheets; and an α-helical domain at the C-terminus of the protein which overlies the β-sheet surface. 
(B) The differing number and position of cysteine residues within each chemokine subfamily is illustrated by a 
schematic overview. Note the mucin-stalk domain of the CX3C class which permits integration with the plasma 
membrane. XC chemokines contain only two cysteine residues and hence only have a single disulphide bridge. 







‘R’ suffix to denote ‘Ligand’ or ‘Receptor’, respectively. Due to their seemingly unorthodox 
lack of bias towards chemokine subfamilies and their lack of intracellular signalling 
activation following chemokine binding, ACKRs are excluded from this systematic 
nomenclature. Furthermore, this approach does not capture the qualities of chemokines 
that may have antagonistic effects on the receptor, a property of chemokines that appears 
to lack any congruent feature (Zlotnik and Yoshie, 2000; Zlotnik and Yoshie, 2012).  
1.1.2 Functional classification of chemokines 
An abundance of chemokine discovery occurred throughout the late 1980’s and throughout 
the 1990’s. These discoveries were biased towards chemokines that are highly expressed in 
activated leukocytes, due to the relatively high quantity of these transcripts allowing more 
reliable isolation and characterisation according to the available methods of the time. Early 
understanding was therefore dominated by evidence of chemokine contributions to the 
innate immune response and their capacity to induce cellular migration as a consequence 
of interaction with their respective chemokine receptor(s) during inflammatory states. 
A second round of discovery of chemokine genes was achieved as a consequence of the 
development of more elaborate genetic databases. Subsequent investigation of these 
chemokines has since illuminated the capacity of some chemokines to function during 
homeostatic states, display more restricted receptor affinities and to have greater 
exclusivity to the tissue and cellular origin of expression (Zlotnik and Yoshie, 2000). Despite 
these differences, all chemokines consistently demonstrate the capacity to induce 
chemotaxis and as such have been referred to as ‘master regulators’ of cellular migration. 
As a consequence of this divergence in observed function, chemokines have been 
functionally categorised as inflammatory, homeostatic and dual function. Dual function 
chemokines are an example of those which have recognised roles in both inflammation and 
homeostasis. Furthermore, additional subgroups of inflammatory chemokines have been 
proposed.  Platelet and Plasma chemokines are those that require proteolytic cleavage for 
their activation in serum and/or are stored in the α-granules of platelets (Flad and Brandt, 
2010; Nomiyama, Osada and Yoshie, 2010), typically acting as early mediators of the 
inflammatory response to vascular injury.  
The recognition that chemokines can participate in homeostatic as well as inflammatory 
processes makes an important distinction which has aided the appreciation of the broader 
roles that chemokines occupy. However, this method of classification is considered 
operational and doesn’t capture the elementary properties of individual chemokines. A 
further caveat is the promiscuous and redundant binding properties of chemokines that 









CXCR1 CXCL6, CXCL7, CXCL8  
CXCR2 
CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, 
CXCL8  
CXCR3 CXCL4, CXCL9, CXCL10, CXCL11, CXCL13 CCL11 
CXCR4 CXCL12  
CXCR5 CXCL13  
CXCR6 CXCL16  




CCR1 CCL3, CCL3L1, CCL5, CCL7, CCL8, CCL13, CCL14, 
CCL15, CCL16, CCL23 
CCL26 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 CCL11, CCL26 
CCR3 CCL3L1, CCL5, CCL7, CCL11, CCL13, CCL14, 
CCL15, CCL24, CCL26, CCL28 
CXCL9, CXCL10, CXCL11, 
CCL18 
CCR4 CCL17, CCL22  
CCR5 CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL8, 
CCL11, CCL16 
CCL7, CXCL11, CCL26 
CCR6 CCL20  
CCR7 CCL19, CCL21  
CCR8 CCL1, CCL16  
CCR9 CCL25  
CCR10 CCL27, CCL28  
XC family   
XCR1 XCL1, XCL2  
CX3C family   
CX3CR1 CX3CL1, CCL26  
ACKRs   
CCBP2 CCL2, CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL7, 
CCL8, CCL11, CCL13, CCL14, CCL17, CCL22, 
CCL23, CCL24 
CCRL1 CCL19, CCL21, CCL25, CXCL13  
CCRL2 CCL19  
DARC CXCL1, CXCL2, CXCL3, CXCL7, CXCL8, CCL2, 
CCL5, CCL11, CCL13, CCL14, CCL17 
 
Table 1.1 Human Chemokine Receptors and their ligands. Ligands are colour coded according to their 
chromosomal location. This illustrates how agonists of individual chemokine receptors originate from the same 
chromosomal location. The affinity of ‘atypical’ chemokine receptors shows greater promiscuity to that of 
‘typical’ chemokine receptors. This likely reflects greater functional redundancy. Table created from evidence 


























Figure 1.2 Chromosomal mapping of Human Chemokines and Chemokine Receptors. Chemokines are highlighted 
to indicate their functional category: Red = Inflammatory; Yellow = Dual Function; Green = Homeostatic. Note 
that all inflammatory chemokines are found as part of a cluster, whilst dual function and homeostatic 




ligands to bind multiple chemokine receptors and some chemokine receptors to bind 
several chemokine ligands. This can lead to oversimplification of individual chemokines 
based on their grouping with other chemokines that bind that receptor, particularly when 
evaluating chemokine function by the use of heterologous expression systems in vitro.  
A milestone in understanding the fundamental bases to chemokine function has been to 
take an evolutionary approach to the conceptualisation of chemokine function. This 
approach has rationalised the understanding of this superfamily by identifying molecular 
characteristics of individual chemokines according to their phylogeny. Table 1.1 and Figure 
1.2 illustrate how the genomic mapping of human chemokines has identified traits that 
correspond with the observed affinity to chemokine receptors. Chemokines that reside 
close to one another in a genomic context have similar receptor targets and hence have 
related functions, whilst those identified in isolated genomic regions have more specific 
receptor affinities and hence have more restricted functional roles. Moreover, those which 
reside as clusters are most likely to participate in inflammatory roles whilst those which 
exist in isolation are most likely to perform homeostatic or dual function roles (Nomiyama, 
Osada and Yoshie, 2013; Zlotnik, Yoshie and Nomiyama, 2006; Zlotnik and Yoshie, 2012). 
Thus, the genetic properties of an individual chemokine in tandem with their physical 
homology to other chemokines can strongly inform their likely function. 
1.2 Chemokines and the Central Nervous System 
Chemokine research has centred on their role within the immune system. However, there 
is now substantial evidence that demonstrates the capacity of chemokines to function 
within the nervous system and, although their defining function, this is not just as mediators 
of cellular migration. Chemokines have now been described to be expressed by neurons, 
astrocytes, microglia and oligodendrocytes. Perhaps most importantly, several of these 
chemokines are expressed constitutively and perform homeostatic functions, indicating 
essential roles within the CNS. This is in addition to the more expected function in mediating 
immunological recruitment to sites of inflammation. 
1.2.1 Immunological privilege of the CNS parenchyma 
Under physiologic conditions the CNS parenchyma is immunologically privileged. This is 
characterised by a low presence of peripheral immune cells within the tissue, a feature that 
is most strongly associated with the presence of the blood-brain barrier (BBB) that 
surrounds the majority of CNS capillaries that serve the brain and spinal cord. Immune cells 
are, however, found in specific regions of the CNS in which the permeability of vessels 
supplying blood and cerebrospinal fluid (CSF) is reduced or compromised. This includes (i) 






    
















    
    
     
Figure 1.3. Schematic overview of Antigen Presenting Cell (APC) and T-cell circulation within the CSF. 1) Entry to 
the CSF is suggested to occur via chemotactic gradients established by choroid plexus epithelia which permit 
the transmigration of immune cells from the underlying capillary in to the CSF. 2) Within the CSF, immune cells 
are able to circulate within the ventricles of the brain and throughout the spinal cord central canal.  The presence 
of small openings (foramina) within the fourth ventricle permit the movement of cells in to the subarachnoid 
space that surrounds the brain and spinal cord. 3) The turnover of perivascular immune cells within specific 
‘Virchow-Robin’ spaces enables the constant surveillance of CSF antigen. 4, 5) Immune cells home to the 
lymphoid network following the entrance in to lymphatic vessels within the dura matter (4) and along peri-
neural lymph vessels that exit the cranium via the cribiform plate (5). Chemokine signalling via CCR7 appears 
to be particularly important for the circulation of immune cells within the CNS. The chemokine ligands CCL21 
and CCL19 are indicated to be make essential contributions to the migration of CCR7-positive cells due to their 
enrichment within specific CSF and lymph entry points (see text for details). 
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choroid plexus; (ii) Virchow-Robin spaces - a perivascular niche that surrounds some 
meningeal arteries that infiltrate the CNS brain parenchyma (a component of the 
“glymphatic” system (Ma et al., 2017)); and (iii) post-capillary venules (Ousman and Kubes, 
2012). In all three of these regions, without the presence of inflammation, peripheral 
immune cells are maintained in perivascular spaces which provide a cellular niche for co-
ordinating immune surveillance or activation (Abbott et al., 2010; Williams et al., 2014). 
Importantly there is a broad distinction in the presence of immune cells between the two 
main fluid compartments of the CNS: the CSF and the interstitial fluid (ISF). This results 
from the intricate passage of these fluids at specific gateways to the CNS parenchyma as well 
as the distinct access that they each have to recirculating lymph (Figure 1.3). CSF is 
separated from the brain and spinal cord parenchyma by the pial membrane and contains 
circulating T-lymphocytes and also Dendritic Cells (DCs). These immune cells are recycled 
via lymphatic drainage, in particular via the newly discovered lymphatic network within the 
dura matter (Louveau et al., 2015; Absinta et al., 2017) and via perineural routes from the 
olfactory bulb to the nasal lymphatics (Engelhardt et al., 2016; Louyeau, Harris and Kipnis, 
2015). A small percentage of CSF may be exchanged with ISF at paravascular gateways to 
the CNS parenchyma (Abbott et al., 2010; Ma et al., 2017).  
The constitutive presence of immune cells within the CSF permits the surveillance of 
antigens within the cranial and vertebral cavities, fulfilling the previously proposed function 
of a surrounding ‘lymph’ of CNS tissue (Ransohoff, Kivisakk and Kidd, 2003). The growing 
evidence of this more extensive immunological function has made it more recognised now 
than ever before that the immune privilege of the CNS is not absolute but is instead 
strategically and intricately controlled.  
1.2.2 Chemokine contribution to immunological coordination within the CNS 
Chemokines make an essential contributions to the control of immune cell migration in all 
vascular regions of the CNS during both homeostatic and inflammatory conditions. In the 
absence of inflammation, localised chemokine expression is associated with recruitment 
and turnover of leukocytes within the perivascular and leptomeningeal spaces containing 
immune cells (Ousman and Kubes, 2012; Engelhardt et al., 2016; Louyeau, Harris and 
Kipnis, 2015; Absinta et al., 2017).  
One of the most prominent chemokine signalling axis for controlling immune cell 
surveillance of the CNS is the CCL19/CCL21/CCR7 signalling axis. It is now demonstrated 
that within the CNS the expression of CCR7 is essential to direct the migration of central 
memory T-lymphocytes (TCM) and DCs from the entry point of the CSF at choroid plexus 
epithelia, through the leptomeningeal spaces that surround the brain and spinal cord and 
facilitate their return to circulating lymph via nasal and dural lymphatics (Figure 1.3) 
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(Absinta et al., 2017; Kida, Pantazis and Weller, 1993).  CCR7 therefore permits the 
surveillance of CNS antigen within the CSF and allows the homing of activated DCs through 
the chemotactic gradients established by CCL21 and CCL19 within lymphatic vessels 
(Absinta et al., 2017; Clarkson et al., 2017) as has been described for the function of CCR7 
in the periphery (Forster, Davalos-Misslitz and Rot, 2008).  The subsequent circulation to 
cervical lymph nodes (CLNs) of TCM and DCs is essential for the presentation of antigen and 
to facilitate appropriate immune responses. CCL19 also allows the physiologic recruitment 
and retention of CCR7+ immune cells at the level of post-capillary venules, one of the key 
sites for immune cell retention within the CNS (Ousman and Kubes, 2012; Williams et al., 
2014). 
In contrast to migratory surveillance of antigen within the fluid compartment of the CNS, 
the CCL2/CCR2 signalling axis has been shown to be essential for maintaining homeostatic 
populations of perivascular macrophages (Schilling et al., 2009). Under physiological 
conditions, there is a constant turnover of macrophages between the blood and the 
perivascular regions of CNS blood vessels (Bechmann et al., 2001). The CCL2-CCR2 axis also 
has a well characterised role in the recruitment of monocytes and macrophages during 
inflammatory conditions to the CNS (Conductier et al., 2010). CCR2 is responsible for the 
migration of a specific population of peripheral Ly6-Chigh monocytes in to the brain 
parenchyma via the chemotactic gradient established by CCL2. The CCL2-CCR2 axis 
therefore contributes to the physiological turnover of perivascular macrophages as well 
being an essential inflammatory mediator that permits entrance of peripheral monocytes in 
to the CNS parenchyma, functions which are determined by the source and level of its 
expression (Stowe et al., 2012; Reaux-Le Goazigo et al., 2013). 
CXCL12 also exerts control of immune cell migration within the CNS. One of the receptors 
for CXCL12, CXCR7, is an ACKR that regulates the turnover and polarity of CXCL12 
expression (Cruz-Orengo et al., 2011). At the BBB, CXCL12 is associated with maintaining 
the localisation of CXCR4+ leukocytes at a perivascular location due to its abluminal 
expression by brain microvasculature endothelial cells (BMEC’s) (McCandless et al., 2006). 
However, in response to pro-inflammatory cytokines, CXCL12 is internalised by CXCR7 and 
redistributed to the luminal surface of BMEC’s. Consequently, the loss of abluminal CXCL12 
disrupts perivascular leukocyte retention and promotes CXCR4+ leukocyte extravasation 
and infiltration, a phenomenon observed in post-mortem examination of patients with 
Multiple sclerosis (MS) and in the murine model of MS, Experimental Autoimmune 
Encephalomyelitis (EAE) (Cruz-Orengo et al., 2011; McCandless et al., 2008). Therefore, as 
well as increasing inflammatory chemokine expression, subtle changes in the expression 














Figure 1.4 The Blood-Brain Barrier and leukocyte migration. Images sourced with permission from (Takeshita 
and Ransohoff, 2012). (A) The abluminal side of the CNS microvasculature is encapsulated by the endothelial 
basement membrane in which pericyte cells reside. Pericyte secretory factors such as TGF-β inhibit endothelial 
cell activation and disruption to tight junction formation. More distal from the abluminal surface to this are 
astrocytic endfeet, defining the glia limitans and the parenchymal aspect of the perivascular space. These 
processes extend from astrocytes and encapsulate the vessel structure providing trophic factors which are 
essential for the development and maintenance of BBB integrity. (B) Extravasation of leukocytes involves 5 
steps: rolling, activation, arrest, crawling and migration. Chemokines expressed on the endothelial surface 






significant contributions to the inflammatory state of the CNS. In response to inflammation, 
chemokines provide directional chemotactic gradients which are essential for the 
extravasation and migration of leukocytes to sites of injury or infection. In comparison to 
peripheral and lymphoid vasculature, there is little known about the exact expression 
patterns and identities of chemokine expression within the CNS microvasculature, 
particularly for inflammatory chemokines (Holman, Klein and Ransohoff, 2011). Although 
the stages of leukocyte migration through the vascular wall has been well documented 
(figure 1.4) the direct relevance of this to leukocyte migration in the CNS is unclear due to a 
lack of in vitro models capable of replicating BBB physiology and allowing more in depth 
characterisation (Takeshita and Ransohoff, 2012). However, it has been observed that 
several chemokines expressed by activated endothelial cells, including CXCL12, CCL11 and 
CCL21, are capable of inducing integrin activation of rolling leukocytes via interaction with 
their cognate receptors. This facilitates interaction with endothelial cell adhesion 
molecules, such as intercellular adhesion molecule-1 (ICAM1) and vascular cell adhesion 
molecule-1 (VCAM-1), and promotes the strong adhesion of leukocytes to the endothelial 
surface that is necessary for subsequent transmigration in to the perivascular space 
(Laudanna et al., 2002; Engelhardt, 2006). In addition to their luminal expression, 
transcellular and perivascular chemokine localisation is ideally situated for providing 
haptotactic guidance for this extravasation (Holman, Klein and Ransohoff, 2011). Indeed, 
the release of inflammatory chemokines by resident glial cells of the CNS is strongly 
implicated in establishing a chemotactic gradient for leukocyte recruitment (Babcock et al., 
2003). Chemokines can also promote extravasation by inducing the degradation of tight 
junction proteins and increasing BBB permeability (Stamatovic et al., 2006; Stamatovic et 
al., 2009).  
CX3CL1 and its receptor CX3CR1 exemplify an additional mode by which chemokines 
influence immunological activity within the CNS. Within the CNS, CX3CL1 is expressed 
predominantly by neurons whereas CX3CR1 is expressed almost exclusively by microglia 
(Cardona et al., 2006; Clark and Malcangio, 2012). As the resident macrophage of the CNS, 
microglia sample the extracellular environment of the CNS parenchyma and exhibit rapid 
activation in response to inflammatory stimuli. However, under physiological conditions 
microglia are maintained in a resting state, a phenotype which is strongly influenced by 
CX3CL1 release from neurons (Cardona et al., 2006). Although the mechanism for this 
remains unclear, the CX3CL1-CX3CR1 signalling axis is an essential mediator for regulating 
microglial neurotoxicity and provides an additional example of how chemokines contribute 
to immune functions within the CNS. Importantly, it provides an example of chemokines 
acting independently of the peripheral immune system. 
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1.2.3 Chemokines and CNS Development 
Chemokines and their receptors are expressed throughout development and maturity 
within the CNS. Their expression is highly regionalised, often exclusive to specific cell types 
and, in tandem with their capacity to modulate cellular migration, it is perhaps unsurprising 
that chemokines are strongly implicated in cellular patterning and morphogenesis of the 
CNS. 
The CXCL12-CXCR4 is currently believed to be the ancestral chemokine signalling axis 
(Nomiyama, Osada and Yoshie, 2010) and has the earliest expression of any chemokine 
during embryogenesis. Genetic knockout of either CXCL12 or CXCR4 leads to perinatal 
death (Ma et al., 1998) and causes abnormalities of neuronal positioning within the 
cerebellum, dentate gyrus, trigeminal ganglia, dorsal root ganglia and cortical interneurons 
as well as deviation of axonal projections from spinal motor neurons (Lazarini et al., 2003; 
Ransohoff, 2009; Bajetto et al., 2001). During adulthood, CXCL12 expression in the granule 
cell layer of the dentate gyrus maintains proliferation of neural progenitor cells and guides 
their migration for subsequent differentiation in to mature granule neurons (Schultheiss et 
al., 2013). Furthermore, CXCL12 expression within the vascular plexus and by ependymal 
cells is essential for the homing of CXCR4+ Neural Stem Cells (NSCs) to the neurogenic niche 
that surrounds the subventricular zone of rodents (Kokovay et al., 2010), a function 
analogous to the role of CXCL12-CXCR4 in the homing and colonisation of the bone marrow 
by hematopoietic stem cells (Sugiyama et al., 2006). Indeed, chemotactic guidance of NSCs 
by CXCL12 is a component of the neurovascular niche that contributes to functional 
recovery following cerebral ischemia (Ohab et al., 2006; Robin et al., 2006). 
Chemokines are also indicated to coordinate synapse remodelling during development. In 
the cerebellum, cells including microglia, Bergmann glia, astrocytes and neighbouring 
neurons all transiently express peak levels of CCR1 at independent time points during which 
they each show close interaction with CCL3-expressing purkinje cells, suggesting a 
functional role in the extensive elaboration of purkinje-cell connectivity (Cowell and 
Silverstein, 2003). CX3CL1 and CX3CR1 are also implicated in homeostatic synaptic pruning 
within the mature hippocampus by facilitating microglial-neuronal interaction. This may 
also be contributed to by modulatory effects of CX3CR1 signalling on synaptic activity and 
Long Term Potentiation (Murphy, 2013).  
Chemokine signalling also contributes to glial development. During the formation of 
presumptive white matter, the expression of CXCL1 by white matter astrocytes provides a 
chemotactic and proliferative cue for oligodendrocyte precursor cells (OPCs) via CXCR2 
(Tsai et al., 2002). In vitro characterisation has extended the involvement of other CXC 
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chemokines in oligodendrocyte development, with CXCL12 and CXCL8 displaying the 
capacity to induce proliferation and differentiation of rat OPCs (Kadi et al., 2006).  
Thus, although maintaining the central function of guiding chemotaxis, chemokine 
signalling provides migrational cues that contribute to the maintenance of essential 
processes for CNS development, maturation and regeneration following injury. This is a 
result of the divergent targets downstream of chemokine receptor binding and G-protein 
activation which can simultaneously promote cellular migration and cellular survival, for 
example. The presence of additional external mediators which signal via convergent 
downstream signalling cascades to chemokine receptors will therefore also influence the 
outcome of chemokine signalling. An example of this is given by the role of chemokines in 
activity dependent neuromodulation, discussed below. 
1.2.4 Neuromodulatory functions of chemokines 
The identification of chemokine and chemokine receptor expression by neurons and their 
localisation to nerve terminals and synaptic vesicles prompted an altogether different 
perspective on chemokine function (Rostene, Kitabgi and Melik-Parsadaniantz, 2007). 
Several chemokines, including CCL2 (Gosselin et al., 2005), CXCL12 (Banisadr et al., 2003), 
CX3CL1 (Ragozzino et al., 2006), CCL21 (de Jong et al., 2005) and CXCL8 (Puma et al., 2001), 
have demonstrated characteristics that are consistent with chemokines performing 
neuromodulatory functions (Figure 1.5).  
The concept of neuromodulation centres on the capacity of an agent to modulate neuronal 
sensitivity as a consequence of altering the permeability of neuronal membranes (both 
internal and external membranes) to ionic flux.  Neuromodulators can act at synaptic or 
extra-synaptic locations and, as a general summary of action, influence the thresholds 
required for a neuron to generate an action potential or release presynaptic vesicles (Nadim 
and Bucher, 2014).  
As a distinct subfamily of G-Protein Coupled Receptors (GPCRs), chemokine receptors are 
capable of influencing cellular properties that are consistent with affecting neuronal 
activity. Indeed, their specific anatomical distribution within the CNS, amongst other 
characteristics discussed below, have led some to speculate chemokines and their receptors 
to represent the third major signalling system of the CNS, after neurotransmitters and 
neuropeptides (Adler and Rogers, 2005). 
An important feature to this evidence of neuromodulation is the consistent colocalisation of 
individual chemokines to neuronal populations with distinct neurochemical phenotypes, in 
particular the association with neuronal populations and networks that are associated with 
diffuse neuromodulation. Immunohistochemical detection has found CXCL12 to localise to  
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Figure 1.5. Chemokines as Neuromodulators. A) Plot of whole cell recordings from septal cholinergic neuron 
illustrating modulation of Ca2+ current by IL-8 (CXCL8). Image used with permission from (Puma et al., 2001). 
Before (a), during (b) and after (c) application of 10mM IL-8 clearly shows reversible modulation of Ca2+ 
currents. Inhibition of Ca2+ currents by IL-8 was found to be mediated by closure of N- and L-type Ca2+ channels, 
due to reduced inhibition following application of nimodipine and ω-CgTX-GVIA, respectively. Furthermore, 
inhibition of Ca2+ currents was sensitive to application of Gi/o inhibitor, NEM, demonstrating a G-protein-
dependant mechanism of IL-8-mediated Ca2+ current inhibition. B) Subcellular localisation of CCL2, CXCL12 and 
CXCR4. Electron micrograph shows synthesis, microtubule transport and loading in to large dense-core vesicles, 
within the synaptic bouton, of both chemokines and the chemokine receptor. Image used with permission from 






dopaminergic, cholinergic and vasopressinergic neurons (Banisadr et al., 2003), whilst 
CCL2 and it’s receptor CCR2 have been localised to cholinergic and dopaminergic neurons 
(Banisadr et al., 2005). Furthermore, administration of both CXCL12 and CCL2 to the dorsal 
striatum is capable of increasing dopamine release and promoting circling behaviour in rats 
(Skrzydelski et al., 2007; Guyon et al., 2009).  CCR2 is also expressed throughout the spinal 
cord, particularly within the dorsal horn.  Signalling via this receptor is strongly implicated 
in the development of pain following acute and chronic insult (Abbadie et al., 2003) as a 
result of reducing GABA-mediated currents in spinal neurons by CCL2-induced CCR2 and 
GABAA receptor interaction (Gosselin et al., 2005). Chemokines are also able to modulate 
neuronal activity by influencing the composition of post-synaptic receptors (Ragozzino et 
al., 2006) (Nicolai et al., 2010).  Perhaps most importantly of all, both CXCL12 and CCL2 are 
demonstrated to be present within large dense-core vesicles of neuronal synapses (Jung et 
al., 2008) (Callewaere et al., 2008). This localisation is characteristic of molecules, such as 
neuropeptides, that act in a modulatory capacity and supports the capacity of these 
chemokines to act as neuromodulators. 
The neuromodulatory capacity of chemokines, using such diverse mechanisms, highlights 
the numerous intracellular pathways that chemokines may exploit to exert their function. 
This is an important consideration to be made when evaluating experimental evidence of 
chemokine function. In vitro expression systems, for example, may utilise cellular models 
which do not include the intracellular substrate which these signalling systems would 
normally target in vivo. 
1.3 Chemokine Expression and CNS Disease 
Neuroinflammation is characterised by activation of glial cells, recruitment of leukocytes 
and the release of inflammatory mediators and is a common component of CNS pathology. 
Given the role of chemokines in many of these processes they are therefore implicated in 
the pathophysiology of disease and trauma of the CNS. 
1.3.1 Chemokines and Pain 
The development of pain is a cardinal feature of inflammation. Inflammation of the CNS can 
ensue as a result of direct injury or disease of the organ or as a consequence of peripheral 
nerve damage also. It is now recognised that activation of central glial cells, particularly 
microglia, is a key contributor for the development of chronic pain following central and 
peripheral nerve injury (PNI) (Watkins, Milligan and Maier, 2001). As essential signalling 
peptides, chemokines including CX3CL1, CXCL1, CCL2, CCL21 and CCL7 have been shown to 
contribute to this process (Ji, Xu and Gao, 2014). CX3CR1 expression is upregulated in 
chronic pain conditions (Verge et al., 2004) and likely responds to increased CX3CL1 
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signalling as a consequence of cleavage of this chemokine from the membrane of injured 
neurons. Activation of CX3CR1 in spinal microglia is associated with activation of p38 MAPK 
signalling which likely drives neuropathic pain symptoms through the increased release of 
pro-inflammatory mediators such as IL-1b and TNF-a that can directly lead to 
hyperexcitability of surrounding neurons (Zhuang et al., 2007; Kawasaki et al., 2008).  This 
is supported by the observed analgesic effect of CX3CR1 antibody administration that is 
capable of reducing mechanical allodynia in models of neuropathic pain (Zhuang et al., 
2007). The evidence for a role of CCL21 is similar in nature, indicating that neuronal release 
of CCL21 following PNI upregulates P2X4 expression in microglia. The absence or block of 
CCL21 signalling abrogates tactile allodynia, with concomitant reduction of microglial P2X4 
expression (Biber et al., 2011) suggesting a causal link between neuronal CCL21 release, 
microglial P2X4 expression and the development of neuropathic pain.  
An alternative mechanism by which chemokines may modulate sensitivity to pain relates to 
their capacity as neuromodulators. Descending activity of opioid-sensitive neurons of the 
peri-aqueductal grey matter (PAG) is associated with the analgesic effects of opioid 
compounds which are able to suppress ascending activity of peripheral nociceptive 
afferents. Within the PAG it has been shown that the administration of chemokines CXCL12, 
CX3CL1 or CCL5 prior to the administration of opioids was sufficient to diminish the anti-
nociceptive activity of such compounds (Szabo et al., 2002; Chen et al., 2007; Heinisch, 
Palma and Kirby, 2011).  This inhibition of the anti-nociceptive effect by chemokines is 
associated with the activity of their receptors, which are each expressed within the PAG, to 
inhibit opioid receptors following ligand activation by heterologous desensitisation. CXCR4 
and CCR5 have both been shown to cross-desensitise opioid receptors via targeted 
phosphorylation of GPCRs by downstream protein kinases or by the formation of GPCR 
heterodimers (Szabo et al., 2002; Chen et al., 2004). Therefore the coexpression of 
chemokine receptors, including CCR5, CXCR4 and CX3CR1, with opioid receptors by neurons 
within the PAG underlie the capability of CCL5, CX3CL1 and CXCL12 to inhibit the anti-
nociceptive capacity of descending opioid-sensitive neurons.  
Chemokine release by astrocytes also contributes to chronic pain symptoms. Following 
spinal nerve ligation (SNL) the expression of CCL2 was observed to be increased in 
astrocytes and application of CCL2 to ex-vivo spinal cord slices potentiated glutamatergic 
currents in lamina II neurons that express CCR2 (Gao et al., 2009). In addition, transgenic 
mouse models that overexpress CCL2, specifically within astrocytes, display hypersensitive 
nociception (Menetski et al., 2007) strongly indicating a role for CCL2-mediated 
neuromodulation underlying behavioural symptoms of chronic pain. Increases in CXCL1 
and CXCR2 expression in astrocytes and dorsal horn neurons, respectively, is also observed 
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following spinal nerve ligation. Blocking either ligand or receptor with specific antibodies 
is capable of attenuating behavioural symptoms of neuropathic pain (Zhang et al., 2013) 
lending further credence to the role of chemokine cross-talk between astrocytes and 
neurons as important mediators in the development of chronic pain.  
Another important aspect of the contribution of chemokines to the development of pain, is 
the recruitment of peripheral immune cells following central or peripheral nerve injury. 
Like surrounding glia in the CNS, the release of pro-inflammatory mediators by activated 
immune cells heighten neuronal excitability, increasing afferent nociceptive input that 
facilitate plastic changes within the local synaptic environment of the dorsal horn. Both of 
these consequences are key mechanisms of central sensitisation that is intimately linked to 
the development of chronic neuropathic pain (Latremoliere and Woolf, 2009; Ren and 
Dubner, 2010). 
Chemokines can therefore directly contribute to acute and chronic pain symptoms by 
modulating the activity of neurons in multiple domains of the CNS that are responsible for 
the transmission and integration of nociceptive sensory information. This includes primary 
afferent terminals of the dorsal horn and supraspinal centres such as the PAG. Additionally, 
chemokines can indirectly contribute to neuronal sensitisation by facilitating the 
recruitment and activation of glial and immune cells following peripheral and central nerve 
injury that can further perpetuate inflammatory signals that heighten neuronal sensitivity. 
The breadth of mechanisms by which chemokines and their receptors can modulate 
neuronal sensitivities is therefore wide and reflects their activity to not only contribute to 
immunological function during disease, but to also facilitate adaptive behaviours by 
providing a neurophysiological substrate within specific CNS domains. 
1.3.2 Chemokines and Neurodegenerative Disease 
Many of the functions of chemokines that contribute to neurodegenerative disease have 
been eluded to throughout this review. Most prominently, chemokines are implicated in 
almost all neurodegenerative diseases due to the important neuroinflammatory component 
of these disorders. 
MS is an autoimmune disorder characterised by chronic inflammation and lesions of 
neuronal white matter that is associated with demyelination of axonal tracts (Hoglund and 
Maghazachi, 2014). Within the inflammatory lesions are substantial numbers of peripheral 
lymphocytes and macrophages as well as activated microglia and astrocytes. Numerous 
inflammatory chemokines have therefore been implicated in the pathogenesis of the disease 
by contributing to the recruitment and activation of these cells. The expression of CCL2, as 
seen following peripheral and central nerve injury, is again localised to hypertrophic 
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astrocytes that surround demyelinating lesions (Simpson et al., 1998) and probably 
represents the most important chemotactic mediator for the recruitment of peripheral 
monocytes in MS (Bose and Cho, 2013). 
In contrast to promoting the migration of immune cells, other astrocyte-derived 
chemokines may contribute to the pathogenesis of MS by inhibiting the migration of 
oligodendrocytes. Around the edge of white matter lesions, oligodendrocytes expressing 
CXCR2 are found in close apposition to astrocytes expressing CXCL1. This signalling axis is 
known to promote proliferation of oligodendrocyte precursor cells and inhibit their 
migration (Tsai et al., 2002). Indeed, oligodendrocyte hyperplasia is observed within this 
region, but in inhibiting their migration CXCL1 release by astrocytes may actually inhibit 
remyelination also (Omari et al., 2005; Omari et al., 2006). 
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that is characterised by 
the loss of upper and/or lower motor neurons of the motor cortex and ventral spinal cord. 
The aetiology of this disease is unclear although numerous genetic and environmental 
factors have been implicated in the pathogenesis (Ling, Polymenidou and Cleveland, 2013). 
However, an important progression in the understanding of ALS was the recognition of non-
cell autonomous pathology; that is the disease is not simply a disorder of motor neurons 
and in fact is strongly influenced by surrounding microglia and astrocytes (Clement et al., 
2003; Di Giorgio et al., 2008; Haidet-Phillips et al., 2011). Indeed, the role of central 
neuroinflammation in disease pathogenesis is strongly associated with the production of a 
toxic neuronal environment and the presence of activated astrocytes and microglia is 
considered a pathological hallmark of the disease (Barber and Shaw, 2010). In addition, 
there is clear infiltration of immune cells within areas of motor neuron degeneration 
including macrophages, mast cells and T-cells (Graves et al., 2004; Henkel et al., 2004; 
Henkel et al., 2006).  
Direct evidence for a role of chemokines in ALS is indicated from observations of elevated 
chemokine levels within the CSF of ALS patients in comparison to controls. Increased CCL2 
and CXCL8 CSF levels negatively correlate with survival time of affected individuals, whilst 
CCL4 and CXCL10 have a positive correlation with the ALS functional rating score, indicative 
of a better clinical prognosis (Tateishi et al., 2010; Kuhle et al., 2009). Although a functional 
explanation for these correlations is lacking it is suggested that elevated CCL2 and CXCL8 
levels reflect greater glial activation and also contribute to greater monocyte recruitment 
(Kuhle et al., 2009). CCL4 and CXCL10 on the other hand can provide neuroprotection from 
excitotoxicity, a mechanism that has been heavily implicated in ALS pathology (Tateishi et 
al., 2010; Foran and Trotti, 2009). Therefore, chemokines may provide a useful avenue for 
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the development of biomarkers for this disease, however further investigation is clearly 
needed to characterise their contribution to the pathophysiology of ALS.  
Chemokines have also been implicated in Alzheimer’s disease (Liu et al., 2014) and 
Parkinson’s disease (Kalkonde et al., 2007) and this is again due to their contribution in 
neuroinflammatory mechanisms. Indeed this is the predominant role suggested for 
chemokines in the pathogenesis of neurodegenerative diseases. However, it should be 
appreciated that these signalling networks may well contribute to other aspects of disease 
pathology via alternative mechanisms, as has been discussed. 
1.4 Summary and Perspectives 
Chemokines represent a diverse repertoire of proteins which have been extensively 
characterised for their role in the immune system but are now becoming increasingly 
relevant to the CNS. The sheer number of these proteins makes elucidating their individual 
biology difficult, time consuming and may lead to contradictory conclusions - a result of 
physiologically redundant expression patterns and signalling pathways.  
Recent bioinformatic investigation of chemokine evolution has significantly improved the 
understanding of this superfamily however, by refining chemokine classification according 
to their principle genetic characteristics. This has distinguished chemokine function and 
allowed a global perspective that has identified common features within chemokine groups, 
whilst further delineating chemokines that show distinct sequence, structural and 
physiological characteristics. As a framework to guide future hypotheses, the molecular 
evolution of chemokines can provide important clues to the primary aspects of individual 
chemokines due to the logical relationship between evolutionary pressures, chemokine 
function and genomic organisation. Indeed, this method has been suggested to represent an 
important method for investigating gene superfamilies in the future (Zlotnik and Yoshie, 
2000; Zlotnik, Yoshie and Nomiyama, 2006).  
The identification of chemokines and their receptors within the CNS represents an 
important milestone in the understanding of chemokine biology; principally it has 
highlighted the capacity of these signalling networks to participate in functions outside of 
the immune system. Despite this, chemokines retain their central characteristics as master 
regulators of cellular migration. Chemokines participate in the development and 
regeneration of the CNS whilst simultaneously contributing to immunological surveillance 
both in concert with, and independently to, the peripheral immune system. Furthermore, it 
is perhaps unsurprising that the diverse downstream signalling pathways which 
chemokines propagate are exploited by cells of the CNS to perform novel functions, most 
notably in the modulation of neuronal excitability. 
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In the context of disease chemokines are unanimously implicated regardless of the affected 
tissue due to their fundamental role in coordinating the immune response. The CNS is no 
exception for this, but the immunological privilege of the CNS is an important aspect to 
consider under any inflammatory state. Additionally, the immunological capacity of 
resident CNS cells exerts a profound influence on the immune response. As essential 
components of intercellular communication chemokines therefore participate in the 
inflammatory response by both controlling the immediate response of resident glia and 
providing the essential bridge of communication that can facilitate the recruitment of 
peripheral immune cells. Currently, there is no evidence to suggest that chemokines directly 
underlie the pathology of CNS disease. However, as a result of their universal participation 
in numerous pathophysiologies chemokines are sure to represent important future targets 
for therapeutic intervention or as disease biomarkers. The purpose of this work is to 
investigate a novel role for the class C chemokine, XCL1, and its receptor, XCR1, within the 
CNS. 
1.5 A Potential Role for XCR1 and XCL1 in the CNS 
1.5.1 XCR1 and XCL1 
XCR1 and XCL1 represent the exclusive ligand and receptor signalling axis for the class C 
subfamily of dual-function chemokines. In humans, there are two highly homologous 
ligands, XCL1 and XCL2, which differ at only 2 amino acid positions within the N-Terminal 
domain. XCL1 exhibits an Aspartate (D7) and Lysine (K8) at amino acid positions 7 and 8, 
whilst XCL2 exhibits a substituted Histidine (H7) and Arginine (R8) at these positions 
(Yoshida et al., 1995). Both XCL1 and XCL2 genes are located in chromosome 1 of humans. 
For mice, only a single isoform, Xcl1, exists for the class C chemokine family and also resides 
on chromosome 1 of mus musculus. 
Currently, the functional consequences of the amino acid changes between XCL1 and XCL2 
are unknown. However, both ligands demonstrate a structural dichotomy that is unique 
amongst chemokines. At physiological temperatures and salt concentrations, both XCL1 and 
XCL2 demonstrate a dynamic conformational equilibrium within which they exist in 
monomeric form (LTN10) or as a highly interactive dimer (LTN40) (Kuloglu et al., 2001; 
Kuloglu et al., 2002). LTN10 demonstrates the canonical chemokine fold structure 
(illustrated in figure 1.1) and is capable of binding XCR1. LTN40, however, does not exhibit 
XCR1 binding and instead binds with high affinity to extracellular glycosaminoglycans and 
may confer antimicrobial activity (Nevins et al., 2016). Regardless of the adopted structure 
for either XCL1 or XCL2 however, functional comparisons suggest both proteins 
demonstrate almost identical characteristics and the difference in physiological role for the 
two isoforms is likely mediated by alternative transcriptional regulation and expression 
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patterns (Fox et al., 2015).  For example, both XCL1 and XCL2 are constitutively expressed 
by Natural Killer (NK) cells, but only XCL1 demonstrates an upregulation in response to 
Interleukin-2  (Fox et al., 2015). In contrast, CD8+ T-cells exhibit constitutive expression of 
both ligands and induce the upregulation of both ligands following activation (Yamazaki et 
al., 2010).    
XCR1 is a seven transmembrane GPCR that was originally identified from the functional 
characterisation of the orphan GPCR, GPR5. It was found that application of recombinant 
XCL1 and XCL2 to murine L1.2 cells stably expressing GPR5 was capable of inducing 
intracellular Ca2+ mobilisation and chemotaxis. The observed sensitivity to the class C 
chemokines therefore led to GPR5 being designated as XCR1 (Yoshida et al., 1998).  
1.5.2 XCR1 and XCL1 in health and disease 
The XCR1 gene is located on chromosome 3 of humans and encodes a 333aa protein. 
Phylogenetic analyses demonstrates XCR1 to be evolutionary conserved from fish to 
humans (Nomiyama, Osada and Yoshie, 2011) with XCL1 residing within an isolated 
chromosomal location for both human and mouse genomes (Figure 1.2), suggesting an 
essential and conserved functional role of this chemokine axis. Indeed, investigations have 
demonstrated XCR1 to define an evolutionary conserved population of classical dendritic 
cells (cDCs) between mice and humans (Yamazaki et al., 2010; Bachem et al., 2010; Crozat 
et al., 2011; Dorner et al., 2009) that are distinct from the other category of cDCs which are 
defined by their expression of CD11b. Xcr1+ cDCs are categorised as lymphoid (CD8α+) or 
non-lymphoid resident (CD103+) DCs and are found in all primary, secondary and tertiary 
lymphoid organs as well as laying resident in non-lymphoid organs/tissues where they 
perform antigen surveillance during physiological states. They are distinguished by their 
function to cross present exogenous antigen in complex with Major Histocompatibility 
Protein-I protein, an essential component for immune response to non-cytosolic proteins 
arising from viruses and intracellular bacteria (Bedoui et al., 2009). This XCR1+ cDC 
population in both mice and humans therefore perform essential roles in mediating a 
cytotoxic, Th1-type immune response. In support of this, the co-release of XCL1 alongside 
CCL3, CCL4, CCL5 and IFN-γ by Th1-polarised CD4+ and CD8+ T-cells (Dorner et al., 2002; 
Dorner et al., 2004) is considered to represent an archetypal protein secretion that defines 
a Th1 immune response (Moser and Loetscher, 2001).  
In addition to this role during the Th-1 type immune response, the expression of XCL1 by 
thymic medullary epithelial cells (mTECs) is an essential component for the homeostatic 
maintenance and development of regulatory T-cells in the thymus. Expression of XCL1 by 
mTECs is required for the recruitment of XCR1+ DCs to the central region of the thymic 
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medulla where the interaction between mTECs, XCR1+ DCs and developing thymocytes 
mediate antigen presentation and the development of self-tolerance (Lei and Takahama, 
2012).  
Investigations of XCL1 in the context of disease has demonstrated XCL1 expression to be 
elevated in several autoimmune diseases including rheumatoid arthritis (Endres et al., 
2010), Crohn’s disease (Middel et al., 2001) and Th-1 cells that infiltrate the pancreas and 
cause insulin-dependent diabetes mellitus (Bradley et al., 1999). The capacity of XCR1+ DCs 
to mediate cross-presentation to cytotoxic CD8+ T-cells also implicates this chemokine 
signalling axis in anti-tumour immunity, through the co-ordination of DC migration and the 
facilitation of cell-cell interactions within lymphoid tissues (Lei and Takahama, 2012). 
XCR1 and XCL1 may also contribute to other functions of the body outside of the immune 
system. Immunohistochemical analysis demonstrated constitutive expression of XCR1 by 
healthy oral epithelial cells in vivo that was upregulated in epithelial cells collected from 
subjects diagnosed with inflammatory or metastatic disease, in addition to the upregulation 
of XCL1 also. Furthermore, in vitro analysis of normal oral keratinocytes supported the 
constitutive surface expression of XCR1 observed in vivo, with XCR1 and XCL1 expression 
observed to be increased within several cancer cell lines. This increased expression of XCR1 
was associated with increased cellular proliferation, migration and invasion in response to 
XCL1 by cancer cell lines. Moreover, the examined cancer cell lines also demonstrated a 
qualitatively different response to XCL1 than normal keratinocytes, with enhanced adhesive 
capacity and a differential expression profile of matrix metalloproteinase enzymes. In 
tandem with the observed increase of XCL1 by surrounding cells in vivo, this together 
suggests that increased expression of XCR1 may contribute to the enhanced survival and 
potential metastatic capacity of malignant oral epithelia (Khurram 2010).  
1.5.3 Evidence for a role of XCR1-XCL1 signalling in the CNS 
The evidence for a role of XCL1-XCR1 within the CNS is scarce. Protein expression profiles 
have indicated the expression of XCL1 to be induced within whole brain homogenates up to 
120 hours post-infection with Pneumococcal meningitis (Klein et al., 2006) and XCL1 is also 
upregulated in the cornea and trigeminal ganglion of mice following infection with herpes 
simplex virus type 1 (Araki-Sasaki et al., 2006). Additionally, in a transgenic mouse model 
overexpressing the Human Immunodeficiency Virus-1 (HIV-1) Tat protein specifically 
within the CNS, XCL1 transcript and protein levels were significantly upregulated, with 
expression predominating within astrocytes and to a lesser extent in microglia (Kim et al., 
2004). However, the function of this upregulation has not been tested and has instead not 
been commented upon or incorrectly assumed to represent an additional signal for the 
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chemotactic recruitment of T-cells (Kim et al., 2004; Dorner et al., 2009; Lei and Takahama, 
2012). 
During the course of this project, a publication by Zychowska and colleagues reported a 
contribution of Xcl1 to the development of symptoms observed within a mouse model of 
diabetic neuropathy. From this investigation, the authors concluded that the central 
expression of Xcr1 by neurons of the mouse spinal cord mediated increased sensitisation of 
streptozotocin-treated mice (Zychowska et al., 2016).  The details of this investigation are 
discussed in depth throughout this thesis and at this point, to our knowledge, represents 
the sole investigation of Xcr1 expression and function within the CNS of mice.  
In addition to the data by Zychowska et al.,  investigations by the Oral Neuroscience research 
group at the University of Sheffield, in collaboration with colleagues at the University of 
Leeds, has demonstrated Xcl1-Xcr1 signalling to enhance neuronal excitability within the 
rat trigeminal nucleus (Bird et al., 2018). This study observed Xcr1 to be expressed within 
the subnucleus caudalis (Vc) of the trigeminal brainstem nucleus, a region containing the 
synaptic terminals of nociceptive neurons that innervate the facial region. Application of 
Xcl1 to ex-vivo slices of rat brainstem was demonstrated to enhance spontaneous neuronal 
excitability and increase expression of c-Fos, pERK and pp38 by Vc neurons. The effect of 
Xcl1 was blocked following the application of viral Macrophage Inflammatory Protein-II, a 
viral protein that acts as an antagonist at the XCR1 receptor. In addition, the expression of 
Xcr1 along peripheral axons of the mental nerve was observed by immunohistochemistry 
to be increased in rats at 3 days following chronic constriction injury (CCI) in comparison 
to a complete lack of Xcr1 reactivity along the peripheral axons of sham animals. Xcr1 
reactivity within the brainstem demonstrated colocalisation to oligodendrocyte markers 
and also localised to superficial regions of Vc. However, this reactivity was unable to be 
colocalised with a particular cellular marker but was observed to demonstrate 
colocalisation with vGlut2 (Bird et al., 2018). 
Together this data suggests a contribution of XCL1-XCR1 signalling to the 
neuroinflammatory response to peripheral nerve injury. In addition, it suggests that the 
activation of Xcr1 by Xcl1 is capable of modulating neuronal activity, a feature that has been 
described for other chemokine receptor and neuromodulators. 
1.5.4 Project aims and objectives  
Despite the relative lack of evidence for a function of XCR1 and XCL1 within the CNS in 
comparison to that for other chemokines (see above), the emerging and current evidence, 
in addition to the molecular characteristics of this chemokine signalling axis, provides a 
rational basis to investigate the potential function of XCR1 and XCL1 in the CNS. The 
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molecular evolution of this chemokine axis indicates an evolutionary conserved function 
that, based on chromosomal location, is highly specific, as has been demonstrated for its 
expression by a specific population of cDCs. Such ancient phylogeny and functional 
characteristics associated with homoestasis, are qualities that some have used to debate the 
evolution of chemokines to have arisen within the primitive nervous system (Huising et al., 
2003a; Huising et al., 2003b; Shields, 2003). Indeed, as discussed for other chemokines such 
as CXCL12 and CCL2 (section 1.2), there is now a consistent body of evidence to suggest that 
chemokines perform independent functions within the CNS to those that they perform 
within the periphery and immune system. Recent evidence now supports the capacity of 
XCR1 and XCL1 modulate neuronal activity (Bird et al. 2018; Zychowska et al 2016). 
However, the link of XCR1 to define a specific cDC population, and the known capacity for 
DC surveillance of the CNS (Section 1.2.2) provides another route by which the Class C 
chemokine axis may contribute to the function of the CNS in health and disease.  
The overall objective of this project was to investigate the expression of Xcr1 and Xcl1 
within the CNS of mice. Due to the significant contribution of murine models to the 
understanding of the human CNS and to the development of novel therapeutic strategies it 
was therefore aimed to provide a comprehensive detail of the expression of this chemokine 
receptor and ligand within the mouse CNS. This would inform further characterisation of 
the potential role for this chemokine signalling axis within the nervous system. In particular, 
three main objectives were sought to be obtained in the mouse which could inform 
subsequent investigation within humans. 
1. Determine the molecular identity of mRNA and protein produced by Xcr1. 
2. Characterise the expression of Xcr1 and Xcl1 within the CNS. 
3. Determine the influence of a central inflammatory response on the gene and protein 
expression of Xcr1 and Xcl1 within the CNS. 




Chapter 2: Materials and Methods 
2.1 Animal Procedures and Sample collection 
All samples of mouse tissue were collected from mice that were cared for and housed under 
the terms of the UK Animals (Scientific Procedures) Act 1986 and under a UK Home Office 
project License. Procedures of tissue collection were performed following the designated 
Schedule 1 Appropriate Methods of Humane Killing of the UK Animals (Scientific 
Procedures) Act 1986. 
2.1.1 Collection of Tissue  
Animals were sacrificed by terminal anaesthesia following intraperitoneal sodium 
pentobarbital injection. Conformation of sufficient anaesthetic depth was achieved by 
observing the absence of a withdrawal reflex following pinching of hind paws. 
Animals were subsequently transcardially perfused with 0.01M Phosphate Buffered Saline 
(PBS), to clear residual blood, and 4% (w/v) Paraformaldehyde (PFA, BDH chemicals Ltd.) 
in PBS. To do this, a horizontal incision was made along the subcostal plane to allow vertical 
retraction of the dermis and expose the underlying viscera. A horizontal incision was then 
made immediately below the thorax to reveal the diaphragm which was then pierced and 
the blade drawn horizontally to the lateral edge of the bottom ribs. The blade was then 
drawn upwards to sever the ribs and allow the ribcage to be lifted to expose the heart. The 
vena cavae were severed above the right atrium and a 25 gauge catheter inserted to the left 
ventricle. 8-10ml of PBS was then perfused until returning fluid to right atrium was clear of 
blood. The syringe of PBS was then replaced with 4% PFA and tissue perfused for fixation. 
2.1.1.1 Collection of Spinal cord 
For collection of spinal cord, the head was first decapitated by a single cut with scissors. An 
incision was then made along the entire sagittal plane of the spinal column to allow 
resection of the dermis. This was then peeled away to expose the vertebral column. Scissors 
were then placed immediately lateral to the spinal column and cut all along this axis, parallel 
to the column, stopping once the cut had severed hips. This was repeated for both lateral 
sides of the spinal column. A cut was then made horizontally, just below the hip, severing 
the most caudal spinal cord regions. These three cuts isolated the spinal column and allowed 
its removal from the body. 
To isolate the spinal cord, laminectomy was performed using microsurgical scissors to 
break each vertebra independently along the entire vertebral column. The bottom blade 
was inserted underneath both lateral sides of the vertebra, starting at the rostral end of the 
spinal column. The scissors were then closed and pulled upwards, away from the dorsal 
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aspect of the column, to break the vertebra. Once severed on both sides the vertebra was 
pulled away from the spinal canal using forceps. Repeating this along the entire dorsal 
aspect of the spinal column allows exposure of the spinal cord located within the spinal 
canal. For isolation of the spinal cord only, microsurgical scissors were ran along the spinal 
canal immediately adjacent to the spinal cord in order to sever fibres of the dorsal and 
ventral roots. The cord was then removed by lifting away from the spinal canal.  
2.1.1.2 Collection of Spleen 
For isolation of spleen, a vertical incision was drawn along the midline towards the hind 
limbs from the subcostal incision used for the initial transcardial perfusion. This fully 
exposed the abdominal cavity. The spleen was identified within an anterodorsal lateral 
position to the liver, below the stomach. The major vessels supplying the spleen were 
severed with a pair of microsurgical scissors and the spleen removed with forceps. 
2.1.2 Preparation of Tissue for histological processing 
Following collection, tissue was fully immersed within 4% PFA solution and left to incubate 
at 4°C for 24 hours to permit a complete fixation of the tissue. The tissue was then treated 
in sucrose solutions of ascending concentration (5%, 10%, 15%) for 5 minutes each before 
incubation for 24 hours in 20% sucrose at 4°C in order to protect the tissue during 
cryopreservation. 
The whole tissue was then immersed within optimal cutting temperature (OCT) compound 
(ThermoScientific) within a rubber mould. The tissue and OCT was frozen above a cold plate 
at -50°C before transfer to a -80°C freezer. Tissue was frozen for at least 24 hours at -80°C 
before sectioning.  
2.1.3 Immunohistochemistry 
Immunohistochemistry was performed using free-floating sections of sample tissue. All 
tissue sections were cut at 30um using a chilled microtome at -20°C within a cryostat and 
then immersed within PBS. For the long-term storage of sectioned tissue, sections were 
immersed within a 60% glycerol (v/v) solution within PBS and chilled to -20°C. 
2.1.3.1 Chromogenic immunohistochemistry 
Detection of primary antibody (see table 2.1, A for details) was visualised using the 
chromogenic Diaminobenzidine (DAB) Horseradish peroxidase (HRP) substrate following 
primary antibody detection using the VectaStain® ABC HRP kit (Vector Labs). Sections 
were washed 2x in PBS before a 30 minute incubation with 0.3% H2O2 in PBS to quench 
endogenous peroxidase activity. This was followed by 2 further washes for 10 minutes in 
27 
 
PBS and a 1 hour block in 10% normal goat serum (NGS) in PBS. NGS was then removed 
from test sections and primary antibody added overnight at 4°C. Negative controls without 
primary antibody were left in NGS or had primary antibody added that had been pre-
incubated for 24 hours with the antigenic peptide. Sections were then washed 3x for 10 
minutes in PBS and incubated with a biotinylated goat anti-rabbit secondary antibody. A 
further 2 washes for 10 minutes in PBS was then performed before a 30 minute incubation 
with the vectastain avidin-biotin HRP-complex. A final 2 washes for 10 minutes in PBS was 
performed before addition of DAB. The reaction was allowed for up to 10 minutes after 
which the sections were flooded with PBS to quench peroxidase activity. Sections were 
subsequently dehydrated by sequential dehydration through 70%, 90% and 100% EtOH 
followed by 1 minute incubation in histo-clear (ThermoFisher). Sections were then 
mounted on to glass slides and covered in Pertex solution (CellPath Ltd). 
2.1.3.2 Fluorescent immunohistochemistry 
Free-floating tissue sections (30µm) were washed 3x for 10 minutes in PBS. Sections were 
then blocked for 1 hour in appropriate blocking buffer (10% serum/PBS) at room 
temperature (RT). Blocking buffer was removed and primary antibody was added to 
sections overnight at 4°C (see table 2.1 for antibody preparation). Negative controls had 
primary antibody omitted and sections were left in blocking buffer or had primary antibody 
added that had been pre-incubated for 24 hours with the antigenic peptide. After incubation 
overnight, sections were washed 3x for 10 minutes in PBS and then secondary antibody(ies) 
was added for 2 hours at RT on an orbital rotor. Sections were washed for a final 3 times, 
each for 10 minutes, with PBS and subsequently mounted on to glass slides. Excess PBS was 
removed from slides and then sections were covered with Vectashield® mounting reagent 
(Vector Labs) or Prolong® Gold mounting reagent with 4’,6-diamidino-2-phenylindole 
(DAPI) (ThermoFisher) with glass coverslips placed over the top in preparation for imaging. 
2.1.4 Collection of RNA from Tissue 
Prior to the collection of RNA, all mice were culled according to the designated Schedule 1 
Appropriate Methods of Humane Killing of the UK Animals (Scientific Procedures) Act 1986. 
2.1.4.1 Spinal Cord 
For the collection of RNA from spinal cord, the animal was first decapitated by a single 
horizontal cut at the rostral end of the cervical region. Spinal column was exposed by a 
vertical incision through the dermis along the entire midline. Horizontal retraction of the 
dermis then permitted the exposure of the underlying spinal column. A horizontal cut was 
then made at the rostral end of the spinal column, anterior to the line of the hips. In 
combination with decapitation, this exposed the spinal canal containing the spinal cord at 
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both rostral and caudal ends of the column. In order to retrieve the entire spinal cord, a 
200ul pipette (and associated tip) was filled with PBS and inserted firmly in to the rostral 
end of the spinal column to form a complete a seal as possible between tip and spinal 
column. Extraction of the cord was achieved by aspiration of the pipette and PBS with 
sufficient pressure to eject the cord from the column. The ejected spinal cord was collected 
within a sterile petri dish filled with ice cold PBS and stored over ice. The tissue was then 
transferred to 1ml TRIzol ® reagent in a 1.5ml Eppendorf tube.  
2.1.4.2 Spleen 
For collection of RNA from spleen, the spleen was identified within the animal located 
within an anterodorsal lateral position to the liver, below the stomach. To enable efficient 
homogenisation, spleen tissue was cut in to smaller pieces before transferring 50-90mg to 
1ml of TRIzol ® reagent. For some samples prepared from frozen spleen tissue, tissue was 
first prepared using RNAlater ®-Ice Frozen Tissue Transition Solution (Ambion) according 
to manufacturer’s instructions.  
2.1.4.3 Tissue homogenisation and RNA extraction 
Spinal cord and spleen tissue was homogenised using either a hand-held tissue 
homogeniser (Argos Technologies) or dissociated completely by sonication at 25-30 kHz 
using a hand-held ultrasonicator (Jencons Scientific Ltd). Homogenised samples in TRIzol 
® were then processed according to manufacturer recommendations for RNA isolation. 
Following isolation, RNA was resuspended in RNase and DNase-free H2O to achieved a 
concentration of <1000ng/µl. RNA samples were then used immediately for Reverse 
Transcription-PCR (RT-PCR) (see below) or stored at -80°C until further use. 
2.1.5 Primary microglia collection and cell seeding 
A method for the collection and culture of brain-derived primary microglia was deduced 
from a method kindly provided by Dr Laura Ferraiuolo and further optimised according to 
protocols published in the literature (Saura, Tusell and Serratosa, 2003; Moussaud and 
Draheim, 2010). 
Each microglial preparation was performed using the brains of 3 age and gender-matched 
mice from the same genetic background. Brain from each mouse was removed following 
cervical dislocation and decapitation of the mouse. A sagittal incision was made from the 
posterior of the head along the dorsal aspect to the midline. This allowed the dermis to be 
peeled away to expose the cranium. Three breaks to the skull were then made on the dorsal 
and both lateral sides of the foramen magnum by inserting the tips of scissors and drawing 
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3rd extracellular domain 
(Human) 19aa, position 
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(Human) 34aa, position 
1-34 




2nd cytoplasmic domain 
(Human) 19aa, position 
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Mouse Monoclonal N/A 1ug/ml 
Anti-Iba-1 
(Ab5076) 
Abcam - Goat Polyclonal 1ug/ml - 
Anti-GFAP 
(Ab7260) 




























Cy3 550 570 1:500 
5% NDS, PBS 
(ICC) or PBS-T 
(IHC) 





FITC 495 520 1:500 
5% NDS, PBS 
(ICC) or PBS-T 
(IHC) 





Cy3 550 570 1:500 
5% NDS, PBS 
(ICC) or PBS-T 
(IHC) 
1.5% NDS, PBS 
 
 
Table 2.1. Details of primary and secondary antibodies used for immunocytochemistry and immunohistochemistry. A) Details of primary antibodies and their 
respective preparation. Determination of antibody concentration was based upon manufacturer’s recommendations. B) Details of fluorescent secondary 
antibodies used for the detection of primary antibodies raised in Rabbit, Mouse and Goat. Cy3 = Cyanine Dye 3; FITC = Fluorescein Isothiocyanate; NDS = 
Normal Donkey Serum; PBS at 0.01M concentration. PBS-T = 0.2% Triton™ X-100,  0.01M PBS. ICC = Immunocytochemistry; IHC = Immunohistochemistry. 
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underlying brain tissue. The skull was then peeled away to reveal the brain. To remove the 
brain, the tissue was lifted and the optic nerve severed and then pulled upwards and 
backwards. Collected brains were placed immediately in to ice cold PBS and stored over ice 
until all 3 brains were collected. Following collection, the cerebellum was removed and the 
remaining tissue washed thoroughly with ice cold PBS. Brains were then thoroughly 
fragmented using a scalpel to provide a homogenous tissue devoid of large tissue clumps. 
This was performed for all 3 brains and the collective brain tissue then added to 6ml papain 
enzyme solution (dissolved in dH2O: papain (20 units/ml, Sigma), 1000 units/ml penicillin 
and 0.01mg/ml streptomycin (Sigma), 116mM NaCl, 1M KCl, 26mM NaHCO3, 1mM NaH2PO4, 
1.5mM CaCl2, 1mM MgSO4, 25mM glucose, 1mM cysteine). Note that the addition of papain 
enzyme to the solution was made after the addition of brain tissue. Inclusion of pen/strep 
antibiotic was made in response to bacterial infections that were experienced during 
preliminary attempts of the method and was found to aid the prevention of any 
contamination during subsequent preparations.   
Tissue was dissociated by incubation in papain enzyme solution for 1 hour at 37°C within a 
water bath, with agitation of the sample every 10-15 minutes to maximise dissociative 
activity. After 1 hour, any clumps of tissue were dissociated by aspiration with a p1000 
pipette. Papain enzyme activity was quenched by the addition of a 1:1 volume of 40% Fetal 
Bovine Serum (FBS) (ThermoFisher) in Hanks Balanced Salt Solution (-Ca2+/Mg2+) (HBSS) 
to papain enzyme solution. The solution was mixed and then centrifuged at 200xg for 4 
minutes. The resulting supernatant was removed and the pellet resuspended in 2ml DNase 
I solution (0.5mg/ml DNase I (Sigma), 1x HBSS) and incubated at room temperature for 5 
minutes. Tissue was then filter dissociated through a 70µm cell strainer (strainer was 
washed with an additional 1ml 1x HBSS to improve cellular yield). The sample was then 
centrifuged for 4 minutes at 200xg to pellet the collected cell dissociate. The cell pellet was 
then resuspended in 10 ml 20% isotonic Percoll (Sigma) (2ml isotonic percoll (200µl 10x 
HBSS, 1.8ml Percoll), 8ml 1x HBSS). To isolate the cells by centrifugation, 10ml 1x HBSS was 
dispensed carefully above the cell/Percoll suspension. Addition of the overlying HBSS was 
done without disrupting the cell/Percoll suspension. The combined cell/Percoll suspension 
and overlying HBSS solution was then centrifuged for 20 minutes at 200xg using the slowest 
acceleration and no brake. The resultant solution demonstrated a large interphase layer 
containing cell debris and myelin (visible white band in solution). Cells were contained 
within a pellet at the bottom of the tube. The entire solution above the cell pellet was 
removed and the pellet washed by the application of 2ml 1x HBSS and gentle agitation. Cells 
were then re-pelleted by centrifugation for 4 minutes at 200xg. The overlying supernatant 
was removed and purified cells resuspended in 8ml of complete glial cell media 
(DMEM/F12 (ThermoFisher), 10% FBS (ThermoFisher), 4000 units/ml penicillin and 
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0.04mg/ml streptomycin (Sigma), 5ng/ml Granulocye-Macrophage Colony Stimulating 
Factor (GM-CSF) (Peprotech). Cells were seeded to poly-L-ornithine-coated T25 flasks 
(incubated for 18-24 hours with 1:200 0.01% poly-L-ornithine (dH2O) at room 
temperature) following a single wash of the flask with PBS. 
2.1.5.1 Primary microglia cell culture 
Following cell seeding, cells were monitored daily. 48 hours post-seeding, half of the cell 
media was replaced with complete glial cell media (note GM-CSF concentration was doubled 
to maintain effective concentration). From 48 hours post-seeding, unless cell numbers and 
growth was particularly high (judged according to appearance of media), only half the 
volume of complete glial cell media was replaced at 48-72 hour intervals. Note that GM-CSF 
concentration was adjusted to maintain a constant 5ng/ml concentration in the total media 
volume. This was performed until confluence was achieved in the T25 flask (typically after 
10-14 days). Complete glial cell media was prepared on the day of use.  
To achieve appropriate cell numbers for the desired applications, once cells had reached 
confluence within the T25 flask the entire cell population was dissociated and re-seeded in 
to a T75 flask coated in Poly-L-ornithine, as described above. To do this, total media 
(containing dissociated, floating microglia), was removed and stored. 5ml of 0.25% Trypsin- 
Ethylenediamineteraacetic acid (EDTA) (ThermoFisher) was then added and incubated at 
37°C for 10 minutes. Vigorous tapping and pipetting of the flask was required to dissociate 
cells. Previously collected media was then added back to trypsinised cells to maximise 
collection of microglia. The solution was then centrifuged for 5 minutes at 200xg and the 
resulting cell pellet resuspended in complete glia cell media and seeded to a T75 flask. Cells 
were maintained in T75 flasks until further use, by 50% media replacement with complete 
glia cell media every 2-3 days.  
2.1.5.2 LPS treatment of primary brain-derived microglia 
Lipopolysaccharide (LPS) treatment of primary brain-derived microglia was performed 
according to protocol described by Zychowska et al., 2016. Following culture and expansion 
of primary brain-derived microglia, cells contained within T75 flasks were treated with 8ml 
0.25% Trypsin-EDTA (ThermoFisher) and dissociated and centrifuged as described in 
2.1.5.1. Cell pellets were resuspended in 5ml complete glial cell media (without GM-CSF) 
and counted using a hemocytometer. For cells to be evaluated by immunocytochemistry, 60, 
000 cells were seeded to each well of a 24 well plate. The seeded well was first covered with 
sterile 12mm2 glass slides. Cells were seeded in 1ml complete glial cell media, without GM-
CSF. For cells to be used for RNA collection, 200,000 cells were seeded to 6 well plates in 
2ml complete glial cell media (- GM-CSF). Note that seeding to both 6 and 24 well plates was 
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preceded by poly-L-ornithine coating of wells and glass coverslips for 24 hours.  72 hours 
after cell seeding, cells were treated with complete glial cell media (- GM-CSF) or complete 
glial cell media (- GM-CSF) with the addition of 100ng/ml LPS derived from E. Coli 
(ThermoFisher) and incubated for 24 hours. RNA was then collected from cells, as described 
in section 2.2.7. For immunocytochemistry, cells were processed as described in section 
2.2.6. 
2.1.5.3 Evaluation of microglial purity: Iba-1 and GFAP immunocytochemistry 
The presence of microglia and astrocytes were identified in primary cell cultures by the 
detection of Ionised calcium binding adaptor molecule-1 (Iba-1) and Glial Fibrillary Acidic 
Protein (GFAP) proteins, respectively, using double immunocytochemistry (section 2.2.6). 
Images were obtained at magnifications of 10x and 40x and analysed as described in section 
2.3. Microglial purity was estimated by counting the number of Iba-1-positive and GFAP-
positive cells and determining their relative abundance to total cell numbers as determined 
by DAPI staining. Semi-quantitative analysis of Iba-1 reactivity was determined from the 
RawIntDensity of the corresponding colour channel to the fluorophore conjugated to the 
desired secondary antibody. 
2.2 Cell Culture 
2.2.1 HeLa cells 
HeLa cells were obtained from frozen stocks kindly donated by Dr Yolanda Gibson. Cells 
were resurrected and cultured in a complete HeLa growth media composed of high glucose 
(+ sodium pyruvate) Dulbecco’s Modified Essential Medium (DMEM, ThermoFisher), 10% 
FBS (ThermoFisher), 1000 units/ml penicillin and 0.01mg/ml streptomycin (Sigma). Cells 
were incubated in T75 flasks at 37°C supplemented with 5% CO2.  
2.2.2 Parental EA-CHO cells 
A parental CHO cell line for the use in the DiscoverX ® PathHunter™ β-arrestin assay  were 
maintained in complete CHO cell media (Ham’s F12-K media (ThermoFisher), 10% FBS, 
Penicillin (1000 units/ml) Streptomycin (0.01mg/ml)), unless otherwise stated. 
2.2.3 Subculture of Cells 
Upon confluency of cells, both CHO and HeLa cells were subcultured by incubation with 5ml 
0.05% Trypsin-EDTA (ThermoFisher) and resuspended in 5ml Complete growth media. 
1ml of this cell suspension was then added to 15ml of Complete growth media and the cells 
reseeded to a T75 flask to maintain cell stocks. 
2.2.4 Cryopreservation of cells 
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Cell stocks were created by the cryopreservation of existing cell lines. Cells were initially 
dissociated and centrifuged at 200xg for 5 minutes. Cells were then resuspended in 
complete growth media and counted using a hemocytometer. Cells were centrifuged at 
200xg for 5 minutes and then resuspended to achieve a concentration of 1x106 cells/ml in 
Cell freezing media composed of the respective cell complete growth media with an 
additional 10% concentration of FBS and a 10% concentration of dimethyl sulfoxide 
(DMSO). Cells were then frozen at a steady rate to -80°c from room temperature within a 
Mr. Frosty™ freezing container (Nalgene). 
2.2.5 Cell Transfection 
2.2.5.1 Lipojet™ Transfection of HeLa cells 
Cells were seeded the day before transfection (at least 18 hours prior) at a density aimed to 
achieve ~80% by the time of transfection (table 2.2). For cells to be tested by 
immunocytochemistry, cells were seeded in 24 well plates containing 12mm circular glass 
slides or in glass-bottomed 96-well plates (Greiner, Merck). For cells to be used for the 
collection of cell lysate for western blot, cells were seeded to 6 well plates. Plasmid 
transfection of HeLa cells was performed using the LipoJetTM In Vitro DNA and siRNA 
Transfection Kit (SignaGen Laboratories). 1 hour prior to transfection a fresh volume of 
complete HeLa growth media (including serum) was added to the wells. 15 minutes prior 
to transfection the designated amount of plasmid DNA was added to the 1x LipoJetTM 
transfection buffer and vortexed briefly. The determined amount of LipoJetTM reagent was 
then added to the 1x buffer plus plasmid solution and vortexed. After incubating these three 
components for 15 minutes the plasmid-transfection reagent solution was added dropwise 
to the overlying cell media and the plate gently shaken to maximise transfection coverage. 
An equal number of wells to the number that were transfected were left untransfected as 
negative controls. Cells were then incubated for 24 hours at 37°C in 5% CO2 before 
preparation for immunocytochemistry (2.2.6) or western blot (2.4.2 and 2.4.3). 
Final LipoJetTM and plasmid concentrations were made to achieve a 1:1, 2:1, or 3:1 ratio of 
LipoJetTM reagent (µl): plasmid DNA (µg), with plasmid concentrations tested at 1ng/µl, 
2ng/ul and 3ng/ul of total transfection volume (transfection solution + cell media). See table 
2.2 for details of transfection solution composition.  
2.2.5.2 PolyPlus PEIpro® transfection of CHO cells 
1x106 EA-expressing CHO cells were seeded to T25 flasks 16-24 hours prior to transfection 
to achieve 60-80% confluency. On the day of transfection, cells were washed twice with PBS 
and complete CHO cell media was replaced with 5ml Opti-MEM serum-free medium 
(ThermoFisher). pCMV-ProLink2 vectors were prepared by the addition of the desired 
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amount of plasmid to 250µl Opti-MEM media. The corresponding amount of PEIpro 
transfection reagent (Polyplus-transfection Inc.) was prepared in a separate 250µl volume 
of OptiMEM media. Plasmid amounts were calculated based on achieving a plasmid 
concentration of 750ng/ml of total cell media volume. PEIpro transfection volume was 
determined based on a 2:1 ratio of PEIpro (µl): plasmid DNA (µg). Both plasmid and PEIpro 
solutions were then gently vortexed, mixed together and vortexed once more, with the 
combined plasmid-PEIpro solution then allowed to incubate at room-temperature for 15 
minutes. Plasmid-PEIpro solution was then added to the T25 flask and incubated with the 
cells for 24 hours. After this time, cell media was replaced with complete CHO cell media 
and left to incubate for a further 24 hours, following which cells were either seeded for 
ligand application, or underwent antibiotic selection.  
2.2.5.2.1 Antibiotic selection of CHO Cells stably expressing pCMV-Prolink2 plasmids 
Cells successfully transfected with pCMV-ProLink2 vectors were selected for by culturing of 
cells in G418-CHO cell media (Ham’s F12-K medium (Sigma), 10% FBS, 2mg/ml G418 
(Insight). 24 hours after cell transfection, G418-CHO cell media was replaced every 2-3 days 
for 8-12 days prior to ligand application. Conformation of G418 efficacy was determined by 
the use of non-transfected CHO cells. 
2.2.6 Immunocytochemistry  
Cells were washed twice in PBS and fixed in 4% PFA for 60 minutes at 4°C. Cells were then 
washed a further 2 times in PBS and stored in PBS at 4°C until use.  
Cells were washed 3x for 10 minutes in PBS and 1x for 10 minutes in PBS containing 0.2% 
Triton x-100 (Sigma) (PBS-T). Cells were then blocked for 1 hour in appropriate blocking 
serum at room temperature (RT) on an orbital rotor. The blocking serum was removed and 
primary antibody was added to coverslips overnight at 4°C on an orbital rotor (for details 
of antibodies used see table 2.1). Negative controls had primary antibody omitted and left 
in blocking serum or had primary antibody added that had been pre-incubated for 24 hours 
with the antigenic peptide. The following day, coverslips were washed 3x for 10 minutes in 
PBS. Secondary antibody(ies) were then added for 2 hours at RT on an orbital rotor (see 
table 2.1 for details of antibodies used and their concentrations). Cell nuclei were stained 
with 1:2000 DAPI in PBS for 10 minutes. This was followed by a final 3 washes for 10 
minutes with PBS. For cells in 24 well plates, excess PBS was removed from wells and then 
coverslips were removed and placed on to glass slides with Vectashield® mounting reagent. 














Table 2.2. Composition of LipoJetTM transfection solutions used for transient transfection of HeLa cells with RC221929 or MR225748 plasmids. The composition of transfection solution was 


























300,000 1-3ng/µl 1:2 200µl 2ml 
24 Immuno-
cytochemistry 
100,000 0.4-3ng/µl 1:2 50µl 0.5ml 
96 Immuno-
cytochemistry 
20,000 1-3ng/µl  1:2 5µl 0.05ml 
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In addition to the standard protocol above, antibody reactivity was also tested by 
immunocytochemistry following Heat Induced Epitope Retrieval (HIER). This was 
performed following cell fixation by heating the cells in a pH 6 sodium citrate buffer (10mM 
Sodium citrate, 0.05% Tween-20, pH 6.0) at 95°C for 10 minutes and then allowing the 
samples to cool to room temperature. 
2.2.6.1 Custom Ab design 
A custom polyclonal anti-Xcr1 antibody was designed under consultation with 
representatives from Eurogentec Ltd. The protein sequence of mouse Xcr1 corresponding 
to NCBI reference sequence NP_035928.2 was used for antigen identification and peptide 
design (Figure 2.1). A 16-amino acid region corresponding to the 3rd cytoplasmic region of 
the receptor was produced for immunisation in conjugation with a Keyhole limpet 
hemocyanin (KLH) carrier protein (Figure 2.1). Polyclonal antibody production was 
achieved by an 87 day immunisation protocol of two Rabbits. Immunisations with the 
antigenic peptide plus carrier was performed at day 0, 21, 49 and 77. A final bleed was 
performed at day 87 and the antibody provided following affinity-purification to the 
antigenic peptide. Confirmation of antibody specificity and affinity was evaluated by 
Enzyme Linked Immunosorbant Assay (ELISA) to the antigenic peptide. For an illustration 
of Xcr1 epitopes targeted by the anti-Xcr1 antibodies used, please see figure 2.1. 
2.2.7 RNA collection from cells 
Preparation of RNA from cell samples was performed using TRIzol ® reagent. For all 
preparations from cells, samples were prepared from ≤ 1 x 106 cells. Provided frozen cell 
pellets were immersed in 1ml TRIzol ® reagent immediately from storage and then 
incubated for 5 minutes at room temperature prior to resuspension of the cells by 
aspiration of the solution. For adherent cell monolayers collected from culture, 1ml TRIzol 
® reagent was added to the cell culture container. Cells were completely dissociated in to 
the reagent by use of a rubber cell scraper. Samples were then aspirated and collected in to 
a sterile 1.5ml Eppendorf tube. From the homogenised cell samples RNA was collected using 
the Direct-Zol RNA microprep kit (ZymoResearch) following the associated manufacturer 
protocol WITHOUT the optional DNase treatment. RNA samples were then quantitatively 
and qualitatively analysed by NanoDrop Spectrophotometer (ThermoFisher) to ensure 
sufficient RNA quantity and purity according to 260/230 and 260/280 ratios of >2.0 and 
>1.8, respectively. RNA samples were then used immediately for RT-PCR or stored at -80°C 
until further use. 
2.2.8 Collection of cell lysate and purification of protein 
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A)  B) 










               LS-C373870 (43-222) 
Xcr1-myc 1   MDSESDALSIPASRVQMESSTAFYDYHDKLSLLCENNVIFFSTISTIVLYSLVFLLSLVG  60 
                        :|:: :| || |: |:|::|::|||::  | |: | |||:||||||||| 
XCR1-myc 1   ----------MESSGNPE-STTFF-YYDLQSQPCENQAWVFATLATTVLYCLVFLLSLVG  48 
        Atlas HPA013169 (1-34) 
 
Xcr1-myc 61  NSLVLWVLVKYENLESLTNIFILNLCLSDLMFSC-LLPVLISAQWSWFLGDFFCKFFNMI  119 
             |||||||||||| |||||||||||||||||:| | |:::::  :|:|:||||:||::||| 
XCR1-myc 49  NSLVLWVLVKYESLESLTNIFILNLCLSDLVFACLLPVWISPYHWGWVLGDFLCKLLNMI  108 
 
 
Xcr1-myc 120 FGISLYSSIFFLTIMTIHRYLSVVSPISTLGIHTLRCRVLVTSCVWAASILFSIPDAVFH  179 
             |:||||||:|||||||||||||||||:|||:: |||||||||: ||:||||:||:|  || 
XCR1-myc 109 FSISLYSSSFFLTIMTIHRYLSVVSPLSTLRVPTLRCRVLVTMAVWVASILSSILDTIFH  168 
                                 Abcam188896 (127-146) 
            CustomAb (222-236) 
Xcr1-myc 180 KVISLNCKYSEHHGFLASVYQHNIFFLLSMGIILFCYVQILRTLFRTRSRQRHRTVRLIF  239 
             ||:|::|:||| : :| ||||||:||||| ||||||||:||||||| ||::|||||:||| 
XCR1-myc 169 KVLSSGCDYSELTWYLTSVYQHNLFFLLSLGIILFCYVEILRTLFRSRSKRRHRTVKLIF  228 
 
 
Xcr1-myc 240 TVVVAYFLSWAPYNLTLFLKTGIIQQSCESLQQLDIAM---IICRHLAFSHCCFNPVLYV  296 
               |||||||| |||:|||| | :::|  :|:::: :     :|||:|||||||||||||| 
XCR1-myc 229 AIVVAYFLSWGPYNFTLFLQTLFRTQIIRSCEAKQQLEYALLICRNLAFSHCCFNPVLYV  288 
           LS-A158 248-266 
                 Anti-myc (345-354) 
Xcr1-myc 297 FVGIKFRRHLKHLFQQVWLCRKTSSTVPCS-PGTFTYE---GPSFYTRTRPLEQKLISEE  352 
               |||:||| ||||:::| |:||      : | |  :  :   |:||||||||||||||||| 
XCR1-myc 289 FVGVKFRTHLKHVLRQFWFCRLQAPSPA-SIPHSPGAFAYEGASFYTRTRPLEQKLISEE  347 
                 Anti-myc (340-349) 
Xcr1-myc 353 DLAANDILDYKDDDDKV  369 
             ||||||||||||||||| 
XCR1-myc 348 DLAANDILDYKDDDDKV  364 
 
Figure 2.1. Epitopes of human and mouse XCR1 homologues. Schematic overview of structures of protein 
produced from MR225748 (Xcr1-myc, A) and RC221929 (XCR1-myc, B) with highlighted regions of antibody 
epitopes detailed in C. C) Sequence alignment of XCR1-myc and Xcr1-myc. Annotated regions correspond to 
epitopes of tested antibodies (table 2.1 (A)). Annotations above = antibody raised to immunogen of Xcr1; 





Cell lysates were collected from 6 well plates by the addition of 300ul RIPA buffer (Sigma) 
plus complete protease and phosphatase inhibitor (Roche). Cells were removed from the 
well surface using a cell scraper and then the cell solution aspirated several times before 
loading in to a sterile 1.5ml Eppendorf tube. Samples were stored on ice and vortexed every 
5 minutes for 6 repeats. Protein was then separated from larger cell debris by centrifugation 
at 14,000xg for 15 minutes. The resultant supernatant was then transferred to a sterile 
vessel and evaluated for protein content by BCA assay. Protein concentrations were 
calculated based on absorbance in reference to a standard curve established from bovine 
serum albumin concentrations between 0 and 2mg/ml. 
2.2.8.1  PNGase F treatment of protein 
For the removal of N-linked oligosaccharides, 15µg cell lysate was treated by denaturing 
and non-denaturing deglycosylation with PNGase F (NEB) according to manufacturer’s 
instruction. For the non-denaturing protocol, PNGase F was added for 24 hours at 37°C 
before preparation for western blot. The total amount of enzyme used was limited to 
prevent glycerol concentration exceeding 5% of the total reaction volume. A positive control 
was established via the use of WFDC2 protein that was kindly donated by Miss Hannah 
Armes (University of Sheffield). 
 
2.3 Microscopy and image analysis 
2.3.1 Microscopy 
Fluorescent and chromogenic samples were inspected with a Zeiss Axioplan 2 imaging 
microscope (Carl Zeiss International). For fluorescent samples, a Lumen 200 Fluorescent 
illumination system (Prior Inc.) was used to illuminate samples. Microscopy filters were 
applied to select the appropriate wavelength for excitation of FITC, DAPI and Cy3 
fluorophores. Digital images were obtained with a QI Click colour CCD camera (Q-Imaging) 
and processed using Image Pro-plus software (Media Cybernetics Inc.). For images used for 
semi-quantitative comparison, identical exposure times were used for the target 
fluorophore(s). 
2.3.2 Image analysis with Fiji 
2.3.2.1 Quantification of antibody binding: Manual image analysis with Fiji 
For the manual assessment of antibody specificity and reactivity, the image analysis 
software Fiji (Schindelin et al., 2012) was used. RawIntensity values were measured from 
each channel corresponding to the desired fluorophore for semi-quantitative evaluation of 
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antibody binding. Cell numbers were manually counted based on DAPI reactivity or 
estimated based on RawIntensity values of the DAPI (blue) channel. To eliminate 
background signal from samples the RawIntensity values for each channel from a secondary 
only control was subtracted from the test images. All evaluations were based on analysis of 
at least 3 images per condition. Quantitative evaluation of cell number and transfection 
positive cells (judged according to presence of appropriate reactivity within cell cytoplasm) 
were used to evaluate total cell counts and transfection efficiency (number of fluorescent 
cells/Total cells).  
In order to evaluate antibody binding, two methods were devised. The first method aims to 
determine the antibody reactivity per cell based on manual counting of cells according to 
DAPI reactivity and morphology. An alternative and more objective method, approximates 
cell number according to DAPI RawIntensity of the image. Due to comparative images being 
taken with identical exposure times, this method offered the opportunity to make the 
analysis more efficient. A relative measure of antibody binding to cell presence was then 
calculated according to the RawIntensity values of signal obtained from the fluorescent 
secondary antibody (used for the detection of the test primary antibody) and the 
RawIntensity of DAPI signal(Antibody/DAPI Rawintensity). This measure could then be 
used to compare antibody binding to non-transfected and transfected cells to establish 
antibody binding to the test protein (Xcr1-myc or XCR1-myc). 
2.3.2.2. Area of antibody binding 
2.3.2.2.1 Quantification of area of Fluorescently labelled antibodies 
The area of antibody presence was identified as a percentage of the total measure of the 
image area or selected Region of Interest (ROI). ROIs were delineated by freehand selection 
of the desired area. To identify specific staining each image was split to RGB channels. The 
channel corresponding to the fluorophore used for detection of the desired antibody was 
then used. The ‘Subtract background’ removed background staining, according to a rolling 
ball radius of 25 pixels. The threshold of the greyscale image was then adjusted to reflect 
specific staining and the % Area of specific staining relative to the total ROI area was used 
for analysis. Measurements were collected using Microsoft Excel (2013) and then analysed 
using Prism 7.0 (Graphpad Inc.). 
2.3.2.2.2 Quantification of DAB staining Area 
The area of DAB reactivity was quantified as a percentage of total image area. DAB staining 
was identified within the image using the Colour Deconvolution process of Fiji according to 
the appropriate “H DAB” colour vectors. The threshold of detected DAB staining was then 
adjusted to permit identification of positive staining and %Area of staining measured. 
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Quantified DAB area (as a percentage of the total image area) was then exported to 
Microsoft Excel (2013) for subsequent data processing.    
2.3.3. Opera Phenix™ High Content Screening system 
For the analysis of antibody specificity to XCR1 proteins expressed in transfected HeLa, cells 
seeded and treated in 96 well plates were evaluated by automated image capture and 
analysis using the Opera Phenix High Content Confocal Screening system (PerkinElmer). 
Images were captured at 20x for each fluorophore and analysed using Harmony image 
acquisition and analysis software (PerkinElmer). Cell nuclei and cell cytoplasm were 
identified using the most suitable algorithm available within the Harmony software. Semi-
quantitative evaluation of antibody binding was performed for all cells within the test 
image. Quantification was based upon the Mean Cell Intensity of the signal emitted from the 
corresponding secondary antibody used for detection of the respective primary antibody.  
Colocalisation of test antibody reactivity with C-myc reactivity was performed to support 
antibody specificity. This was achieved by specifying regions of the individual image that 
demonstrated the highest intensity of signal corresponding to C-myc binding. Quantification 
of the emitted signal arising from the test antibody within this specified region was then 
used as a measure of colocalisation.  
Raw data from Harmony analysis was exported to Microsoft Excel (2013) and subsequently 
analysed as described in section 2.9. Automated image acquisition provided images that 
were auto-contrasted according to individual images. To display a consistent display range 
of pixel intensity and accurately represent differences in antibody signal, the display range 
of images used for comparison presented in the Results section were adjusted using Fiji 
Image analysis software (Schindelin et al., 2012). 
 
2.4 Molecular Biology Methods 
2.4.1 BCA assay 
Protein concentrations of collected samples were determined using the Pierce™ 
bicinchoninic acid (BCA) assay (ThermoFisher). The protein concentration of unknown 
samples was determined from the standard curve of optical density at 560nm for a series 
of protein samples of known concentration between 0 and 2000µg/ml of Albumin. 
2.4.2 SDS-Polyacrylamide Gel electrophoresis 
15-30µg of protein was diluted in 6x protein loading buffer (National Diagnostics) and 
incubated for at least 30 minutes at room temperature or heated to 95°C for 10 minutes 
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before cooling to room temperature. Samples were then loaded in to a 12-15% sodium 
dodecyl sulphate-polyacrylamide gel along with the Ez-run Rec protein molecular weight 
ladder (ThermoFisher) and separated by electrophoresis (SDS-PAGE) at 100 – 150V until 
the desired travel of protein was achieved. 
2.4.3 Immunoblotting 
Following SDS-PAGE, protein was transferred from the gel to a nitrocellulose membrane 
(GE Healthcare) using the Trans-Blot® Turbo™ blotting system (BioRad). Protein transfer 
was evaluated by ponceau S (ThermoFisher) staining before incubating the membrane in 
blocking buffer (0.1% Tween-20, Tris Buffered Saline (50mM Tris-Cl, pH 7.5, 150mM NaCl) 
(TBS-T), 5% dried non-fat milk powder) for 1 hour. Primary antibodies were then added at 
concentrations as detailed in table 2.1 in blocking buffer and incubated at 4°C whilst rolling 
overnight. The membrane was then washed 2x for 5 minutes and 2x for 10 minutes in TBS-
T before adding the desired HRP-conjugated secondary antibody for 2 hours whilst rolling 
at RT. A further 3x 10 minute washes of the membrane in TBS-T was then performed. 
Localisation of HRP-conjugated secondary antibody was then identified by the addition of 
the Clarity™ Western ECL chemiluminescent substrate (BioRad) for 1 minute. 
Chemiluminscence was then detected by exposure to light-sensitive film for the desired 
time period. The exposed film was then developed using the automated Compact X4 Film 
developer (Xograph Imaging Systems). 
Estimation of molecular weight of proteins identified by western blot was made based on 
the relative migration distance of protein standards loaded within the same gel. For each 
protein standard a relative migration distance (Rf) was calculated based upon the following 
equation: 
𝑅𝑓 =  
𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑜𝑓 𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑜𝑓 𝑑𝑦𝑒 𝑓𝑟𝑜𝑛𝑡
  
Rf values of each protein standard were plotted against the Log10(molecular weight) of the 
protein standards and linear regression was performed using Prism 7.0 (Graphpad Inc.) to 
determine the standard curve formula. The Rf value of an identified (unknown) protein was 
then used to calculate the molecular weight according to the standard curve formula: 
Log10(Molecular Weight) = (A*Rf) + C 
2.4.4 Polymerase Chain Reaction 
2.4.4.1 Primer Design 
The design of primers was performed using the NCBI Primer-Blast Tool (Ye et al., 2012) in 
combination with the manual selection of primer targets according to the recorded gene 
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sequences detailed on the NCBI Nucleotide and Ensemble Gene databases. Selected primer 
pairs were then chosen according to the matching of primer melting temperatures, 
calculated from the Online Custom Oligo Ordering Tool (Merck).  
2.4.4.2 DreamTaq Hot Start Green PCR 
Polymerase Chain Reaction (PCR) amplification of target amplicons ≤1kb was performed 
using DreamTaq Hot Start Green PCR Master Mix (ThermoFisher). Primers were prepared 
to a concentration of 1µM and cDNA was used at a concentration of 50-100ng per 50µl 
Reaction. PCR was performed according to a three step protocol consisting of primer 
annealing at (Tm-5)°C, amplicon extension at 72°C and denaturation at 95°C. The 
performed time parameters for each step were determined according to the size of target 
amplicon as described by the manufacturer.  
2.4.4.3 Phusion PCR  
For the amplification of PCR inserts for subsequent cloning in to a host vector (section 2.4.6) 
the high fidelity Phusion DNA polymerase (NEB) was used. Reaction components and 
buffers were determined according to manufacturers recommendation for the size and 
quality of target amplicon. An internal control to confirm efficiency of PCR amplification of 
large (10kb) amplicons was included with each reaction, using the provided bacteriophage 
lambda DNA template. 
2.4.5 Agarose Gel electrophoresis 
DNA fragments produced by PCR or restriction endonuclease digest were separated by 
agarose gel electrophoresis. The desired concentration of agarose powder was added to 
200ml 1x TAE buffer (40mM Tris-Acetate, 1mM EDTA (dH2O)) and heated in a microwave 
until the agarose powder had completely dissolved. EtBr was added to achieve a 
concentration of 0.003% (v/v) and then the solution was poured in to a cassette to cool with 
an inserted comb to permit sample aspiration to the gel. The gel was placed in to a tank of 
1x TAE and samples loaded along with a desired molecular weight ladder. Samples were 
ran at 100V until the desired separation of fragments had been achieved. Separated 
fragments were then imaged using the InGenius 3 Gel documentation system (SynGene). 
2.4.6 Plasmid Cloning   
2.4.6.1 Plasmids 
Two plasmids were purchased from Origene. Origene RC221929 is a plasmid composed of 
a pCMV6 entry vector with an insert containing the Human XCR1 protein coding sequence 






















































































                                                             >T7                              >BamHI                                                                                             
  GTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAATTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGTA  < 100 
  CACCCTCCAGATATATTCGTCTCGAGCAAATCACTTGGCAGTCTTAAAACATTATGCTGAGTGATATCCCGCCGGCCCTTAAGCAGCTGACCTAGGCCAT 
           10        20        30        40        50        60        70        80        90  
             >Xcr1 CDS 
  CCGAGGAGATCTGCCGCCGCGATCGCCATGGACTCAGAGTCAGATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTATG  < 200 
                             M  D  S  E  S  D  A  L  S  I  P  A  S  R  V  Q  M  E  S  S  T  A  F  Y  D 
  GGCTCCTCTAGACGGCGGCGCTAGCGGTACCTGAGTCTCAGTCTACGAGAGTCATAGGGACGTAGGGCGCAGGTCTACCTCAGGAGATGTCGGAAAATAC 
           110       120       130       140       150       160       170       180       190  
   
  ATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTTTTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCCT  < 300 
    Y  H  D  K  L  S  L  L  C  E  N  N  V  I  F  F  S  T  I  S  T  I  V  L  Y  S  L  V  F  L  L  S  L  
  TAATAGTACTATTTAACTCAGAAGATACACTCTTGTTACAGTAGAAGAAAAGGTGGTAGAGATGGTAACAGGACATGAGAGACCATAAAGAGGAGTCGGA 
           210       220       230       240       250       260       270       280       290  
   
  TGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAGAATCTAGAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGACCTGATG  < 400 
   V  G  N  S  L  V  L  W  V  L  V  K  Y  E  N  L  E  S  L  T  N  I  F  I  L  N  L  C  L  S  D  L  M   
  ACACCCATTGTCGGACCAAAACACCCAGAACCACTTCATACTCTTAGATCTCAGTGAGTGGTTATAGAAGTAGGAGTTGGACACAGAGAGTCTGGACTAC 
           310       320       330       340       350       360       370       380       390  
   
  TTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCCTCT  < 500 
  F  S  C  L  L  P  V  L  I  S  A  Q  W  S  W  F  L  G  D  F  F  C  K  F  F  N  M  I  F  G  I  S  L  Y 
  AAGAGGACAGATGACGGACACAACTAGAGTCGTGTTACCTCAACCAAAGATCCACTGAAGAAGACGTTCAAGAAGTTGTACTAGAAGCCGTAGTCGGAGA 
           410       420       430       440       450       460       470       480       490  
   
  ACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATACCTGTCTGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCTGCCGTGT  < 600 
    S  S  I  F  F  L  T  I  M  T  I  H  R  Y  L  S  V  V  S  P  I  S  T  L  G  I  H  T  L  R  C  R  V  
  TGTCGTCGTAGAAGAAGGAATGGTAGTACTGGTAGGTGGCTATGGACAGACATCACTCGGGGTAGAGATGAGACCCATAGGTATGGGAGGCGACGGCACA 
           510       520       530       540       550       560       570       580       590  
                                                                            
  GCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCCATCCCTGATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTCTGAACAT  < 700 
   L  V  T  S  C  V  W  A  A  S  I  L  F  S  I  P  D  A  V  F  H  K  V  I  S  L  N  C  K  Y  S  E  H   
  CGACCACTGTAGTACACACACCCGTCGGTCGTAGGACAAGAGGTAGGGACTACGACAGAAGGTGTTTCACTAGAGGAATTTAACATTTATAAGACTTGTA 
           610       620       630       640       650       660       670       680       690  
   
  CATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCCTCCTCTCCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGACTTTGTTTC  < 800 
  H  G  F  L  A  S  V  Y  Q  H  N  I  F  F  L  L  S  M  G  I  I  L  F  C  Y  V  Q  I  L  R  T  L  F  R 
  GTACCCAAGAACCGGAGTCAGATGGTCGTGTTGTAGAAGAAGGAGGAGAGGTACCCTTAGTAGGATAAGACAATACATGTCTAAGAGTCCTGAAACAAAG 
           710       720       730       740       750       760       770       780       790  
   
  GCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTTCACCGTCGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACACTCTTCCT  < 900 
    T  R  S  R  Q  R  H  R  T  V  R  L  I  F  T  V  V  V  A  Y  F  L  S  W  A  P  Y  N  L  T  L  F  L  
  CGTGTTCCAGGTCTGTCTCTGTGGCTTGTCAGTCCGAGTAGAAGTGGCAGCACCATCGTATGAAGGAGTCGACCCGAGGGATGTTGGAGTGTGAGAAGGA 
           810       820       830       840       850       860       870       880       890  
   
  GAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAACTGGACATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAAC  < 1000 
   K  T  G  I  I  Q  Q  S  C  E  S  L  Q  Q  L  D  I  A  M  I  I  C  R  H  L  A  F  S  H  C  C  F  N   
  CTTTTGACCTTAGTAGGTCGTCTCGACACTCTCGGAAGTCGTTGACCTGTAACGATACTAATAGACAGCGGTAAACCGGAAGAGAGTAACGACAAAGTTG 
           910       920       930       940       950       960       970       980       990  
   
  CCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACACCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACTGTTCCCT  < 1100 
  P  V  L  Y  V  F  V  G  I  K  F  R  R  H  L  K  H  L  F  Q  Q  V  W  L  C  R  K  T  S  S  T  V  P  C 
  GGTCACGAAATACAGAAACAACCCTAGTTCAAGGCGTCTGTGGATTTTGTAGAGAAGGTCGTCCAGACCGACACGGCCTTCTGTAGGTCGTGACAAGGGA 
           1010      1020      1030      1040      1050      1060      1070      1080      1090  
 
                                                            >XhoI          >c-Myc tag                                                                            
  GCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGA  < 1200 
    S  P  G  T  F  T  Y  E  G  P  S  F  Y  T  R  T  R  P  L  E  Q  K  L  I  S  E  E  D  L  A  A  N  D  
  CGAGGGGACCATGGAAATGTATACTCCCTGGGAGGAAGATGTGCGCATGCGCCGGCGAGCTCGTCTTTGAGTAGAGTCTTCTCCTAGACCGTCGTTTACT 
           1110      1120      1130      1140      1150      1160      1170      1180      1190  
 
                    >Flag tag                               <M13 Rev                                                             
  TATCCTGGATTACAAGGATGACGACGATAAGGTTTAAACGGCCGGCCGCGGTCATAGCTGTTTCCTGAACAGATCCCGGGTGGCATCCCTGTGACCCCT  < 1299 
   I  L  D  Y  K  D  D  D  D  K  V  *                                                                 
  ATAGGACCTAATGTTCCTACTGCTGCTATTCCAAATTTGCCGGCCGGCGCCAGTATCGACAAAGGACTTGTCTAGGGCCCACCGTAGGGACACTGGGGA 
















                                                                 >T7                           >BamHI                                                                                                     
  CGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAATTTTGTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGG  < 100 
  GCCACCCTCCAGATATATTCGTCTCGAGCAAATCACTTGGCAGTCTTAAAACATTATGCTGAGTGATATCCCGCCGGCCCTTAAGCAGCTGACCTAGGCC 
           10        20        30        40        50        60        70        80        90  
                               >XCR1 CDS                            
  TACCGAGGAGATCTGCCGCCGCGATCGCCATGGAGTCCTCAGGCAACCCAGAGAGCACCACCTTTTTTTACTATGACCTTCAGAGCCAGCCGTGTGAGAA  < 200 
                               M  E  S  S  G  N  P  E  S  T  T  F  F  Y  Y  D  L  Q  S  Q  P  C  E  N  
  ATGGCTCCTCTAGACGGCGGCGCTAGCGGTACCTCAGGAGTCCGTTGGGTCTCTCGTGGTGGAAAAAAATGATACTGGAAGTCTCGGTCGGCACACTCTT 
           110       120       130       140       150       160       170       180       190  
   
  CCAGGCCTGGGTCTTTGCTACCCTCGCCACCACTGTCCTATACTGCCTGGTGTTTCTCCTCAGCCTAGTGGGCAACAGCCTGGTCCTGTGGGTCCTGGTG  < 300 
   Q  A  W  V  F  A  T  L  A  T  T  V  L  Y  C  L  V  F  L  L  S  L  V  G  N  S  L  V  L  W  V  L  V   
  GGTCCGGACCCAGAAACGATGGGAGCGGTGGTGACAGGATATGACGGACCACAAAGAGGAGTCGGATCACCCGTTGTCGGACCAGGACACCCAGGACCAC 
           210       220       230       240       250       260       270       280       290  
  
  AAGTATGAGAGCCTGGAGTCCCTCACCAACATCTTCATCCTCAACCTGTGCCTCTCAGACCTGGTGTTCGCCTGCTTGTTGCCTGTGTGGATCTCCCCAT  < 400 
  K  Y  E  S  L  E  S  L  T  N  I  F  I  L  N  L  C  L  S  D  L  V  F  A  C  L  L  P  V  W  I  S  P  Y 
  TTCATACTCTCGGACCTCAGGGAGTGGTTGTAGAAGTAGGAGTTGGACACGGAGAGTCTGGACCACAAGCGGACGAACAACGGACACACCTAGAGGGGTA 
           310       320       330       340       350       360       370       380       390  
   
  ACCACTGGGGCTGGGTGCTGGGAGACTTCCTCTGCAAACTCCTCAATATGATCTTCTCCATCAGCCTCTACAGCAGCAGCTTCTTCCTGACCATCATGAC  < 500 
    H  W  G  W  V  L  G  D  F  L  C  K  L  L  N  M  I  F  S  I  S  L  Y  S  S  S  F  F  L  T  I  M  T  
  TGGTGACCCCGACCCACGACCCTCTGAAGGAGACGTTTGAGGAGTTATACTAGAAGAGGTAGTCGGAGATGTCGTCGTCGAAGAAGGACTGGTAGTACTG 
           410       420       430       440       450       460       470       480       490  
   
  CATCCACCGCTACCTGTCGGTAGTGAGCCCCCTCTCCACCCTGCGCGTCCCCACCCTCCGCTGCCGGGTGCTGGTGACCATGGCTGTGTGGGTAGCCAGC  < 600 
   I  H  R  Y  L  S  V  V  S  P  L  S  T  L  R  V  P  T  L  R  C  R  V  L  V  T  M  A  V  W  V  A  S   
  GTAGGTGGCGATGGACAGCCATCACTCGGGGGAGAGGTGGGACGCGCAGGGGTGGGAGGCGACGGCCCACGACCACTGGTACCGACACACCCATCGGTCG 
           510       520       530       540       550       560       570       580       590  
 
  ATCCTGTCCTCCATCCTCGACACCATCTTCCACAAGGTGCTTTCTTCGGGCTGTGATTATTCCGAACTCACGTGGTACCTCACCTCCGTCTACCAGCACA  < 700 
  I  L  S  S  I  L  D  T  I  F  H  K  V  L  S  S  G  C  D  Y  S  E  L  T  W  Y  L  T  S  V  Y  Q  H  N 
  TAGGACAGGAGGTAGGAGCTGTGGTAGAAGGTGTTCCACGAAAGAAGCCCGACACTAATAAGGCTTGAGTGCACCATGGAGTGGAGGCAGATGGTCGTGT 
           610       620       630       640       650       660       670       680       690  
   
  ACCTCTTCTTCCTGCTGTCCCTGGGGATTATCCTGTTCTGCTACGTGGAGATCCTCAGGACCCTGTTCCGCTCACGCTCCAAGCGGCGCCACCGCACGGT  < 800 
    L  F  F  L  L  S  L  G  I  I  L  F  C  Y  V  E  I  L  R  T  L  F  R  S  R  S  K  R  R  H  R  T  V  
  TGGAGAAGAAGGACGACAGGGACCCCTAATAGGACAAGACGATGCACCTCTAGGAGTCCTGGGACAAGGCGAGTGCGAGGTTCGCCGCGGTGGCGTGCCA 
           710       720       730       740       750       760       770       780       790  
   
  CAAGCTCATCTTCGCCATCGTGGTGGCCTACTTCCTCAGCTGGGGTCCCTACAACTTCACCCTGTTTCTGCAGACGCTGTTTCGGACCCAGATCATCCGG  < 900 
   K  L  I  F  A  I  V  V  A  Y  F  L  S  W  G  P  Y  N  F  T  L  F  L  Q  T  L  F  R  T  Q  I  I  R   
  GTTCGAGTAGAAGCGGTAGCACCACCGGATGAAGGAGTCGACCCCAGGGATGTTGAAGTGGGACAAAGACGTCTGCGACAAAGCCTGGGTCTAGTAGGCC 
           810       820       830       840       850       860       870       880       890  
   
  AGCTGCGAGGCCAAACAGCAGCTAGAATACGCCCTGCTCATCTGCCGCAACCTCGCCTTCTCCCACTGCTGCTTTAACCCGGTGCTCTATGTCTTCGTGG  < 1000 
  S  C  E  A  K  Q  Q  L  E  Y  A  L  L  I  C  R  N  L  A  F  S  H  C  C  F  N  P  V  L  Y  V  F  V  G 
  TCGACGCTCCGGTTTGTCGTCGATCTTATGCGGGACGAGTAGACGGCGTTGGAGCGGAAGAGGGTGACGACGAAATTGGGCCACGAGATACAGAAGCACC 
           910       920       930       940       950       960       970       980       990  
  
  GGGTCAAGTTCCGCACACACCTGAAACATGTTCTCCGGCAGTTCTGGTTCTGCCGGCTGCAGGCACCCAGCCCAGCCTCGATCCCCCACTCCCCTGGTGC  < 1100 
    V  K  F  R  T  H  L  K  H  V  L  R  Q  F  W  F  C  R  L  Q  A  P  S  P  A  S  I  P  H  S  P  G  A  
  CCCAGTTCAAGGCGTGTGTGGACTTTGTACAAGAGGCCGTCAAGACCAAGACGGCCGACGTCCGTGGGTCGGGTCGGAGCTAGGGGGTGAGGGGACCACG 
           1010      1020      1030      1040      1050      1060      1070      1080      1090  
                                             >XhoI          >c-Myc tag                                                    
  CTTCGCCTATGAGGGCGCCTCCTTCTACACGCGTACGCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATGATATCCTGGATTAC  < 1200 
   F  A  Y  E  G  A  S  F  Y  T  R  T  R  P  L  E  Q  K  L  I  S  E  E  D  L  A  A  N  D  I  L  D  Y   
  GAAGCGGATACTCCCGCGGAGGAAGATGTGCGCATGCGCCGGCGAGCTCGTCTTTGAGTAGAGTCTTCTCCTAGACCGTCGTTTACTATAGGACCTAATG 
           1110      1120      1130      1140      1150      1160      1170      1180      1190  
      >Flag tag                                <M13 Rev                                                      
  AAGGATGACGACGATAAGGTTTAAACGGCCGGCCGCGGTCATAGCTGTTTCCTGAACAGATCCCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTC  < 1300 
  K  D  D  D  D  K  V  *                                                                               
  TTCCTACTGCTGCTATTCCAAATTTGCCGGCCGGCGCCAGTATCGACAAAGGACTTGTCTAGGGCCCACCGTAGGGACACTGGGGAGGGGTCACGGAGAG 
           1210      1220      1230      1240      1250      1260      1270      1280      1290  
   
  C  < 1301 
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Figure 2.2. Schematic and sequence data of plasmids used for antibody testing containing myc-tagged Xcr1 and 
XCR1 inserts. A,B) Schematic overview of A) MR225748 plasmid containing the Xcr1-myc coding sequence and 
B) RC221929 plasmid containing the XCR1-myc coding sequence. C, D) Sequences of C) MR225748 and D) 
RC221929 inserts as provided by manufacturer (Origene). Highlighted regions: Blue – SV40 origin of replication 
and CMV promoter; Red- primers used for sequencing of plasmids (T7 and M13 Rev); Purple - Restriction 
endonuclease sites used for confirming plasmid size following E.Coli amplification (BamHI and XhoI); Orange – 
Coding sequence of desired Xcr1 (MR225748) or XCR1 (RC221929) proteins; Green – C-terminal sequences 
coding for Myc and Flag tag peptides; Pink – hGH termination sequence for 3’ polyadenylation and termination 




also a pCMV6 entry vector with an insert containing the Murine Xcr1 protein coding 
sequence (NCBI reference NM_011798.4) with a C-terminal Myc-DDK tag (Figure 2.2). 
Transfection with pcDNA5/FRT/TO GFP (Addgene #1944), kindly donated by Dr Adrian 
Higginbottom (University of Sheffield), and a TDP-43-C-myc plasmid, kindly donated by Dr 
Yolanda Gibson (University of Sheffield),  were also used to evaluate transfection efficiency 
and optimise transfection conditions. pCMV-PK2 and pCMV-ARMS2-PK2 vectors for use in 
the DiscoverX® PathHunter™ β-arrestin assay were kindly provided by the laboratory of Dr 
Gareth Richards (University of Sheffield).  
2.4.6.2 DH5α E.Coli Transformation and Selection 
To amplify plasmid stock, transformation of competent DH5α E.Coli cells (Invitrogen) was 
performed. E.Coli bacteria stocks were thawed on ice. 50µl of thawed E.Coli was then 
aspirated gently using a 200µl pipette with the pipette tip cut with scissors to minimise 
shear forces introduced to the bacteria during pipetting. This was done to ensure collection 
of cells within the suspension that may have deposited to the bottom of the vial. 50µl of 
E.Coli was then aliquoted in to a pre-chilled (on ice) 1.5ml Eppendorf tube. 1-5µl of plasmid 
(up to 50ng) was then added dropwise to the top of the cells and incubated in ice for 30 
minutes. As a positive control for transformation, 2.5µl (250pg) of the supplied pUC19 
control plasmid (Invitrogen) was added to a separate 1.5ml Eppendorf tube containing 50µl 
of DH5α E.Coli cells. After 30 minutes on ice cells were heat shocked at 42°C, in a pre-heated 
heat block, for 40-45 seconds and then returned immediately to ice for 2 minutes. 950µl of 
pre-warmed (37°C) Super Optimal Broth with Catabolite suppression (SOC) media was then 
added to the 1.5ml Eppendorf tube. Eppendorf tubes were shaken at 225RPM at 37°C for 90 
minutes before 100µl of each transformed culture was streaked across a pre-warmed 
(37°C) agar selection plate containing the appropriate concentration of selective antibiotic 
(Ampicillin 100µg/ml, Kanamycin 50µg/ml). Agar plates were then incubated for 24-72 
hours at 37°C. Individual colonies were then selected and transferred to 5ml lysogeny broth 
(LB) containing the appropriate concentration of antibiotic (Ampicillin 100µg/ml, 
Kanamycin 50µg/ml) within a falcon tube. Transformed E.Coli cultures were then incubated 
overnight (16-18 hours) at 37°C whilst shaking at 225RPM on a rotator plate. 
2.4.6.3 Plasmid Mini-prep and MaxiPrep 
After overnight culture, plasmids were isolated from 1ml transformed E.Coli using the 
Isolate II Plasmid mini-kit (Bioline) according to manufacturer’s instructions for isolation 
of low-copy plasmids. Plasmids from each colony were then preliminarily identified by 
restriction endonuclease digest (see 2.4.6.4). Following confirmation of identity, 500ml of 
LB containing the appropriate concentration of antibiotic (50µg/ml Kanamycin, 100µg/ml 
Ampicillin) was inoculated with 1ml from one of the cultures of E.Coli to provide a larger 
48 
 
bacterial stock. This 500ml culture was then incubated for 18-20 hours at 37°C whilst 
shaking at 225RPM on a rotator plate. Plasmids were isolated from this 500ml culture using 
the Plasmid Maxi kit (Qiagen) using a high speed Avanti J-26 XP centrifuge (Beckman 
Coulter™). Isolated plasmids prepared using the Isolate II Plasmid mini-kit (Bioline) or 
Plasmid Maxi kit (Qiagen) were eluted or resuspended with RNase and DNase free water. 
1µl of each sample was then quantitatively and qualitatively analysed using a NanoDrop 
1000 spectrophotometer (ThermoScientific, USA) and then stored at -80°C until subsequent 
use.  
2.4.6.4 Restriction Endonuclease Digest 
Plasmids isolated from E.Coli were identified by a preliminary restriction endonuclease 
digest to determine the presence of predicted DNA fragment sizes and to provide DNA 
fragments for the subsequent directional cloning of plasmids. Restriction endonuclease 
sites were first identified using the online NEBcutter tool (Vincze, Posfai and Roberts, 2003). 
500ng of plasmid DNA was incubated with the chosen restriction enzymes according to 
manufacturer’s instruction. 10µl of digested plasmid DNA was then loaded in to a 1% 
agarose gel with 2µl 6x protein loading buffer (ThermoFisher). 5µl of GeneRuler 1kb DNA 
ladder (ThermoFisher) was loaded for fragment size reference. Fragments were then 
separated by agarose gel electrophoresis. The separated fragments were imaged within the 
agarose gel using InGenius 3 Gel documentation system (SynGene). 
2.4.6.5 Plasmid Subcloning 
The production pCMV-PK2 plasmids containing the coding sequences of either Xcr1L or 
Xcr1S proteins was achieved by directional cloning of Xcr1L and Xcr1S nucleotide inserts in 
to pCMV-PK2 and pCMV-ARMS2-PK2 vectors. 
Xcr1L and Xcr1S inserts were generated by PCR amplification of the target coding sequences 
from the OriGene MR225748. Coding inserts were cloned in to pCMV-PK2 and pCMV-
ARMS2-PK2 vectors by directional cloning to the vector multiple cloning site as detailed in 
Figure 2.3. PCR of target insert amplicons was performed using the High Fidelity Phusion 
PCR kit (NEB). Due to the high melting temperatures of the primers used, cycling 
parameters were performed using a 2 step PCR protocol composed of a 98°C denaturation 
step for 1 minute, followed by 40 cycles of 98°C for 10 seconds to 72°C for 30 seconds. A 
final elongation step was performed for 10 minutes at 72°C and then returned to 4°C for 
storage. Confirmation of amplicon production was determined by agarose gel 
electrophoresis. 
PCR inserts and vectors were digested with BgIII and HindIII restriction enzymes for 4 
hours at 37°C using 3.1 buffer (NEB). A total of 1µg vector and insert were used for digestion. 
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To prevent autoligation, shrimp alkaline phosphatase (SAP) (NEB) was added to digested 
inserts for 30 minutes at 37°C at a concentration of 1.5µl SAP/µg of insert DNA. All samples 
digested with BgIII and HindIII were then heated to 80°C to inactivate the enzymes. 
Following digestion, vector backbone and inserts were separated by agarose gel 
electrophoresis and purified using the Isolate II PCR and gel kit (Bioline) according to 
manufacturer’s instruction. Target insert and vector were then ligated at a 2:1 molar ratio 
of insert to vector by overnight incubation at 16-18°C with T4 DNA ligase (NEB) according 
to manufacturer’s instruction. 
Recombinant plasmid vectors were then transformed to competent E.Coli for the 
production of plasmid stocks, as detailed in section 2.4.6.1 and 2.4.6.2. Produced plasmids 
are referred to collectively as ‘pCMV-Prolink2 vectors’ and individually as follows: pCMV-
Xcr1L-PK2 (L-PK2); pCMV-Xcr1S-PK2 (S-PK2); pCMV-Xcr1L-ARMS2-PK2 (L-ARMS2); 
pCMV-Xcr1S-ARMS2-PK2 (S-ARMS2). 
2.4.6.6 DNA sequencing 
Conservation of Plasmid coding sequences were determined by DNA sequencing by the Core 
Genomics Facility (University of Sheffield). Sequencing of plasmids obtained from Origene 
was performed using the T7 forward (5’-TAATACGACTCACTATAGGG-3’) and M13 Reverse 
(5’-CAGGAAACAGCTATGACC-3’) primers (Figure 2.2). Sequencing of pCMV-Prolink2 
vectors was performed using a combination of primers targeted to the Xcr1 sequence. 
Confirmation of nucleotide identity was evaluated by FinchTV (GeoSpiza Inc.). Pairwise 
sequence alignment was performed using EMBOSS Needle Nucleotide pairwise alignment 
tool (Rice, Longden and Bleasby, 2000) and/or Serial Cloner Software 
(http://serialbasics.free.fr/Serial_Cloner.html). 
 
2.5 Gene Expression profiling 
2.5.1 DNase Treatment of RNA 
Prior to preparation of cDNA, all RNA samples underwent DNase I treatment after RNA 
isolation. The appropriate RNA quantity required for analysis was treated by DNase I 
(amplification grade; specific activity >10,000 units/mg, ThermoFisher) at a concentration 
ratio of 1µg RNA to 1µl DNase I and prepared according to manufacturer’s instruction.   
DNase-treated RNA was then heated at 72°C for 10 minutes before being placed 
immediately on ice for at least 5 minutes. This ensured sufficient denaturation of RNA 
secondary structure prior to cDNA synthesis and was found to significantly improve the 
reliability and consistency of subsequent cDNA production. 
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   TAGGCGATCGCGATGGCCTGAGTCTAGAGCTCGAGTTCGAAGCTTAACCCTCCA 
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Figure 2.3. Directional cloning of Xcr1L and Xcr1S PCR inserts in to pCMV-Prolink2 vectors. A) Multiple cloning 
site of pCMV-ProLink2 vectors, as provided by manufacturer. BgIII and HindIII restriction sites were used for 
cloning of inserts. ProLink sequence highlighted in red conferred coding sequence for either ProLink2 or 
ARMS2-ProLink2 enzyme donor (ED) tags. B) Coding sequence of Xcr1L protein to be amplified by PCR from 
Origene MR225748 plasmid. Sequence in Red highlights 5’ Sequence that distinguishes Xcr1L from Xcr1S.  C) 
Coding sequence of Xcr1S protein to be amplified by PCR from Origene MR225748 plasmid. D) Details of primers 
used for PCR amplification of Xcr1L and Xcr1S inserts. Underlined sequence corresponds to sequence for 
restriction enzyme recognition. Sequence in italics represents complementary sequence to target amplicon. 
Start codons of Xcr1L and Xcr1S coding sequences are highlighted in bold.  
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2.5.2 Reverse Transcription-PCR 
cDNA was prepared using the High Capacity RNA to cDNA kit (ThermoFisher) according to 
manufacturer’s instruction. RNA samples of ≤1µg/µl of RT enzyme were used. Note that the 
reverse transcription mixture was thoroughly chilled prior to addition to the DNase-treated 
RNA sample. Reverse transcription was performed for 1 hour at 37°C followed by 
inactivation of the transcriptase enzyme for 5 minutes at 95°C. Samples were then stored at 
4° until use or at -80° for long term storage. 
2.5.3 Quantitative Polymerase Chain reaction 
Assessment of mRNA expression was performed via quantitative evaluation of cDNA 
presence by quatitative-PCR (qPCR) using Power SYBR ® master mix (ThermoFisher). 
Primers were designed for the amplification of sequences from Gapdh, Xcr1, Xcl1, Tmem119, 
Cg-Tmed2 and Cg-Xcl1 (Table 2.3). All primers were designed to achieve a melting 
temperature (Tm) of between 61°C and 63°C. qPCR was performed using the Rotor Gene Q 
(Qiagen) Thermal Cycler and associated Rotor Gene Q Series Software (Qiagen). Cycling 
parameters were performed using a two-step protocol that included an initial 10 minute 
incubation at 95°C followed by 40 cycles of 95°C to primer (Tm-5)°C. Cycle threshold (Ct) 
values were obtained by setting a threshold fluorescence that was above the observed 
fluorescent background for each experiment. After cDNA quantification, melt curve analysis 
was performed to determine the specificity of primer amplification by heating the samples 
from 50°C to 99°C at a rate of 10 seconds per 1°C and measuring the associated fluorescence. 
Melt curve analysis is presented by dF/dT, corresponding to the rate of change of 
Fluorescence per change in Temperature. The production of specific amplicons was also 
evaluated by agarose gel electrophoresis. 
2.5.3.1 qPCR analysis 
Ct values of the target amplicons were exported from the provided report of the Rotor Gene 
Q Series Software (Qiagen) to Microsoft Excel (2013). Gene expression was quantified 
according to the relative expression level of the target gene to an internal reference gene, 
otherwise known as the delta Ct method. For evaluation of mouse transcripts the internal 
reference gene used was Gapdh, whilst for evaluation of transcripts from Chinese Hamster 
Ovary (CHO) cells the internal reference gene used was Cg-Tmed2 according to published 
recommendations (Brown 2017).  Comparative expression of target genes between samples 
were calculated according to the difference of the relative target gene expression between 
samples, otherwise known as the delta-delta Ct method (Pfaffl 2001). 










-3’ (Exon 1) 
5’ – 
CTTCACCAAGACCCACAAA 







-3’ (Exon 2) 
5’ – 
CTTCACCAAGACCCACAAA 







-3’ (Exon 2) 
5’- 
GCTTCTGGATCAGCACAAAT 








-3’ (Exon 2) 
5’- 
AATGGTGAAGGTCGGTGTG 
































Table 2.3. Primer sequences used for quantitation of associated genes by qPCR. All primer sequences are 
designed to nucleotide sequences corresponding to mouse genes unless indicated by Cg-prefix to denote 
targeting of primers to associated gene of Cricetulus griseus (Chinese Hamster). Primers targeting Cg-Tmed2 















For some samples, due to the low presence of associated transcripts, the generation of 
amplicons failed to reach the detection threshold. These non-detects were dealt in 
accordance with previous recommendations (McCall et al., 2014). From these 
recommendations it was determined that non-detects would be accounted for by assigning 
a Ct value of 35.  
2.5.3.3 Comparison of Xcr1L and Xcr1S expression 
Due to the structure of Xcr1 and its potential mRNA sequences, amplicons detected by the 
amplification of cDNA by Xcr1S primers also detect the same cDNA as Xcr1L primers. 
Therefore, in order to calculate the difference in expression of Xcr1S-specific to Xcr1L 
amplicons, the component of Xcr1S amplicons that shared the same cDNA origin as that of 
Xcr1L amplicons had to be first subtracted from the total Xcr1S expression. Assuming 100% 
efficient PCR amplification, the expression of Xcr1S-specific amplicons can be determined 
by the subtraction of Xcr1L amplicon expression from Xcr1S amplicon expression. Hence the 
expression of Xcr1S-specific amplicons is determined as follows: 
Xcr1S-specific expression = Xcr1S expression – Xcr1L expression 
Where the expression of Xcr1S and Xcr1L amplicons is determined by the delta Ct method 
with reference to the internal GAPDH reference gene. For all comparisons between Xcr1S 
and Xcr1L expression this correction to Xcr1S expression was first applied. For clarity, all 
references to Xcr1S expression in result sections refers to this Xcr1S-specific calculation. 
The relative expression of Xcr1S amplicons to Xcr1L amplicons has therefore been 
calculated as follows: 
Relative Xcr1S/Xcr1L expression = (Xcr1S expression – Xcr1L expression)  
      Xcr1L expression 
2.5.3.4 Comparison of gene expression changes between biological replicates 
For the evaluation of Xcl1 expression between control primary microglial cultures and 
primary microglial cultures treated with LPS, data was first processed according to the 
recommendations by Willems et al., 2008. This method provides a method to correct for the 
variability in gene expression quantification that typically arises between biological 
replicates. To provide a more robust comparison between control and LPS-treated primary 
microglia, mean Ct values of Xcl1 and the internal Gapdh reference, calculated from their 
respective technical triplicates, were inputted to the supplementary spreadsheet provided 
(Willems, Leyns and Vandesompele, 2008). Mean, SEM and N values from Ct values that 
were log-transformed and mean-centred were then inputted to Prism 7.0 (Graphpad Inc.). 
Statistical comparisons were made by independent T-test. 
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2.5.4 Retrospective microarray analysis 
Microarray data collected from Neuroblastoma Spinal Cord 34 (NSC-34) cells was kindly 
provided by Dr Matthew Stopford. To evaluate the differential expression of RNA arising 
from Xcr1 exon 1 or Xcr1 exon 2, the provided RMA-ALT-SPLICE CHP files were opened with 
the Transcriptomics Analysis Console (Affymetrix). For all data analysed, the performance 
of each array had been evaluated according to quality control metrics recommended by the 
manufacturer using the Affymetrix ® Expression ConsoleTM (Stopford, 2016). The 
comparison between each of the arrays compared by retrospective analysis was therefore 
considered valid according to the assessment of quality control demonstrating consistent 
metrics from each array that did not occur outside the two SD threshold for more than one 
metric.  
Individual probe intensities corresponding to the detection of each exon were then collected 
and averaged to determine the mean probe intensity for the detection of exon 1 and exon 2 
of Xcr1 from 9 independent microarray replicates. The relative difference in expression of 
each exon was then compared by normalisation of mean exon probe intensity to the mean 
exon probe intensity of exon 1. Statistical comparisons were then made by independent t-
test using Prism 7.0 (Graphpad Inc.)  
2.6 Investigation of Xcr1 mRNA sequence composition 
2.6.1  5’ Rapid Amplification of cDNA ends 
mRNA sequences were analysed by 5’ Rapid Amplification of cDNA Ends (RACE) using the 
5’/3’ RACE kit (Sigma) according to manufacturer’s instruction. Target transcripts were 
amplified by two rounds of PCR amplification. The first round of PCR amplification was 
performed using the High Fidelity Phusion PCR kit (NEB). The second round of PCR was 
performed using DreamTaq Hot Start Green PCR master mix. Details of primers used and 
their location in respect to Xcr1 mRNA are detailed in Figure 2.4.  
Produced amplicons were provided to the Core Genomics Facility at the University of 
Sheffield for DNA sequencing with the Sp3 primer. Resultant sequences were inspected 
using FinchTV, with provided sequences deduced from the most prominent nucleotide peak 
at each position. 
2.6.2 Testing of Xcr1 intron retention 
To evaluate the retention of intron 1 within Xcr1 mRNA, PCR was performed using reverse-
transcribed and RT-negative samples of DNase I-treated RNA from 3 x spleen. Forward PCR 
primers tested were located as follows within the Xcr1 intron (for bp location, see appendix 
1) and used in conjunction with the Sp2 Rev primer (figure 2.4): 
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  > Xcr1 Coding sequence (ENSMUST00000182350.1) 
 
  GTTACCTACGTGAAACTCTAGCACTGGAGGAGATCAAAGGAAGCACAAAGCGTACAGACTTGAAACCCTGACATGGACTCAGAGTCAGATGCTCTCAGTA  < 100 
           10        20        30        40        50        60        70        80        90  
   
  TCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTTTTCCAC  < 200 
           110       120       130       140       150       160       170       180       190  
   
  CATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAGAATCTAGAGTCA  < 300 
           210       220       230       240       250       260       270       280       290  
   
  CTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTTGGTTTCTAGGTG  < 400 
           310       320       330       340       350       360       370       380       390  
   
  ACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCCTCTACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATACCTGTCTGTAGT  < 500 
           410       420       430       440       450       460       470       480       490  
      
  GAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCTGCCGTGTGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCCATCCCTGATGCT  < 600 
           510       520       530       540       550       560       570       580       590  
   
  GTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTCTGAACATCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCCTCCTCTCCATGG  < 700 
           610       620       630       640       650       660       670       680       690  
   
  GAATCATCCTATTCTGTTATGTACAGATTCTCAGGACTTTGTTTCGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTTCACCGTCGTGGT  < 800 
           710       720       730       740       750       760       770       780       790  
   
  AGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACACTCTTCCTGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAACTGGACATTGCT  < 900 
           810       820       830       840       850       860       870       880       890  
 
  ATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAACCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACACCTAAAACATCTCT  < 1000 
           910       920       930       940       950       960       970       980       990  
   
  TCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACTGTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACTGA  < 1089 
           1010      1020      1030      1040      1050      1060      1070      1080 
 
Figure 2.4. Primer design for detection of Xcr1 mRNA sequence by 5’ RACE. Detailed sequence corresponds to 
coding sequence of Xcr1 mRNA as described by Ensemble Transcript ID ENSMUST00000182350.1 (Assembly 
GRCm38.p6). 5’ RACE was achieved by first strand cDNA synthesis using primer Sp1 (5’ – 
TGCTGCTGTAGAGGCTGATG – 3’) followed by two subsequent PCR amplifications. The first PCR amplification of 
cDNA utilised Sp2 primer (5’ – CTTCACCAAGACCCACAAAA – 3’) with the oligo-DT primer provided with the 
5’/3’ RACE kit (Sigma). The second PCR amplification utilised Sp3 primer (5’ – GACAATGGTAGAGATGGTGG – 3’) 
with the provided PCR anchor primer. A control PCR amplification utilised a Fwd Ctl primer (5’ – 
GAAACCCTGACATGGACTCA – 3’) in combination with primer Sp3 to confirm successful production of cDNA 
product that was specific to Xcr1 mRNA. Underlined sequences indicate location of sequences to which primers 









Xcr1 Intron Fwd1 5’ - GGATTTAAACCCAACATGTCTATCA – 3’ Location 5799 – 5824bp 
Xcr1 Intron Fwd2 5’ – AGCCCAATTCTCAATCTTGTTA – 3’ Location 5696 – 5618bp 
Xcr1 Intron Fwd3 5’ – TTGATTTCAAGCCTTTCGGT – 3’  Location 5504 – 5523bp 
Xcr1 Intron Fwd4 5’ – GAAAGTGATAGCCAGAAAGGG – 3’ Location 5328 – 5348bp 
Xcr1 Intron Fwd5 5’ – GATGTTCAAGCTTCCTGGTTT – 3’  Location 5192 – 5212bp 
2.7 DiscoverX ™ PathHunter ® β-Arrestin Assay 
To evaluate ligand binding to Xcr1L and Xcr1S isoforms, the DiscoverX ® PathHunter β-
arrestin assay was used (Figure 2.5). Donor Enzyme-Acceptor (EA) expressing parental 
CHO cell lines and pCMV-ProLink 2 (pCMV-PK2) mammalian cloning vectors were kindly 
provided by the laboratory of Dr Gareth Richards. An overall workflow of the assay is 
presented in Figure 2.6. 
2.7.1 Xcl1 application and evaluation of β-arrestin recruitment to Xcr1 isoforms 
After transfection (2.2.5.2) and (where specified) antibiotic selection (2.2.5.2.1), cells were 
dissociated from the flask using cell dissociation buffer (Sigma) and counted in trypan blue 
using Countess II Automated cell counter (ThermoFisher). 5 x 103 cells were then seeded to 
each well of a 384 well plate (details) in 20µl of complete CHO cell media and briefly 
centrifuged to collect cells at the bottom of each well. A sample of 1 x 106 cells were also 
collected and used for RNA collection. Cells were then left for 18-24 hours prior to the 
addition of ligand. 
Recombinant Xcl1 (R&D systems) and his-tagged recombinant Xcl1 (his-Xcl1) (Sino 
Biological) were prepared by serial half-Log10 dilutions in 1x HBSS to achieve 
concentrations between 1 x 10-6 M and 1 x 10-12M final concentration. Recombinant Xcl1 
protein was applied to CHO cells and incubated for 20, 40, 60 or 90 minutes at 37°C. Each 
application was performed in quadruplicate. The PathHunter ® Detection Kit (DiscoverX) 
was then prepared and applied to cells according to manufacturer’s instruction. 
Chemiluminescent detection was performed using an Ensight™ MultiMode Plate Reader 
(Perkin Elmer). Collected luminescence data was exported to Microsoft Excel (2013) and 
subsequently analysed using Prism 7.0 (Graphpad Inc.).  
2.8 Detection of XCR1 within Human Cervical Cord 
All cervical cord sections were obtained from Autopsy donations to the Sheffield Brain 
Tissue Bank (SBTB) that were made with the written consent of the next of kin for the use 












Figure 2.5. DiscoverX® PathHunterTM β-arrestin assay. Schematic illustration of the process by which ligand binding to GPCRs is assayed by the PathHunterTM β-arrestin assay. The assay 
provides a method to measure β-arrestin recruitment to the target GPCR through enzyme fragment complementation (EFC). Parental cell lines constitutively expressing β-arrestin conjugated 
to an enzyme acceptor (EA) were transfected with ProlinkTM2 (PK2) vectors containing a nucleotide insert corresponding to the coding sequence of Xcr1L or Xcr1S proteins that reside in-
frame with a C-terminal enzyme donor (ED) fragment. EFC of the EA and ED domains of the β-galactosidase enzyme occurs as a consequence of ligand binding and β-arrestin-EA conjugate 
recruitment to the ED-tagged GPCR. β-arrestin recruitment to the GPCR is then measured from the production of a chemiluminescent product from β-galactosidase catabolism of the provided 






        
        
        
          
        
        
        








    
    
        
        
        
          
              
Figure 2.6. Workflow of cell preparation and treatment for DiscoverX® PathHunterTM β-arrestin assay. Solid black arrows indicate standard workflow. Red arrows and boxes 
indicate additional, optional cell treatment. Dashed black arrow indicates simultaneous preparation of cells for RNA collection and for seeding to 384 well plate. 
Cells seeded in T25 flasks at a density to achieve 
60-80% confluency at the point of transfection 
Cells Transfected with pCMV-ProLink2 vector 
Media replaced with Complete CHO cell media 
Cells dissociated, counted and seeded to 384 well 
plate 
Xcl1 ligand applied and β-arrestin recruitment 
assayed using PathHunter ® Detection kit 
Selection of cells stably expressing pCMV-ProLink2 
insert by G418 selection (7-10 days) 
Collection of 1 x 106 cells for RNA collection and 









patients and 5 age and gender-matched neurological controls. The SBTB Management 
Board gave ethical approval for use of tissue in this study under the provision to act as a 
Research Tissue Bank as approved by the Scotland A Research Ethics Committee (ref. 
08/MRE00/103). 
Reactivity of the HPA013169 anti-XCR1 antibody (Atlas) within the human cervical cord 
was identified by chromogenic immunohistochemistry using 14µm paraffin-embedded 
sections mounted on to glass slides. Immunohistochemistry was optimised by testing 
antibody concentrations between 0.5µg/ml and 4µg/ml following antigen retrieval. Antigen 
retrieval was tested using a pH6 or a pH9 buffer with heat HIER by pressure cooker or by 
microwaving for 10 minutes at 800W.  
The optimised protocol for the detection of XCR1 by HPA013169 was determined to consist 
of the following steps, using the Rabbit Vectastain ABC detection kit (Vector Labs). Sections 
were first washed with xylene for 2x 5 minutes to remove wax. Sections were then 
rehydrated through sequential 5 minute incubations in absolute ethanol (repeat x2), 95% 
ethanol, 70% ethanol and then in to H2O. Endogenous peroxidase activity was minimised by 
incubation of samples in 3% H2O2 dissolved in methanol, for 20 minutes. Sections were then 
washed for 5 minutes within running tap water. HIER was then performed using a pH6 
antigen retrieval buffer and heated for 10 minutes at full power using an 800W microwave. 
The buffer was then rinsed from sections using tap water until sections were cooled and all 
buffer had been removed and for a further 1 minute beyond this. Sections were then 
incubated in TBS for 5 minutes and then blocked using the normal serum provided with the 
Vectastain ABC kit, prepared according to manufacturer’s instruction, for 30 minutes. 
Blocking solution was then drained from the sections and the HPA013169 antibody added 
to the sections at a concentration of 4µg/ml overnight at 4°C. To maximise section coverage, 
sections were covered with parafilm to prevent loss of the antibody solution. Sections were 
then washed in TBS twice for 5 minutes. The biotinylated anti-Rabbit IgG secondary 
antibody provided with the Vectastain ABC kit and prepared according to manufacturer’s 
instruction, was then added to sections for 30 minutes. Sections were then washed twice in 
TBS for 5 minutes followed by a 30 minute incubation with the prepared ABC reagent. 
Sections were then washed in TBS twice for 5 minutes. The addition of a DAB solution 
(vector labs) was then made to permit the localisation of the HRP-conjugated streptavidin 
used for the detection of primary antibody. This was added to the samples for 10 minutes 
before rinsing continuously with tap water for 5 minutes to stop the production of coloured 
staining produced by DAB oxidation. Cell nuclei were then counterstained by a 60 second 
incubation in Gills Hematoxylin followed by a further 1 minute wash with tap water. Nuclei 
were then coloured blue by immersion in Scott’s tap water for 10 seconds. Sections were 
60 
 
then washed once more in tap water for 1 minute before dehydrating the sections by 
sequential 1 minute incubation in 70%, 95% and 100% (twice) ethanol. Sections were then 
transferred to xylene for 5 minutes prior to the addition of coverslips with DPX mountant. 
Prepared slides were then incubated at 37°C to facilitate the setting of the DPX mountant 
prior to imaging.   
Following optimisation, chromogenic immunohistochemistry for the detection of XCR1 
within the cervical cord of sALS patients and neurological controls was performed by the 
histology team at the Sheffield Institute for Translational Neuroscience (SITraN), University 
of Sheffield. Provided sections were then qualitatively examined and analysed for DAB 
staining as described in section 2.3.2.2.2. 
 
2.9 Statistical analysis and Data Presentation 
Statistical analysis was performed with GraphPad prism v7.03. Comparisons between 
three or more independent groups were made using Ordinary One-Way ANOVA. Post-hoc 
Tukey’s multiple comparison test was performed to compare means between individual 
groups with significance reported as multiplicity adjusted P values. Comparisons between 
two independent groups were performed using the independent T-test. Two-tailed P-
values are reported and corrected for multiple comparisons using the Holm-Sidak method. 
Statistical significance for all comparisons are based on a family-wise error rate of 0.05. (*, 




Chapter 3: An Investigation of Xcr1 and Xcl1 Gene Expression and the Functional 
Assessment of Potential Xcr1 Isoforms 
3.1 Introduction 
To provide an insight in to the presence and expression of Xcr1 and Xcl1 within the mouse 
CNS, this study has focussed on the characterisation of the expression of Xcr1 and Xcl1 
transcripts. An important consideration for the evaluation of Xcr1 expression is the current 
lack of clarity surrounding the functional isoform of the Xcr1 protein (see below). Therefore, 
in addition to assessing Xcr1 gene expression, the functional capacity of proposed Xcr1 
isoforms was also evaluated.  
3.1.1 Xcr1 and Xcl1 gene expression 
The identification of Xcr1 and Xcl1 genes were simultaneously described by several research 
groups during the 1990s. Identification of the mRNA sequence and corresponding proteins 
were achieved by the screening of cDNA libraries produced from a variety of murine 
lymphocyte cell lines. The identification of murine Xcr1 and Xcl1 was supported by the 
parallel description of their Human homologues following similar investigational methods 
in Human cell samples. 
Xcl1 was provisionally described as Lymphotactin based on its capacity to induce 
chemotaxis and Ca2+-flux in a CD8+-enriched lymphoid cell population. Expression of Xcl1 
was localised to a collection of mature and precursor CD8+ thymocyte populations following 
their activation. The Xcl1 sequence corresponded to a 345bp clone, producing a 115aa 
protein (Kelner et al., 1994). Adherence to the systematic nomenclature proposed by 
Zlotnik et al, led to the classification of Lymphotactin as Xcl1 due to the protein representing 
the sole member of the Class C chemokine family in mice (Zlotnik and Yoshie, 2000). The 
relevance of this preliminary biochemical and functional characterisation of Lymphotactin 
was given credence by the original descriptions of the Human XCL1 homologues, 
provisionally described as AcTivation induced And Chemokine-related molecule (ATAC) 
(Muller 1995) and Single Cysteine Molecule-1 (SCM-1) (Yoshida et al., 1995). These two 
descriptions identified expression in activated CD8+ T-cell populations but did not define 
any T-cell population that were sensitive, based on either chemotaxis or Ca2+-flux assays, to 
ATAC (Muller et al., 1995). However, the recognition that homologous XCL1 gene sequences 
were well conserved across mammalian species, including mice, was confirmed (Yoshida et 
al., 1995). 
Subsequent investigations have demonstrated Xcl1 expression to be primarily associated 
with a Th1-type immune response, with Xcl1 expression identified by CD8+ (Kelner et al., 
1994), CD4- CD8-T-Cell Receptor (TCR-)αβ+, TCRγδ+ (Boismenu et al., 1996; Ohta et al., 
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2016) lymphocytes, NK cells (Dorner et al., 2004) and Thymic Medullary Epithelial cells 
(mTECs) (Lei et al., 2011). Based on this cellular expression, Xcl1 expression is therefore 
most readily observed within the large intestine, thymus and spleen (Yue et al., 2014). The 
Xcl1 gene is localised to chromosome 9 in mice and is composed of 3 exons. 
Xcr1 was originally identified following the observation of migratory responses by a murine 
pre-B cell line stably expressing Xcr1 (Yoshida et al., 1999). The coding sequence of Xcr1 
was identified by hybridisation of genomic DNA from C57BL/6 mice with the previously 
characterised Human XCR1 cDNA (Yoshida et al., 1998). The identified coding sequence 
produced a predicted protein of 322aa protein, arising from a 966bp coding sequence, 
which demonstrated a 71% homology to XCR1 (Figure 3.1.1) (Yoshida et al., 1999). The 
authors proposed this coding sequence to lie entirely within a single exon. RT-PCR using 
primers designed within this exon was then used to determine the expression of Xcr1 within 
a CD8+-enriched cell population, isolated from spleen. 
More recent analysis of Xcr1 expression has recognised the presence of 2 exons within the 
Xcr1 gene (Dorner et al., 2009)(Figure 3.1.2). Previous studies had determined the 
expression of Xcr1 within a variety of cell types, with claims of cellular effects being assumed 
based upon the interdependence of functional evidence obtained from both Murine and 
Human cell lines. Evidence included expression of Xcr1 by neutrophils, T-lymphocytes 
(Cairns et al., 2001; Huang et al., 2001; Kurt et al., 2001), NK cells, CD8+-spleen cells (Yoshida 
et al., 1999) and B-cells (Huang et al., 2001).However, all of these studies used primers that 
amplified a sequence located entirely within exon 2. Hence, these studies were susceptible 
to detection of amplicons arising from genomic DNA, something later identified as leading 
to the inaccurate documentation of Xcr1 expression (Dorner et al., 2009). The recognition 
of an additional exon within the Xcr1 gene has since enabled a more reliable assessment of 
Xcr1 mRNA that was not susceptible to genomic DNA contamination due to the intron-
spanning design of primers. This genomic organisation was used to greater refine the 
expression of Xcr1 in specific cell types and tissues and indicated splenic CD8+ DCs (and 
associated non-lymphoid populations) to be the principal expressor of Xcr1 (Dorner et al., 
2002). This evidence has since been expanded to demonstrate the expression of Xcr1 to 
define a distinct population of resident-lymphoid (CD8+) and migratory non-lymphoid 
(CD103+) cross-presenting cDCs in mice (Crozat et al., 2011; Dorner et al., 2009; Kroczek 
and Henn, 2012). A homologous cell population is also supported in Humans, with XCR1 
expression associated with CD141+ cross-presenting DCs (Crozat et al., 2010; Bachem et al., 
2010; Yamazaki et al., 2013). Therefore it should be noted that the previous descriptions of 
Lymphotactin function at T-cells (Kelner et al., 1994) and Xcr1 expression by several cell 
types (see above) were erroneous. Instead, these seminal studies utilising the two-exon  
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>ENA|AB028459|AB028459.1 Mus musculus gene for SCM1 receptor mXCR1, 
complete cds 
  GG AAA AAA AAA TGT TCC TTA ATG ACT TTT ATG TAG TAG CCC AAT TCT CAA TCT TGT TAT AAA TAG TTC ACT AGT GGA ATC  < 80 
              10           20            30           40           50            60           70  
   
  TGG CCC ACA GAC TTT ACT TTT TTG CAG CAT GGA TAA TAA TGA TCC CCA TTC CAA CTA TGT GGA TTT AAA CCC AAC ATG TC  < 160 
                                                                                            M   S  
              90           100          110           120          130          140           150  
   
  T ATC ATT TCA GAT GCT CTC AGT ATC CCT GCA TCC CGC GTC CAG ATG GAG TCC TCT ACA GCC TTT TAT GAT TAT CAT GAT A  < 240 
    I   I   S   D   A   L   S   I   P   A   S   R   V   Q   M   E   S   S   T   A   F   Y   D   Y   H   D   K 
               170          180          190          200           210          220          230  
 
  AA TTG AGT CTT CTA TGT GAG AAC AAT GTC ATC TTC TTT TCC ACC ATC TCT ACC ATT GTC CTG TAC TCT CTG GTA TTT CTC  < 320 
     L   S   L   L   C   E   N   N   V   I   F   F   S   T   I   S   T   I   V   L   Y   S   L   V   F   L    
              250          260           270          280          290           300          310  
   
  CTC AGC CTT GTG GGT AAC AGC CTG GTT TTG TGG GTC TTG GTG AAG TAT GAG AAT CTA GAG TCA CTC ACC AAT ATC TTC AT  < 400 
  L   S   L   V   G   N   S   L   V   L   W   V   L   V   K   Y   E   N   L   E   S   L   T   N   I   F   I  
              330          340          350           360          370          380           390  
   
  C CTC AAC CTG TGT CTC TCA GAC CTG ATG TTC TCC TGT CTA CTG CCT GTG TTG ATC TCA GCA CAA TGG AGT TGG TTT CTA G  < 480 
    L   N   L   C   L   S   D   L   M   F   S   C   L   L   P   V   L   I   S   A   Q   W   S   W   F   L   G 
               410          420          430          440           450          460          470  
   
  GT GAC TTC TTC TGC AAG TTC TTC AAC ATG ATC TTC GGC ATC AGC CTC TAC AGC AGC ATC TTC TTC CTT ACC ATC ATG ACC  < 560 
     D   F   F   C   K   F   F   N   M   I   F   G   I   S   L   Y   S   S   I   F   F   L   T   I   M   T    
              490          500           510          520          530           540          550  
   
  ATC CAC CGA TAC CTG TCT GTA GTG AGC CCC ATC TCT ACT CTG GGT ATC CAT ACC CTC CGC TGC CGT GTG CTG GTG ACA TC  < 640 
  I   H   R   Y   L   S   V   V   S   P   I   S   T   L   G   I   H   T   L   R   C   R   V   L   V   T   S  
              570          580          590           600          610          620           630  
   
  A TGT GTG TGG GCA GCC AGC ATC CTG TTC TCC ATC CCT GAT GCT GTC TTC CAC AAA GTG ATC TCC TTA AAT TGT AAA TAT T  < 720 
    C   V   W   A   A   S   I   L   F   S   I   P   D   A   V   F   H   K   V   I   S   L   N   C   K   Y   S 
               650          660          670          680           690          700          710  
   
  CT GAA CAT CAT GGG TTC TTG GCC TCA GTC TAC CAG CAC AAC ATC TTC TTC CTC CTC TCC ATG GGA ATC ATC CTA TTC TGT  < 800 
     E   H   H   G   F   L   A   S   V   Y   Q   H   N   I   F   F   L   L   S   M   G   I   I   L   F   C    
              730          740           750          760          770           780          790  
   
  TAT GTA CAG ATT CTC AGG ACT TTG TTT CGC ACA AGG TCC AGA CAG AGA CAC CGA ACA GTC AGG CTC ATC TTC ACC GTC GT  < 880 
  Y   V   Q   I   L   R   T   L   F   R   T   R   S   R   Q   R   H   R   T   V   R   L   I   F   T   V   V  
              810          820          830           840          850          860           870  
   
  G GTA GCA TAC TTC CTC AGC TGG GCT CCC TAC AAC CTC ACA CTC TTC CTG AAA ACT GGA ATC ATC CAG CAG AGC TGT GAG A  < 960 
    V   A   Y   F   L   S   W   A   P   Y   N   L   T   L   F   L   K   T   G   I   I   Q   Q   S   C   E   S 
               890          900          910          920           930          940          950  
 
  GC CTT CAG CAA CTG GAC ATT GCT ATG ATT ATC TGT CGC CAT TTG GCC TTC TCT CAT TGC TGT TTC AAC CCA GTG CTT TAT  < 1040 
     L   Q   Q   L   D   I   A   M   I   I   C   R   H   L   A   F   S   H   C   C   F   N   P   V   L   Y    
              970          980           990          1000         1010          1020         1030 
   
  GTC TTT GTT GGG ATC AAG TTC CGC AGA CAC CTA AAA CAT CTC TTC CAG CAG GTC TGG CTG TGC CGG AAG ACA TCC AGC AC  < 1120 
  V   F   V   G   I   K   F   R   R   H   L   K   H   L   F   Q   Q   V   W   L   C   R   K   T   S   S   T  
              1050         1060         1070          1080         1090         1100          1110  
   
  T GTT CCC TGC TCC CCT GGT ACC TTT ACA TAT GAG GGA CCC TCC TTC TAC TGA GAG GAG AGG ATG GGC ACA TGG AGA TGA C  < 1200 
    V   P   C   S   P   G   T   F   T   Y   E   G   P   S   F   Y   *                                         
               1130         1140         1150         1160          1170         1180         1190  
   
  TA TGG GAG GTA AAG GAA GAC AAG GAG AAG TGG ATC AGG AAG GAA AAT ATA ACT GAA GAT ACT ACA GAG GTG TGG AGG AAA  < 1280 
              1210         1220          1230         1240         1250          1260         1270  
   
  GAC ATG ATA CCT ATG GGA AAG TGG CTT CCA GCT GGG CAA GCC AAA GCA ACA CTT TGT GCA CTC AGT TCA TCA TTT ATT CT  < 1360 
              1290         1300         1310          1320         1330         1340          1350  
 
  C TTA CGT AGA CAT AGA TTG CTT GTT AGT GAT GGT CAG AAG ATC CTA AAT AGA AGG ATT TCT AGA CTT TAG AGG GCT TGA A  < 1440 
               1370         1380         1390         1400          1410         1420         1430  
   
  GC TTA TAG TAT GTG CTA ACT GTG CAG TGA TGT TGC TGG TAC ATA GGG  < 1487 
              1450         1460          1470         1480 
Figure 3.1.1. Original description of Xcr1 mRNA and coding sequence. The entire sequence corresponding to the 
detection of Xcr1 mRNA as identified by Yoshida et al., 1999 is presented (obtained from the European 
Nucleotide Archive, access number AB028459). Highlighted in green is the total predicted coding sequence. Two 
alternative start codons are located at position 156 and 204  (indicated by red arrows). Both start codons are 
present in-frame with a Stop Codon at position 1170, producing two potential proteins of 338aa (Start Codon 1) 
and 322aa (Start Codon 2). Start Codon 2 was assumed to represent the canonical start site. The sequence arising 













  GTT ACC TAC GTG AAA CTC TAG CAC TGG AGG AGA TCA AAG GAA GCA CAA AGC GTA CAG ACT TGA AAC CCT GAC ATG GAC TC  < 80 
                                                                                                  M   D   S  
              10           20           30            40           50           60            70  
   
  A GAG TCA GAT GCT CTC AGT ATC CCT GCA TCC CGC GTC CAG ATG GAG TCC TCT ACA GCC TTT TAT GAT TAT CAT GAT AAA T  < 160 
    E   S   D   A   L   S   I   P   A   S   R   V   Q   M   E   S   S   T   A   F   Y   D   Y   H   D   K   L 
               90           100          110          120           130          140          150  
   
  TG AGT CTT CTA TGT GAG AAC AAT GTC ATC TTC TTT TCC ACC ATC TCT ACC ATT GTC CTG TAC TCT CTG GTA TTT CTC CTC  < 240 
     S   L   L   C   E   N   N   V   I   F   F   S   T   I   S   T   I   V   L   Y   S   L   V   F   L   L    
              170          180           190          200          210           220          230  
   
  AGC CTT GTG GGT AAC AGC CTG GTT TTG TGG GTC TTG GTG AAG TAT GAG AAT CTA GAG TCA CTC ACC AAT ATC TTC ATC CT  < 320 
  S   L   V   G   N   S   L   V   L   W   V   L   V   K   Y   E   N   L   E   S   L   T   N   I   F   I   L  
              250          260          270           280          290          300           310  
 
  C AAC CTG TGT CTC TCA GAC CTG ATG TTC TCC TGT CTA CTG CCT GTG TTG ATC TCA GCA CAA TGG AGT TGG TTT CTA GGT G  < 400 
    N   L   C   L   S   D   L   M   F   S   C   L   L   P   V   L   I   S   A   Q   W   S   W   F   L   G   D 
               330          340          350          360           370          380          390  
   
  AC TTC TTC TGC AAG TTC TTC AAC ATG ATC TTC GGC ATC AGC CTC TAC AGC AGC ATC TTC TTC CTT ACC ATC ATG ACC ATC  < 480 
     F   F   C   K   F   F   N   M   I   F   G   I   S   L   Y   S   S   I   F   F   L   T   I   M   T   I    
              410          420           430          440          450           460          470  
   
  CAC CGA TAC CTG TCT GTA GTG AGC CCC ATC TCT ACT CTG GGT ATC CAT ACC CTC CGC TGC CGT GTG CTG GTG ACA TCA TG  < 560 
  H   R   Y   L   S   V   V   S   P   I   S   T   L   G   I   H   T   L   R   C   R   V   L   V   T   S   C  
              490          500          510           520          530          540           550  
   
  T GTG TGG GCA GCC AGC ATC CTG TTC TCC ATC CCT GAT GCT GTC TTC CAC AAA GTG ATC TCC TTA AAT TGT AAA TAT TCT G  < 640 
    V   W   A   A   S   I   L   F   S   I   P   D   A   V   F   H   K   V   I   S   L   N   C   K   Y   S   E 
               570          580          590          600           610          620          630  
   
  AA CAT CAT GGG TTC TTG GCC TCA GTC TAC CAG CAC AAC ATC TTC TTC CTC CTC TCC ATG GGA ATC ATC CTA TTC TGT TAT  < 720 
     H   H   G   F   L   A   S   V   Y   Q   H   N   I   F   F   L   L   S   M   G   I   I   L   F   C   Y    
              650          660           670          680          690           700          710  
   
  GTA CAG ATT CTC AGG ACT TTG TTT CGC ACA AGG TCC AGA CAG AGA CAC CGA ACA GTC AGG CTC ATC TTC ACC GTC GTG GT  < 800 
  V   Q   I   L   R   T   L   F   R   T   R   S   R   Q   R   H   R   T   V   R   L   I   F   T   V   V   V  
              730          740          750           760          770          780           790  
   
  A GCA TAC TTC CTC AGC TGG GCT CCC TAC AAC CTC ACA CTC TTC CTG AAA ACT GGA ATC ATC CAG CAG AGC TGT GAG AGC C  < 880 
    A   Y   F   L   S   W   A   P   Y   N   L   T   L   F   L   K   T   G   I   I   Q   Q   S   C   E   S   L 
               810          820          830          840           850          860          870  
   
  TT CAG CAA CTG GAC ATT GCT ATG ATT ATC TGT CGC CAT TTG GCC TTC TCT CAT TGC TGT TTC AAC CCA GTG CTT TAT GTC  < 960 
     Q   Q   L   D   I   A   M   I   I   C   R   H   L   A   F   S   H   C   C   F   N   P   V   L   Y   V    
              890          900           910          920          930           940          950  
   
  TTT GTT GGG ATC AAG TTC CGC AGA CAC CTA AAA CAT CTC TTC CAG CAG GTC TGG CTG TGC CGG AAG ACA TCC AGC ACT GT  < 1040 
  F   V   G   I   K   F   R   R   H   L   K   H   L   F   Q   Q   V   W   L   C   R   K   T   S   S   T   V  
              970          980          990           1000         1010         1020          1030  
   
  T CCC TGC TCC CCT GGT ACC TTT ACA TAT GAG GGA CCC TCC TTC TAC TGA  < 1089 
    P   C   S   P   G   T   F   T   Y   E   G   P   S   F   Y   *    





















   
      
        
        
        
         
          
           
           
           
      
Figure 3.1.2. Current description of Xcr1 and potential Xcr1 isoforms. A) Schematic illustration of Xcr1 gene 
structure as detailed by Ensemble (Assembly GRCm38.6). Black boxes represent exons separated by intron 1. 
Xcr1 coding sequence highlighted by grey and black solid fill regions. Grey fill = coding sequence from start 
codon 1 to start codon 2; Black fill = coding sequence from start codon 2 to stop codon. B) Coding sequences 
arising from Exon 1 (Orange) and Exon 2 (Green) of Xcr1 mRNA as described by Ensemble database (Assembly 
GRCm38.6, Transcript ID ENSMUST00000182350.1). Alternative Start Codons 1 (position 74) and 2 (position 
122) of Xcr1 mRNA are highlighted with Red Arrows and represent Start Codons of two alternative, in-frame 
sequences of 1014bp (Start codon 1 to Stop codon, Xcr1L) and 966bp (Start Codon 2 to Stop codon, Xcr1S). 
Translated sequence of Xcr1L (338aa) = Blue + Red Amino Acid sequence; Translated Sequence of Xcr1S (322aa) 








structure of Xcr1 have determined the expression of this chemokine receptor to be exclusive 
to the above cross-presenting population of cDCs.  
3.1.2 Xcl1 and Xcr1 expression by cells of the CNS 
Prior to the start of this project there was a scarce amount of published information 
regarding the expression of Xcr1 or Xcl1 transcripts in the CNS. The expression of Xcl1 had 
been investigated in a murine model of neuroinflammation, as a consequence of CNS-
specific expression of the HIV-1 Tat protein (Kim et al., 2004). In this model, an inducible 
HIV-1 Tat sequence was inserted downstream of the astrocyte-specific GFAP promoter. At 
7 days post-induction of Tat expression, Xcl1 expression was evaluated by In-Situ 
Hybridisation (ISH) and by RT-PCR. The expression of Xcl1 was significantly increased to 
~4x that observed in controls within whole brain total RNA samples according to RT-PCR. 
This correlated to an increased production of Xcl1 protein within whole brain homogenates, 
as determined by ELISA. Furthermore, ISH of Xcl1 was colocalised to astrocytes, monocytes 
and macrophage/microglia by dual ISH-IHC for the respective cell markers. Notably, Xcl1 
hybridisation to the ISH probe was not identified in neuronal cells identified by MAP-2 
reactivity. As a further measure of the capacity for XCL1 expression by astrocytes, the 
authors also demonstrated the capacity of Tat expression to activate the XCL1 promoter and 
increase constitutive XCL1 protein secretion in a Human astrocyte cell line (Kim et al., 
2004).  
Further to this evidence, the recent study performed by Zychowska et al., provided a further 
basis to support Xcl1 and Xcr1 mRNA expression by cells of the CNS. In particular, this study 
investigated Rn-Xcl1 (Rattus norvegicus-Xcl1) and Rn-Xcr1 (Rattus norvegicus-Xcr1) 
expression by primary microglial and astrocyte cells obtained from the cortex of rat pups at 
postnatal day 1, following LPS and minocycline treatment. Evidence from quantitative RT-
PCR demonstrated Rn-Xcl1 expression to increase by an average of 400x following LPS 
treatment of primary microglia and an average of 15x following LPS treatment of primary 
astrocytes, in comparison to untreated cells. For both cell types, treatment with minocycline 
caused a reduction in the magnitude of Rn-Xcl1 mRNA increase following LPS treatment. In 
contrast to the increases observed for Rn-Xcl1, evaluation of Rn-Xcr1 expression 
demonstrated a reduction in primary microglia and no change of expression in primary 
astrocytes, following LPS treatment. Interestingly, the decrease in Rn-Xcr1 expression 
observed in microglia was associated with a ~3x increase of Xcr1 protein expression, as 
determined by western blot. No detection of Rn-Xcr1 protein was identified from the lysate 
of primary astrocytes under any experimental condition (Zychowska et al., 2016). However, 




From the little published information that is available, the expression of Xcr1 and Xcl1 by 
cells of the CNS is so far generally indicated as a consequence of inflammatory stimuli. This 
is further supported by the lack of detection of either Xcl1 or Xcr1 related transcripts within 
the CNS of healthy mice, as documented by online transcriptomic databases (see e.g. (Yue 
et al., 2014; Lein et al., 2007). It should be noted, however, that neither of these databases 
evaluates gene expression within the spinal cord.  Despite this evidence, the documentation 
of Xcr1 and Xcl1 expression in the CNS is extremely limited.  
3.1.3 The Xcr1 protein has two potential isoforms 
A survey of the available protein databases reveals a conflict in the consensus of Xcr1 amino 
acid sequence identity. This conflict has arisen as a consequence of the recent identification 
of an additional exon to the Xcr1 gene, as discussed above. Prior to this identification, the 
coding sequence of Xcr1 was assumed to be located entirely within a single exon and 
represent a protein of 322 amino acids (Uniprot Accession no. Q9R0M1; Yoshida et al., 
1999). The annotation of Xcr1 to include an additional exon has led to bioinformatic 
databases to subsequently document  Xcr1 to be instead composed of 338 amino acids, as a 
result of the presence of an additional, in-frame, alternative start codon in Exon 1 (see 
Ensembl CCDS23665; NCBI RefSeq NP_035928.2; UniProt S4R1K3). However, 
bioinformatic records still include the documentation of Xcr1 coding sequences to lie 
entirely within exon 2 as determined from cDNA libraries (European Nucleotide Archive 
Sequence BC141369.1, (Strausberg et al., 2002)).  Figure 3.1.2 illustrates this evidence of 
the two potential Xcr1 isoforms which will from hereafter be referred to as ‘Xcr1L’ (Xcr1-
Long, representing the 338 amino acid protein encoded by the coding sequence beginning 
at Start Codon 1 (Figure 3.1.2, C)) and ‘Xcr1S’ (Xcr1-Short, representing the 322 amino acid 
protein encoded by the coding sequence beginning at Start Codon 2 (Figure 3.1.2, D)). The 
corresponding nucleotide sequences that encode the potential Xcr1L and Xcr1S protein 
isoforms will be referred to as Xcr1L and Xcr1S, respectively. 
The first functional evaluation of Xcr1 was based upon the stable expression of Xcr1S within 
a Murine Precursor B-cell line. Application of Xcl1 demonstrated this to be a specific ligand 
for Xcr1S based on the induction of chemotaxis and Ca2+ mobilisation (Yoshida et al., 1999). 
The only subsequent publication to document Xcr1 function was performed by Luttichau 
(Luttichau, 2008). In this article, the function of both Murine and Human XCL1 homologues, 
along with two viral chemokine mimics (vCCL2 and vCCL3), were evaluated against XCR1 
and Xcr1 which were transiently expressed by COS-7 cells. Importantly, the sequence of 
insert used for the transient transfection of these cells represented a nucleotide sequence 
that included exon 1 of Xcr1 mRNA (GenBank Accession number AK089908.1). Without 
clarification in the article regarding the protein identity produced from this cDNA insert, it 
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is not clear whether the expressed protein used for functional analysis represented Xcr1L 
or Xcr1S.  This investigation demonstrated efficacy of XCL1 only when tested with cells 
expressing XCR1 and not for cells transfected with the Xcr1 insert. In contrast, Xcl1 
demonstrated efficacy at both XCR1 and Xcr1. However, it was noted that relatively high 
concentrations of Xcl1 were required to elicit a response in cells transfected with the Xcr1 
insert, suggesting that Xcl1 had a low potency at the expressed Xcr1 protein. The author 
attributed this feature to the potential impact of an additional N-terminal methionine or the 
lack of appropriate glycosylation to the recombinant Xcl1 protein used for evaluation 
(Luttichau, 2008). However, without clarification of the protein identity produced from the 
transfected Xcr1 vector, the expression of alternate Xcr1 isoforms may also have 
contributed to the lack of Xcl1 potency.   
3.1.4 Functional consequences of proposed Xcr1 isoforms 
Due to the proposed difference in Xcr1L and Xcr1S amino acid sequences to lie within the 
N-terminal domain, there is the potential that such changes could impact various aspects of 
receptor function. The N-terminal domain of GPCRs has been implicated in several essential 
processes that are required for the effective translation, export, trafficking and ligand 
binding of the receptor. These functions rely on the presence of consensus motifs within the 
N-terminal sequence. For example, N-terminal domains may contain hydrophobic signal 
peptide sequences that provide essential signals for the effective export of some GPCRs from 
the endoplasmic reticulum (ER) (Schuelein et al., 2012). In addition, post-translational 
modification of the receptor by N-linked glycosylation at NxS/T motifs can also facilitate the 
integration of the receptor in to the cell membrane (Dong et al., 2007). However, just as the 
N-terminal domain can facilitate efficient transport to the cell membrane, important 
examples have demonstrated how some N-terminal domains actually prevent receptor 
translocation to the cell membrane (Kochl et al., 2002; Alken et al., 2009; Coleman, Ngo and 
Smith, 2017). For these receptors, the lack of signal peptide cleavage reduces presentation 
at the cell membrane whilst also mediating other functions, such as to inhibit receptor 
dimerization or increasing the competency of ligand binding (Jahnsen and Uhlen, 2012; 
Coleman, Ngo and Smith, 2017). 
In relation to ligand binding and receptor activation, N-terminal domains of GPCRs display 
an array of functions. Most typical of these functions is for the N-terminus to mediate 
receptor activation via the provision of essential ligand binding sites. However, yet other 
mechanisms exist by which the N-terminus can modulate receptor activation due to 
qualities that are intrinsic to the N-terminus, or their associated metabolites. This has been 
well documented for the GPCR sub-family of protease activated receptors for which the 




        
       
  
 
     
        
       
         
         
     
     
    
    
     
      
       
        
      
     
     
     
     
        
         
        
         
            
 
Figure 3.1.3. Chemokine receptors: ligand binding and receptor activation. Schematic diagrams have been made 
with reference to motifs found within the Xcr1L sequence according to previous descriptions of GPCR and 
chemokine receptor consensus motifs (Bohm, Grady and Bunnett, 1997).  a) In resting state, chemokine 
receptors, like other GPCRs, exist as a heptahelical transmembrane bundle that associates with an inactive GDP-
bound heterotrimeric G-protein. For Xcr1, the associated G-protein α-subunit is a member of the pertussis-
sensitive Gαi subclass. Chemokines (red schematic) demonstrate a secondary topology consisting of a disordered 
N-terminal domain, that is followed by a succession of three β-strands and a C-terminal alpha helix (Fernandez 
and Lolis, 2002). For Xcr1, a Cysteine residue (aa316) located within the C-terminal domain is consistent with 
that described to be sensitive to palmitoylation and may faciliate membrane anchoring of the C-terminus. b) 
Chemokine binding and signal transduction relies on a two-step binding interaction (see text), following which 
the receptor is stabilised to an active conformation that facilitates the exchange of GDP for GTP to the Gα-subunit. 
This leads to the dissociation of the α and β/γ subunits which then mediate their respective downstream 
signalling cascades. Exposure of intracellular motifs as a consequence of receptor activation permits the 
association of G-protein Receptor Kinases (GRKs). c) GRKs phosphorylate specific motifs,  particularly 
Serine/Threonine residues within the intracellular C-terminus (yellow circles). For Xcr1L, 8 such residues exist 






G-Protein Independent Signalling 
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(between residues 319 and 336). Phosphorylation of these residues may also be mediated by Protein Kinase C 
and/or Protein Kinase A to exert regulation of receptor activity by heterologous desensitisation. 
Phosphorylation of these residues is associated with a conformation the permits the association with arrestins. 
d) Following arrestin recruitment, the interaction between the receptor and any trimeric G-proteins is blocked, 
thereby inhibiting any subsequent G-protein signalling. Arrestin recruitment results in two primary outcomes 
for the membrane-bound GPCR: internalisation or G-protein independent signalling. e) The binding of arrestin 
and stabilisation of the receptor in a particular conformation is thought to expose specific tyrosine containing 
motifs that interact with the clathrin associated protein, AP-2. For GPCRs, an NPxxxY motif is highly conserved 
within transmembrane domain seven and is indeed identified within the Xcr1L sequence. Association of the AP-
2 protein is essential for the subsequent recruitment of clathrin subunits that encapsulate the membrane and 
results in internalisation and subsequent degradation or recycling of the receptor following unbinding of the 
chemokine ligand. f) Arrestin proteins are also capable of stabilising an array of signalling proteins at the 
membrane following binding to the GPCR. This results in the formation of an Arrestin-signalling scaffold that 
can subsequently initiate diverse intracellular, G-protein independent, signalling (Bohm, Grady and Bunnett, 




agonising the receptor from which it was released (Ossovskaya and Bunnett, 2004). N-
terminal domains may also exhibit constitutive agonist activity at the receptor without any 
prior proteolytic processing (Srinivasan et al., 2004). This ‘tethered-agonist’ mechanism 
results in basal activation of the receptor that can be inhibited by the presence of 
antagonistic ligands (Ersoy et al., 2012). In direct contrast to these ‘tethered-agonists’ GPCR 
N-terminal domains may also demonstrate intrinsic suppressive activity that are required 
to constrain agonist-induced and constitutive receptor activation (Belmer et al., 2014). 
Thus, the N-terminal domain contributes to a myriad of receptor functions via an array of 
mechanisms, many of which are only beginning to be appreciated. In direct relation to 
chemokine receptors, current evidence that has been gathered from a select number of the 
chemokine receptor family, indicates a two-step binding mechanism for chemokines at their 
cognate receptor(s) (Allen, Crown and Handel, 2007). In this model, the C-terminal domain 
of the chemokine first binds to the N-terminus and extracellular loops of the receptor. This 
first step of binding precedes a subsequent interaction between the transmembrane helical 
bundle of the receptor and the N-terminal domain of the chemokine ligand. This results in 
the stabilisation of the receptor in an active conformation that is capable of inducing 
subsequent downstream intracellular signalling cascades, via the dissociation of activated 
G-proteins and/or the recruitment of arrestins that can mediate G-protein independent 
signalling (Figure 3.1.3) (Bohm, Grady and Bunnett, 1997; Allen, Crown and Handel, 2007; 
Scheerert and Sommer, 2017).  
In the absence of a resolved, crystallised structure of Xcr1 there is a clear conflict in the 
foundation to the evidence of Xcr1 function: that is, there is no consensus to the amino acid 
sequence of the Xcr1 protein. Xcr1L differs from Xcr1S by the presence of an additional 16 
amino acids within the N-terminal domain. In light of the essential and divergent 
mechanisms by which this domain can contribute to receptor function, the differences 
between these two potential isoforms may therefore have important consequences on 
receptor function. Moreover, the validity of these two potential isoforms is difficult to 
conclude based on sequence analysis alone and has not yet been tested. This is primarily 
due to the small change in sequence length between the two isoforms and because of the 
two alternative start codons lying in-frame with one another within Xcr1 mRNA. Hence the 
two isoforms exhibit highly similar amino acid sequences. Furthermore, whilst functional 
evaluations of Xcr1S have been performed, the evidence provided by Luttichau provides 
some inconsistencies of Xcl1 efficacy at this receptor, a result that may be associated with 
the use of a coding sequence that is capable of producing both of the potential Xcr1 isoforms.   
In reviewing this evidence, it cannot be discounted that the initial functional 
characterisation of Xcr1 (Yoshida et al., 1999) may have provided evidence for a protein 
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that does not accurately reflect the Xcr1 receptor expressed endogenously in vivo. The more 
recent identification of an additional exon to the Xcr1 gene, provides an alternative start 
codon that lies upstream and in-frame to that assumed for Xcr1S. Consequently, the 
endogenously produced protein arising from the translation of Xcr1 mRNA may therefore 
represent either Xcr1S, Xcr1L or a combination of the two. Further complexity to this arises 
from the potential array of mechanisms that regulate the transcriptional identity of Xcr1 
mRNA itself, as has been observed for other chemokine receptors (Mummidi et al., 2007; 
Wierda and van den Elsen, 2012). Consequently transcriptional regulation that may 
influence the composition of Xcr1 mRNA may therefore influence the amino acid 
composition of the produced Xcr1 protein. An investigation in to the function of Xcr1L and 
Xcr1S and an interrogation of their associated genetic transcripts is therefore necessary to 
validate the existing description of Xcr1. 
3.1.5 Aims  
The focus of this study has been to determine a method to examine the expression of both 
Xcr1 and Xcl1 transcripts. In particular, the aim was to provide a method that would 
accurately quantify the expression of Xcr1 transcripts that reflects the expression of the 
potential Xcr1 isoforms. This assessment of Xcr1-related transcripts was performed in a 
variety of cell types and tissues from the CNS, alongside the evaluation of Xcl1 expression, 
to further validate and expand upon the expression patterns of Xcr1 and Xcl1 observed by 
others. In order to clarify the functional isoform of the Xcr1 protein, an in vitro assay of β-
arrestin recruitment was utilised in order to test the ligand binding and receptor activation 
of Xcr1L and Xcr1S, with the aim of providing clear evidence regarding the functional 













3.2.1 Assessment of Xcr1 and Xcl1 expression in the CNS 
3.2.1.1 Optimisation of Xcr1- and Xcl1- specific primers 
To reliably detect the expression of target mRNA transcripts, primers were evaluated for 
specificity to the target cDNA by agarose gel electrophoresis and melt-curve analysis of the 
produced DNA amplicons following the determined qPCR protocol. Primers designed to 
Xcr1-related transcripts were either designed to produce an amplicon that spanned intron 
1 (Xcr1L) or an amplicon that corresponded to exon 2 only (Xcr1S). These two primer pairs 
utilised the same reverse primer with an alternative forward primer located either in exon 
1 (Xcr1L) or exon 2 (Xcr1S). For the evaluation of Xcl1 mRNA expression, a single, intron-
spanning, primer pair was utilised with the forward primer located in exon 2 and the 
reverse primer located in exon 3 of the Xcl1 gene. To facilitate the simultaneous evaluation 
of Xcr1- and Xcl1-related transcripts from the sample using the same qPCR protocol, each 
primer was designed to achieve a melting temperature within 1°C of one another.  
Testing of primer efficiency was done by serial dilution of spleen cDNA over five Log10 
concentrations using primer concentrations between 0.1µM and 1µM. Primers were 
assessed to achieve an efficiency of 90-100% and an R2 value of >0.98 (Svec et al., 2015).  
Figure 3.2.1 and figure 3.2.2 illustrate the specificity and efficiencies of the primers used for 
the detection of Xcr1L, Xcr1S and Xcl1 cDNA. Xcl1 primers were observed to generate 
competing amplicons at concentrations of 0.5µM and 1µM. These likely arose from primer 
dimerisation based on the presence of these amplicons in negative controls that did not 
contain any cDNA. However, adequate efficiency and a lack of competing amplicon 
production was achieved by reducing the primer concentrations to 0.1µM. Evaluation of 
Xcl1 cDNA was therefore performed using the primers at 0.1µM. Primers used for the 
detection of Xcr1S and Xcr1L sequences were observed to achieve the desired criteria of 
performance at all primer concentrations tested. The produced amplicons using Xcr1L, 
Xcr1S and Xcl1 primers were determined to produce specific amplicons according to melt-
curve analysis and agarose gel electrophoresis. 
3.2.1.2 Validation of DNA-free preparations for cDNA synthesis 
A key consideration to be made for the evaluation of Xcr1S amplicons was the presence of 
contaminating genomic DNA (gDNA) within RNA preparations. Due the intra-exon design 
of Xcr1S primers, gDNA contamination would lead to the false-positive detection of Xcr1S 
mRNA. This contaminating factor was previously identified as leading to the erroneous 
description of Xcr1 expression within various cell types following PCR analysis (Dorner et 
al., 2009; Lei and Takahama, 2012).  
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Figure 3.2.1. Validation of primers for the detection of Xcr1 cDNA. Forward and reverse primers for the detection 
of cDNA containing Xcr1L (A-C, G) and Xcr1S sequences (D-F, G) were tested at concentrations of 1µM, 0.5µM 
and 0.1µM using serially diluted cDNA prepared from spleen. Ct values obtained following qPCR of serially 
diluted spleen cDNA is displayed for the Xcr1L (A) and Xcr1S (D) primers. Melt curve analysis of amplicons 
produced from Xcr1L (B) and Xcr1S (E) primers demonstrate the production of dsDNA that displays a peak of 
fluorescence at a temperature of 80°C (Xcr1L) and 78°C (Xcr1S). (C, F) Linear regression analysis demonstrates 
the linear amplification of amplicons with an efficiency close to that expected (M = -3.332) for the serial Log10 
dilution of cDNA. R2 values demonstrate a strong correspondence of both Xcr1L (C) and Xcr1S (F) data to the 
linear regression model applied. G) Agarose gel electrophoresis illustrates production of amplicons with 




           
          
     
  
   
   
   
        
         






       
      
  
  
   
   
   
   
      
      
      
       
            
Figure 3.2.2. Validation of primers for the detection of Xcl1 cDNA. A) Ct plots obtained from the amplification of 
cDNA produced from spleen using primers specific for Xcl1 cDNA at concentrations of 1µM, 0.5µM and 0.1µM. 
B) Linear regression analysis demonstrates the linear amplification of product to correspond well to the 
observed data, as supported by R2 values. However, the amplification efficiency is above that expected, at 
concentrations of 1µM. Amplicon production using Xcl1 primers at 0.5µM and 0.1µM more closely resembles the 
amplification expected. Melt curve analysis (C, D, E) suggests the production of a non-specific amplicon when 
using primers at 1µM and 0.5µM concentrations (red arrows). Importantly, this amplicon was produced in 
negative controls and accounts for the lack of expected linearity of amplification at these concentrations. Melt 
curve analysis for primers used at 0.1µM, demonstrates a lack of this additional product in all samples, including 
negative controls (E) . F) Agarose gel electrophoresis demonstrates the production of an amplicon within the 
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However, based on the conflicting evidence as to the location of Xcr1 coding sequences and 
also a lack of conformation as to whether Xcr1 mRNA can be composed of only exon 2 or 
exon 1 plus exon 2, or potentially both, the evaluation of Xcr1L and Xcr1S sequences was 
performed independently using the corresponding primers described above (section 
3.2.1.1). In order to support the valid assessment of cDNA sequences arising from mRNA 
only by Xcr1S primers, conformation that the protocol for the production of cDNA lacked 
any genomic DNA contamination was essential. 
A combination of evidence has been used for this. Firstly, confirmation of DNase efficacy 
was determined by incubating cDNA samples produced from spleen with DNase I. 
Subsequent qPCR evaluation demonstrated a complete lack of amplicon expression that was 
supported by absence of amplicon presence following agarose gel electrophoresis of the 
sample. This supported the capacity of DNase I treatment to efficiently eliminate any DNA 
within the RNA sample that would subsequently be used for cDNA production. Secondly, 
reverse transcription negative (RT-) controls were included for each experiment. These 
controls corresponded to the DNase-treated RNA sample that was used for cDNA 
production. Use of this control would indicate the presence of any DNA contamination, 
gDNA or otherwise, that could generate false-positive detection of Xcr1S mRNA. Where 
amplicons were produced, the validity of these amplicons to relate to the specific 
amplification of an Xcr1S sequence was tested by melt curve analysis and/or agarose gel 
electrophoresis (see below). Preliminary evaluations also tested the capacity of the 
untreated RNA sample, collected from spleen, to produce amplicons that were detectable 
by qPCR and hence determine if the RNA collection protocol was capable of providing an 
RNA sample that was devoid of any DNA contamination. This analysis failed to detect any 
amplicon produced by Xcr1S primers demonstrating the RNA collection protocol to provide 
a DNA-free sample, even without DNase treatment. Thirdly, post-hoc analysis of amplicon 
identity by melt curve analysis and/or agarose gel electrophoresis provided additional 
verification that the fluorescent signal detected by qPCR corresponded to the amplification 
of the specific amplicon by confirming the melting temperature and/or amplicon length. 
By combining these three sources of evidence, each experiment to evaluate Xcr1S amplicons 
was confirmed to assess Xcr1S mRNA presence and not reflect the presence of gDNA based 
on the evidence that: i) DNase efficacy was sufficient to abolish any contaminating DNA 
prior to cDNA production; ii) RT- controls lacked the capacity to provide a substrate for 
Xcr1S amplicon production; iii) the RNA collection protocol provided an RNA sample that 
was free of DNA contamination; and iv) post-hoc analysis of amplicon identity could confirm 
the specificity of amplicon production in test cDNA samples whilst also verifying the identity 
of any amplicon produced from RT- controls.  
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Extensive controls have therefore been made to ensure the validity of amplicon production 
from Xcr1S primers to reflect the production of amplicons from RNA only. Consequently, 
unless otherwise stated, all qPCR data presented can be assumed to be free of contaminating 
gDNA and all assessments of Xcr1S expression represent a true indicator of Xcr1S RNA 
presence. 
3.2.1.3 Evaluation of Xcr1L, Xcr1S and Xcl1 expression in whole spinal cord 
Examination of Xcr1L and Xcr1S expression was performed using RNA extracted from the 
whole spinal cord of non-transgenic (NTg) male and female mice at the age of 6 and 10 
months (Figure 3.2.3). This demonstrated a low expression of both Xcr1 isoforms in the 
spinal cord. Considerable variation in the detection of Xcr1L arose from the lack of detected 
amplicons within a number of samples. However, the detection of Xcr1S was more reliable 
and was relatively higher than Xcr1L expression in all samples evaluated. Interestingly, 
within the spinal cord of 6 month mice, particularly for males, this relative increase was 
much higher than that seen for samples collected at 10 months. Indeed, Xcr1S expression 
was observed to be 4.01x and 6.17x higher than Xcr1L for females and males at 6 months of 
age, respectively. This increase was statistically significant for male Xcr1S vs Xcr1L 
expression (p = 0.011) at 6 months. The validity of this relative increase of Xcr1S to Xcr1L 
amplicon detection to reflect a genuine relative change in mRNA expression is supported by 
the observed expression of the two mRNA isoforms in mouse spleen (Figure 3.2.3, A). 
Analysis of the expression of the two Xcr1 isoforms in this sample demonstrates a decreased 
expression of Xcr1S in comparison to Xcr1L, corresponding to a 4.23x higher expression of 
Xcr1L to Xcr1S. Correlation analysis between Xcl1 expression and the expression of the two 
Xcr1 isoforms indicates a very similar correlation of Xcl1 expression with both Xcr1S and 
Xcr1L. 
Evaluation of Xcl1 expression identified a higher and more consistent expression of this 
mRNA than Xcr1 in whole spinal cord RNA. Xcl1 expression was not identified to be 
statistically different between any of the groups tested, suggesting a consistent expression 
of this chemokine for both genders at both 6 and 10 months. 
3.2.1.4 Evaluation of Xcr1L, Xcr1S and Xcl1 expression in mouse motor neurons 
In order to refine the identification of Xcr1 or Xcl1 expression to a particular cell type in the 
CNS, analysis of gene expression was conducted using RNA collected from in vitro samples 
of neurons, astrocytes and microglia.  
Analysis of both Xcr1 isoforms in neurons was performed by qPCR using RNA collected from 
cell cultures of mouse embryonic stem cell (mESC)-derived motor neurons kindly donated 
by Dr Matthew Stopford (University of Sheffield). These cells express Green Fluorescent 
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Protein (GFP) under the transcriptional control of the motor neuron-specific Homeobox 
Protein-9 (HB9) promoter. Motor neurons were obtained by the differentiation of mESCs 
according to the protocol described previously (Haidet-Phillips et al., 2011; Meyer et al., 
2014) to generate a cell sample that was enriched with mouse motor neurons. Cells were 
provided as a cell pellet and processed as described in section 2.2.7. qPCR analysis 
demonstrated an  82x relative expression of Xcr1S in comparison to Xcr1L, however this did 
not achieve statistical significance (Figure 3.2.4). Further support for the higher expression 
of Xcr1 mRNA that does not contain exon 1 arose from the retrospective analysis of 
microarray data collected from NSC-34 cells. In these cells, the signal arising from 
oligonucleotide probes that were specific to exon 2 was 44% higher than that observed for 
probes specific to exon 1. This increase was consistent across analysis of 9 cell samples and 
obtained statistical significance. Moreover, signals arising from oligonucleotide probes that 
spanned exon 1 and exon 2 were not identified within these cells, suggesting that the 
expression of Xcr1 mRNA by NSC-34 cells did not include exon 1 and exon 2 together. 
The expression of Xcl1 mRNA was also identified by qPCR analysis of mESC-derived motor 
neurons. This expression was consistent but low across the 3 samples analysed.  
3.2.1.5 Evaluation of Xcr1L, Xcr1S and Xcl1 in Astrocytes   
qPCR analysis was also performed to evaluate the presence of Xcr1L, Xcr1S and Xcl1 within 
the RNA prepared from primary cortical astrocytes collected from P1 mouse pups, kindly 
donated by Dr Scott Allen (University of Sheffield). Although the cDNA prepared was from 
viable RNA and the results obtained from a valid qPCR protocol, as determined by 
assessment of GAPDH expression and according to positive amplification of control cDNA, 
no detection of Xcr1L, Xcr1S or Xcl1 was observed within these cell samples.    
3.2.1.6 Evaluation of Xcl1 expression in microglia 
Xcl1 was recently described to be expressed by microglia, with this expression being 
sensitive to treatment by LPS and minocycline (Zychowska et al., 2016). However, this 
evidence formed part of a study investigating the function of Xcl1 and Xcr1 within the Mouse 
CNS, but the evaluation of Xcl1 in primary cells was restricted to evidence from primary Rat 
microglial cells collected from P1 rat pups. In order to reconcile the evidence of Xcl1 
expression by primary Rat microglial cells with the proposed expression of Xcl1 by Mouse 
microglia in vivo, primary cultures of Mouse microglia were prepared from NTg mouse 
brains at 10 months of age. To further investigate the proposed sensitivity of microglial Xcl1 
expression, these cells were treated with LPS, according to the protocol performed by 




         
   
   
   
  
   
   
       
           
        
     





Figure 3.2.3. Xcr1L, Xcr1S and Xcl1 expression in the spinal cord. A) Expression of Xcr1L, Xcr1S and Xcl1 in mouse 
spleen (N=3). No statistically significant difference between Xcr1L and Xcr1S expression is observed. B) 
Expression of Xcr1L, Xcr1S and Xcl1 in RNA collected from whole spinal cords of Male and Female NTg mice at 6 
and 10 months of age. No statistically significant difference in expression for either transcript was observed 
following comparison between groups by one-way ANOVA with post-hoc Tukey’s multiple comparison. N = 3 
for all groups. C) Relative expression of Xcr1S to Xcr1L in whole spinal cord of NTg mice. Xcr1S demonstrates 
6.17x higher expression than Xcr1L in NTg male mice at 6 months (*, p = 0.013).  N=3 for all groups. D) Pearson 
correlation identifies a non-significant positive correlation between Xcr1L (dashed red line: r = 0.408, p = 0.188) 
and Xcr1S (dashed blue line: r= 0.4055, p = 0.191) expression to Xcl1 expression. N = 12 for both groups. Error 
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Figure 3.2.4. Evaluation of Xcr1L, Xcr1S and Xcl1 in neuronal cells. A) qPCR analysis of Xcr1L, Xcr1S and Xcl1 in 
RNA isolated from mESC-derived mouse motor neurons demonstrates Xcr1S expression to be 82.77x higher 
than Xcr1L (p = 0.071). A low but consistent amount of Xcl1 expression is also identified. N=3 for each amplicon; 
Error bars = ±SD B) Retrospective analysis of microarray data prepared using RNA collected from NSC-34 cells 
indicates a significantly higher detection of RNA originating from exon 2 than exon 1 of Xcr1 (***, mean 






































































































3.2.1.6.1 Characterisation of microglia 
In order to characterise the purity of microglial cells, immunocytochemical detection of Iba-
1 was performed using control treated primary microglial cultures. As a further 
consideration, due to the protocol of primary cell preparation, cell expression of GFAP was 
also tested by immunocytochemistry. 
Figure 3.2.5 (A, a-c) illustrates the typical composition of the primary cell cultures obtained. 
The cell numbers demonstrating Iba-1 reactivity varied between preparations, suggesting 
the presence of a number of other cells. A low number of these cells (~2%) were astrocytes, 
as indicated by GFAP reactivity. These cells were not numerous and did not distribute 
homogenously, in comparison to Iba-1 positive cells. Overall the cells were therefore 
considered to be composed of mainly microglial cells and supported later analysis to 
evaluate changes that primarily related to that of microglia. 
3.2.1.6.2 Evaluation of Xcl1 expression in primary microglial cultures: Control vs LPS 
treatment 
LPS treatment represents one of the most potent methods to elicit microglial activation 
(Chhor et al., 2013). Quantification of Xcl1 expression by control and LPS-treated primary 
microglial cultures demonstrated a statistically significant reduction in Xcl1 expression 
following LPS treatment, in comparison to their respective controls, in all 3 primary 
microglial cultures evaluated. This reduction corresponded to an expression, following LPS 
treatment, that was 26% lower than that observed for untreated controls (figure 3.2.5, D).   
To further support this change in Xcl1 expression to relate to the activation of microglia, 
semi-quantitative evaluation of Iba-1 reactivity was performed for untreated and LPS 
treated microglial cultures. This demonstrated a 50% increase in Iba-1 reactivity by cells 
treated with LPS in comparison to untreated cells (figure 3.2.5, C). Furthermore, Iba-1-
positive cells treated with LPS adopted a rounded, amoeboid morphology (Figure 3.2.5, 
A(d)) in comparison to the ramified structure of untreated, Iba-1-positive, microglial cells 
(Figure 3.2.5, A(a)).  
3.2.2. Assessment of Xcr1 mRNA sequence : 5’ RACE 
From the data gathered, the discrepancy in detection of amplicons arising from Xcr1S and 
Xcr1L primers suggests an additional component of Xcr1 mRNA that includes exon 2 and 
not exon 1. If Xcr1 mRNA was composed of a single type, it would be expected that qPCR 
detection by Xcr1S and Xcr1L primers would be consistent between one another. 





         
        
    
    
   
    
     
      
  
    
           
         
       
    
     
       
       
       
      
        
         
Figure 3.2.5. Evaluation of Xcl1 expression by primary microglial cell cultures. A) Immunocytochemical detection 
of Iba-1 (red) and GFAP (green) was performed to determine the presence of microglia and astrocytes, 
respectively, in control (CTL) cell cultures (a-c) and in cultures treated for 24 hours with LPS. Note the 
morphological change in Iba-1-positive cells as a consequence of LPS treatment (d) in comparison to CTL (a). B) 
Quantification of Iba-1-positive and GFAP-positive cells in three preparations of primary glia cultures. Iba-1 
positive cells account for the majority of cells within these cultures. C) Semi-quantitative analysis of Iba-1 
reactivity demonstrates a 50% increase by cultures treated for 24 hours with LPS in comparison to their 
respective controls that were treated with media only. D) Evaluation of Xcl1 expression indicates a small but 
consistent decrease as a consequence of LPS treatment by primary microglial cultures in comparison to control 
(*, Mean difference vs CTL = -0.26, p = 0.014). N=3 for both LPS and CTL groups. 
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 > Xcr1 Coding sequence (ENSMUST00000182350.1) 
  GTTACCTACGTGAAACTCTAGCACTGGAGGAGATCAAAGGAAGCACAAAGCGTACAGACTTGAAACCCTGACATGGACTCAGAGTCAGATGCTCTCAGTA  < 100 
           10        20        30        40        50        60        70        80        90  
   
  TCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTTTTCCAC  < 200 
           110       120       130       140       150       160       170       180       190  
   
  CATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAGAATCTAGAGTCA  < 300 
           210       220       230       240       250       260       270       280       290  
   
  CTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTTGGTTTCTAGGTG  < 400 
           310       320       330       340       350       360       370       380       390  
   
  ACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCCTCTACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATACCTGTCTGTAGT  < 500 
           410       420       430       440       450       460       470       480       490  
      
  GAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCTGCCGTGTGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCCATCCCTGATGCT  < 600 
           510       520       530       540       550       560       570       580       590  
   
  GTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTCTGAACATCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCCTCCTCTCCATGG  < 700 
           610       620       630       640       650       660       670       680       690  
   
  GAATCATCCTATTCTGTTATGTACAGATTCTCAGGACTTTGTTTCGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTTCACCGTCGTGGT  < 800 
           710       720       730       740       750       760       770       780       790  
   
  AGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACACTCTTCCTGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAACTGGACATTGCT  < 900 
           810       820       830       840       850       860       870       880       890  
 
  ATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAACCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACACCTAAAACATCTCT  < 1000 
           910       920       930       940       950       960       970       980       990  
   
  TCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACTGTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACTGA  < 1089 




































































    
 
 
> Spleen 1 sequenced product 
 
                              >Unidentified sequence        
                              | 
  TTTTTTGGCCTTCCGAAAGGGGTGGGCAAAATGCCGATTTTTAAATGTGCCGTTTTTTGTTACCTACGTGAAACTCTAGCACTGGAGGAGATCAAAGGAA  < 100 
           10        20        30        40        50        60        70        80        90  
   >Exon1                                                                                >Exon 2        
   |                                                                                     | 
  GCACAAAGCGTACAGACTTGAAACCCTGACATGGACTCAGAGTCAGATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTT  < 200 
           110       120       130       140       150       160       170       180       190  
 
   
  ATGATTATCATGATAAATTGAGTCTTCTAA  < 230 








> Spleen 2 sequenced product 
                                              >5' Flanking        
                                                | 
  TTAAAAAAAAAAACTTTAGTCCAAAATTTCATTTTAAGAAGGGGAAGTTTGAGGCCAGCCTAGACAATTTAATAGAACCTTTATCAAGCTAGGGTTACCT  < 100 
           10        20        30        40        50        60        70        80        90  
                              >Exon 1        
                              | 
  ACGTGAAACTCTAGCACTGGAGGAGATCAAAGGAAGCACAAAGCGTACAGACTTGAAACCCTGACATGGACTCAGAGTCAGATGCTCTCAGTATCCCTGC  < 200 
           110       120       130       140       150       160       170       180       190  
                >Exon 2        
                | 
  ATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTATGATTATCATGATAAATTGAGTCTAAGA  < 264 






























> Spleen 3 sequenced product 
 
 >Polyadenylated 5’ Cap 
        | 
  TCTTTTTTTTTTTTTTTGGGTTTTGGGGAAGATGTAAATCAATGTGTGTCCTTGGTTGAAATTTTTCGAAAAAAAAATGTTCCTTAATGACTTTATGTAG  < 100 
           10        20        30        40        50        60        70        80        90  
                                     >Intron 1        
                                     | 
  TAGCCCAATTCTCAATCTTGTTATAAATAGTTCACTAGTGGAATCTGGCCCACAGACTTTACTTTTTTGCAGCATGGGATATAATGATCCCTATTCCAAC  < 200 
           110       120       130       140       150       160       170       180       190  
                                                                               >Exon 2        
                                                                               | 
  TATGTGGATTTAAACCCAACATGTACTATCATTTCAGATGCTCTCAGTATCCTGCATCCCGCGTCCAGATGGAGTCCTTACAGCCTTTTATGATTATCAT  < 300 
           210       220       230       240       250       260       270       280       290  
 
   
  GATAAATTGAGTTAGAA  < 317 









Figure 3.2.6. Xcr1 mRNA sequence analysis by 5’ RACE. A) Proposed Xcr1 mRNA sequence with annotated 
locations of primers used for 5’ RACE. B) PCR amplification of produced cDNA following 5’ RACE of total RNA 
from 3x spleen and 1x spinal cord samples. A control PCR amplification (Fwd Ctl + Sp3) was used to confirm 
specific reverse transcription of target Xcr1 mRNA by the 5’ RACE protocol. Anchor + Sp3 amplification produced 
amplicons corresponding to sequences that lie upstream to Sp3 binding sequences and are located within the 5’ 
region of Xcr1 mRNA. Region highlighted (dashed red box) corresponds to predicted amplicon size produced 
from 5’ RACE Anchor primer being located at 5’ end of Exon 1 to Sp3 primer. C, D, E) Sequenced products of 5’ 
RACE from spleen 1, 2 and 3. Highlighted regions are confirmed following sequence alignment to Xcr1 mRNA as 
detailed by Ensembl. Nucleotide chromatogram provided below each sequence corresponds to region 
immediately preceding exon 2 (highlighted in blue). F) Agarose gel electrophoresis of amplicons produced 
following PCR amplification of cDNA and RT- RNA samples using exon 2 Sp2 reverse primer in conjunction with: 
Xcr1 intron Fwd 1 (lanes 1) Fwd2 (lanes 2) Fwd3 (Lanes 3) Fwd 4 (lanes 4) Fwd 5 (lanes 5) and Fwd Ctl (Lanes 
6).  Predicted amplicon sizes: Lanes 1, 225bp; Lanes 2, 329bp; Lanes 3, 521bp; Lanes 4, 697bp; Lanes 5, 833bp; 
Lanes 6, 121bp. 
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from these comparisons. Based on evaluation of these methods and according to internal 
controls of qPCR experiments, gDNA contamination does not account for the observed 
discrepancies of Xcr1S and Xcr1L amplicon production.  In order to investigate the potential 
sequence of Xcr1 mRNA and provide further clarity for its quantification, RNA was collected 
from spleen and spinal cord and evaluated by 5’ Rapid Amplification of cDNA Ends (5’ RACE, 
see section 2.7). This method allows the evaluation of mRNA sequence identity by sequence 
specific cDNA production from a sequence that is located downstream (3’) to the unknown 
mRNA transcriptional start site. Subsequent capping of this unknown sequence by 
polyadenylation then permits PCR amplification of the unknown cDNA sequence that can 
be subsequently provided for sequencing. The predicted amplicon size produced from PCR 
amplification of Xcr1, assuming Xcr1 mRNA to be composed of Exon 1 and exon 2, is 255bp 
(anchor primer + exon 1 + exon 2 (to 3’ complement of Sp3)). Any alternative mRNA 
composed of exon 2 only would have to be determined from DNA sequencing. 
Figure 3.2.6 illustrates the results obtained following 5’ RACE of RNA collected from 3x 
spleen and 1x spinal cord samples. All samples were collected from NTg 10 month female 
mice. Preliminary attempts were also made to analyse RNA from spleen that was enriched 
with mRNA, however this was unsuccessful (data not shown). Following 5’ RACE, all 
samples were confirmed to contain Xcr1 mRNA that included both exon 1 and exon 2 by PCR 
amplification of the produced cDNA using a Ctl forward primer located in exon 1 and the 
test Sp3 primer located in exon 2 (Figure 3.2.6, B).  This confirmed the capacity of the 5’ 
RACE protocol to produce cDNA that was specific to Xcr1 mRNA. Notably, the expression of 
this mRNA was considerably lower in spinal cord, as reflected by the intensity of produced 
amplicon from spinal cord RNA. Testing of amplicons produced by the use of the 5’ RACE 
anchor primer in conjunction with the test Sp3 primer, produced a varied composition of 
amplicon sizes. Spleens 2 and 3 demonstrate the most prominent band at an amplicon 
length that far exceeds that expected from the amplification of a sequence composed of exon 
1 and exon 2. For both samples 2 and 3 an amplicon of ~400bp is produced, with an 
additional band of approximately 450bp observed from spleen 2. For the spinal cord 
sample, the most prominent band lies at between 500 and 600bp, which is again far larger 
than would be expected for Xcr1 mRNA that is composed of Exon 1 and exon 2 only.  
However, consistent to all samples was an amplicon with a size of ~250bp. For spleen 1, 
this amplicon was the only observable amplicon. This size corresponds to the predicted 
amplicon size produced from Xcr1 mRNA composed of exon 1 and part of exon 2 (as detailed 
above).  
Subsequent sequencing of the produced amplicons from 5’ RACE reflected the observed 
amplicon production following agarose gel electrophoresis. Sequencing products from 
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spleen corresponded to identifiable regions of the Xcr1 gene sequence, however sequencing 
of products from spinal cord were unable to be clarified due to poor consistency of 
nucleotide sequences and have not been reported.  
For two of the spleen samples characterised, both exon 1 and exon 2 sequences are 
observed as a continuous sequence, supporting Xcr1 mRNA to be composed of exon 1 and 
exon 2. As suggested from the observable amplicon produced by agarose gel 
electrophoresis, sequencing of samples from spleen 1 produced a product that 
corresponded to exon 1 and exon 2. This sequence was well conserved and corresponds to 
the reported mature Xcr1 mRNA sequence (ENSMUST00000182350.1). Furthermore, for 
sequencing of Spleen 2, a sequence that corresponded to the described 5’ flanking sequence 
(located upstream of Exon 1 within Xcr1) plus exon 1 plus exon 2 was identified.  However, 
for both spleen 2 and spleen 3 samples it can be seen from the nucleotide chromatogram 
that the sequence immediately preceding exon 2 has competing nucleotide signals, 
suggesting alternative sequences to exist.  For sequencing of samples from spleen 3, this 
preceding sequence corresponds to the sequence originating from intron 1 of the Xcr1 gene. 
Although the entire sequence was not discernible due to low sequencing fidelity, 
particularly within the 3’ region of DNA, the sequencing product of spleen 3 had a length of 
~370bp. This corresponds well with the most prominent amplicon observed by agarose gel 
electrophoresis. Moreover, the sequencing reaction provided a clear indication of where the 
polyadenylated cap was added, as indicated by the 5’ poly-T sequence highlighted in figure 
3.2.6, E. The presence of this capping sequence is indicative of a consistent point at which 
reverse transcription ends and provides a putative 5’ terminus to an alternative Xcr1 RNA 
species. 
Due to the sequencing reactions providing an indication that Xcr1 mRNA may include an 
intron sequence, PCR was performed using Reverse Transcribed (RT+) and RT- DNase-
treated RNA samples from the test spleens to support the sequenced products to arise from 
RNA sequences only (Figure 3.2.6, F). PCR utilised forward primers located within the 3’ 
region of intron 1 and were coupled with the Sp2 reverse primer in exon 2. In support of the 
detailed sequencing products to arise solely from the amplification of cDNA arising from the 
reverse transcription of RNA and to not include genomic DNA contamination, no amplicons 
were produced in any of the 3 spleen RNA samples without reverse transcription. This 
provides further confidence in the identified sequences to reflect only RNA sequences 
arising from Xcr1. Furthermore, it adds additional support to the use of DNase treatment as 
a method to eradicate gDNA contamination of RNA samples used for genetic analyses (as 




3.2.3 Functional evaluation of proposed Xcr1 isoforms 
There currently exists two proposed proteins arising from the Xcr1 gene. The first of these 
proteins, Xcr1L, is encoded from a sequence arising from exon 1 and exon 2. Xcr1L is 
composed of 338 amino acids and has an estimated molecular weight of 39 kDA. The second 
proposed protein, referred to here as Xcr1S, is translated from a sequence that lies 
exclusively within exon 2. Xcr1S is composed of 322 amino acids and has an estimated 
molecular weight of 37.3 kDA. Confirmation of which of these proteins is expressed in vivo 
has not yet been determined.  
Suggestive evidence for the production of both of these proteins from Xcr1 RNA has been 
provided during the process of this investigation following the transfection of HeLa cells 
with the MR225748 plasmid. Western Blot detection of C-myc from cell lysates prepared 
from these cells, demonstrates the production of two proteins that have very similar 
molecular weights. Treatment of this protein with PNGase was performed to test if these 
proteins may represent a glycosylated and non-glycosylated form of the Xcr1 protein. 
However, conclusive evidence from this treatment could not be made due to enzyme 
treatment resulting in receptor aggregation (Figure 3.2.7). 
To functionally evaluate the two Xcr1 protein isoforms, Xcr1L and Xcr1S, the PathHunter ® 
β-arrestin assay was used to assess ligand binding and receptor activation. The use of this 
assay was used in order to provide an indication of any difference in ligand binding and/or 
receptor activation as a consequence of the divergence in N-terminal amino acid sequences 
between the two receptor isoforms. The assay relies on the transient transfection of 
parental CHO cells with plasmids containing enzyme-donor (ED)-tagged receptor coding 
sequences. The expression of an enzyme-acceptor (EA)-conjugated β-arrestin by the 
parental CHO cell permits assessment of β-arrestin recruitment to the receptor. This is 
achieved by the measurement of luminescence as a consequence of substrate metabolism 
following enzyme fragment complementation (EFC) between the EA and ED. Hence, 
luminescence is only produced following recruitment of β-arrestin to the receptor. 
In order to perform the assay, molecular cloning of insert sequences corresponding to the 
coding sequences of either Xcr1L or Xcr1S in to the desired Prolink cloning vectors first had 
to be achieved. For this investigation, two of the Prolink vectors were used: pCMV-Prolink2 
(PK2) and pCMV-ARMS2-Prolink2 (ARMS2). The two vectors produce alternative C-
terminal ED tags that have different affinities for the EA: proteins produced from ARMS2 
vectors contain a C-terminal ED tag that has a higher affinity for the EA tag than proteins 



















Figure 3.2.7. C-myc detection of alternative Xcr1 proteins within transfected HeLa cells. A) C-myc detection of 
lysate collected from HeLa cells transfected with MR225748 plasmid demonstrates the production of two 
proteins that have a very similar molecular weight. Calculated molecular weights: Red arrow = 41.78kDA; Blue 
arrow = 38.8kDA. Predicted molecular weight of Xcr1L-myc = 42.53 kDa; Xcr1S-myc = 40.84 kDa. Lane a: 
untreated HeLa cell lysate. Lane b: HeLa cell lysate treated by non-denaturing PNGase F deglycosylation. Lane c: 
HeLa cell lystate treated by denaturing PNGase F deglycosylation. The glycosylated nature of these proteins 
could not be concluded due to lack of confirmation of PNGase efficacy that arose from protein aggregation of the 
Xcr1 protein. Aggregation of the protein occurs as a consequence of lysate heating as displayed in Lane c and 
Lane b. B) The capacity of non-denaturing PNGase F treatment to deglycosylate proteins at N-linked 
glycosyslation motifs is confirmed by treatment of the FLAG-tagged WFDC2 protein. Lane a: WFDC2 treated by 
non-denaturing PNGase F treatment results in the expected 19kDA size of the unglycosylated protein. Lane b: 
Untreated WFDC2 protein. Observed sizes for glycosylated and non-glycosylated products were validated 
according to previous observations (Drapkin et al., 2005) and personal correspondence with Ms Hannah Armes 
(University of Sheffield).  
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3.2.3.1 Assessment of ligand binding and β-arrestin recruitment to Xcr1S-ARMS2 and Xcr1L-
ARMS2 
Initial tests of ligand binding to Xcr1L and Xcr1S proteins were performed using L-ARMS2 
and S-ARMS2 plasmids that express the higher affinity C-terminal ARMS2 tag in-frame with 
the respective Xcr1 isoforms. Figure 3.2.8 and Figure 3.2.9 demonstrate the presence of 
Xcr1L and Xcr1S inserts within L-ARMS2 and S-ARMS2 plasmids, respectively. 
Tests were performed using a recombinant mouse Xcl1 protein (produced in E.Coli) and a 
recombinant his-tagged Xcl1 protein (his-Xcl1, produced by Baculovirus-insect cell 
expression). Representative examples of results from the β-arrestin assay are presented in 
figure 3.2.10. Luminescent signal was produced by cells transfected with L-ARMS2 or S-
ARMS2, suggesting recruitment of β-arrestin to both of the receptor isoforms. No 
luminescent signal was observed from non-transfected cells or from cells transfected with 
the empty vector. This supported the luminescent signal observed from cells transfected 
with L-ARMS2 and S-ARMS2 to arise as a consequence of EFC following the valid expression 
of ED-tagged Xcr1L and Xcr1S proteins from the respective plasmids. 
Despite evidence to support the valid expression of the two Xcr1 isoforms, no reproducible 
response was observed following the application of the ligand at any concentration. Instead, 
the level of luminescent signal arising from transfected cells treated with Xcl1 at all 
concentrations remained at a level that was consistent with cells without ligand application. 
Furthermore, sensitivity to the ligand was not influenced by increasing the incubation time 
with Xcl1. 
A consistent observation however, was the significant difference in luminescent signal 
produced by cells transfected with S-ARMS2 and L-ARMS2. For all repeats performed (n=4 
with Xcl1, n=3 with his-Xcl1), regardless of the ligand incubation time or concentration of 
ligand applied, cells transfected with S-ARMS2 produced a consistently higher baseline level 
of luminescence than cells transfected with L-ARMS2. To confirm that this difference in 
luminescence was not a consequence of a difference in the transfection efficiency or 
expression of the associated vector inserts, qPCR was performed to evaluate the expression 
of RNA arising from the transcription of plasmids within transfected cells. This analysis 
demonstrated a high expression of Xcr1 RNA within cells transfected with L-ARMS2 or S-
ARMS2 that was multiple times higher than that observed for the internal reference control, 
TMED2. Cells transfected with L-ARMS2 were indicated to express a lower amount of Xcr1 
mRNA, corresponding to 78% of that observed for cells transfected with S-ARMS2. Given 
the extremely high expression within cells transfected with both plasmids this difference 
was not considered sufficient to account for the higher luminescent signal that was 




A                                
                          BgIII     HindIII  >ProLink         
                            |           |    | 
    ATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTGGGAGGT 
   TAGGCGATCGCGATGGCCTGAGTCTAGAGCTCGAGTTCGAAGCTTAACCCTCCA 
               10        20        30        40        50 
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> Sequenced L-ARMS2 plasmid start codon aligned to predicted L-ARMS2 plasmid 
sequence (Restored BgIII site; Start codon) 
 
Predicted      ----------------ATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGACTCAG 
5'-L-ARMS2     TTTAGTGAACCGTCAGATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGACTCAG 
                               ******************************************** 
 
Predicted      AGTCAGATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTT 
5'-L-ARMS2     AGTCAGATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTT 
               ************************************************************ 
 
Predicted      ATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTTTTCCACCA 
5'-L-ARMS2     ATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTTTTCCACCA 
               ************************************************************ 
 
Predicted      TCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGCCTGG 
5'-L-ARMS2     TCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGCCTGG 
               ************************************************************ 
 
Predicted      TTTTGTGGGTCTTGGTGAAGTATGAGAATCTAGAGTCACTCACCAATATCTTCATCCTCA 
5'-L-ARMS2     TTTTGTGGGTCTTGGTGAAGTATGAGAATCTAGAGTCACTCACCAATATCTTCATCCTCA 
               ************************************************************ 
 
Predicted      ACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAAT 
5'-L-ARMS2     ACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAAT 
               ************************************************************ 
 
Predicted      GGAGTTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCC 
5'-L-ARMS2     GGAGTTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCC 
               ************************************************************ 
C 
> Translated product of sequenced L-ARMS2 plasmid (From start codon) aligned to 
predicted translated product of L-ARMS2 plasmid 
Predicted      MDSESDALSIPASRVQMESSTAFYDYHDKLSLLCENNVIFFSTISTIVLYSLVFLLSLVG 
5'-L-PKII      MDSESDALSIPASRVQMESSTAFYDYHDKLSLLCENNVIFFSTISTIVLYSLVFLLSLVG 
               ************************************************************ 
 
Predicted      NSLVLWVLVKYENLESLTNIFILNLCLSDLMFSCLLPVLISAQWSWFLGDFFCKFFNMIF 
5'-L-PKII      NSLVLWVLVKYENLESLTNIFILNLCLSDLMFSCLLPVLISAQWSWFLGDFFCKFFNMIF 













>Sequenced L-ARMS2 plasmid stop codon aligned to predicted L-ARMS2 plasmid 
sequence(restored hindIII site; C-terminal prolink tag) 
 
3'-Predicted      TATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAACCCAGTGCTTTATGTCTTTGT 
3'-L-PKII         ----------------------------------NNNNNNNNNNNGCTTTATGTCTTTGT 
                                                               *************** 
 
3'-Predicted      TGGGATCAAGTTCCGCAGACACCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAA 
3'-L-PKII         TGGGATCAAGTTCCGCAGACACCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAA 
                  ************************************************************ 
 
3'-Predicted      GACATCCAGCACTGTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTA 
3'-L-PKII         GACATCCAGCACTGTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTA 
                  ************************************************************ 
 
3'-Predicted      CGCAAGCTTCGAAT---------------------------------------------- 
3'-L-PKII         CGCAAGCTTGAGAGGATCCGTGCCATCAAGGGAGACAACCAACCTGTCTGCTCTGACAGC 




> Translated product of sequenced L-ARMS2 plasmid surrounding stop codon aligned 
to predicted translated product (Xcr1L coding sequence; in-frame Prolink tag) 
 
3'-predicted      GIIQQSCESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGIKFRRHLKHLFQQVWLCRKTS 
3'-L-PKII         ---------------------------------LYVFVGIKFRRHLKHLFQQVWLCRKTS 
                                                   *************************** 
 
3'-predicted      STVPCSPGTFTYEGPSFYASFELGG----------------------------------- 
3'-L-PKII         STVPCSPGTFTYEGPSFYASLRGSVPSRETTNLSALTAPGGGGSGGGGSLELAVVLQRRD 
                  ********************:. .                                     
 
3'-predicted      ---------------------------- 




























Figure 3.2.8. Sequencing of L-ARMS2 plasmid. A) Multiple cloning site of prolink2 vectors as provided by 
manufacturer. B) Sequenced region of L-ARMS2 plasmid surrounding start codon. C) Translated product of 
sequenced region from L-ARMS2 start codon. D) Sequenced region of L-ARMS2 surrounding stop codon. Note 
that sequence corresponding to ARMS2-tag sequence (red) does not align as provided sequence from 
manufacturer contains Prolink-tag sequence and not ARMS2 sequence. E) Translated product of sequenced 
region surrounding L-ARMS2 stop codon. F) L-ARMS2 digest with BgIII and HindIII enzymes demonstrate 
products of ~5500bp, ~4500bp and ~1000bp, corresponding to the undigested plasmid, vector backbone and 
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> Sequenced S-ARMS2 plasmid aligned to predicted S-ARMS2 plasmid sequence 
(restored HindIII site; in-frame Prolink Tag) 
predicted          1 ATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGAGTCCTCTACAG     50 
                                                                        
S-ARMS2            1 --------------------------------------------------      0 
 
predicted         51 CCTTTTATGATTATCATGATAAATT----------------GAGTCTTCT     84 
                                                              ||||||||| 
S-ARMS2            1 -------------------------CCNNNNNNNNNNNNNNGAGTCTTCT     25 
 
predicted         85 ATGTGAGAACAATGTCATCTTCTTTTCCACCATCTCTACCATTGTCCTGT    134 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2           26 ATGTGAGAACAATGTCATCTTCTTTTCCACCATCTCTACCATTGTCCTGT     75 
 
predicted        135 ACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGCCTGGTTTTGTGG    184 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2           76 ACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGCCTGGTTTTGTGG    125 
 
predicted        185 GTCTTGGTGAAGTATGAGAATCTAGAGTCACTCACCAATATCTTCATCCT    234 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          126 GTCTTGGTGAAGTATGAGAATCTAGAGTCACTCACCAATATCTTCATCCT    175 
 
predicted        235 CAACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTACTGCCTGTGTTGA    284 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          176 CAACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTACTGCCTGTGTTGA    225 
 
predicted        285 TCTCAGCACAATGGAGTTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTC    334 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          226 TCTCAGCACAATGGAGTTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTC    275 
 
predicted        335 AACATGATCTTCGGCATCAGCCTCTACAGCAGCATCTTCTTCCTTACCAT    384 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          276 AACATGATCTTCGGCATCAGCCTCTACAGCAGCATCTTCTTCCTTACCAT    325 
 
predicted        385 CATGACCATCCACCGATACCTGTCTGTAGTGAGCCCCATCTCTACTCTGG    434 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          326 CATGACCATCCACCGATACCTGTCTGTAGTGAGCCCCATCTCTACTCTGG    375 
 
predicted        435 GTATCCATACCCTCCGCTGCCGTGTGCTGGTGACATCATGTGTGTGGGCA    484 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          376 GTATCCATACCCTCCGCTGCCGTGTGCTGGTGACATCATGTGTGTGGGCA    425 
 
predicted        485 GCCAGCATCCTGTTCTCCATCCCTGATGCTGTCTTCCACAAAGTGATCTC    534 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          426 GCCAGCATCCTGTTCTCCATCCCTGATGCTGTCTTCCACAAAGTGATCTC    475 
 
predicted        535 CTTAAATTGTAAATATTCTGAACATCATGGGTTCTTGGCCTCAGTCTACC    584 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          476 CTTAAATTGTAAATATTCTGAACATCATGGGTTCTTGGCCTCAGTCTACC    525 
 
predicted        585 AGCACAACATCTTCTTCCTCCTCTCCATGGGAATCATCCTATTCTGTTAT    634 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          526 AGCACAACATCTTCTTCCTCCTCTCCATGGGAATCATCCTATTCTGTTAT    575 
 
predicted        635 GTACAGATTCTCAGGACTTTGTTTCGCACAAGGTCCAGACAGAGACACCG    684 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
96 
 
S-ARMS2          576 GTACAGATTCTCAGGACTTTGTTTCGCACAAGGTCCAGACAGAGACACCG    625 
 
predicted        685 AACAGTCAGGCTCATCTTCACCGTCGTGGTAGCATACTTCCTCAGCTGGG    734 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          626 AACAGTCAGGCTCATCTTCACCGTCGTGGTAGCATACTTCCTCAGCTGGG    675 
 
predicted        735 CTCCCTACAACCTCACACTCTTCCTGAAAACTGGAATCATCCAGCAGAGC    784 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          676 CTCCCTACAACCTCACACTCTTCCTGAAAACTGGAATCATCCAGCAGAGC    725 
 
predicted        785 TGTGAGAGCCTTCAGCAACTGGACATTGCTATGATTATCTGTCGCCATTT    834 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          726 TGTGAGAGCCTTCAGCAACTGGACATTGCTATGATTATCTGTCGCCATTT    775 
 
predicted        835 GGCCTTCTCTCATTGCTGTTTCAACCCAGTGCTTTATGTCTTTGTTGGGA    884 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          776 GGCCTTCTCTCATTGCTGTTTCAACCCAGTGCTTTATGTCTTTGTTGGGA    825 
 
predicted        885 TCAAGTTCCGCAGACACCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGC    934 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          826 TCAAGTTCCGCAGACACCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGC    875 
 
predicted        935 CGGAAGACATCCAGCACTGTTCCCTGCTCCCCTGGTACCTTTACATATGA    984 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          876 CGGAAGACATCCAGCACTGTTCCCTGCTCCCCTGGTACCTTTACATATGA    925 
 
predicted        985 GGGACCCTCCTTCTACACAAGCTTCGAAT---------------   1021 
                     |||||||||||||||||||||||| ..|              




> Translated product of sequenced S-ARMS2 plasmid aligned to predicted S-ARMS2 
plasmid sequence (Xcr1S coding sequence; in-frame prolink tag) 
Predicted          1 MESSTAFYDYHDKLSLLCENNVIFFSTISTIVLYSLVFLLSLVGNSLVLW     50 
                              .....|||||||||||||||||||||||||||||||||||| 
S-ARMS2            1 ---------XXXXXSLLCENNVIFFSTISTIVLYSLVFLLSLVGNSLVLW     41 
 
Predicted         51 VLVKYENLESLTNIFILNLCLSDLMFSCLLPVLISAQWSWFLGDFFCKFF    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2           42 VLVKYENLESLTNIFILNLCLSDLMFSCLLPVLISAQWSWFLGDFFCKFF     91 
 
Predicted        101 NMIFGISLYSSIFFLTIMTIHRYLSVVSPISTLGIHTLRCRVLVTSCVWA    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2           92 NMIFGISLYSSIFFLTIMTIHRYLSVVSPISTLGIHTLRCRVLVTSCVWA    141 
 
Predicted        151 ASILFSIPDAVFHKVISLNCKYSEHHGFLASVYQHNIFFLLSMGIILFCY    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          142 ASILFSIPDAVFHKVISLNCKYSEHHGFLASVYQHNIFFLLSMGIILFCY    191 
 
Predicted        201 VQILRTLFRTRSRQRHRTVRLIFTVVVAYFLSWAPYNLTLFLKTGIIQQS    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          192 VQILRTLFRTRSRQRHRTVRLIFTVVVAYFLSWAPYNLTLFLKTGIIQQS    241 
 
Predicted        251 CESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGIKFRRHLKHLFQQVWLC    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-ARMS2          242 CESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGIKFRRHLKHLFQQVWLC    291 
 
Predicted        301 RKTSSTVPCSPGTFTYEGPSFYTSFELGG---------------------    329 
                     ||||||||||||||||||||||||:.                      

















Figure 3.2.9. Sequencing of S-ARMS2 plasmid. A) Multiple cloning site of prolink2 vectors as provided by 
manufacturer. B) Sequenced region of S-ARMS2 plasmid. Note that sequence corresponding to ARMS2-tag 
sequence (red) does not align as provided sequence from manufacturer contains Prolink-tag sequence. C) 
Translated product of sequenced region from S-ARMS2 plasmid. D) S-ARMS2 digest with BgIII and HindIII 
enzymes demonstrate products of ~5500bp, ~4500bp and ~1000bp, corresponding to the undigested plasmid, 











    
    
   
    
   
   
    
     
   
   
    
   
   
         
         
         
      
       
         
        
        
       
        
         
           
         
Figure 3.2.10. Evaluation of β-arrestin recruitment to ARMS2-PK2 conjugated Xcr1L and Xcr1S. A-C) 
Representative examples of measured luminescence following application of recombinant Xcl1 at half-Log10 
concentrations between 10-7M and 10-12M. Luminescence from cells treated without ligand is plotted at 10-
14M.  Xcl1 ligand was applied for 20 (A), 40 (B) or 60 (C) minutes to CHO cells transfected with L-ARMS2 (red) 
or S-ARMS2 (blue). Error bars = ±SD. D) Measured luminescence following application of his-Xcl1 for 60 
minutes. F) qPCR evaluation (n=1) of relative abundance of mRNA arising from L-ARMS2 (red) or S-ARMS2 
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3.2.3.2 Assessment of ligand binding and β-arrestin recruitment to Xcr1S-PK2 and Xcr1L-PK2 
Despite the consistent observation that S-ARMS2 transfected cells produced a higher 
luminescent signal, suggestive of increased β-arrestin recruitment, than cells transfected 
with L-ARMS2, a specific luminescent response to the application of ligand could not be 
determined. Due to the high expression observed by qPCR, it was decided that the high 
affinity ARMS2-ED tag produced by the ARMS2 plasmids may be generating too high of a 
background signal. Therefore, Xcr1L and Xcr1S coding sequences were next cloned in to PK2 
plasmids that express an ED-tag with a lower affinity to the endogenous EA expressed by 
host CHO cells. Figures 3.2.11 and 3.2.12 detail the successful cloning of Xcr1S and Xcr1L 
coding sequences in to S-PK2 and L-PK2 plasmids, respectively. By lowering the affinity, the 
use of PK2 plasmids aimed to maximise the signal-to-noise ratio and aid the identification 
of β-arrestin recruitment that was specific to Xcl1 binding to the respective Xcr1 isoforms. 
As was observed following the use of L-ARMS2 and S-ARMS2 plasmids, no dose-response of 
luminescent signal could be observed to the application of recombinant Xcl1 or his-Xcl1 
from cells transfected with either L-PK2 or S-PK2 plasmids. However, the use of these 
plasmids expressing a lower affinity ED C-terminal tag did reduce background luminescent 
signal. In comparison to cells transfected with ARMS2 plasmids (Figure 3.2.10) the 
luminescent signal obtained from PK2 plasmids (Figure 3.2.13) was much reduced. Notably, 
despite this reduction of background signal the basal level of luminescent signal remained 
significantly higher for cells transfected with S-PK2 plasmid in comparison to L-PK2. 
qPCR analysis sought to determine if this discrepancy in basal luminescent signal could be 
attributed to a variation in expression of the two receptor isoforms within cells transfected 
with S-PK2 or L-PK2 plasmids. Cells transfected with both plasmids demonstrated a high 
and consistent expression of Xcr1 RNA arising from the respective plasmids (figure 3.2.13, 
C). This demonstrated a significant difference between cells transfected with S-PK2 and L-
PK2 plasmids, corresponding to a 1.79x higher expression of Xcr1S within cells transfected 
with S-PK2 in comparison to L-PK2. However, basal luminescent signal remained largely 
consistent despite the variation in relative Xcr1 RNA presence observed between replicates 
of transfection with the same plasmid (figure 3.2.13, D). Moreover, for those cells 
transfected with L-PK2 and S-PK2 plasmids which showed the closest relative Xcr1S RNA 
expression, the difference in basal luminescent signal remained the same as that for those 
with relatively larger differences in RNA expression levels. This suggests that the 
differences in expression of Xcr1 RNA arising from the transcription of plasmid DNA by 
transfected cells does not account for the differences in basal luminescent signal observed 
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                             |           |     | 
    ATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTGGGAGGT 
   TAGGCGATCGCGATGGCCTGAGTCTAGAGCTCGAGTTCGAAGCTTAACCCTCCA 
               10        20        30        40        50 
B 
Predicted          1 ATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGACTCAGAGTCAG     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2              1 ATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGACTCAGAGTCAG     50 
 
Predicted         51 ATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCC    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2             51 ATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCC    100 
 
Predicted        101 TTTTATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCAT    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            101 TTTTATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCAT    150 
 
Predicted        151 CTTCTTTTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCC    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            151 CTTCTTTTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCC    200 
 
Predicted        201 TCAGCCTTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAG    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            201 TCAGCCTTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAG    250 
 
Predicted        251 AATCTAGAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGA    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            251 AATCTAGAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGA    300 
 
Predicted        301 CCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTT    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            301 CCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTT    350 
 
Predicted        351 GGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATC    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            351 GGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATC    400 
 
Predicted        401 AGCCTCTACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATA    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            401 AGCCTCTACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATA    450 
 
Predicted        451 CCTGTCTGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCT    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            451 CCTGTCTGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCT    500 
 
Predicted        501 GCCGTGTGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCC    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            501 GCCGTGTGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCC    550 
 
Predicted        551 ATCCCTGATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTC    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            551 ATCCCTGATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTC    600 
 
Predicted        601 TGAACATCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCC    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            601 TGAACATCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCC    650 
 
Predicted        651 TCCTCTCCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGACT    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 





Predicted        701 TTGTTTCGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTT    750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            701 TTGTTTCGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTT    750 
 
Predicted        751 CACCGTCGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACAC    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            751 CACCGTCGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACAC    800 
 
Predicted        801 TCTTCCTGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAA    850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            801 TCTTCCTGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAA    850 
 
Predicted        851 CTGGACATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTG    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            851 CTGGACATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTG    900 
 
Predicted        901 TTTCAACCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACACC    950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            901 TTTCAACCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACACC    950 
 
Predicted        951 TAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACT   1000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            951 TAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACT   1000 
 
Predicted       1001 GTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACGC   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2           1001 GTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACGC   1050 
 
Predicted       1051 AAGCTTCGAATTGGGAGGT   1069 
                     ||||||||||||||||||| 
L-PK2           1051 AAGCTTCGAATTGGGAGGT   1069 
 
C 
Xcr1               1 MDSESDALSIPASRVQMESSTAFYDYHDKLSLLCENNVIFFSTISTIVLY     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2              1 MDSESDALSIPASRVQMESSTAFYDYHDKLSLLCENNVIFFSTISTIVLY     50 
 
Xcr1              51 SLVFLLSLVGNSLVLWVLVKYENLESLTNIFILNLCLSDLMFSCLLPVLI    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2             51 SLVFLLSLVGNSLVLWVLVKYENLESLTNIFILNLCLSDLMFSCLLPVLI    100 
 
Xcr1             101 SAQWSWFLGDFFCKFFNMIFGISLYSSIFFLTIMTIHRYLSVVSPISTLG    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            101 SAQWSWFLGDFFCKFFNMIFGISLYSSIFFLTIMTIHRYLSVVSPISTLG    150 
 
Xcr1             151 IHTLRCRVLVTSCVWAASILFSIPDAVFHKVISLNCKYSEHHGFLASVYQ    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            151 IHTLRCRVLVTSCVWAASILFSIPDAVFHKVISLNCKYSEHHGFLASVYQ    200 
 
Xcr1             201 HNIFFLLSMGIILFCYVQILRTLFRTRSRQRHRTVRLIFTVVVAYFLSWA    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            201 HNIFFLLSMGIILFCYVQILRTLFRTRSRQRHRTVRLIFTVVVAYFLSWA    250 
 
Xcr1             251 PYNLTLFLKTGIIQQSCESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGI    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
L-PK2            251 PYNLTLFLKTGIIQQSCESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGI    300 
 
Xcr1             301 KFRRHLKHLFQQVWLCRKTSSTVPCSPGTFTYEGPSFY-------    338 
                     ||||||||||||||||||||||||||||||||||||||        








       
       
       
       
       
        
        
       
       
       
        
        
        
        
        
           
    
 
Figure 3.2.11. Characterisation of L-PK2 plasmid. A) Sequence of pCMV-PK2 multiple cloning site, as provided 
by manufacturer. B) Characterised sequence of L-PK2 plasmid following sequencing. Determined sequence of 
plasmid (L-PK2) has been aligned to predicted L-PK2 sequence (Predicted). Restored sites for BgIII and HindIII 
digest (blue) and in-frame PK2 C-terminal tag (red) is confirmed. ORF start codon is highlighted in green. C) 
Predicted translated product from sequenced L-PK2 plasmid (L-PK2) was determined using NCBI ORFfinder 
and aligned to Xcr1 protein sequence (NCBI protein accession number NP_035928.2). In-frame translated PK2 
tag is highlighted in red. D) Restriction digest of L-PK2 plasmid with BgIII and HindIII enzymes produces two 
products of ~4500bp and ~1000bp, corresponding to pCMV-PK2 backbone and Xcr1L insert, respectively 











A                                
                               BgIII                    HindIII         >ProLink         
                                |           |         | 
    ATCCGCTAGCGCTACCGGACTCAGATCTCGAGCTCAAGCTTCGAATTGGGAGGT 
   TAGGCGATCGCGATGGCCTGAGTCTAGAGCTCGAGTTCGAAGCTTAACCCTCCA 
               10        20        30        40        50 
B 
Predicted          1 ATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGAGTCCTCTACAG     50 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2              1 ATCCGCTAGCGCTACCGGACTCAGATCTGCCACCATGGAGTCCTCTACAG     50 
 
Predicted         51 CCTTTTATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTC    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2             51 CCTTTTATGATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTC    100 
 
Predicted        101 ATCTTCTTTTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCT    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            101 ATCTTCTTTTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCT    150 
 
Predicted        151 CCTCAGCCTTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATG    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            151 CCTCAGCCTTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATG    200 
 
Predicted        201 AGAATCTAGAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCA    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            201 AGAATCTAGAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCA    250 
 
Predicted        251 GACCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAG    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            251 GACCTGATGTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAG    300 
 
Predicted        301 TTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCA    350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            301 TTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCA    350 
 
Predicted        351 TCAGCCTCTACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGA    400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            351 TCAGCCTCTACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGA    400 
 
Predicted        401 TACCTGTCTGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCG    450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            401 TACCTGTCTGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCG    450 
 
Predicted        451 CTGCCGTGTGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCT    500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            451 CTGCCGTGTGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCT    500 
 
Predicted        501 CCATCCCTGATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATAT    550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            501 CCATCCCTGATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATAT    550 
 
Predicted        551 TCTGAACATCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTT    600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            551 TCTGAACATCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTT    600 
 
Predicted        601 CCTCCTCTCCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGA    650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            601 CCTCCTCTCCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGA    650 
 
Predicted        651 CTTTGTTTCGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATC    700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            651 CTTTGTTTCGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATC    700 
 
Predicted        701 TTCACCGTCGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCAC    750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 






Predicted        751 ACTCTTCCTGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGC    800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            751 ACTCTTCCTGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGC    800 
 
Predicted        801 AACTGGACATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGC    850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            801 AACTGGACATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGC    850 
 
Predicted        851 TGTTTCAACCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACA    900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            851 TGTTTCAACCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACA    900 
 
Predicted        901 CCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCA    950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            901 CCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCA    950 
 
Predicted        951 CTGTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTAC   1000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            951 CTGTTCCCTGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTAC   1000 
 
Predicted       1001 ACAAGCTTCGAATTGGGAGGT   1021 
                     ||||||||||||||||||||| 
S-PK2           1001 ACAAGCTTCGAATTGGGAGGT   1021 
 
C 
Xcr1               1 MDSESDALSIPASRVQMESSTAFYDYHDKLSLLCENNVIFFSTISTIVLY     50 
                                     |||||||||||||||||||||||||||||||||| 
S-PK2              1 ----------------MESSTAFYDYHDKLSLLCENNVIFFSTISTIVLY     34 
 
Xcr1              51 SLVFLLSLVGNSLVLWVLVKYENLESLTNIFILNLCLSDLMFSCLLPVLI    100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2             35 SLVFLLSLVGNSLVLWVLVKYENLESLTNIFILNLCLSDLMFSCLLPVLI     84 
 
Xcr1             101 SAQWSWFLGDFFCKFFNMIFGISLYSSIFFLTIMTIHRYLSVVSPISTLG    150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2             85 SAQWSWFLGDFFCKFFNMIFGISLYSSIFFLTIMTIHRYLSVVSPISTLG    134 
 
Xcr1             151 IHTLRCRVLVTSCVWAASILFSIPDAVFHKVISLNCKYSEHHGFLASVYQ    200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            135 IHTLRCRVLVTSCVWAASILFSIPDAVFHKVISLNCKYSEHHGFLASVYQ    184 
 
Xcr1             201 HNIFFLLSMGIILFCYVQILRTLFRTRSRQRHRTVRLIFTVVVAYFLSWA    250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            185 HNIFFLLSMGIILFCYVQILRTLFRTRSRQRHRTVRLIFTVVVAYFLSWA    234 
 
Xcr1             251 PYNLTLFLKTGIIQQSCESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGI    300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
S-PK2            235 PYNLTLFLKTGIIQQSCESLQQLDIAMIICRHLAFSHCCFNPVLYVFVGI    284 
 
Xcr1             301 KFRRHLKHLFQQVWLCRKTSSTVPCSPGTFTYEGPSFY-------    338 
                     ||||||||||||||||||||||||||||||||||||||        











       
       
       
       
       
         
         
       
       
       
         
         
         
         
         
         
Figure 3.2.12. Characterisation of S-PK2 plasmid. A) Sequence of pCMV-PK2 multiple cloning site, as provided 
by manufacturer. B) Characterised sequence of S-PK2 plasmid following sequencing. Determined sequence of 
plasmid (S-PK2) has been aligned to predicted S-PK2 sequence (Predicted). Restored sites for BgIII and HindIII 
digest (blue) and in-frame PK2 C-terminal tag (red) is confirmed. ORF start codon is highlighted in green. C) 
Predicted translated product from sequenced S-PK2 plasmid (L-PK2) was determined using NCBI ORFfinder 
and aligned to Xcr1 protein sequence (NCBI protein accession number NP_035928.2). In-frame translated PK2 
tag is highlighted in red. D) Restriction digest of S-PK2 plasmid with BgIII and HindIII enzymes produces two 
products of ~4500bp and ~1000bp, corresponding to pCMV-PK2 backbone and Xcr1S insert, respectively 











          
 
   
   
   
    
   
       
          
      
  
  
   
    
    
   
     
         
           
        
 
Figure 3.2.13. Evaluation of β-arrestin recruitment to PK2 conjugated Xcr1L and Xcr1S. A,B) Mean Luminescent 
signal obtained following the application of recombinant Xcl1 (n=3) (A) or recombinant his-Xcl1 (n=3) (B) to 
CHO cells transfected with L-PK2 and S-PK2 plasmids. Error bars = ±SD. C) qPCR evaluation of Xcr1 RNA 
produced by cells transfected with L-PK2  and S-PK2 plasmids (*, mean difference = 9.93, p = 0.034) n=3, Error 
bars = ±SD. qPCR evaluation was performed using stock cells used for the evaluation of β-arrestin recruitment 
in A and B. D) Plot of mean luminescent signal from cells untreated with ligand against relative Xcr1 RNA 
expression by cells from 3 independent β-arrestin assays of cells transfected with L-PK2 or S-PK2 plasmids. 
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The use of PK2 plasmids was therefore effective in reducing background luminescent signal, 
yet was still unable to provide a specific luminescent signal that was indicative of β-arrestin 
recruitment to the respective Xcr1 isoforms as a consequence of ligand binding. 
Furthermore, luminescent signal arising from cells transfected with S-PK2 maintained a 
consistently higher level of basal luminescent signal than that observed for cells transfected 
with the L-PK2 plasmid in all repeats performed. This is consistent with the evidence 
obtained from cells transfected with ARMS2-plasmids and suggests that despite the 
reduction in background luminescent signal an alternative mechanism was preventing the 
observation of ligand-specific induction of β-arrestin recruitment to Xcr1L or Xcr1S. 
3.2.3.3 Assessment of ligand binding and β-arrestin recruitment to CHO cells stably expressing 
Xcr1L-PK2 or Xcr1S-PK2 
Given the high expression, demonstrated by qPCR, of the two Xcr1 isoforms expressed by 
cells transfected with S-PK2 or L-PK2, CHO cells were next selected for the stable expression 
of plasmid coding sequence by antibiotic selection with G418. By selecting cells with G418 
it was aimed to establish a population of cells that expressed a stable and lower level of the 
plasmid insert. This would permit a lower level of protein expression and reduce the 
possibility for receptor aggregation that may have inhibited the sensitivity of expressed 
Xcr1 isoforms to the applied ligand when using transiently transfected cells, as performed 
previously. 
Successful transfection and expression of the desired plasmids was confirmed by G418 
selection for 10-12 days prior to performing the β-arrestin assay (figure 3.2.14). 
Untransfected cells were typically lost after 5-7 days of antibiotic treatment. In contrast, 
cells transfected with L-PK2 or S-PK2 demonstrated continued cell viability throughout this 
period suggestive of a maintained and stable expression of the plasmid. 
Evaluation of chemiluminescent production from cells transfected with L-PK2 or S-PK2 
plasmids, following G418 selection, did indeed demonstrate the eradication of background 
luminescent signal by cells transfected with L-PK2. Furthermore, the basal level of 
luminescence produced by cells transfected with S-PK2 was also reduced, in comparison to 
cells transfected with the two plasmids that did not undergo G418 selection (Figure 3.2.13). 
This suggested a reduction in the overall expression of the two receptor isoforms within 
cells transfected with L-PK2 and S-PK2 as a consequence of G418 selection. 
This observation is substantiated by the observed reduction of relative Xcr1 RNA presence 
within RNA samples as compared to that observed for cells without G418 selection (Figure 




           







Figure 3.2.14. Evaluation of β-arrestin recruitment to PK2-conjugated Xcr1L and Xcr1S following G418 selection 
of CHO cells. A) G418 selection of CHO cells. Microscope images demonstrate survival of cells transfected with L-
PK2 and S-PK2 plasmids following 9 days of G418 treatment at 2mg/ml. Complete cell death of non-transfected 
CHO cells confirms the efficacy of G418 treatment. Transfected cells were subsequently dissociated and seeded 
to 384 well plates for evaluation of β-arrestin recruitment following the application of recombinant ligands. B) 
Assay of β-arrestin recruitment (n=1) to cells transfected with L-PK2 and S-PK2 following G418 selection as 
shown in A. Error bars = ±SD C) qPCR evaluation (n=1) of Relative Xcr1S expression in RNA extracted from cells 
transfected with L-PK2 and S-PK2 plasmids following G418 selection. Error bars = ±SD. 
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of 1787x for cells transfected with L-PK2 and 19x for cells transfected with S-PK2, in 
comparison to cells transfected with these plasmids that did not undergo G418 selection. As 
suggested by such substantial reductions in cells transfected with L-PK2, cells transfected 
with L-PK2 demonstrated a 164x lower expression of Xcr1 RNA in comparison to cells 
transfected with S-PK2, following G418 selection. Overall, the evaluation of luminescent 
signal and RNA expression confirms the process of G418 selection to successfully reduce 
the expression of both RNA and protein from associated plasmids, although the reduction 
in Xcr1 RNA expression is significantly more prominent in cells transfected with L-PK2. 
Despite the capacity for G418 selection to successfully reduce expression from associated 
plasmids, no dose-response was observed by the cells in response to the application of Xcl1 
ligand. Therefore, despite every effort being made to refine the sensitivity of the assay by 
reducing background luminescence and by reducing expression of receptor isoforms within 
transfected cells, no specific response of either receptor isoform was observed to the 
application of ligand. However, a consistent observation in all experiments was the higher 
level of basal luminescence observed in cells expressing the Xcr1S receptor isoform in 
comparison to cells expressing the Xcr1L isoform. This suggests a higher constitutive 


















The results presented in this chapter have sought to provide some clarity regarding the 
expression of Xcr1 and Xcl1 within the murine CNS. As a consequence of the conflicting 
evidence currently available for Xcr1 mRNA, evaluation of Xcr1 expression has targeted two 
alternative amplicons, namely Xcr1L and Xcr1S. This method aimed to provide an insight as 
to the relative proportion of Xcr1 mRNA arising from exon 1 and exon 2 sequences or exon 
2 sequences only. Furthermore, this study sought to provide the first direct functional 
comparison between the two proposed Xcr1 isoforms and provide evidence to substantiate 
which isoform reflects the Xcr1 protein produced in vivo. 
3.3.1 Xcr1 and Xcl1 expression is low in the murine CNS 
In line with one of the primary objectives of this project the expression of Xcr1 and Xcl1 was 
investigated in whole spinal cord samples. Evaluation of Xcr1 expression within the spinal 
cord of male and female mice at six and 10 months indicated a low expression of Xcr1 RNA 
within these samples. This was regardless of whether evaluation of Xcr1S or Xcr1L 
amplicons was used to determine the expression of this gene. For all investigations 
performed of Xcr1 expression in RNA samples collected from cells or tissue of the CNS, Ct 
values were consistently low (≥ 30). In comparison, evaluation of Xcl1 expression indicated 
the expression of the chemokine ligand to be consistently higher than that obtained for Xcr1 
in whole spinal cord regardless of the age or gender of the sample. This low expression of 
associated RNA was expected based on the lack of previous evidence to suggest that this 
chemokine and its receptor were expressed prominently within the CNS. Indeed, with the 
exception of CXCL12/CXCR4, CX3CL1/CX3CR1, this low expression is in correspondence 
with evidence for other chemokines, for which the expression within cells specific to the 
CNS parenchyma, is typically made in response to inflammatory stimuli with low, if any, 
expression during physiological conditions (Reaux-Le Goazigo et al., 2013).  
Despite the low expression in whole spinal cord samples, it was sought to refine the cellular 
source of Xcr1 and Xcl1 expression using in vitro samples of CNS cells. Evaluation of Xcr1 
expression demonstrated the expression in neuronal cells, a feature that was not observed 
for samples collected from primary astrocytes. This is in concordance with previous 
evidence suggesting a low expression of Xcr1 by primary astrocytes collected from rats 
(Zychowska et al., 2016). Furthermore, no detection of Xcl1 expression was observed by 
primary astrocytes. Should neuronal cells express the Xcr1 protein, this suggests the source 
of Xcl1 to originate from cells other than astrocytes. The results provided here collected 
from a primary cell population enriched with microglia suggest that these cells may 
represent a source of Xcl1 expression within the CNS. Again, this supports the recent 
suggestion that microglia express this chemokine ligand (Zychowska et al., 2016) and is in 
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line with other reports demonstrating the expression of chemokine ligands, most 
prominently of the CC family, by microglia (Lee, Nagai and Kim, 2002; Babcock et al., 2003; 
Kremlev, Roberts and Palmer, 2004). 
3.3.2 Xcl1 expression in NTg primary mouse microglia is only moderately influenced by LPS 
Following on from the recent identification of microglial Xcl1 expression to be significantly 
increased in response to LPS stimuli (Zychowska et al., 2016), this study sought evidence to 
clarify the expression of Xcl1 by murine microglia. LPS treatment has become the standard 
treatment used to induce a potent innate immune response by many cells. The presence of 
LPS leads to the induction of several intracellular signalling cascades as a result of Toll-like 
Receptor 4 (TLR4) engagement. A key outcome of these TLR4-induced cascades is the 
resultant translocation of NF-κβ and AP-1 transcription factors to the nucleus where they 
act as potent inducers of transcription from the genes of pro-inflammatory mediators, 
including chemokines (Lu, Yeh and Ohashi, 2008). LPS treatment of microglia is associated 
with a polarisation towards an activated, cytotoxic (previously referred to as ‘M1’) cellular 
phenotype (Chhor et al., 2013). As such, the influence of LPS stimulation on the expression 
of Xcl1 by microglia was used to provide an indication to the role of this chemokine in the 
innate immune response by microglia. By adopting the same method of LPS treatment for 
the treatment of primary Mouse microglia to that performed by Zychowska et al. for the 
treatment of primary Rat microglia,  it was aimed to provide the first characterisation of the 
Xcl1 response to LPS by Mouse microglia. Furthermore, we sought to test the validity of 
evidence from primary Rat microglia to suggest the expression of Xcl1 by Mouse microglia 
in vivo (Zychowska et al., 2016).  
The primary cell populations used for evaluation of Xcl1 expression were observed to 
predominantly contain microglial cells, as indicated by Iba-1 immunoreactivity, whilst the 
presence of astrocyte cells was limited. The presence of other cells within the culture was 
made necessary according to preliminary attempts that demonstrated the lack of microglial 
cell numbers and viability in cultures from which these additional cells were removed. 
Evaluation of Xcl1 expression in untreated cells suggest that Xcl1 expression is very low 
under physiological conditions. However, a small but consistent change in expression as a 
consequence of LPS treatment was identified in all biological replicates. This equated to an 
observed reduction of ~22% from that of untreated cells and was supported to arise from 
the activation of microglia following LPS treatment according to quantitative analysis of Iba-
1 reactivity and qualitative assessment of cellular morphology. This small reduction in Xcl1 
expression following LPS treatment is in contrast to the observed magnitude of increase in 
Xcl1 expression observed previously (Zychowska et al., 2016).  
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An important distinction of the microglial cells studied here was their origin from adult 
mouse brains in comparison to those collected by Zychowska et al., from neonatal Rat 
brains. This difference in the age and method of cell preparation is likely to influence the 
behaviour of primary microglial cells. Indeed, the contrast in microglial phenotypes 
between neonates and adults suggests a contrast in their behaviour in response to stimuli. 
It has been indicated for example, that the recently described microglial-specific marker 
TMEM119, does not achieve an expression that is characteristic of mature microglia until 
postnatal day 14 in mice (Bennett et al., 2016). This is alongside the changes observed for a 
myriad of other microglial proteins that are dynamically regulated within these cells as a 
consequence of both intrinsic regulatory mechanisms and as a function of cellular cross-talk 
during CNS development and maturation (Tuan Leng et al., 2017). A further consideration 
to this is the sex of animal from which microglial cells are collected. It has been 
demonstrated that the presence of testosterone can influence the contribution of microglia 
to pathological mechanisms within a mouse model of neuropathic pain in vivo (Sorge et al., 
2015), although the influence of sex within in vitro preparations of microglia remains 
unclear. Furthermore, contemporary studies of primary microglia function still include 
preparations from animals of both sexes (see e.g. (Chhor et al., 2013)). For the evidence 
collected here, each preparation was prepared from a group of animals of the same sex. 
However, of the three biological replicates performed, two were collected from female 
animals and one was collected from male animals. Despite this, the consistency of Xcl1 
expression observed suggests that the sex of animal does not influence the expression of 
this gene, either constitutively or in response to LPS. In support of this, levels of Xcl1 
expression observed from RNA samples collected from whole spinal cord did not display 
any significant changes between sexes at either 6 or 10 months of age. Overall, the evidence 
collected here to evaluate Xcl1 expression in primary microglia suggests that these cells 
express a low level of Xcl1 mRNA that is very moderately influenced following LPS 
treatment. 
3.3.3 Evaluation of Xcr1 mRNA composition and expression in the CNS 
The Xcr1 gene is composed of two exons, in comparison to three exons for human XCR1 
(Shinkai et al., 2005). Currently, there is a conflict of evidence regarding both the coding 
sequence and mRNA sequence of Xcr1. Documented cDNA arising from exon 1 and exon 2, 
or exon 2 only does exist. Therefore, we have performed quantitative analysis of Xcr1 RNA 
expression utilising primers that either span exon 1 and exon 2 (Xcr1L) or are located within 
exon 2 only (Xcr1S).  
In an effort to identify if there is the potential for the alternative expression of mRNA 
transcripts arising from Xcr1, a comparative expression of Xcr1L and Xcr1S has been 
113 
 
performed. Due to the nature of this analysis and the potential for confounding factors to 
influence the expression of each transcript, this analysis has been problematic. However, 
evidence has been provided which indicates the differential expression of Xcr1L and Xcr1S 
amplicons within certain samples. For RNA samples collected from whole spinal cord of 
male and female mice at 6 months of age, the relative expression of Xcr1S was higher than 
that observed for Xcr1L, a feature that was not observed for the same samples collected at 
10 months of age. In addition, a more substantial difference was observed between Xcr1S 
and Xcr1L expression in RNA samples collected from mouse motor neurons derived from 
mESCs. Although substantial, this difference did not achieve statistical significance, a feature 
which arose from the prominence of Xcr1L non-detects. A method was employed to counter 
this issue based on recommendations to provide a more reasonable estimation of gene 
expression from non-detects. Following this, the Ct value presumed for non-detects has 
been reduced to 35 in comparison to the value of 40 that is suggested by some methods 
(McCall et al., 2014). Indeed, use of a higher Ct value for Xcr1L non-detects identified from 
this investigation would have led to more substantial differences and resulted in statistically 
significant differences in expression in comparison to that identified from Xcr1S. However, 
according to the recommendations provided (McCall et al., 2014) and the results obtained 
from primer optimisations, a Ct value of 35 was deemed most appropriate. 
Despite these difficulties, the relative differences in Xcr1L and Xcr1S expression identified 
by qPCR in ESC-derived mouse motor neurons were substantiated by the retrospective 
analysis of microarray data collected from NSC-34 cells, an immortalised mouse motor 
neuron-like cell line. This data provided consistent and statistically significant support for 
the higher relative abundance of RNA derived from exon 2 of Xcr1, than exon 1. Together 
this suggests that motor neurons may express low quantities of Xcr1 mRNA that is 
composed primarily from the transcription of exon 2.  
3.3.4 5’ RACE analysis reveals the potential for intron 1 retention in Xcr1 mRNA 
To provide further clarity to the composition of Xcr1 mRNA within both spleen and spinal 
cord, 5’ RACE analysis was employed with the aim of identifying potential alternative start 
codons. 5’ RACE of Xcr1 has previously been performed for mouse RNA collected from 
spleen (Shinkai et al., 2005). Despite efforts to evaluate this sequence within the spinal cord, 
evidence could only be reliably determined from RNA samples from spleen. These results 
provided a varied sequence arising from the 5’ region of Xcr1 RNA. Evidence from two 
samples provided validation for the existing descriptions of Xcr1 mRNA to include both 
exons 1 and 2 and supported that which had been previously characterised (Shinkai et al., 
2005). However sequencing from one sample also demonstrated the most prominent 
sequence that lies 5’ to exon 2 to arise from intron 1. Furthermore, assessment of amplicons 
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following agarose gel electrophoresis indicated the presence of amplicons that were far 
larger than the expected size of amplicons generated from Xcr1 RNA composed of exon 1 
and exon 2 as documented by bioinformatics databases. In addition, PCR evaluation of cDNA 
produced from spleen RNA demonstrated the consistent retention of intron 1 sequences.  
The retention of intron sequences as a mechanism of alternative splicing has been well 
documented for GPCRs and can arise from the use of alternative promoters (Markovic and 
Challiss, 2009). The presence of a large intron within the Xcr1 gene presents the possibility 
that certain sequences within this region may give rise to transcriptional regulation of exon 
2. In support of this, bioinformatics records and annotation, provided by Ensembl 
(ENSMUST00000182350.1), demonstrate the presence of two promoter sequences to lie in 
the region of Xcr1 (Figure 3.3.1). One of these promoters lies 5’ to exon 1, whilst the second 
is located within intron 1. There is also an additional enhancer located within intron 1. This 
presents a plausible mechanism by which the transcription of exon 1 and exon 2 sequences 
from Xcr1 could be independently regulated. Moreover, the tissue and cell-specific nature 
of transcriptional regulators have the capacity to explain the observed differences in Xcr1L 
and Xcr1S expression that appear to be more prominent within the CNS. However, it cannot 
be discounted that the observed intron 1 sequence from 5’ RACE could have arisen from the 
sequencing of Xcr1 pre-mRNA. Therefore, although this method offers the insight that the 
most prominent RNA sequences arising from the Xcr1 gene can arise from the transcription 
of intron 1, the reason for this may be due to the method detecting samples of pre-mRNA 
and not mRNA only. Whilst the presence of mature mRNA species is suggested to vastly 
exceed that of pre-mRNA (Zeisel et al., 2011), the source of this result to arise exclusively 
from Xcr1 mRNA cannot be confirmed. Consequently, although suggested by qPCR and 
microarray data, conclusive evidence of an alternative Xcr1 mRNA that does not include 
exon 1 has not been obtained. However, evidence to support the current consensus of Xcr1 
mRNA to be derived from exon 1 and exon 2 has been provided. 
3.3.5 The two potential Xcr1 protein isoforms demonstrate distinct capacities for the 
interaction with β-arrestin   
The corresponding amino acid sequence to the Xcr1 protein has yet to be confirmed. Current 
assumptions of this are based on the predicted Open Reading Frame (ORF) arising from 
Xcr1 mRNA and has resulted in the prediction of two potential isoforms, referred to here as 
Xcr1L and Xcr1S. This study provided the first functional comparison of these two isoforms 
and aimed to validate the amino acid sequence of Xcr1 expressed in vivo according to the 
recruitment of β-arrestin following binding of the Xcl1 ligand. 
The evidence accrued from these investigations has provided a consistent demonstration 





Figure 3.3.1. Screenshot of online annotation of promoter sequences within and surrounding Xcr1 mRNA according to Ensembl record ENSMUST00000182350.1. Annotation of predicted sites 
for promoter regions within Xcr1 mRNA suggests the existence of promoters that lie upstream of Xcr1 exon 1 and exon 2. Promoter regions (Red arrows) are highlighted in red and pink 
(bottom row); Xcr1 coding (Yellow arrow) sequence is highlighted in yellow (top row). 
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expressing Xcr1L, according to the luminescent signal detected as a consequence of EFC. 
Unfortunately, it has not been possible to achieve a luminescent signal that demonstrated a 
dose response to the presence of Xcl1. However, the consistently higher basal interaction of 
β-arrestin to the Xcr1S isoform is suggestive of functional protein expression and higher 
turnover of the protein from the cell membrane. Moreover, chemokine receptors are known 
to undergo basal levels of receptor internalisation and recycling in the absence of ligand 
(Neel et al., 2005) a feature that has been reported more broadly for the GPCR family as a 
whole (Seifert and Wenzel-Seifert, 2002).   
The consequence of this constitutive β-arrestin recruitment is highlighted by studies of both 
classical, signalling competent chemokine receptors and ACKRs. It has been previously 
reported for the D6 ACKR that the interaction with β-arrestin maintains receptor stability 
and prevents receptor degradation following internalisation, but is not necessary for initial 
receptor internalisation (Weber et al., 2004). D6 has the closest homology to the CC 
chemokine receptors CCR1-5 and serves to scavenge extracellular CCL3. Interaction with β-
arrestin is prevented by the mutation or loss of a serine-rich domain within the C-terminus. 
The loss of β-arrestin interaction does not prevent initial ligand binding and internalisation, 
but instead leads to subsequent receptor degradation and inhibition of progressive 
scavenging (McCulloch et al., 2008). Hence, for some non-classical chemokine receptors, the 
interaction of this intracellular adaptor protein is instead required for essential functions 
that are mediated after receptor internalisation and permit enhanced receptor stability.  
The increased stability of receptors afforded by the constitutive interaction with β-arrestin 
is also suggested for signalling-competent chemokine receptors. CCR1 has been 
demonstrated to perform basal levels of ligand-independent intracellular G-protein 
signalling and β-arrestin recruitment that is associated with constitutive levels of receptor 
phosphorylation and receptor internalisation, a characteristic that is not observed for the 
homologous CCR2 or CCR5 receptors. Moreover, this basal activity is associated with the 
formation of a CCR1-Gαi-β-arrestin complex that remains stably associated following ligand 
binding.  However, the formation of this complex to occur to individual receptors or 
following receptor oligomerisation was unclear. Together, this basal activity of CCR1 was 
suggested to contribute to a previously undescribed chemokine scavenging activity of the 
receptor. Furthermore, this was a function considered to be reliant upon the constitutive 
interaction of the receptor with β-arrestin (Gilliland et al., 2013).  Although this function of 
chemokine scavenging appears to be a relatively new, and potentially unusual, addition to 
the repertoire of chemokine function, a function for Xcr1 in relation to this cannot be 
excluded. In fact, considering the exclusive binding of Xcl1 to Xcr1, it may not only be 
plausible, but also a necessary function of Xcr1 to regulate extracellular Xcl1 concentrations 
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through constitutive receptor activity. Furthermore, the phylogenetic analysis of Xcr1 
suggests this receptor to be most closely related to the CC chemokine receptor family 
(Nomiyama, Osada and Yoshie, 2011). XCR1 is also located adjacently to human and mouse 
CCR1 genes within their respective genomic locations, indicative of an evolutionary 
conserved function (Chapter 1).  
Although such functions remain intriguing, further analysis and investigation is clearly 
required to interrogate this potential function of the Xcr1S protein. Most notable for this 
study however, is the outcome of the PathHunterTM β-arrestin assay to provide evidence 
that the Xcr1S protein exhibits a greater association to β-arrestin than the Xcr1L protein. 
The implications of this will also require further investigation, but it provides a further 
premise to suggest that the produced protein arising from Xcr1 is encoded entirely within 
exon 2 as previously suggested (Yoshida et al., 1998; Shinkai et al., 2005). The reasons for 
the divergent β-arrestin activity between Xcr1L and Xcr1S can only be speculated upon, 
particularly considering the extensive functions that are associated with the N-terminal 
domain of chemokine receptors (see section 3.1). Furthermore, sequence analysis and 
alignments were unable to identify any functional motifs within the longer amino acid 
sequence found at the N-terminal of Xcr1L in comparison to Xcr1S, suggesting that this 
additional sequence does not convey any positive functional characteristics to the Xcr1 
protein. However, in correspondence with identified Xcr1 mRNA sequence identified here 
and by others (Dorner et al., 2009; Shinkai et al., 2005) the translation of Xcr1L from this 
mRNA cannot be excluded.  
To progress this work further and provide a more reliable and physiologically relevant 
expression system to evaluate the activity of Xcr1L and Xcr1S proteins, it will be essential 
to generate stably expressing cell lines. The evidence provided here has demonstrated a 
consistent difference in β-arrestin recruitment between Xcr1L and Xcr1S proteins when 
qPCR analysis confirmed a similar expression of RNA arising from the two plasmid inserts. 
However, attempts at reducing insert expression by antibiotic treatment did introduce 
more substantial differences in RNA presence from the 2 inserts. Use of stably expressing 
cell lines will permit a more balanced evaluation of protein function that will allow the 
assessment of protein function under expression levels that more closely resemble that in 
vivo. A principal outcome that should be sought to be achieved from this will be to attain a 
dose-response to an appropriate ligand. Despite extensive attempts and the use of 2 
recombinant Xcl1 ligands, and a recombinant human XCL1 ligand (data not shown) a 
specific response by the expressed receptor isoforms was not observed in this study. This 
will be of utmost importance to provide further certainty as to the identity of the functional 
Xcr1 protein.  
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Chapter 4: Validation of antibody specificity and reliability 
4.1 Introduction 
One of the key aims of this project was to identify the localisation and cellular source of 
XCR1 protein expression within the CNS by immunohistochemistry. The principal aim was 
to first determine Xcr1 expression within the murine CNS as this would permit greater 
exploration of receptor expression and potential function in various physiological contexts. 
The information gleaned from such investigations could then be used to inform the choice 
of Human samples for investigation of XCR1 within the Human CNS. 
At the beginning of this project, no documented evidence of Xcr1 expression within the 
murine CNS was available within the literature. Furthermore, no evidence of 
immunohistochemical detection of Xcr1 expression in situ, within any tissue type, was 
identified within the published literature. The presence of Xcr1-expressing cells was instead 
limited to the use of methods involving genetic recombination of a reporter protein to the 
Xcr1 locus (see e.g. (Dorner et al., 2009; Yamazaki et al., 2013)). However, in the process of 
this investigation, evidence of Xcr1 expression within the murine CNS emerged from a study 
performed by Zychowska et al. In this study, Xcr1 presence was investigated within the 
lumbar spinal cord of a murine model of diabetic neuropathy. Following 7-days treatment 
of streptozotocin treatment, Xcr1 was determined to be co-localised to the soma of NeuN-
positive neurons located throughout the dorsal laminae of the lumbar spinal cord when 
evaluated by immunohistochemistry. In addition, Western blot protein analysis was 
performed to provide a quantitative comparison of Xcr1 presence within the lumbar spinal 
cord of streptozotocin-treated mice and untreated mice. This demonstrated an increase of 
Xcr1 protein expression within the protein samples from lumbar spinal cord of 
streptozotocin-treated mice. The magnitude of this increase in Xcr1 presence was 
decreased when administered minocycline vs vehicle (Zychowska et al., 2016). However, 
the reliability of this evidence is called in to question, particularly for the detection of Xcr1 
by immunohistochemistry, as the antibody used is specified for the detection of Human 
XCR1 and not Xcr1. No additional details were provided in relation to the validity of this 
antibody’s specificity to Xcr1. The specificity of the other antibody used in this study was 
also not characterised and could also not be validated in-house due to discontinued 
production by the manufacturer. 
Based on the paucity of available evidence for the use of any particular antibody to detect 
Xcr1, a valid method for the assessment of Xcr1 expression in the murine CNS by 
immunohistochemistry would first require the validation of an antibody (or antibodies) to 
provide a reliable, reproducible and specific detection of Xcr1. An antibody of the same 
nature would also be required for the detection of XCR1 within Human tissue. 
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There are numerous methods suggested for the validation of antibody specificity. However, 
no established standard practice is universally applied. This arises from the unique 
requirements from each antibody investigation and the methods by which both the 
antibody and sample are prepared. The characterisation detail for antibodies provided by 
commercial sources also varies considerably and is often not translatable to the use of the 
antibody for the detection of the protein expressed endogenously in vitro or in vivo 
(Bordeaux et al., 2010).  However, a key requirement for the validation of antibody 
specificity is the use of samples that have proven expression of the desired protein target. 
This is in contrast to some methods of validation that rely on assessing antibody affinity to 
the peptide immunogen to which the antibody is raised.  These immunogens represent short 
peptides that may not accurately reflect the 3-dimensional conformation of that peptide 
amino acid sequence when produced as part of the larger tertiary structure of the target 
protein. Moreover, this tertiary structure is also influenced by the method of sample 
preparation. Hence, use of samples that produce the entire target protein provide a 
presentation of antibody epitope that can therefore more reliably validate the use of the 
antibody for detection of endogenous protein (Bordeaux et al., 2010). Such samples can then 
be prepared by various methods according to the intended application that the antibody 
will be used for the detection of protein in test samples. 
The traditional method of establishing a positive antibody control is to use a sample of tissue 
that is documented to contain the target protein. This method has a major flaw however, in 
that it doesn’t provide an accurate measure of antibody binding to alternative proteins as a 
consequence of cross-reactivity to competing epitopes. When using biological samples such 
as tissue specimens, the presence of such competing epitopes is high. This has typically been 
overcome by the use of pre-incubation controls, for which the antibody is first saturated 
with its specific immunogen prior to the application to test samples. Although this provides 
effective control for determining antibody binding to epitopes that correspond to the 
peptide immunogen, due to the impact of tertiary folding, as discussed above, this does not 
necessarily prove specificity of the antibody to native target protein. Furthermore, blocking 
of antibody binding by the immunogen will equally prevent binding of the antibody to both 
on- and off-target epitopes and is not necessary for antibodies that have been affinity 
purified to the immunogen. Indeed, the insufficient evidence that immunogen pre-
incubation provides in relation to antibody specificity has been criticised for validating the 
specificity of antibodies to several GPCRs (Michel, Wieland and Tsujimoto, 2009).  
A more contemporary method to provide samples with the reliable presence of desired 
protein is to transfect non-expressing cells with an appropriate vector construct to produce 
the protein of interest. Testing of antibody specificity can then be determined from the 
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observed reactivity to transfected cells. In addition, a lack of antibody reactivity to non-
transfected cells of the same cell line provides an intrinsic negative control that gives 
additional conformation of antibody specificity by testing for the presence of non-specific 
binding (Bordeaux et al.,  2010).  
The use of transfected cells also enables an additional mode of validation to support 
antibody specificity by adding an N- or C- terminal molecular tag to the vector protein 
coding sequence. Antibody specificity for the application of immunohistochemistry can then 
be determined based upon co-localisation of the test antibody with the antibody used for 
detection of the protein tag. Furthermore, preparation of cell lysates from transfected cells 
can also be used to assess antibody specificity to the denatured target protein by western 
blot.  This method has been used for the evaluation of antibody specificity to GPCRs such as 
the cannabinoid-1 receptor (Grimsey et al., 2008) and GPR120 (Miyauchi et al., 2009). Both 
studies were able to accurately demonstrate the specificity of certain antibodies to the 
target protein based on the corresponding signals obtained from the test antibodies and the 
anti-tag antibodies when applied to samples prepared from transfected cells. This was in 
addition to demonstrating the lack of non-specific binding to non-transfected cells. 
Moreover, the flexibility by which samples could be prepared from transfected cells and 
their corresponding non-transfected controls enabled the specificity of the antibodies to be 
determined for a variety of methods, including immunohistochemistry and western blot. 
4.1.1 Aims 
The principal aim of this study was to determine the specificity of available antibodies to 
Xcr1 and XCR1.  An in vitro assay of antibody binding that would utilise the benefits of 
cellular transfection with a plasmid encoding Xcr1 or XCR1 with an appropriate molecular 
tag was therefore sought. For the validation of antibody specificity to Xcr1, this in vitro assay 
would be used in addition to the use of tissue samples that were expected to provide a 
relatively high endogenous expression of Xcr1. The method devised has been demonstrated 
to provide a reliable source of target protein that can then be used to validate antibody 









4.2.1 Preliminary optimisation of Xcr1 detection by immunohistochemistry 
Initial tests of antibody specificity were made using spleen tissue from NTg mice. Spleen, 
along with thymus and other secondary lymphoid organs, demonstrates a high expression 
of Xcr1 in mice due to the expression of the receptor by CD8+ dendritic cells that localise 
most prominently in the marginal zones, red pulp and central regions of the spleen (Dorner 
et al., 2009).  
Preliminary attempts of Xcr1 detection within spleen were made using LS-A158 and LS-
C37380. LS-A158, although raised against an immunogen arising from XCR1, was used 
based on the positive reactivity identified in rat, previously established by colleagues within 
our lab (Bird et al., 2018). LS-C37380 was used due to the stated reactivity of this antibody 
to an immunogen arising from Xcr1. Therefore, despite targeting separate epitopes of 
human and mouse XCR1 isoforms (Figure 2.1), the use of spleen tissue was used in order to 
i) identify Xcr1 localisation within mouse spleen based on LS-C37380 reactivity and ii) 
compare LS-A158 reactivity with that identified by LS-C37380 and determine LS-A158 
specificity to Xcr1. Ultimately, identification of Xcr1 reactivity within spleen would serve as 
an appropriate positive control for subsequent investigations of Xcr1 localisation within the 
CNS. 
Figure 4.2.1 illustrates the reactivity of LS-A158 and LS-C37380 within mouse spleen. Both 
antibodies demonstrate a high amount of DAB reactivity that declined with decreasing 
antibody concentration, supporting the notion that the reactivity observed was specific to 
the presence of antibody. However, evidence of a consistent staining pattern, either based 
on cellular localisation or anatomical region, was not observed suggesting a lack of antibody 
specificity to a particular epitope. A lack of antibody specificity by LS-A158 was supported 
by the same pattern of staining in sections treated with LS-A158 that had been pre-
incubated for 24 hours with its respective immunogenic peptide. Moreover, the addition of 
rabbit IgG at the same concentration as the antibody resulted in high background staining, 
further adding to the difficulty of distinguishing any antibody-specific reactivity from that 
contributed to by background staining as a result of rabbit IgG accumulation within the 
tissue. Overall, the specificity of LS-A158 and LS-C37380 to Xcr1 was not supported by 
reactivity observed in spleen. 
4.2.2 In vitro assessment of antibody specificity to Xcr1 and XCR1 : HeLa transfection assay 
Due to the difficulties in establishing a reliable positive control using mouse spleen tissue, 









Figure 4.2.1. Test reactivity of LS-A158 and LS-C37380 in mouse spleen. LS-A158 was applied at concentrations 
of 5µg/ml (a), 2.5µg/ml (b), 1.25µg/ml (c) and 0.75µg/ml (d). LS-C37380 was applied at concentrations of 
5µg/ml (e), 2.5µg/ml (f), 1.25µg/ml (g) and 0.75µg/ml (h). i) 5µg/ml Rabbit IgG; j) LS-A158 pre-incubation 
control; k) Primary antibody omitted; l) Blank spleen tissue. Scale bar = 100µm. 
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characterise antibody reactivity to the respective proteins. Transient transfection of HeLa 
cells was used to achieve this by transfection with plasmids containing an open reading 
frame encoding a C-myc tagged human XCR1 protein (XCR1-myc) or a C-myc tagged mouse 
Xcr1 protein (Xcr1-myc) (Figure 2.2). The addition of a myc tag to the proteins would enable 
a confirmation of transfection and protein expression. Importantly, double 
immunocytochemistry using the test and anti-C-myc antibodies would enable the 
colocalisation of the tested antibodies to cellular regions with a confirmed presence of XCR1 
or Xcr1 epitope.  
4.2.2.1 Amplification and confirmation of RC221929 and MR225478 plasmid sequence 
identity 
Plasmids encoding XCR1-myc (RC221929) and Xcr1-myc (MR225748) were amplified, 
isolated and characterised by restriction digest and DNA sequencing as described in section 
2.5.6. Isolation of plasmids from a 500ml culture of E.Coli transformants using the Plasmid 
Maxi-prep kit (Qiagen) typically resulted in a yield of 0.5-0.8mg plasmid DNA of high purity 
as determined by spectrophotometric ratios of 260/230 ≥ 2.0 and 260/280 ≥ 1.8,  indicating 
low contamination by phenolic substances and proteins, respectively.  
Preliminary confirmation of plasmid identity and sequence conservation was provided by 
restriction endonuclease digest of the plasmids by BamHI and XhoI. Digest of the plasmids 
with these enzymes resulted in the production of DNA fragments at the predicted sizes 
(RC221929 = 4829bp + 1051bp ; MR225748 = 4829bp + 1066bp), demonstrating the 
presence of plasmids with a conservation of restriction site and fragments corresponding 
to the presence of backbone vector plus the respective coding sequence insert (Figure 
4.2.2). Definitive evidence of sequence conservation within the plasmid insert was provided 
by DNA sequencing with T7 Fwd and M13 Rev primers (Figure 4.2.2, Appendix 4.2). 
Together this evidence supported the successful amplification of RC221929 and MR225478 
plasmids that would provide a valid plasmid stock for transfection of HeLa cells to express 
XCR1-myc or Xcr1-myc proteins for the evaluation of antibody specificity.   
4.2.2.2 Optimisation of transfection conditions and manual analysis methods for assessment of 
antibody specificity by immunocytochemistry 
Transient transfection of HeLa cells using LipoJetTM transfection reagent was first optimised 
with the use of a pCDNA5/FRT/TO GFP plasmid (GFP-plasmid) (Figure 4.2.3, A-E). This 
plasmid, like the plasmids encoding XCR1-myc and Xcr1-myc, contains a coding sequence 
that is under the transcriptional control of a CMV promoter. In addition, the expression of 
the GFP protein generates a luminescent signal that provides a more reliable indication of  
124 
 






Figure 4.2.2. Characterisation of RC221929 and MR225748 plasmid clones following amplification and isolation. 
Predicted fragment sizes following BamHI + XhoI digest of RC221929 (A) and MR225748 (C). Agarose gel 
electrophoresis of RC221929 (B) and MR225748 (D) plasmid clones following isolation by Plasmid Maxi Kit 





















   






    
Figure 4.2.3. Optimisation of transfection parameters with LipoJetTM transfection reagent in 24 well plate. HeLa 
cells were transfected with pCDNA5/FRT/TO GFP plasmid (A-E) and MR225748 (F-J) to evaluate optimal 
transfection conditions for cellular expression of plasmid insert. A) Cell number and GFP transfection 
efficiency of cells transfected with 0.4-2ng/µl of pCDNA5/FRT/TO GFP plasmid. Cell numbers significantly 
decrease between 0.4ng/µl and 1ng/µl (* p =0.0211). B) Semi-quantitative evaluation of plasmid insert 
expression as determined by GFP RawIntensity/cell and GFP/DAPI RawIntensity. C-E) Images of HeLa cells 
transfected with 0.4ng/µl (C), 1ng/µl (D) and 2ng/µl (E) pCDNA5/FRT/TO GFP plasmid. F) Cell number and 
transfection efficiency of HeLa cells transfected with 0.4ng/µl and 1ng/µl MR225748 plasmid and non-
transfected controls, as determined by RawIntensity values corresponding to detection of C-myc primary 
antibody. G) Semi-quantitative evaluation of MR225748 plasmid insert expression as determined by 
associated RawIntensity values of C-myc primary antibody detection per cell (C-myc RawIntensity/Cell) or in 
relation to RawIntensity of DAPI channel (C-myc/DAPI RawIntensity). H-J) Images of immunocytochemical 
detection of Myc expression in: H) Non-transfected HeLa cells; I) HeLa cells transfected with 0.4ng/µl 
MR225748;  J) HeLa cells transfected with 1ng/µl MR225478 plasmid. N=3 for all groups. Scale bars = 100µm. 
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transfection efficiency than antibody mediated protein detection, as a consequence of the 
linear relationship between GFP expression and luminescent signal (Soboleski, Oaks and 
Halford, 2005). Therefore, initial testing of transfection efficiency with the GFP-plasmid was 
performed in order to evaluate the optimum transfection conditions that would permit the 
greatest expression of a plasmid coding sequence under the transcriptional control of a CMV 
promoter. 
Manual image analysis of images taken from cells transfected with 0.4ng/µl, 1ng/µl and 
2ng/µl GFP plasmid DNA demonstrated a consistent transfection efficiency regardless of 
the amount of plasmid used for transfection. However, cell numbers significantly declined 
as a consequence of increasing plasmid concentration to 2ng/µl, suggesting that although 
the proportion of transfected to total cells remained consistent with all plasmid amounts, at 
2ng/µl this became toxic to the cells either due to the high expression of GFP protein or 
because of the higher amount of LipoJetTM transfection reagent.  Cell numbers of wells 
treated with 0.4ng/µl and 1ng/µl of plasmid remained consistent indicating a similar 
tolerance of the cells to these transfection conditions. GFP expression however, as indicated 
by RawIntensity per cell, was highest in cells transfected with 1ng/µl plasmid.  Overall, this 
supported the use of 0.4 – 1ng/µl plasmid DNA for transfection of HeLa cells, with 1ng/µl 
plasmid indicated to generate the optimum transfection conditions according to cell 
viability and cell expression of plasmid insert. 
Indeed, for HeLa cells transfected with 0.4ng/µl and 1ng/µl MR225748, transfection with 
1ng/µl plasmid demonstrated a significantly higher transfection efficiency and C-myc 
reactivity per cell (Figure 4.2.3). Although cell numbers do decrease at 1ng/µl of plasmid in 
comparison to non-transfected and 0.4ng/µl of plasmid (Figure 4.2.3, F), this was not 
statistically significant. Furthermore, for the purpose of this assay, the viability of protein 
production was paramount for antibody testing. Therefore, 1ng/µl of plasmid was used for 
future transfections to evaluate antibody specificity for immunocytochemistry, based on 
effective protein production and cell viability. 
In support of the use of a more efficient method of manual analysis to assess antibody 
binding (as detailed in section 2.3.2.1) the results displayed in Figure 4.2.3 B and G 
demonstrate the correspondence in values obtained from analysis based on manual cell 
counting and analysis based on DAPI RawIntensity as a measure of cell presence. Due to the 
variation of cell number in each image, it is not suitable to simply approximate antibody 
binding and specificity based on RawIntensity values of the associated channel from the 
entire image. This is because antibody binding is dependent on the presence of the target 
protein that is, of course, expressed by cells. In particular, evaluation of antibody binding to 
a transmembrane protein such as Xcr1 requires expression within a cellular membrane and 
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therefore cellular number will directly influence the capacity of antibody binding due to the 
effect of cell number on epitope presence. 
Statistical testing identified no significant differences in the normalised changes in C-myc 
reactivity, determined by quantifying C-myc RawIntensity per cell or C-myc/DAPI 
RawIntensity, within the same sample population (Figure 4.2.3, G). Moreover, this 
correspondence of the two methods in evaluating C-myc antibody binding in relation to cell 
presence permitted both methods to identify similar statistical differences in C-myc 
reactivity between non-transfected HeLa and those transfected with the test plasmid 
amounts. In addition, comparison of GFP RawIntensity per cell to GFP/DAPI RawIntensity 
highlights the strong correlation in these two measurements (Figure 4.2.3, A). Overall, this 
supports the manual analysis method which calculates the Rawintensity values of the test 
antibody channel divided by the Rawintensity values of DAPI (i.e. Antibody/DAPI 
Rawintensity) to provide a reliable measure of antibody binding per cell. This measure, in 
conjunction with the primary measure of antibody specificity according to C-myc 
colocalisation, can therefore be used as a semi-quantitative evaluation of antibody binding 
and used to support the specificity of the tested antibodies. 
4.2.2.3 Optimisation of transfection conditions and automated analysis methods for 
assessment of antibody specificity by immunocytochemistry 
In addition to manual image acquisition and analysis, some antibodies were also evaluated 
by automated image acquisition and analysis as described in section 2.3.3. The advantage 
of this method to the manual analysis methods is that the analysis software is capable of 
identifying cells within an image, allowing analysis of antibody reactivity to be performed 
on pixel intensity values from regions that correspond specifically to the total area of an 
image occupied by cells. Thus, this method specifically identifies the cellular area to account 
for the impact of cellular presence on total availability of epitope presentation, rather than 
using DAPI assessment (either by counting nuclei or quantifying Rawintensity) as 
performed for manual image analysis methods. The automated image acquisition and 
analysis therefore refines the quantification of pixel intensity, corresponding to antibody 
binding, to the specific image region that contains the cell and its cytoplasm, providing a 
more accurate estimation of antibody binding to the specific Xcr1 epitopes expressed by 
transfected cells.  
As performed for 24 well plates used for manual image acquisition and analysis, 
optimisation of transfection conditions within 96 well plates that were used for automated 
image acquisition and analysis was also performed using the GFP and MR225748 plasmids 
(Figure 4.2.4). Direct comparison of analysis outcomes using automated and manual 
analysis methods was performed to test the reliability and accuracy of each method to 
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Figure 4.2.4. Optimisation of transfection conditions for LipoJetTM transfection reagent in 96 well plate for 
automated analysis. Evaluation of transfection efficiency and effect on cell viability following transfection with 
GFP (A-C) and MR225748 (D-F) plasmids. A) Quantification of cell viability when transfected with 0.5ng/ul, 
1ng/ul and 2ng/ul of GFP-Plasmid. No statistical difference in cell numbers between cells treated with 1ng/ul 
or 2ng/ul was observed. **, p < 0.01; ***, p < 0.001 B) Comparison of manual (GFP/DAPI RawIntensity) and 
automated (GFP RawIntensity/Cell) analysis to evaluate optimum transfection conditions for GFP-plasmid.. D) 
Viability of non-transfected cells and cells transfected with 0.5ng/ul, 1ng/ul and 2ng/ul. No significant 
differences were observed between cell numbers transfected with 1ng/ul and 2ng/ul. E) Comparison of signal 
ratios obtained by manual (C-myc/DAPI RawIntensity) and automated (Mean C-myc intensity/cell) analysis of 
cells transfected with 0.5ng/ul, 1ng/ul and 2ng/ul of MR225748 in comparison to non-transfected cells. F) 
Representative images acquired by Opera Phenix High Content Screening System of HeLa cells non-transfected 
(a) or transfected with MR225748 plasmid at 0.5ng/ul (b), 1ng/ul (c) and 2ng/ul (d). N=3 for all quantitative 
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quantify antibody binding (Figure 4.2.4, B and D). In particular, comparison to the 
automated analysis outcomes was done to support the validity of the manual analysis 
method for the assessment of antibody binding, which has been used to assess the 
specificity of some antibodies (see later sections).  
To determine the optimum concentration of plasmid to use for transfection, GFP and C-myc 
reactivity were assessed following transfection with 0.5ng/µl, 1ng/µl and 2ng/µl. Despite 
GFP reactivity demonstrating a clear increase in reactivity per cell using transfection at 
2ng/µl in comparison to 1ng/µl (Figure 4.2.4, B), C-myc reactivity demonstrated no 
significant difference between these two conditions (Figure 4.2.4, E). Moreover, there was 
no impact on cell viability by increasing the concentration of either plasmid from 1ng/µl to 
2ng/µl (Figure 4.2.4, A and D).  Therefore the transfection of cells using 1ng/µl was used for 
future transfection protocols in 96 well plates.  
Comparison of manual and automated analysis methods to quantify antibody reactivity, 
demonstrated a strong correlation in the outcomes for both methods.  Evaluations of GFP 
expression in relation to cell number  supported both GFP RawIntensity/cell (Automated) 
and GFP/DAPI RawIntensity (Manual) to identify similar relative quantification of GFP 
expression and similar statistical differences in GFP expression between the transfection 
conditions (Figure 4.2.4, B). Similarly, automated and manual image analysis methods were 
able to identify almost identical quantitative and statistical changes of C-myc reactivity 
between non-transfected cells and cells transfected with MR225748 at 0.5ng/µl, 1ng/µl and 
2ng/µl (Figure 4.2.4, E).  Together, this supported both manual and automated image 
analysis methods to effectively evaluate antibody binding to transfected cells evaluated by 
immunocytochemistry. 
4.2.2.4 Confirmation of desired protein expression by Western Blot 
To confirm that the C-myc reactivity observed by immunocytochemistry represented the 
detection of a C-myc tagged protein of the expected size and hence to support the valid 
expression of Xcr1 or XCR1, protein content from the cell lysate extracted from transfected 
and non-transfected HeLa was evaluated by western blot (Figure 4.2.5). Initial efforts using 
cell lysate from cells transfected with MR225748 suggested the presence of a particularly 
large protein. Subsequent efforts utilised a transfection control with a plasmid encoding a 
myc-tagged TAR DNA Binding protein 43-kDa (TDP-43-myc) to confirm that the developed 
method was suitable for the detection and separation of protein by SDS-PAGE. Indeed, the 
43-kDa protein was observed following C-myc detection by western blot (Figure 4.2.5, B,C). 
However, despite detection of TDP-43-myc validating the protocol, detection of Xcr1-myc 
remained in a region far higher than the expected ~42kDa size. This suggested that the 
protein produced from MR225748 plasmid was aggregating as a consequence of protein 
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Figure 4.2.5. C-myc detection of protein from HeLa cell lysate by Western Blot. Initial attempts to detect a single 
band corresponding to Xcr1-myc within the lysate of HeLa cells transfected with MR225748 presented a band 
at a much higher molecular weight than the predicted 39.4 kDA (A and B). This band of higher molecular weight 
was not a result of a failed western blot protocol as demonstrated by the successful identification of TDP-43-
myc within the lysate of HeLa cells overexpressing this protein (B). Excluding sample heating to 95°C from 
western blot protocol resulted in the identification of C-myc reactivity within the appropriate size range 
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 denaturation. Confirmation of c-myc detection of a protein within an appropriate size range 
of the predicted molecular weight was achieved by the use of a cell lysate preparation that 
did not include heating to 95°C prior to loading of the sample. Use of this protocol was also 
used to confirm the molecular size of XCR1-myc produced from the RC221929 plasmid 
(Figure 4.2.5, D). 
The predicted molecular weights of Xcr1-myc and XCR1-myc are 42.6kDa and 42.0 kDa, 
respectively. The detection of these proteins by western blot (Figure 4.2.5, C, D) with the 
anti-C-myc antibody demonstrates the presence of proteins that, according to the molecular 
weight standards, is of a much smaller size than anticipated. This is further highlighted by 
the discrepancy in size between Xcr1-myc and TDP-43-myc which has a molecular weight 
of 44kDa (Figure 4.2.5, C). However, the anomalous migration of transmembrane proteins 
has been well documented in the literature, with a recently proposed correction factor for 
a more accurate quantification of molecular weight based on the relative molecular mass 
identified following SDS-PAGE (Rath and Deber, 2013). Following the application of the 
correction factor proposed for sample proteins migrating faster than the predicted 
molecular weight (Rath and Deber, 2013), the estimated molecular weight of proteins 
identified by C-myc reactivity was: Xcr1-myc 41.7kDa and 43.6kDa (Figure 4.2.5, C and D); 
XCR1-myc 42.9kDa (Figure 4.2.5 D). Taking this correction in to consideration provides an 
estimated molecular weight that much more closely resembles the predicted values. 
 In summary, C-myc detection of protein within the lysate of HeLa cells transfected with 
MR225748 and RC221929 supports the production of proteins with the molecular 
characteristics that are consistent with the production of Xcr1-myc and XCR1-myc, 
respectively. The overexpression of Xcr1-myc and XCR1-myc by HeLa will therefore provide 
a reliable production of appropriate epitope for testing antibody specificity against the 
respective Mouse and Human XCR1 homologues. 
4.2.3 Evaluation of antibody specificity to Mouse Xcr1 by immunocytochemistry 
Using the optimised method for transfection and analysis of Xcr1-myc expression by 
immunocytochemistry (section 4.2.2.2), the HeLa transfection assay was next used to 
evaluate the specificity of LS-A158, LS-C37380, Ab188896, cAb-Xcr1 and HPA013169 to 
Xcr1-myc. Confirmation of antibody specificity using this method was used as a pre-
requisite to validate the detection of Mouse Xcr1 expressed endogenously within tissue 
samples. 
4.2.3.1 Evaluation of LS-A158 specificity to Mouse Xcr1 by immunocytochemistry 
LS-A158 reactivity to HeLa cells expressing Xcr1-myc was tested across a range of 
concentrations between 5µg/ml and 1.25µg/ml according to the recommended working 
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concentration supplied by the manufacturer (Figure 4.2.6). LS-A158 reactivity 
demonstrated diffuse staining across all cells regardless of the antibody concentration used 
and this reactivity pattern was maintained between transfected and non-transfected cells. 
Semi-quantitative evaluation of antibody binding was made based on the raw intensity 
values obtained from the RGB channel corresponding to the fluorescent secondary antibody 
used for detection of LS-A158. At the highest concentration of LS-A158 tested (5µg/ml) 
antibody reactivity was indicated to decline in HeLa cells expressing Xcr1-myc, with no 
significant changes in antibody reactivity observed between transfected and non-
transfected cells at lower antibody concentrations. Qualitative examination of LS-A158 
colocalisation with C-myc was failed to be consistently observed, with the small amounts 
that were identified deemed to be a result of the diffuse background staining of all cells. 
In an attempt to provide greater exposure of Xcr1 antigen for antibody binding, cells 
underwent HIER treatment (Figure 4.2.7). LS-A158 testing at 5µg/ml was excluded based 
on the high background reactivity observed in non-transfected cells above.  Despite HIER 
treatment, LS-A158 reactivity remained diffuse, as seen for cells left untreated prior to the 
addition of primary antibody (see above) and again this reactivity pattern was consistent 
between transfected and non-transfected cells. Semi-quantitative evaluation also failed to 
identify any changes in antibody reactivity against HeLa cells expressing Xcr1-myc in 
comparison to non-transfected cells. Furthermore, no specific colocalisation of LS-A158 
reactivity with C-myc was observed. Overall, this data suggested that LS-A158 does not 
demonstrate specific binding to Mouse Xcr1.      
   
4.2.3.2 Evaluation of LS-C37380 specificity to Mouse Xcr1 by immunocytochemistry 
LS-C37380 was tested at concentrations between 5µg/ml and 20µg/ml as recommended by 
the manufacturer. Initial testing was performed without antigen retrieval (Figure 4.2.8) and 
demonstrated a diffuse cellular signal that was consistent for all cells, regardless of Xcr1-
myc expression, as demonstrated by C-myc reactivity, in transfected cells. This staining 
pattern was observed for all concentrations used and therefore clear colocalisation of LS-
C37380 with C-myc was not evident above the background reactivity demonstrated for cells 
transfected with MR225748. Semi-quantitative evaluation of antibody binding supported a 
clear increase in C-myc reactivity within transfected cells, confirming the qualitative 
evaluation of Xcr1-myc expression. Despite this, comparisons in LS-C37380 reactivity were 
inconsistent – at the highest concentration tested (20µg/ml), a statistically significant 
decrease in LS-C3780/DAPI RawIntensity was observed. LS-C37380/DAPI reactivity 
remained almost identical between cells treated with 10µg/ml, whilst antibody binding was 
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Figure 4.2.6. Test of LS-A158 specificity to HeLa cells expressing Xcr1-myc by immunocytochemistry. A) 
Representative images of HeLa cells either transfected with MR225748 or non-transfected controls following 
double immunocytochemistry with LS-A158 (red) and anti-C-myc (green). a-d = LS-A158 5µg/ml non-
transfected; e-h = LS-A158 5µg/ml transfected. Scale bars =100µm. B) Semi-quantitative evaluation of LS-
A158/DAPI reactivity demonstrates no change in antibody binding to transfected cells regardless of LS-A158 
concentration. A significant reduction in LS-A158/DAPI reactivity is observed for transfected cells treated with 
5µg/ml LS-A158 in comparison to non-transfected cells (***, p < 0.001). N=3 for all groups. C) C-myc/DAPI 
RawIntensity demonstrates a significant increase (***, p < 0.001) in cells transfected with MR225748, 
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Figure 4.2.7. Evaluation of LS-A158 specificity to Xcr1-myc by immunocytochemistry following HIER. A) 
Representative images of HeLa cells either transfected with MR225748 or non-transfected controls following 
double immunocytochemistry with LS-A158 (red) and anti-C-myc (green). a-d = LS-A158 2.5µg/ml non-
transfected; e-h = LS-A158 2.5µg/ml transfected. Scale bars =100µm. B) Semi-quantitative evaluation of LS-
A158/DAPI reactivity demonstrates no effect of Xcr1-myc expression within HeLa cells on LS-A158 binding in 
comparison to non-transfected cells (N=3 for all groups). C) Semi-quantitative evaluation of C-myc/DAPI 
reactivity demonstrates a significant increase in C-myc reactivity in cells transfected with MR225748 (***, p 
<0.001) supporting the valid expression of the Xcr1-myc protein in transfected cells. N=9 for both groups. Error 
Bars = ±SD.          
           







In tandem with the lack of colocalisation to C-myc, this evidence did not support the 
specificity of LS-C37380 to Xcr1. 
Further attempts via the use of antigen retrieval (Figure 4.2.9) also failed to improve the 
specificity by which LS-C37380 appeared to bind to cells; reactivity was again diffuse in all 
cells whether they were transfected or not. Colocalisation of LS-C37380 with C-myc was 
also absent, with LS-C37380 reactivity again failing to demonstrate a reactivity higher than 
background in cells expressing Xcr1-myc.  This lack of increased reactivity in transfected 
cells, as observed by qualitative inspection, was supported by semi-quantitative evaluation 
failing to demonstrate any significant increases in LS-C3730/DAPI reactivity in cells 
expressing Xcr1-myc in comparison to non-transfected cells, despite the clear evidence of 
Xcr1-myc expression as evidenced by semi-quantitative evaluation of C-myc/DAPI 
RawIntensity (Figure 4.2.9, B and C). 
Overall, despite LS-C37380 being raised to an immunogen corresponding to a peptide that 
is specific to mouse Xcr1, the lack of specific colocalisation with C-myc and a lack of clear 
semi-quantitative increase in antibody binding does not support the specificity of LS-
C37380 to Xcr1. 
4.2.3.3 Evaluation of Abcam 188896 specificity to Mouse Xcr1  
Although raised to an immunogen with a peptide sequence that corresponds to the Human 
XCR1 protein, Abcam 188896 has been previously used to support the presence of Xcr1 in 
the mouse spinal cord by Zychowska et al., 2016. In an attempt to validate the use of this 
antibody for further characterisation of Xcr1 in the Mouse CNS, Abcam188896 was tested 
by single immunocytochemistry against HeLa cells expressing Xcr1-myc (Figure 4.2.10). 
The signal obtained from this antibody was very low in both transfected and non-
transfected cells, with fluorescent reactivity specific to the antibody difficult to observe 
above background at both 10µg/ml and 2.5µg/ml. C-myc reactivity observed by 
independent immunocytochemistry, but from the same transfection procedure, 
demonstrated the clear presence of Xcr1-myc in transfected cells. In addition to qualitative 
evidence demonstrating a lack of reactivity by Abcam188896, semi-quantitative evaluation 
also demonstrated no significant differences in Abcam188896/DAPI reactivity between 
cells expressing Xcr1-myc and non-transfected cells. Due to the extremely low reactivity 
observed, further characterisation of Abcam 188896 was instead based upon testing against 
Human XCR1 (see section 4.2.4.2). Although further characterisation is needed, this 
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Figure 4.2.8. Evaluation of LS-C37380 reactivity to Xcr1-myc by immunocytochemistry. A) Representative images 
of HeLa cells either transfected with MR225748 or non-transfected controls following double 
immunocytochemistry with LS-C37380 (red) and anti-C-myc (green). a-d = LS-C37380 20µg/ml non-
transfected; e-h = LS-C37380 20µg/ml transfected. Scale bars =100µm. C) Semi-quantitative evaluation of LS-
C37380 binding to cells expressing Xcr1-myc and non-transfected cells. A statistically significant reduction in 
LS-C37380/DAPI RawIntensity was observed at cells treated with 20µg/ml (***, p=0.004) of LS-C37380 in 
comparison to non-transfected cells. Data is normalised to non-transfected mean. N=3 for all groups. D) Semi-
quantitative evaluation of C-myc/DAPI reactivity demonstrates a significant increase in C-myc reactivity in cells 
transfected with MR225748 (***, p <0.001) supporting the valid expression of the Xcr1-myc protein in 
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Figure 4.2.9. Evaluation of LS-C37380 binding to Xcr1-myc by immunocytochemistry following HIER. A) 
Representative images of HeLa cells either transfected with MR225748 or non-transfected controls following 
double immunocytochemistry with LS-C37380 (red) and anti-C-myc (green). a-d = LS-C37380 20µg/ml non-
transfected; e-h = LS-C37380 20µg/ml transfected. Scale bars =100µm. B) Semi-quantitative evaluation of LS-
C37380 binding to cells expressing Xcr1-myc and non-transfected cells. A statistically significant reduction in 
LS-C37380/DAPI RawIntensity was observed for cells treated with 20µg/ml and 5µg/ml of LS-C37380 in 
comparison to non-transfected cells. Data is normalised to non-transfected mean. N=3 for all groups. C) Semi-
quantitative evaluation of C-myc binding to cells expressing Xcr1-myc and non-transfected cells demonstrates 
a large and significant increase of C-myc/DAPI reactivity as a consequence of transfection and supports the 
qualitative evaluation of C-myc presence to confirm the high expression of Xcr1-myc. Data is normalised to non-





           
          
        
    
 
 
   
  
 
       
     
Figure 4.2.10. Evaluation of Abcam188896 specificity to Xcr1 by immunocytochemistry. A) 
Immunocytochemistry performed with Abcam188896 or anti-C-myc against Non-Transfected HeLa cells (a-c) 
or HeLa cells transfected with MR225748 (d-f) (DAPI signal not shown due to loss of data). B) Semi-quantitative 
evaluation of Abcam188896 antibody binding as calculated by Abcam188896/DAPI RawIntensity. N=3 per 
group. C) Semi-quantitative evaluation of C-myc/DAPI RawIntensity demonstrates a significant increase of C-
myc binding in cells transfected with MR225748 and supports the qualitative evaluation of C-myc presence to 





























































































N o n - T r a n s f e c t e d
T r a n s fe c t e d















































































B C * 
b a c 
f d e 
143 
 
4.2.3.4 Evaluation of cAb-Xcr1 specificity to Mouse Xcr1  
To overcome the lack of available antibodies that demonstrated specificity to Mouse Xcr1, a 
custom designed polyclonal antibody (cAb-Xcr1) was produced using a 19 amino acid 
peptide derived from the 3rd intracellular loop of Mouse Xcr1 (Figure 2.1). This antibody 
was prepared by affinity-purification to the peptide immunogen and tested by ELISA for 
specificity alongside total serum and purification column flow-through (Ft), collected 
following affinity-purification (Figure 4.2.11). The purified antibody that was received from 
the manufacturer and used for testing by immunocytochemistry demonstrated a sigmoidal 
binding curve to the immunogenic peptide, with binding evident over 3 log10 concentrations 
from a 1:100 dilution to a 1:100000 dilution. A similar sigmoidal binding to that of the 
purified antibody was also observed following application of total serum (Figure 4.2.11, A). 
Binding of Ft also demonstrated a sigmoidal response, with statistical testing demonstrating 
significantly less binding to the peptide, in comparison to purified antibody, at all dilutions 
apart from 1:72900 and 1:218700 (Figure 4.2.11, B). This binding characteristic of Ft 
suggests the presence of a significant amount of low affinity antibodies within the serum 
that are able to bind the immunogenic peptide. However, in support of a higher specificity 
than Ft to the immunogenic peptide, the purified antibody demonstrates a much lower 
binding affinity to the carrier protein than that demonstrated for total serum and column 
flow through, although there is some residual binding at higher concentrations of the 
purified antibody. Together, the results obtained by ELISA to the immunogenic peptide 
suggest that the purified antibody does exhibit specificity for the peptide, but that this 
specificity may not be a result of the immunisation producing antigen-specific antibody. 
Rather, the immunogenic peptide appears to bind multiple antibodies contained within the 
serum and the purified antibody provided by the manufacturer simply reflects an enriched 
population of antibodies with a higher relative affinity.  
In order to examine the potential use of cAb-Xcr1 for the detection of Mouse Xcr1 by 
immunohistochemistry, this antibody was then tested by immunocytochemistry at 
10µg/ml, 5µg/ml and 2.5µg/ml against cells expressing Xcr1-myc and their non-transfected 
controls. In addition to manual analysis using ImageJ (Section 2.3.2.1; Figure 4.2.12), the 
evaluation of cAb-Xcr1 reactivity to cells transfected with MR225748 and non-transfected 
cells was also evaluated by automated image capture and analysis as described in Section 
2.3.3 (Figure 4.2.13). As observed for the previous antibodies, cAb-Xcr1 demonstrated a 
diffuse signalling pattern that was observed in all cells of the culture, irrespective of the 
expression of Xcr1-myc that was confirmed by qualitative and semi-quantitative evaluation 














 Mean OD 492nm Statistical comparison (vs PA) 
Dilution PA Serum Ft Serum Ft 
1:100 3527 3308 3122 -219, *** -405, *** 
1:300 3442 3247 2833 -195,*** -609, *** 
1:900 2857 2820 2290 -36, ns -567, *** 
1:2700 1777 1660 1238 -117, ** -538, *** 
1:8100 840 821 556 -19, ns -284, *** 
1:24300 397 393 260 -4, ns -137, ** 
1:72900 231 226 160 -5, ns -71, ns 
1:218700 180 164 124 -16, ns -56, ns 
 
 
Figure 4.2.11. Characterisation of cAb-Xcr1 binding to immunogenic peptide by ELISA. A) Colorimetric 
measurements obtained following assessment of binding to immunogen by Indirect Enzyme-Linked 
ImmunoSorbant Assay (ELISA). Total serum (black), purified antibody (red) and column flow through (grey) 
were tested for binding to the immunogen designed for the production of cAb-Xcr1 (peptide, solid line) and the 
carrier protein used for host immunisation (carrier, dashed line). Error bars = ±SD. B) Numerical and statistical 
comparison of semi-quantitative assessment of binding to immunogenic peptide, according to optical density at 
492nm, between purified antibody (PA), Serum and purification column flow-through (Ft). Data was compared 
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Figure 4.2.12. Evaluation of cAb-Xcr1 reactivity to Xcr1-myc by immunocytochemistry. A) Representative images 
of HeLa cells either transfected with MR225748 or non-transfected controls following double 
immunocytochemistry with cAb-Xcr1 (red) and anti-C-myc (green). a-d = cAb-Xcr1 10µg/ml non-transfected; e-
h = cAb-Xcr1 10µg/ml transfected. Scale bars =100µm. B) Semi-quantitative evaluation of cAb-Xcr1 binding to 
cells expressing Xcr1-myc and non-transfected cells. cAb-Xcr1/DAPI RawIntensity demonstrates a consistent 
level of signal in cells regardless of Xcr1-myc presence. N = 3 for each group. C) Semi-quantitative evaluation of 
C-myc binding to cells expressing Xcr1-myc and non-transfected cells demonstrates a large and significant 
increase of C-myc/DAPI reactivity as a consequence of transfection. This supports the qualitative evaluation of 
C-myc presence demonstrating the high expression of Xcr1-myc. N = 9 for each group; ***, p < 0.001. Error bars 






























Figure 4.2.13. Evaluation of cAb-Xcr1 binding to Xcr1-myc by immunocytochemistry using automated image 
analysis. A) Representative images acquired by Opera Phenix following single immunocytochemistry using anti-
C-myc (b, d) and cAb-Xcr1 (a, c) antibodies with non-transfected cells or cells transfected with MR225748 
(Transfected) and visualised by the application of a Cy3-conjugated secondary antibody. The display range of 
each image has been standardised between non-transfected and transfected samples for each antibody 
condition to allow qualitative evaluation of antibody binding. No difference in cAb-Xcr1 reactivity was observed 
as a consequence of transfection with MR225748. Scale bars = 100µm. B) Semi-quantitative evaluation of cAb-
Xcr1 antibody binding at all concentrations tested, according to mean Cy3 Intensity per cell, demonstrates no 
significant difference between cells transfected with MR225748 and their respective non-transfected controls. 
N=3 per group C) C-myc binding significantly increases as a consequence of transfection in comparison to non-
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Figure 4.2.14. Evaluation of cAb-Xcr1 specificity to Mouse Xcr1 by immunocytochemistry following HIER. A) 
Double immunocytochemistry following HIER of HeLa cells transfected with MR225748 and non-transfected 
controls with cAb-Xcr1 (red) and anti-C-myc (green) primary antibodies. a-d = cAb-Xcr1 5µg/ml non-
transfected; e-h cAb-Xcr1 5µg/ml transfected; Scale bars = 100µm B) Semi-quantitative evaluation of cAb-Xcr1 
binding to transfected cells expressing Xcr1-myc and non-transfected cells. cAb-Xcr1/DAPI RawIntensity 
demonstrates a significant decrease in transfected cells in comparison to non-transfected cells. N=3 per group; 
*, p<0.05. C) Semi-quantitative evaluation of C-myc binding to cells expressing Xcr1-myc and non-transfected 
cells demonstrates a large and significant increase of C-myc/DAPI reactivity as a consequence of transfection 
and supports the qualitative evaluation of C-myc presence demonstrating the high expression of Xcr1-myc. N=3 




evident at all concentrations used. Moreover, no distinct changes in mean cell Cy3 Intensity 
was observed between cells treated with cAb-Xcr1 and cells which were treated with 
secondary antibodies only. Overall, this suggests the antibody to be non-specific to Mouse 
Xcr1 and to show little, if any, non-specific binding that was not influenced by antibody titer. 
The use of HIER prior to immunocytochemistry (Figure 4.2.14) failed to improve antibody 
binding when applied at 5µg/ml, with antibody reactivity demonstrating a similarly diffuse 
pattern to that obtained without HIER. Furthermore, no clear colocalisation between the 
signal obtained from cAb-Xcr1 and C-myc could be identified that was consistently above 
the background staining observed for all cells.  
In summary, cAb-Xcr1 was developed with the aim of providing an antibody that would 
specifically recognise Mouse Xcr1 based on specific binding to the 3rd intracellular loop of 
the protein. However, despite showing obvious binding and specificity to the immunogenic 
peptide, cAb-Xcr1 was unable to demonstrate binding and reactivity to Xcr1 by 
immunocytochemistry when overexpressed by cells in vitro. Overall, this evidence was 
unable to support the use of cAb-Xcr1 for the specific binding and localisation of Xcr1 by 
immunohistochemistry. 
4.2.4 Evaluation of antibody specificity to Human XCR1 by immunocytochemistry 
It was next sought to evaluate antibody specificity to Human XCR1 by utilising the optimised 
HeLa transfection assay to overexpress XCR1-myc. As for the testing of antibody specificity 
to Mouse Xcr1, this assessment aimed to confirm antibody specificity to support their use 
for the detection of endogenous XCR1 expression by immunohistochemistry in the Human 
CNS. 
4.2.4.1 Evaluation of Atlas HPA013169 specificity to Human XCR1 
Evaluation of Atlas HPA013169 to Human XCR1 was performed using both manual (Figure 
4.2.15) and automated (Figure 4.2.16) analysis. Initial testing utilised single 
immunocytochemistry with HPA013169 over a range of concentrations to establish 
antibody reactivity in non-transfected cells and cells expressing XCR1-myc. As established 
with testing against Mouse XCR1, anti-C-myc reactivity provided clear evidence of 
transfected cells expressing XCR1-myc as demonstrated by both qualitative (Figure 4.2.15, 
A (d vs i)) and semi-quantitative evaluation of normalised C-myc/DAPI RawIntensity 
(Figure 4.2.15, D). HPA013169 also demonstrated a clear and significant increase in binding 
to cells transfected with RC221929 in comparison to non-transfected cells (Figure 4.2.15, A 
(a-c vs f-h)). This was supported by semi-quantitative evaluation of antibody binding 
demonstrating a statistically significant increase in HPA013169/DAPI RawIntensity in 
comparison to non-transfected cells for all antibody concentrations tested. Normalised to 
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their respective non-transfected controls, HPA013169 binding increased by 29.86x, 85.07x 
and 15.47x in cells transfected with RC221929 and treated with 1µg/ml, 2.5µg/ml or 
4µg/ml of antibody, respectively (Figure 4.2.15, B). This lack of consistency in relative 
amounts of antibody binding when normalised to their respective non-transfected controls 
suggests a poor relationship between antibody concentration and specific epitope binding. 
However, absolute values of HPA013169/DAPI RawIntensity demonstrate a dose-
dependent increase in antibody binding (Figure 4.2.15, C). This supports the specificity of 
the antibody and indicates that the variation in normalised results is a consequence of 
variability between corresponding non-transfected values that were used for 
normalisation. Indeed, for non-transfected cells treated with 4µg/ml HPA013169, the mean 
HPA013169/DAPI RawIntensity was ~10x higher than that for cells treated with 1µg/ml or 
2.5µg/ml. This therefore reduced the relative magnitude of increase in HPA013169/DAPI 
RawIntensity in transfected cells treated with 4µg/ml HPA013169. Overall, this supported 
the use of HPA013169 at a concentration of 2.5µg/ml for further investigations as this 
provided a signal with a greater distinction to background than that observed for 1µg/ml, 
but did not suffer from the apparent increase in background reactivity observed at 4µg/ml. 
Further to semi-quantitative evaluation demonstrating the increase of HPA013169 binding 
to cells expressing XCR1-myc, double immunocytochemistry provided a clear indication of 
HPA013169 specificity to XCR1-myc. Figure 4.2.15, E illustrates the colocalisation of 
HPA013169 and anti-C-myc, providing strong evidence of the specificity of HPA013169 to 
Human XCR1. 
The evidence of HPA013169 specificity to Human XCR1 provided by manual image analysis 
was further supported by automated analysis (Figure 4.2.16). Images obtained following 
double immunocytochemistry of cells transfected with RC221929 and non-transfected cells 
(Figure 4.2.16, A) using anti-C-myc and HPA013169, demonstrate the increased presence 
of HPA013169 binding to transfected cells. This binding of HPA013169 localises, in 
particular, to peri-nuclear regions of the cell cytoplasm. There is a small but notable 
presence of HPA013169 binding in non-transfected cells also. C-myc binding clearly 
illustrates the expression of XCR1-myc by cells successfully transfected with the RC221929. 
The clearest evidence of HPA013169 specificity to XCR1-myc is provided by the observed 
colocalisation of HPA013169 signal to that of the anti-C-myc antibody. This colocalisation is 
consistent to all cells identified to have XCR1-myc expression by anti-C-myc binding and 
demonstrates the localisation of HPA013169 binding to XCR1-myc. 
Semi-quantitative analysis supports the successful transfection, XCR1-myc expression and 
HPA013169 specificity to XCR1.  Quantitation of C-myc binding (Figure 4.2.16, B) supported 
the qualitative evidence of transfection efficiency and determined a mean increase of 4.4x 
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of anti-C-myc binding per cell following transfection with RC221929 in comparison to non-
transfected cells. Semi-quantitative analysis also supported the qualitative demonstration 
of increased HPA013169 binding to transfected cells (Figure 4.2.16, C), with a 3.1x mean 
increase of Cy3 intensity per cell, for cells transfected with RC221929 in comparison to non-
transfected cells. Moreover, this increase in HPA013169 binding is resilient to the presence 
of the anti-C-myc antibody and demonstrates almost identical increases in binding to 
transfected cells expressing XCR1-myc when used in isolation or as part of a double 
immunocytochemical protocol (images of single immunocytochemistry not shown).  
As an additional mode of analysis to support the specificity of HPA013169 to XCR1-myc, the 
intensity of signal corresponding to HPA013169 binding within regions of the test image 
demonstrating the highest anti-C-myc binding was performed. In cell populations used for 
transfection with RC221929, the intensity of signal arising from anti-C-myc binding 
provided a clear distinction between cells that were or were not successfully transfected. 
Therefore, selection of image regions displaying the highest FITC intensity would identify 
regions of the image corresponding to transfected cells with the highest XCR1-myc 
expression. The same method was also applied to non-transfected cells, but rather than 
identify regions of XCR1-myc expression this method would simply identify the regions that 
displayed the highest amount of background anti-C-myc binding. As displayed in Figure 
4.2.16, D, HPA013169 signal intensity within regions of highest anti-C-myc binding was 
significantly higher in transfected cells, demonstrating a 108% increase in signal intensity 
in comparison to the corresponding image regions identified in non-transfected cells. 
Together, the evidence provided by manual and automated image analysis provides a clear 
validation of Atlas HPA013169 specificity to Human XCR1. This evidence is most clearly 
appreciated by qualitative inspection of HPA013169 colocalisation to anti-C-myc reactivity, 
but is further supported by semi-quantitative analysis that demonstrates a measurable 
increase of HPA013169 binding to cells expressing XCR1-myc that is of a large and 
statistically reliable magnitude in comparison to non-transfected controls.  
4.2.4.2 Evaluation of Abcam 188896 specificity to Human XCR1 
The specificity of Abcam 188896 was tested against Human XCR1 using both manual (Figure 
4.2.17) and automated (Figure 4.2.18) image acquisition and analysis following 
immunocytochemistry with 5µg/ml Abcam188896 using non-transfected HeLa and HeLa 
transfected with RC221929. 
Manual image acquisition and analysis of Abcam 188896 binding was performed using 
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Figure 4.2.15. Evaluation of Atlas HPA013169 specificity to XCR1 by immunocytochemistry. A) Test of Atlas 
HPA013169 (Red) specificity to Non-transfected HeLa cells (a-e) and HeLa cells expressing XCR1-myc (f-j). Anti-
C-myc reactivity (Green, d vs i) was used to confirm expression of XCR1-myc in transfected cells. Scale bars = 
100µm.  B) Semi-quantitative comparison of HPA013169 binding (normalised to non-transfected values) in 
transfected and non-transfected cells demonstrate a large and significant increase in antibody binding in cells 
expressing XCR1-myc in comparison to non-transfected cells. C) HPA013169 demonstrates a dose-dependent 
increase in antibody/DAPI RawIntensity values in cells transfected with RC221929. D) Semi-quantitative 
evaluation of C-myc/DAPI RawIntensity (normalised to Non-transfected values) supports qualitative evidence 
(A, d vs i) of XCR1-myc expression in transfected cells. E) Double immunohistochemistry using anti-C-myc 
(Green, b) and Atlas HPA013169 (2.5µg/ml, Red, c) of HeLa cells transfected with RC221929 demonstrates clear 
colocalisation of the two antibodies (d) at a higher magnification. Scale bars = 50µm.  Error bars = ± SD. N=3 per 












         
   
  
   
    
     
   
    
      
    
Figure 4.2.16. Evaluation of HPA013169 specificity to XCR1-myc by immunocytochemistry using automated 
image analysis. A) Images acquired by Opera Phenix following double immunocytochemistry with HPA013169 
(2.5µg/ml) and C-myc. Antibodies were tested against non-transfected cells (a-d) and cells transfected with 
RC221929 (e-h). Secondary only controls of non-transfected (i) and transfected (j) cells.. In comparison to non-
transfected cells (d), colocalisation of signals from C-myc and HPA013169 antibodies is clearly evident 
throughout cytoplasm of successfully transfected cells (h). Scale bars = 100µm. B) Semi-quantitative evaluation 
of fluorescent signal corresponding to detection of anti-C-myc supports transfection efficiency and identifies a 
consistent and significant increase in C-myc binding to transfected cells in comparison to non-transfected cells. 
N=6 per group;**, p < 0.01. C) Semi-quantitative evaluation of Cy3 signal corresponding to detection of 
HPA013169 demonstrates a consistent and significant increase in HPA013169 binding to transfected cells in 
comparison to non-transfected cells. The magnitude of this difference remains consistent during both single 
(HPA013169) and double (Anti-C-myc + HPA013169) immunocytochemical procedures. N=3 per group; **, 
p<0.01. D) HPA013169 binding in regions of highest C-myc binding. Signal intensity arising from HPA013169 
within regions of highest C-myc binding demonstrates a mean increase of 108% in cells transfected with 
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4.2.17, A-C) and immunocytochemistry protocols that included HIER (Figure 4.2.17, D-F). 
Following the standard immunocytochemistry protocol, qualitative inspection 
demonstrated a diffuse pattern of cellular staining for all cells treated with Abcam 188896, 
a feature that did not demonstrate any change as a consequence of transfection with 
RC221929. Semi-quantitative evaluation identified a small but significant increase in 
Abcam188896 binding by transfected, in comparison to non-transfected, HeLa. This 
corresponded to a 1.49x increase in Abcam188896/DAPI RawIntensity in cells transfected 
with RC221929. This relatively small increase is despite the obviously high expression of 
XCR1-myc by HeLa transfected with RC221929, as supported by anti-C-myc binding.  
The capacity for Abcam188896 binding to XCR1-myc did not appear to improve as a 
consequence of HIER (Figure 4.2.17, D-F). Despite semi-quantitative evaluation suggesting 
a small increase in Abcam188896 binding in comparison to non-transfected cells, the 
quality of Abcam188896 binding remained diffuse and did not demonstrate a localisation 
pattern that resembled that identified by anti-C-myc. Moreover, the small increase in 
Abcam188896/DAPI RawIntensity identified for transfected HeLa in comparison to non-
transfected HeLa, did not achieve statistical significance. This is despite a 6.31x increase of 
C-myc presence, as indicated by C-myc/DAPI RawIntensity, supporting the reliable 
presence of XCR1-myc in HeLa cells transfected with RC221929. Overall, manual analysis of 
Abcam188896 binding to XCR1-myc, following immunocytochemistry both with and 
without HIER, was unable to support the specificity of Abcam188896 to Human XCR1. 
Further confirmation of a lack of Abcam188896 specificity was provided via automated 
image acquisition and analysis (Figure 4.2.18). Both qualitative and semi-quantitative 
evidence failed to provide support for Abcam188896 binding to XCR1-myc expressed by 
HeLa cells transfected with RC221929. Instead, a small but significant decrease of 
Abcam188896/DAPI RawIntensity was identified for HeLa cells transfected with 
RC221929, corresponding to 0.82x the value obtained for non-transfected cells. Based on 
this evidence demonstrating a lack of specificity by Abcam18896 to Human XCR1, the use 
of this antibody for the detection of endogenous XCR1 in Human tissue could not be 
supported. 
4.2.5 Evaluation of Antibody specificity by Western Blot 
4.2.5.1 Evaluation of antibody specificity to Mouse Xcr1 by Western Blot 
Based on the confirmed production of a myc-tagged murine Xcr1 protein by HeLa cells 
transfected with MR225748 (section 4.2.2.3), it was possible to reliably evaluate antibody 































Figure 4.2.17. Evaluation of Abcam188896 specificity to XCR1-myc by immunocytochemistry. A) Images obtained 
of single immunocytochemistry protocol to test the specificity of Abcam 188896 to XCR1-myc. Abcam188896 
was applied to non-transfected cells (a-c) and cells transfected with RC221929 (e-g). Anti-C-myc antibody was 
applied independently to confirm expression of XCR1-myc in transfected cells (d vs h). Scale bars = 50µm. B) 
Semi-quantitative evaluation of Abcam 188896 binding demonstrated a statistically significant increase when 
applied to transfected cells in comparison to non-transfected cells. C) Semi-quantitative evaluation of C-myc 
reactivity demonstrated a large and significant increase when applied to transfected cells in comparison to non-













































































































































































































































Figure 4.2.18. Evaluation of Abcam188896 specificity to XCR1-myc by immunocytochemistry following HIER. A) 
Abcam188896 was applied to non-transfected cells (a-c) and cells transfected with RC221929 (e-g). Anti-C-myc 
antibody was applied independently to confirm expression of XCR1-myc in transfected cells (d vs h). Scale bars 
= 50µm. B) Semi-quantitative evaluation of Abcam 188896 binding demonstrated no statistically significant 
changes to Abcam18896 binding when applied to transfected cells in comparison to non-transfected cells. C) 
Semi-quantitative evaluation of C-myc reactivity demonstrated a large and significant increase when applied to 































































































































































































































           
     
   
     
     
     
   
     
     
     
Figure 4.2.19. Evaluation of Abcam 188896 specificity to XCR1-myc by immunocytochemistry using automated 
image acquisition and analysis. A) Images obtained from the Opera PhenixTM High Content Screening System 
following single immunocytochemistry protocols using Abcam 188896 (a, c) and anti-C-myc (b, d) antibodies 
with non-transfected cells and cells transfected with RC221929. Image contrast thresholds were manually 
adjusted to provide a display range that accommodated the maximum signal range from non-transfected and 
transfected samples for each antibody. Scale bars = 100µm. B, C) Comparison of Mean Cell signal intensity arising 
from the Cy3-conjugated secondary antibody used for the detection of Abcam 188896 (Ab896) (B) and anti-C-
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to Xcr1-myc: LS-A158, LS-C37380, Ab188896, cAb-Xcr1 and HPA013169. For details of 
antibody concentrations used, see Table 2.1. Of the 5 antibodies tested, only LS-A158 and 
LS-C37380 demonstrated any binding to the nitrocellulose membrane following protein 
transfer that could be identified from the associated chemiluminescent detection (Figure 
4.2.19). The reactivity arising from both antibodies however, did not correspond to the 
region of C-myc reactivity used to confirm Xcr1-myc within the protein sample (Figure 
4.2.19, E). LS-A158 instead identified an alternative protein with a molecular weight of 
~17kDa. Moreover, the detection of this alternative protein was not specific to transfected 
cells, further suggesting that the epitope identified by LS-A158 did not correspond to those 
present on Xcr1. LS-C37380 similarly detected proteins consistently within lysates 
prepared from both non-transfected and transfected HeLa. This corresponded to 3 distinct 
bands of binding, all of which resided at a higher molecular weight than that identified for 
Xcr1-myc.  All other antibodies were not detected (data not shown), suggesting a complete 
lack of binding to the nitrocellulose membrane. This evidence suggested that the use of 
these commercial and custom antibodies were unable to specifically detect Mouse Xcr1 by 
western blot.   
4.2.5.2 Evaluation of Atlas HPA013169 specificity to Human XCR1 by Western Blot 
Using the lysate of HeLa cells transfected with RC221929 that were previously 
demonstrated to contain a myc-tagged protein with the molecular characteristics consistent 
with the presence of XCR1-myc (section 4.2.2.3), it was possible to reliably test the 
specificity of Atlas HPA013169 to Human XCR1 by western blot.  
Figure 4.2.20 demonstrates the capacity of HPA013169 to detect a protein at a molecular 
weight that is consistent with predicted molecular weight of XCR1-myc and corresponds to 
the molecular weight of the protein identified by anti-C-myc detection. Of note, HPA013169 
was also tested against cell lysate prepared from HeLa cells transfected with MR225748, 
but did not demonstrate any reactivity. Prolonged exposure of the film to the membrane 
following HPA013169 incubation, also demonstrated the detection of a protein with a lower 
molecular weight than XCR1-myc (data not shown). This additional protein was present in 
lysate obtained from both non-transfected HeLa and HeLa transfected with RC221929. The 
test of HPA013169 specificity to XCR1-myc therefore demonstrated the capacity of 
HPA013169 to reliably bind to XCR1-myc, but also demonstrate a degree of non-specificity 
based on the lower affinity observed for an additional protein within HeLa cell lysate. 
4.2.6 LS-A158 reactivity in mouse spinal cord 
Exemplary images of that obtained following both chromogenic and fluorescent 
immunohistochemistry with LS-A158 are provided in Figure 4.2.21.  
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As was observed in non-transfected HeLa and HeLa expressing Xcr1-myc, LS-A158 
demonstrated a diffuse reactivity that appeared to localise to cells, as indicated by the most 
prominent reactivity being observed in the grey matter of the spinal cord by fluorescent 
immunohistochemistry. Indeed, double immunohistochemistry of LS-A158 and NeuN 
resulted in significant overlap of the signals, suggesting that LS-A158 reactivity did localise 
to neurons, amongst other cell types (Figure 4.2.21, A). Closer inspection of LS-A158 
reactivity reveals the antibody to localise to cell membranes, as evidenced by the reactivity 
to surround regions of NeuN binding that localise to neuronal nuclei.  
Further evidence of LS-A158 non-specific binding is demonstrated by the reactivity 
observed following chromogenic immunohistochemistry protocols (Figure 4.2.21, B). 
Again, LS-A158 reactivity was widespread within the tissue, particularly within the grey 
matter. This non-specific labelling of cells reflects the LS-A158 signal obtained following 
immunohistochemical processing of the spleen (Figure 4.2.1). Low background 
chromogenic signal obtained from the control section supports the identified signal to be 
specific to the presence of LS-A158. 
Tests on other spinal cord sections (not shown) demonstrated the antibody to consistently 
provide widespread reactivity that was particularly evident within the grey matter. These 
evaluations of LS-A158 binding within the mouse spinal cord demonstrate the antibody to 






     
    
     
     
     




    





Figure 4.2.20. Evaluation of LS-A158 and LS-C37380 reactivity to Xcr1-myc by western blot. A) LS-A158 detected 
a protein with an approximate 17kDA molecular weight. Detection of β-actin was used as a loading control and 
confirmed consistent levels of protein loading between transfected and non-transfected cells based on reactivity 
at 42kDa. B) Pre-incubation of LS-A158 with the immunogenic peptide diminished reactivity against the 17kDa 
protein. β-actin again confirmed a consistent amount of protein between samples based on reactivity observed 
at 42kDa. C) Without use of β-actin control, reactivity to a protein with an approximate 17kDa molecular weight 
by LS-A158 was still observed. The discrepancy of reactivity intensities against transfected and non-transfected 
lysates is likely a result of inconsistent levels of protein loading. D) Chemiluminescent detection of LS-C37380 
demonstrates the detection of proteins at 3 distinctive molecular weights, in particular, within the lysate of both 
non-transfected HeLa and HeLa transfected with MR225748.  E) C-myc reactivity confirms presence of Xcr1-
















































           
          
          
          
           
           
           
           
           
           
           
           
          
          
          
           
           
           
           
           
           
           
           
           
Figure 4.2.21. Evaluation of HPA013169 specificity to XCR1-myc by Western Blot. A) HPA013169 demonstrates 
the detection of a protein within the lysate of HeLa cells transfected with RC221929. This protein resides at the 
molecular weight consistent with the presence of XCR1-myc. B) Anti-C-myc demonstrates the presence of XCR1-
myc specifically within the lysate of HeLa cells transfected with RC221929, also used for the evaluation of 




















       
   
















Figure 4.2.22. Representative images of LS-A158 reactivity in Mouse spinal cord identified by fluorescent and 
chromogenic immunohistochemistry. A) LS-A158 reactivity within the sacral spinal cord of a WT mouse following 
double immunohistochemistry with NeuN. Lower power magnification image (a) illustrates the widespread 
reactivity of LS-A158 within grey matter of both spinal cord regions. LS-A158 reactivity demonstrates 
colocalisation to many NeuN-positive cells, but also demonstrates reactivity to a lower level within white matter. 
Dashed white box in (a) highlights regions focussed upon by higher magnification in b,c,d. Scale bars: a = 200µm; 
b-d = 100µm. B) LS-A158 reactivity as detected by chromogenic immunohistochemistry within the thoracic cord 
of a WT mouse. Application of LS-A158 results in background reactivity that is particularly strong within the 
grey matter, with some reactivity observed within the white matter also (a). At higher magnification (b), LS-
A158 reactivity in grey matter does not show any specific localisation within the tissue, although this reactivity 
is higher than observed for control sections (c) suggesting that the signal is specific to the presence of LS-A158. 



































































This investigation aimed to establish the specificity of commercially and custom designed 
antibodies to both XCR1 and Xcr1. In particular, we sought an antibody capable of 
specifically recognising and binding to murine Xcr1. An important limitation of the method 
used, that should be immediately acknowledged, is that the tested antibodies were not all 
raised to immunogens that were specifically designed to detect the protein for which they 
were evaluated here. Figure 2.1 illustrates the epitopes for which the tested antibodies are 
specified to bind and illustrates how the use of some these antibodies are specific to XCR1 
rather than Xcr1, and vice versa. Therefore, in testing the specificity of antibodies to Xcr1 
that were designed to recognise epitopes of XCR1, it is perhaps unsurprising that these 
antibodies were unable to reliably bind to the protein of our interest.  
The reasons for evaluating these antibodies in spite of their specified reactivity was twofold. 
Firstly, user experience within our lab had demonstrated that LS-A158, despite having a 
specified reactivity to Human XCR1, had given a reliable reactivity to samples prepared 
from Rat (Bird et al., 2018). Secondly, the homology of amino acid sequences for the two 
XCR1 protein homologues in Mouse and Human show a high degree of conservation (70% 
amino acid identity; 81% amino acid positives (identity according to amino acid functional 
group properties) (Altschul et al., 1990). In particular, the immunogen sequence used for 
the production of Abcam188896, which was tested against both XCR1 homologues, has a 
high conservation of amino acid sequence between Mouse and Human homologues (80% 
amino acid identity; 95% amino acid positives (Altschul et al., 1990), Figure 2.1). It could 
therefore be predicted that the two XCR1 homologues share a similarity in i) global protein 
tertiary structures and ii) conformation of epitopes for which the antibodies tested here 
were specified to bind. In tandem with the lack of available antibodies that were raised 
specifically to Xcr1, these two reasons provided the premise for testing of these antibodies 
according to the potential cross reactivity to both homologues. Further justification arose 
from the published use of Abcam 188896 to determine Xcr1 expression within the Mouse 
spinal cord, despite being specified for the detection of Human XCR1 (Zychowska et al., 
2016). 
4.4.1 Transient expression of XCR1 homologues provide a reliable sample for validation of 
antibody specificity 
Initially, testing of antibody specificity was based upon reactivity to the Mouse spleen, for 
which the expression of Xcr1 has been previously documented (Dorner et al., 2009). The 
testing of both LS-A158 and LS-C37380 aimed to provide evidence of specific binding to 
Xcr1 based upon the accepted method of demonstrating consistent reactivity between 
distinct antibodies (Michel, Wieland and Tsujimoto, 2009; Saper, 2009). This consistency 
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could then be used to support specificity to Xcr1 according to the stated specificity of LS-
C37380 to Xcr1 by the manufacturer. Despite the stated specificity of LS-C37380 to Xcr1, a 
reactivity of the antibody that was consistent with Xcr1 detection could not be identified. 
This was also the case when evaluating reactivity by LS-A158. Instead, both antibodies 
demonstrated a large background of staining that was widespread within the tissue. The 
level of staining did correlate with the concentration of antibody, but qualitative 
comparison of antibody reactivity between the different concentrations did not achieve a 
refinement to antibody localisation, as would be expected for an antibody that targets a 
specific epitope. Despite this, there was no way of confirming that this lack of antibody 
reactivity was a consequence of poor antibody specificity or a lack of appropriate epitope 
availability according to the endogenous expression of Xcr1. 
In response to this evidence it became clear that a reliable source of target protein was 
required to overcome the lack of reliability arising from the use of tissue sample to validate 
antibody specificity. To achieve this, a method was developed which utilised the transient 
transfection of HeLa cells to express XCR1-myc or Xcr1-myc, in line with recommendations 
provided for antibody validation (Bordeaux et al., 2010; Saper, 2009) and which had been 
successfully used by prior studies to test the specificity of antibodies to other GPCRs 
(Grimsey et al., 2008; Miyauchi et al., 2009). This method was demonstrated to provide a 
reliable source of the target protein, the presence of which was confirmed via the use of a 
monoclonal anti-C-myc antibody using both immunocytochemistry and western blot 
protein analysis. Moreover, by expressing the target protein in mammalian cells, the target 
protein was subject to intracellular processing that resembles that experienced by the 
protein within cells in situ. This is an important consideration for the testing of antibodies 
to target proteins due to the impact of intracellular processing on protein conformation and 
hence epitope presentation.  
The developed in vitro assay therefore provided distinct advantages over the use of tissue 
samples in that it provided a sample of target protein that could be simultaneously 
confirmed and localised by immunocytochemistry. In addition, the use of non-transfected 
cells served as a true negative control. This enables the confirmation of antibody specificity 
by both demonstrating the specific binding to the target protein and supporting a lack of 
non-specific binding to samples without expression of the target. This is in contrast to the 
use of tissue samples for which the signal obtained from an antibody is extremely difficult 
to determine as being a consequence of specific, on-target binding (Rhodes and Trimmer, 
2006). An additional benefit is the variety of methods in sample processing that can be 
applied to the in vitro sample to mimic the intended application of the antibody for detection 
of antigen in tissue. This permitted the evaluation of all test antibodies by both Western Blot 
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and by immunocytochemistry with and without antigen retrieval treatment. This was a key 
consideration for the development of the in vitro HeLa transfection assay, as it provided a 
sample that could be processed in near identical conditions to that which the test tissue 
sample was subjected to. Use of other methods to test antibody specificity, such as flow 
cytometry, would require different sample preparation conditions and hence may lead to 
discrepancies of antibody behaviour when testing against tissue samples. Moreover, the use 
of double immunocytochemistry enables visual confirmation of colocalisation between the 
test antibody and the anti-tag antibody, thus supporting any antibody signal to arise from 
the specific detection of the target protein in transfected cells. In this project, the use of a 
monoclonal anti-C-myc antibody was demonstrated to provide a consistent and specific 
detection of the target protein. Use of an EGFP tag may provide a yet more reliable 
colocalisation signal, as has been performed elsewhere (Skogs et al., 2017).  
4.4.2 Methods of analysis to support antibody binding and specificity 
To provide support of antibody binding and specificity it was sought to provide an objective 
and quantitative method of analysis to further support qualitative evidence. In using 
polyclonal antibodies that were not specifically designed for the detection of the XCR1 
homologue to which it was being tested, there was the potential for the test antibodies to 
demonstrate specific binding but at a low affinity. This would result in a correspondingly 
low signal. Providing an accurate method to quantify and compare antibody binding was 
therefore important to deduce if the antibody sample contained only a small fraction of 
antibody clones that were capable of binding the target and hence identify a 
correspondingly small change in signal between transfected and non-transfected cells. 
Furthermore, there was potential for the anti-c-myc antibody to block the binding of the test 
antibody to the target protein when performing dual immunocytochemistry protocols due 
to the proximity of the potential epitopes and the C-terminal myc-tag. Therefore, for the 
results presented in this investigation that were collected following assessment by single 
immunocytochemistry only, the intention was to support any observed differences 
identified by quantitative analysis by subsequent evidence of colocalisation to anti-C-myc 
binding. 
To provide the quantitative assessment of antibody binding, two methods were adopted. 
For both of these methods, normalisation to the associated non-transfected control was an 
essential measure to identify the specific impact of target protein expression on antibody 
binding. In addition it was essential to provide a measure of antibody binding that was 
proportional to cell presence. The first method of manual analysis achieved this by 
providing a proportional measure of antibody binding to the presence of DAPI. This method 
relied upon the correlation of DAPI presence to the number of cells present in the sample 
168 
 
and indeed demonstrated good correspondence in results when compared to manual cell 
counting. However, due to evaluation of global DAPI reactivity to the entire image, this 
method was sensitive to variation in the DAPI signal that may arise from components of the 
image that were not cell specific. Despite this, this method showed a consistent capacity to 
identify changes in anti-c-myc binding for all comparisons between transfected and non-
transfected cells, supporting its use in providing quantitative evidence to support specific 
antibody binding when comparing between transfected and non-transfected cells. 
In addition, the manual method of analysis showed strong consistency in identifying similar 
changes in antibody binding between non-transfected and transfected cells to that 
identified by automated analysis by the Opera PhenixTM High Content Imaging System. This 
method provided an analysis that made a greater refinement to the identification of cells 
within the image and was capable of imaging a much greater number of cells in comparison 
to that performed for manual analysis. Consequently, the variation of data from individual 
samples was much reduced and provided a more reliable comparison of antibody binding 
between transfected and non-transfected cells. Furthermore, this method offered the 
capacity to colocalise test antibody signal with the signal obtained from anti-C-myc binding. 
This feature proved valuable when analysing samples that, for unknown reasons, 
demonstrated particularly low transfection efficiency and target protein expression and 
provided a quantitative measure that related directly to specific binding of the test antibody 
to the target protein. Furthermore, it suits previous assessment criteria for the evaluation 
of antibody specificity to other GPCRs (Grimsey et al., 2008). 
4.4.3 Limitations to the Method of analysis for antibody binding between transfected and non-
transfected cells 
Regardless of the method of analysis used, the results collected were sensitive to both the 
efficiency of cell transfection and the variability of background signal within non-
transfected controls. Due to the typically low signal obtained from non-transfected cells, 
even relatively small changes in background signal could lead to drastic changes in the 
differences in antibody binding between non-transfected and transfected cells when 
represented by normalised values. Similarly, a low transfection efficiency would result in 
mean antibody signals that were unable to reliably differentiate from non-transfected 
controls, due to the averaging of mean antibody signal from the entire image (manual 
analysis) or by total cell number (automated analysis). However, restricting the 
quantification of antibody signal to individual cells expressing the target protein according 
to C-myc reactivity, as achieved by automated analysis, did improve the tolerance to these 
limitations as only cell-specific signals contributed to the resulting data. 
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Antibody Specificity to Mouse Xcr1 Specificity to Human XCR1 
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Table 4.1. A summary of outcomes investigating antibody specificity to XCR1 and Xcr1 by immunocytochemistry and Western Blot. All antibodies were tested 




Taking these two limitations in to account provides some explanation as to the variation in 
antibody binding signal obtained for transfected and non-transfected cells when testing an 
antibody that clearly demonstrated no specificity to the expressed target protein. In these 
examples it would be expected that a non-specific antibody would demonstrate the same 
amount of binding, per cell, irrespective of transfection. Indeed, these limitations are why 
the majority of measures of antibody binding that were identified to be statistically 
significant were not considered to accurately reflect a change in antibody binding. Instead, 
these statistical differences, which were also of low magnitude, reflected a variation of 
normalised fluorescent signal obtained as a consequence of the limitations that were 
intrinsic to the methods used. 
The use of stably-transfected cell lines would overcome the limitation of transfection 
efficiency, as demonstrated for the testing of antibodies to both human and mouse CB1 
receptor homologues (Grimsey et al., 2008). The use of cell lines stably-expressing a tagged 
target protein has also been recently used to validate the specificity of 197 antibodies 
(Skogs et al., 2017). The results presented here therefore further support the requirement 
of achieving consistent levels of target protein expression by all cells for reliable antibody 
validation.  
4.4.4 In vitro HeLa transfection assay as a method to support antibody specificity 
Despite the limitations of this method, analysis of HPA013169 vividly demonstrated the 
capacity of this method to provide strong evidence to support antibody specificity to a target 
protein. Qualitative inspection of HPA013169 localisation in transfected and non-
transfected cells alone, clearly illustrates an increase of antibody binding to transfected cells 
that demonstrates a subcellular localisation that is consistent with XCR1-myc expression by 
transfected cells. The difference in antibody binding as a consequence of antibody titer, as 
identified by manual image analysis, lacked clarity due to the method of evaluation relying 
upon signal normalisation to the corresponding non-transfected controls. Direct 
comparison of HPA013169/DAPI RawIntensity between transfected cell samples treated 
with 1µg/ml, 2.5µg/ml and 4µg/ml, however, clearly illustrated the dose-dependent 
increase in antibody binding consistent with a specific reactivity of the antibody. Further, 
and most conclusive, evidence of HPA013169 specificity was provided by the clear 
localisation of HPA013169 to specific cellular regions of XCR1-myc presence, as evidenced 
by colocalisation to regions of binding by the monoclonal anti-C-myc antibody. 
The evidence of HPA013169 obtained by manual analysis was further supported by 
automated analysis. As observed for the manual analysis, the results from the automated 
analysis provided clear evidence of: i) XCR1-myc expression by cells transfected with 
RC221929 as evidenced by the increase in Mean cell anti-C-myc binding ; ii) a relative 
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quantitative increase of HPA013169 binding to cells transfected with RC221929 in 
comparison to non-transfected cells that was consistent when used as part of both single 
and double immunocytochemistry protocols; and iii) a quantitative increase in HPA013169 
signal intensity within specific image regions that correspond to the expression of XCR1-
myc within transfected cell populations.  
However, it should be noted that a higher amount of background signal was observed for 
HPA013169 in some samples of non-transfected cells. This background signal appeared 
when using a separate vial of the antibody to that used for manual analysis. Although from 
the same lot of antibody, this does call in to question whether this antibody demonstrates 
non-specific binding when used for immunocytochemistry. Indeed, although HPA013169 
demonstrated the capacity to bind to the XCR1-myc protein by western blot, an additional 
band could also be observed following prolonged exposure. Therefore, whilst providing 
evidence of HPA013169 to reliably bind to XCR1, this analysis suggests that this antibody 
may also bind off-target epitopes, albeit with lower affinity. 
4.4.5 A lack of available antibodies specific to Mouse Xcr1 
Other results from this analysis however, failed to demonstrate the specificity of any other 
of the tested antibodies. Although the specificity of these antibodies to the XCR1 
homologues tested here was not necessarily expected due to the inconsistency between the 
stated and tested target proteins (discussed above), two antibodies (LS-C37380 and 
Abcam188896) did not demonstrate specificity to the protein stated by the vendor. In 
addition, the specificity of a custom-designed antibody to Xcr1 could not be supported. This 
is despite clear evidence of specific recognition by this custom antibody to the target 
immunogen by ELISA. In sum, no evidence was provided to support the specificity of any of 
the five antibodies tested, by both immunocytochemistry and western blot, to Xcr1.  
This lack of available antibodies has provided an obstacle to future investigations of Xcr1 
presence in the Mouse CNS as it has not been possible to reliably determine the presence 
and localisation of Xcr1 protein in situ. Preliminary attempts were made to use LS-A158 
within the mouse CNS and here it was observed that the reactivity from LS-A158 
demonstrated widespread reactivity, particularly within the grey matter of spinal cord. 
Double immunohistochemistry suggested colocalisation of LS-A158 binding to NeuN-
positive neurons within both thoracic and sacral regions. However, as evidenced by the in 
vitro assay of LS-A158, this antibody demonstrated large background staining that was 
observed for both transfected and non-transfected HeLa cells. Therefore, in addition to the 
lack of evidence for LS-A158 specificity to Xcr1, the background signal identified in spinal 
cord sections suggests that this antibody exhibits promiscuous binding to multiple cellular 
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epitopes. Consequently, the signal observed from LS-A158 in the mouse spinal cord could 
not be supported in any way to represent the localisation of Xcr1. 
Furthermore, the specificity of Abcam 188896 to Xcr1 was not supported by this 
investigation and calls in to question the current evidence of Xcr1 presence within the 
mouse spinal cord (Zychowska et al., 2016). Assessment of this antibody by the in vitro HeLa 
transfection assay also failed to demonstrate specificity of Abcam 188896 to XCR1. This is 
the protein for which the manufacturer has claimed specificity. According to the results 
presented here however, this antibody does not provide a reliable or specific recognition of 
either Human or Mouse XCR1 homologues.  
It is noteworthy to add that there are several other sources of anti-Xcr1 antibodies available, 
for example a monoclonal anti-mouse/rat Xcr1 antibody is now available from Biolegend 
and has been extensively tested for specificity using flow cytometry. Use of the in vitro HeLa 
transfection assay described here would provide a useful validation to test the specificity of 
this antibody to mouse Xcr1 following IHC and ICC protocols. 
4.4.6 Summary 
A primary objective of this project was to identify if Xcr1 was expressed in the mouse CNS. 
An essential requirement for this objective is the use of reagents that provide a reliable and 
specific measure of Xcr1 presence. In line with previous (Michel, Wieland and Tsujimoto, 
2009; Bordeaux et al., 2010; Saper, 2009) and current (Skogs et al., 2017) 
recommendations, a method was established to utilise the expression of tagged target 
proteins for the evaluation of antibody specificity. This method was found to provide a 
reliable source of target protein that could be used to assess antibody binding to both native 
and denatured conformations. Via the application of this method, it has not been possible to 
identify any antibody that demonstrates specificity to Mouse Xcr1. However, it has provided 
validation for the use of HPA013169 for the detection of Human XCR1 by both 
immunohistological and Western Blot protein analyses. This evidence has provided the 
basis to perform immunohistochemical detection of XCR1 within the Human spinal cord and 
gives credence to any identified reactivity of this antibody to be a result of the specific 




Chapter 5: Investigation of Xcr1 and Xcl1 expression in Amyotrophic lateral sclerosis 
5.1 Introduction 
As suggested by previous investigation (Zychowska et al., 2016; Bird et al., 2018) the 
expression of Xcr1 and Xcl1 within the CNS is likely modulated by the presence of 
inflammation. Therefore, to provide an assessment of Xcr1 and Xcl1 expression within the 
context of a disease that demonstrates a prominent central inflammatory response, this 
study has evaluated Xcr1 and Xcl1 expression within mouse models of Amyotrophic Lateral 
Sclerosis (ALS). In addition, based on the success of antibody validation to detect human 
XCR1, a preliminary investigation has been made in to the expression of XCR1 within the 
spinal cord of human subjects. 
5.1.1 Amyotrophic Lateral Sclerosis 
ALS, also known as Motor Neuron Disease (MND), is a progressive neurodegenerative 
disorder that is typically fatal within 3-5 years of diagnosis. The disease was originally 
described in the late 19th century by Jean-Martin Charcot and was so named according to 
the observed muscle wastage (amyotrophic) and scarring of the lateral spinal tracts (lateral 
sclerosis) in post-mortem patient tissue. The disease presents an incidence of between 1-3 
persons per 100,000 people per year with an estimated prevalence of disease to be 5 per 
100,000 people (Al-Chalabi and Hardiman, 2013; Taylor, Brown and Cleveland, 2016), 
statistics which vividly illustrate the rapid fatality of the disease. 
ALS is characterised by the loss of lower motor neurons within the ventral horn of the spinal 
cord with concomitant degeneration of descending corticospinal tracts that arise from 
upper motor neurons that reside within layer V of the primary motor cortex. The primary 
bias of pathology can vary between upper and lower motor neurons, resulting in variability 
of initial symptom presentation. Primary degeneration of upper motor neurons is 
associated within increased limb tone, hyperreflexia and spasticity; degeneration of lower 
motor neurons is associated with muscle weakness and reduced voluntary muscle control. 
Hence, the disease presents with a variable focus of onset that is typically classified as spinal 
or bulbar-onset and is associated with symptoms of the body innervated by these respective 
regions (Al-Chalabi and Hardiman, 2013). Irrespective of the focus of disease onset, ALS 
results in the contiguous transmission of disease throughout the CNS (Ravits, Paul and Jorg, 
2007). The resultant fatality of ALS is most commonly a consequence of motor neuron 
degeneration within the brainstem, leading to difficulties in speaking, swallowing and 
breathing that ultimately leads to respiratory failure. 
ALS has been broadly categorised as sporadic (sALS) and familial ALS (fALS) to reflect the 
presence or absence of inheritability. Approximately 10% of ALS cases exhibit transmission 
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within families, whilst the majority of cases occur sporadically (Ling, Polymenidou and 
Cleveland, 2013). However, this categorisation has sometimes been confused with the 
presence or absence of a genetic causation to the disease. Since the discovery of mutations 
in the SOD1 gene to cause ALS (Rosen, 1993), there are now more than 100 identified 
genomic loci that associate with the disease (alsod.iop.kcl.ac.uk). Whilst a causative link 
between all of these loci and the disease is not yet present ALS is now considered to arise 
from a complex interaction between genetic and environmental factors, with a predisposing 
genetic vulnerability considered essential to the precipitation of the disease. 
5.1.2 ALS pathology 
The pathological mechanisms of ALS are varied and only beginning to be elucidated. This is 
due to the relatively recent discovery of a key pathological hallmark of the disease, relating 
to the aggregation of the Transactive response DNA binding protein 43kDa (TDP-43) 
protein, and the capacity of contemporary techniques to illuminate the genetic 
underpinnings of the disease. Indeed, over the past decade, a tremendous progress has been 
made in the understanding of ALS. The associated pathological mechanisms are diverse and 
include: dysregulation of RNA processing; prion-like protein misfolding and aggregation; 
oxidative stress; defective autophagy, protein degradation and ER stress; exicitotoxicity; 
dysfunctional axonal transport; mitochondrial abnormalities; and neuroinflammation (for 
excellent reviews see e.g. (Barber and Shaw, 2010; Ferraiuolo et al., 2011; Ilieva, 
Polymenidou and Cleveland, 2009; Ling, Polymenidou and Cleveland, 2013; Taylor, Brown 
and Cleveland, 2016).   
Previous to the identification of TDP-43-positive inclusions, the major understanding of ALS 
revolved around investigations relating to Cu2+-Zn2+-Superoxide Dismutase (SOD1). SOD1 
is a cytoplasmic antioxidant enzyme that catalyses the reduction of superoxide metabolites. 
In 1993, mutations of the SOD1 gene, including that leading to a G>A mutation at position 
93 of the SOD1 protein, was identified to associate with ALS (Rosen, 1993). The mechanistic 
link between mutations of SOD1 and ALS is still unclear, but is suggested to arise 
independent to the dismutase activity of the enzyme. The pathological consequences of 
mutant SOD1 is instead associated with a toxic gain of function which, among other 
suggestions, includes the misfolding of mutant SOD1 protein and the formation of 
ubiquitinated aggregates that accrue with the progress of disease (Bruijn et al., 1998; Banci 
et al., 2008). Importantly, aggregations of SOD1 protein have so far not been observed to 
occur in patients without SOD1 mutation and represents a specific component to such 
mutations (Mackenzie et al., 2007). Moreover, the pathology caused by mutations in SOD1 
is almost exclusively associated with upper and lower motor neurons unlike that observed 
for other genetic mutations (Joyce et al., 2015). Mutations of the SOD1 gene demonstrate an 
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extremely high penetrance in causing ALS and account for approximately 20% of fALS cases 
(Rosen, 1993).  
The recognition that TDP-43, a protein arising from the TARDBP gene, is present within 
neuronal and glial cytoplasmic inclusions (Neumann et al., 2006) has prompted an 
altogether different understanding of the pathology of ALS. TDP-43 inclusions are estimated 
to occur in 97% of all ALS cases, with the remaining 3% of cases demonstrating aggregations 
of SOD1 and Fused-in Sarcoma (FUS) protein (Ling, Polymenidou and Cleveland, 2013). 
Moreover, mutations of TARDBP have now been identified to cause ALS (Sreedharan et al., 
2008). Thus, the TARDBP gene and its translated protein contribute to the major convergent 
pathology observed in the vast majority of ALS cases. Furthermore, the aggregated presence 
of either TDP-43 or other proteins (including SOD1) support the capacity for distinctive 
pathophysiology to cause ALS. 
TDP-43 is an RNA binding nuclear factor that contributes to the processing and alternative 
splicing of numerous mRNAs (Sephton et al., 2012). Mutations have been identified 
throughout the protein which are associated with causing ALS (alsod.iop.kcl.ac.uk). 
Importantly, TARDBP mutations can also result in inclusion body myopathy (IBM) and 
frontotemporal dementia (FTD), with aggregations of TDP-43 also being a pathological 
hallmark of these diseases (Salajegheh et al., 2009; Neumann et al., 2006). This observation, 
along with growing characterisation of the molecular pathology associated with these 
diseases, suggests that some forms of ALS represent a spectrum of disease. Indeed, the 
presence of ALS symptoms is often observed in conjunction with symptoms of FTD. 
Furthermore, post-mortem assessment has demonstrated the concomitant presence of 
TDP-43 pathology more widely within the brain including frontal, temporal and limbic 
regions, alongside that observed within the motor system for some ALS patients (Cooper-
Knock et al., 2012). 
A further seminal discovery in the understanding of ALS, was the identification of a 
hexanucleotide repeat expansion within a non-coding region of C9ORF72 to cause ALS, FTD, 
or both (C9-ALS/FTD) (DeJesus-Hernandez et al., 2011). The presence of this expansion is 
suggested to account for a significant proportion of patients suffering from ALS and FTD, 
with one study demonstrating 40% of fALS, 25% of familial FTD, 7% of sALS and 6% of 
sporadic FTD cases to arise from this mutation (Majounie et al., 2012). The function of 
C9orf72 is currently unclear, but C9-ALS/FTD is suggested to be a consequence of a toxic 
gain of function that results in repeat associated non-AUG (RAN)-translation of dipeptide 
repeats, formation of RNA foci and the sequestration of RNA binding proteins (DeJesus-
Hernandez et al., 2011; La Spada and Taylor, 2010; Mori et al., 2013) as well as the potential 
for age-related disturbances to microglial activation (O'Rourke et al., 2016). Like the 
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majority of other genetic mutations linked with ALS, TDP-43 neuronal and glial cytoplasmic 
inclusions are evident within the CNS of patients expressing a pathological C9ORF72 
hexanucleotide expansion.  
The consistency of TDP-43 pathology has led to the proposal that for the majority of ALS 
cases, irrespective of the underlying genetic mutation, a disruption to the function of this 
protein is a cornerstone of ALS pathology. Both in vitro and in vivo studies have 
demonstrated the maintenance of TDP-43 expression to a specific level to be essential to 
cell viability and the integrity of motor function in animal models (Wils et al., 2010; Johnson 
et al., 2008). The reason for this is suggested to relate to the phase-separation of TDP-43 
and associated proteins. When bound to RNA, TDP-43 and associated RNA binding proteins 
coalesce and form membraneless organelles within the surrounding media. The phase 
separation of such structures is positively correlated with the concentration of associated 
proteins and arise from the interaction of low-complexity domains of RNA binding proteins. 
The most common ALS-associated mutations in TARDBP occur within coding regions of 
TDP-43 low complexity domains, with a much lower frequency of ALS-associated mutations 
found within in other domains (Chiang et al., 2016). Thus, the formation of TDP-43 
inclusions can be envisaged to occur either as a consequence of mutations within the low 
complexity domain or from mutations in which the nuclear localisation of the protein is 
disrupted. Such mutations would therefore promote the phase separation and subsequent 
fibrillisation of TDP-43 and associated RNA binding partners either as a consequence of 
increasing the endogenous capacity for this or by generating an excessive cytoplasmic 
concentration that results in precipitation of aggregates (Taylor, Brown and Cleveland, 
2016). Moreover, these mutations may not be necessary within TDP-43 itself but instead 
within the proteins with which TDP-43 interacts. A similar mechanism may also be evident 
for other proteins, as mutation within the low complexity domains of other RNA binding 
proteins such as FUS and hnRNP-A1 results in ALS and IBM (Shang and Huang, 2016). Why 
TDP-43 represents the predominant protein identified within inclusions will require 
further characterisation of its binding partners and also of the RNA species that it processes. 
However, it is becoming apparent that a number of ALS-associated genes are processed by 
TDP-43 (White et al., 2018). 
In summary, examination of TDP-43 biology illustrates several concepts that are associated 
with ALS pathology, namely dysregulation of RNA processing and the prion-like formation 
of protein aggregates. The multitude of associated pathologies likely reflect the downstream 
consequences of these initial factors which manifest within the unique environment of the 
CNS. It is important to recognise that, although leading to the aggregation of a distinct 
protein, mutations in SOD1 also recapitulate many of the pathologies observed in patients 
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that display TDP-43 pathology. However, a major distinction appears to arise from the 
prevalent role of TDP-43 in RNA processing, for which SOD1 is not involved.  
5.1.3 Inflammatory and non-cell autonomous mechanisms of ALS 
A unanimous feature of ALS is the activation of resident microglia and astrocytes and the 
recruitment of peripheral immune cells to sites of degeneration within the CNS. In addition 
to the cell autonomous mechanisms of disease exemplified by TDP-43 pathology discussed 
above, the contribution of non-cell autonomous mechanisms to the loss of motor neurons is 
an essential feature of ALS pathology.  
Seminal work to demonstrate this was achieved by the generation of chimeric mice, in 
which mutant SOD1 was heterogeneously expressed by cells throughout the animal. It was 
observed that the presence of mutant SOD1-expressing non-neuronal cells could induce 
SOD1 pathology within adjacent wild-type neuronal cells. Conversely, mutant SOD1-
expressing neuronal cells demonstrated limited signs of pathology and survived much 
longer when surrounded by wild-type non-neuronal cells (Clement et al., 2003). 
Subsequent work has since refined this evidence and demonstrated the essential role of 
non-neuronal cells to the onset and progression of neurodegeneration. In particular, it is 
evident that the activation and/or dysfunction of surrounding microglia, astrocytes and 
oligodendrocytes drives the progression of the disease (Boillee, Vande Velde and Cleveland, 
2006; Yamanaka et al., 2008; Frakes et al., 2014; Ferraiuolo et al., 2011). These cells 
contribute to the loss of motor neurons by reducing trophic support (Hughes et al., 2013), 
enhancing excitoxicity and the release of soluble toxic factors (Di Giorgio et al., 2008; 
Haidet-Phillips et al., 2011; Frakes et al., 2014) . These include pro-inflammatory molecules 
that exacerbate the inflammatory response, as well as highly reactive oxidative species 
(Barber and Shaw, 2010; Hensley et al., 2006). It is important to recognise that the 
phenotype adopted by these glial cells is specific to the presence of disease (Chiu et al., 2013; 
Phatnani et al., 2013). The functions and expression profiles of these cells are therefore 
intricately related to the surrounding environment and cannot be easily categorised 
according to models of polarised states of activation.   
In addition to glia, peripheral immune cells are also recruited to sites of pathology (Henkel 
et al., 2004). These cells play diverse roles dependent on the stage of disease. For example, 
regulatory T-cells (TReg) are indicated to down regulate glial activation and promote the 
expression of immunomodulatory cytokines and neurotrophic factors (Beers et al., 2008; 
Mantovani et al., 2009) and support neuronal function during early stages of disease. As the 
disease progresses however this adaptive immune response contributes to neuronal loss 
and decreased survival following the recruitment of phagocytic and cytotoxic cells, as well 
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as intercellular signalling pathways, such as that mediated by TNF-α, decreasing cellular 
viability (Henkel et al., 2004; Phani, Re and Przedborski, 2012; Mantovani et al., 2009). 
Moreover, the recruitment of peripheral immune cells contributes to the adoption of 
specific activation states by resident glial cells in a mutant SOD1 mouse model. Specifically, 
there appears to be a distinction in the time and activity of CD4+ and CD8+ T cells, in which 
the recruitment of CD4+ T-cells during disease onset and progression appeared to confer a 
protective role for neuronal survival via the modulation of microglial and astrocyte 
activation. The recruitment of CD8+ T-cells was instead observed at the end-stage of disease 
only and suggested to be associated with neuronal injury (Beers et al., 2008).  
5.1.4 The role of chemokines in ALS 
Specific roles pertaining to the pathology of ALS by chemokines has not been demonstrated. 
However, there has been little focus of their role in the disease. One method that has sought 
to provide an insight to the role of cytokines in the disease, and overcome the limitations of 
tissue access during the disease progression, has been to assess the presence of cytokines 
within the blood of ALS patients. A recent meta-analysis of these studies compared the 
expression of 14 inflammatory cytokines between 812 ALS patients and 639 controls (Hu 
et al., 2017). This indicated a consistent increase of TNF-α, CXCL8, VEGF, IL-1β and IL-6. 
Elevations of TNF-α, IL-1β and IL-6 appear to be ubiquitous to neurodegenerative disease 
as they are also observed to be elevated in the blood collected from patients with 
Alzheimer’s (AD) and Parkinson’s Disease (PD).  In contrast, CXCL8 demonstrated 
consistent and robust differences to controls across several studies of ALS patients. 
Interestingly, CXCL8 elevations also appear to be unique to ALS in comparison to AD and PD 
samples (Qin et al., 2016), suggesting CXCL8 to reflect a specific component to the 
inflammatory response in ALS (Hu et al., 2017). 
With the exception of CCL2 and its receptor CCR2, there has been minimal investigations to 
the contribution of chemokines and their receptors to the pathology of ALS within the CNS 
parenchyma. CCL2 is considered the principal chemotactic protein for the recruitment of 
monocytes and its expression by cells of the CNS is observed only in response to 
inflammation. Specifically, the upregulation of CCL2 by glial, endothelial and neuronal cells 
is observed in the spinal cords of ALS patients (Baron et al., 2005; Henkel et al., 2004) and 
is considered a component of the innate immune response to the onset of ALS (Jara et al., 
2017). Indeed, the increased expression of Ccl2 is observed as early as postnatal day 15 in 
a mutant SOD1 mouse model (Henkel et al., 2006) and contributes to the significant 
migration of peripheral immune cells that accumulate within the spinal cord and motor 
cortex as the disease progresses (Jara et al., 2017). Moreover, CCL2 levels are elevated 
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within the CSF and serum of ALS patients in comparison to control samples (Baron et al., 
2005; Henkel et al., 2004). 
5.1.5 A potential role for XCR1 and XCL1 in ALS 
To the best of our knowledge, there has been no documented evidence for the contribution 
of XCR1 or XCL1 to the pathology of ALS. However, ALS demonstrates a consistent 
neuroinflammatory response irrespective of the underlying aetiology. This is characterised 
by a pronounced activation of resident glial cells and the recruitment of peripheral immune 
cells, including dendritic cells (Henkel et al., 2004).  
According to the previous observations of our group (Bird et al., 2018) XCR1 and XCL1 may 
participate in the central inflammatory response to peripheral nerve injury. Moreover, it 
has been suggested that the production of Xcl1 by activated microglia in a mouse model of 
diabetic neuropathy may contribute to the pathological hyperalgesia and allodynia 
observed in model animals through intercellular communication with resident neurons 
(Zychowska et al., 2016). As such, the pathophysiology of ALS lends itself to the previous 
suggestions of XCR1 and XCL1 function in the CNS in that it presents a disease in which there 
is significant damage to central neurons and their efferent axons that is accompanied by the 
consistent and prolific activation of resident glial cells.  
In this study, we sought to evaluate the expression of Xcr1 and Xcl1 within the CNS using 
two distinct mouse models of ALS. The first, and primary model used (referred to as the 
TDP-Q331K model), represents a recently characterised mouse colony (Arnold et al., 2013) 
that expresses a mutant TARDBP under the transcriptional control of the mouse prion 
promoter within a C57BL/6NJ genetic background. This mutation results in the substitution 
of glutamine (Q) to lysine (K) at position 331 of the TDP-43 protein and was detailed to be 
expressed with a copy number of 3 in transgenic mice. This model therefore represents the 
expression of mutant TARDBP primarily within motor neurons and astrocytes at an 
expression level that was aimed to more closely reflect endogenous expression levels of the 
gene. Previous to this study, these mice were demonstrated to exhibit several pathologies 
that reflected that observed in ALS patients, including widespread alterations to gene 
expression and mRNA splicing, motor neuron and motor axon loss and glial activation. 
However, the disease course of this model is comparatively mild to that observed from other 
models, with symptom severity reaching a plateau at ~10 months of age (Arnold et al., 
2013). Throughout the course of this project, available tissue was collected from and 
alongside the ongoing characterisation of the model by Dr Jodie Stephenson (University of 
Sheffield).   
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Samples were also collected from a second model which utilises overexpression of SOD1G93A 
by an inbred C57BL/6 mouse colony (referred to as the SOD1-G93A model) (Mead et al., 
2011). This model demonstrates a comparatively rapid and aggressive disease course and 
has been extensively characterised by numerous groups, including those located at the 
University of Sheffield under the supervision of Dr Richard Mead and others. As observed 
for patients with this mutation, the SOD1-G93A model demonstrates extensive motor 
neuron loss, SOD1 aggregation and glial activation. 
5.1.6 Aims 
In accordance with the objective of this project to identify and characterise the expression 
of Xcr1 and Xcl1 within the mouse CNS, this study aims to evaluate the expression of Xcr1 
and Xcl1 within the spinal cord of control, TDP-Q331K and SOD1-G93A mice. Furthermore, 
primary microglial cultures were prepared from TDP-Q331K and SOD1-G93A mice in order 
to evaluate the expression of Xcl1 within microglia, in line with the suggestions proposed 
by Zychowska et al. By utilising these models with a contrasting genetic underpinning it was 
aimed to capture the expression of Xcr1 and Xcl1 across a spectrum of pathophysiology that 
reflects that observed in ALS. 
In line with previous suggestions that Xcr1 and Xcl1 expression in the CNS is influenced by 
an inflammatory stat, a key pathology to examine within the mouse models used was the 
presence of activated glial cells. In particular, examination of microglial activation according 
to Iba-1 reactivity and morphology (Beynon and Walker, 2012) was performed. This was 
key to identify any association between microglial activation and Xcr1 and Xcl1 expression, 
as these cells were suggested to represent the key source of Xcl1 in a mouse model of 
diabetic neuropathy (Zychowska et al., 2016).  
In light of the failure to obtain a reliable antibody to determine Xcr1 expression (Chapter 
4), characterisation of Xcr1 protein localisation within the CNS of mice has not been 
possible. However, based on the success of identifying a reliable antibody for the detection 
of human XCR1, a preliminary investigation of XCR1 expression has been performed using 
spinal cord samples obtained from ALS patients and neurological controls. This study has 
therefore aimed to provide an insight to the expression of XCR1 and XCL1 within the CNS of 
mouse and man and identify any potential contributions of this chemokine signalling axis 





5.2.1 Xcr1 and Xcl1 expression: Mouse Models of ALS 
As has been observed for other chemokines within the CNS, should Xcr1 and Xcl1 be 
expressed by resident cells of the CNS parenchyma, the presence of an inflammatory 
response is likely to influence their expression. By utilising the TDP-Q331K and SOD1-G93A 
models, it was aimed to assess the expression of Xcr1 and Xcl1 at the level of mRNA in the 
context of a central inflammatory response. Samples of thoracic cord from each of the 
models were collected and processed for the detection of Iba-1 and GFAP in order to assess 
the response of resident microglia and astrocytes test for the presence of central 
inflammation. RNA samples were also collected from whole spinal cord and assessed by 
qPCR for the presence of Xcr1 and Xcl1 transcripts.   
5.2.1.1 Glial reactivity within thoracic cord of ALS mouse models 
The thoracic region of the spinal cord represents the largest subdivision of the spinal cord 
vertebrae. In mice there are 13 thoracic cord segments. In comparison to the cervical and 
lumbar enlargements of the spinal cord, comparatively little investigation of the thoracic 
cord has been made within mouse models of ALS. This is primarily due to the more obvious 
pathology of lower motor neurons within the cervical and lumbar regions that innervate the 
forelimbs and hindlimbs, respectively. Due to the collection of the lumbar and cervical 
regions for other projects, thoracic cord was used to characterise glial reactivity within the 
spinal cord of the mouse models used here.  To do this, double immunohistochemistry to 
detect the reactivity of microglia and astrocytes using Iba-1 and GFAP, respectively, was 
performed according to the protocol described in section 2.1.3.2. 
5.2.1.1.1 Glial reactivity within the thoracic cord of 6 month TDP-Q331K and NTg mice 
For the analysis of TDP-Q331K mice, thoracic cord was collected from mice at age 6 months 
and 10 months, along with the same sample from age-matched controls. For each 
characterisation it was aimed to evaluate glial reactivity using at least 3 NTg and 3 TDP-
Q331K mice. C-myc reactivity of each cord was also evaluated to confirm the expression of 
myc-tagged Human TDP-Q331K within transgenic animals. 
Analysis of thoracic cord from NTg and TDP-Q331K mice demonstrates the consistent 
localisation of TDP-Q331K expression within neurons throughout the grey matter and 
white matter of the thoracic cord. This is in accordance with the expected expression of 
human TDP-Q331K within neurons and astrocytes of transgenic TDP-Q331K mice.  A 
representative example of this is demonstrated for mice aged 6 months (Figure 5.2.1) in 
which no such C-myc reactivity is observed for NTg mice. 
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Figure 5.2.1. Iba-1 reactivity in the thoracic cord of NTg and TDP-Q331K at age 6 months. Representative images 
of Iba-1 reactivity in the thoracic cord of NTg (A) and TDP-Q331K (B) mice at age 6 months. Images display C-
myc (a) and Iba-1 (b) reactivity of entire coronal thoracic cord section. White dashed line of (b) used to identify 
dorsal and ventral regions of thoracic cord. Higher magnification of dorsal (c) and ventral (d) regions of thoracic 
cord. White dashed boxes in B (c) highlight prominent regions of Iba-1 reactivity that are distinct from that 
observed in NTg. Scale bars = 200µm. C) Semi-quantitative comparison of Iba-1 area of reactivity in thoracic 
cord. Iba-1 area increases proportionally in both white and grey matter regions for TDP-Q331K mice, relative to 






































































































Figure 5.2.2. Iba-1 reactivity in the ventral horn of a female NTg (A) and Q331K (B) mouse at 6 months. Images 






























Figure 5.2.3 Iba-1 reactivity in the lateral white matter of a female NTg (A) and Q331K (B) mouse at 6 months. 











Iba-1 reactivity demonstrated a uniform distribution throughout the thoracic cord of NTg 
animals, and identified the homogeneous presence of ramified microglial cells across the 
entire thoracic cord region. In contrast, Iba-1 reactivity in TDP-Q331K animals 
demonstrated an enhanced level of reactivity and also detected the presence of distinct sites 
of reactivity increase. This was most prominent within the dorsal and lateral regions of the 
thoracic cord white matter. In addition, the morphology of Iba-1 positive cells within the 
grey matter of cord becomes more constricted, demonstrating processes which are thicker 
and more compact in comparison to those observed from NTg mice (Figure 5.2.2 and 5.3.3). 
The enhanced reactivity of microglia is supported by quantification of Iba-1 area across the 
thoracic cord. For this analysis, 6 sections of thoracic cord were analysed from 3 TDP-Q331K 
mice and 1 NTg mouse. Collection of three NTg mice was performed but Iba-1 reactivity 
could not be determined from 2 of these mice due to disruption of thoracic cord integrity. 
In comparison to the NTg mouse, Iba-1 area is increased across the entire thoracic cord of 
TDP-Q331K mice by an average of 49%. This increase is consistent within both white (55%) 
and grey matter (48%) regions, supporting the global activation of microglia within the 
spinal cord of TDP-Q331K mice at 6 months of age. 
To provide an indication of how microglial activation occurs throughout the entire spinal 
cord, Iba-1 reactivity along the entire rostral-caudal axis of thoracic cord was analysed at 
intervals of 180µm for a 6 month TDP-Q331K mouse. The increased Iba-1 reactivity seen 
within the dorsal region of thoracic cord in figure 5.2.1 (B, b) was observed for every section. 
Reactivity in the lateral regions however was less consistent and observed more prevalently 
within some sections than others, suggesting distinct regions of microglial activation within 
lateral regions of the white matter. 
5.2.1.1.2 Glial reactivity within the thoracic cord of 10 month TDP-Q331K and NTg mice 
As performed for 6 month mice, Iba-1 reactivity was assessed in 10 month TDP-Q331K and 
NTg mice to evaluate microglial activation. In addition, GFAP reactivity was also analysed 
to evaluate the activation of astrocytes (Figure 5.2.4). 
As observed for mice at 6 months of age, TDP-Q331K mice demonstrate Iba-1 reactivity that 
is indicative of the global activation of microglia. In comparison to NTg mice, Iba-1 reactivity 
was observed to be increased and this was particularly evident in white matter regions 
(Figure 5.2.6) in comparison to grey matter regions (Figure 5.2.5). Distinct to NTg mice, 
TDP-Q331K mice demonstrated increased Iba-1 reactivity predominantly within dorsal and 
lateral regions of the white matter. This is associated with the presence of numerous, highly 



















          














         
         
   
    
   
   
   
    
     
      
  
Figure 5.2.4. Glial reactivity within the thoracic cord of NTg and TDP-Q331K mice at 10 months. Iba-1 (red) and 
GFAP (green) reactivity were used to identify microglia and astrocytes, respectively, in thoracic cord of NTg (A) 
and TDP-Q331K (B) mice at 10 months of age. White dashed line in a and d used to distinguish Dorsal and Ventral 
regions of thoracic cord. Higher magnification of dorsal region in b and e; higher magnification of ventral region 
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TDP-Q331K that is distinct to NTg. Scale bars = 200µm. C) Quantitative evaluation of Iba-1 Area in total, white 
matter and grey matter regions of thoracic cord. Iba-1 area is significantly increased in total area of thoracic 
cord (*, mean difference = 0.719, p = 0.014) and White matter (*, mean difference = 1.193, p = 0.036) of TDP-
Q331K mice in comparison to NTg. D) Quantitative evaluation of GFAP area in total, white matter and grey 
matter regions of thoracic cord of NTg and TDP-Q331K mice. GFAP reactivity is increased in grey matter of TDP-
Q331K mice in comparison to NTg, although this does not achieve statistical significance after Holm-Sidak 




























Figure 5.2.5. Iba-1 reactivity in the ventral horn of a female NTg (A) and Q331K (B) mouse at 10 months. Images 






























Figure 5.2.6. Iba-1 reactivity in the lateral white matter of a female NTg (A) and Q331K (B) mouse at 10 months. 











Differences in Iba-1 reactivity within grey matter were less distinct than that observed at 6 
months. This appears to arise from changes in the microglial state of NTg mice rather than 
a decreased activation of microglia within TDP-Q331K mice. Indeed, Iba-1 reactivity within 
microglia of NTg mice demonstrates the presence of cells with a more constricted 
morphology, indicative of a more activated phenotype.  
In support of these qualitative examinations, quantitative assessment of Iba-1 area 
demonstrated a significant increase of Iba-1 presence within the thoracic cord of TDP-
Q331K mice. This corresponded to an increase of 72% across the entire cord, in comparison 
to NTg mice. However, independent assessment of Iba-1 area within grey and white matter 
regions demonstrates this increase to arise predominantly from increases of Iba-1 presence 
within the white matter. Here, Iba-1 area was significantly increased by an average of more 
than 2-fold (119%) in comparison to NTg mice. In comparison, the increase of Iba-1 area in 
grey matter was less obvious, corresponding to an increase of 30% within thoracic cord of 
TDP-Q331K mice compared to NTg. However, this difference did not achieve statistical 
significance. 
The consistency of increased Iba-1 reactivity within the white matter of TDP-Q331K mice 
at 10 months of age was supported by evaluation of Iba-1 reactivity along the entire rostro-
caudal axis of the thoracic cord of a single TDP-Q331K mouse (Appendix 5). As performed 
for mice at 6 months, Iba-1 reactivity was assessed at 180µm along the thoracic cord. In 
contrast to that observed for the 6 month mouse, Iba-1 reactivity within the thoracic cord 
white matter was observed to be consistently increased within both dorsal and lateral 
regions for every section. This suggests a more widespread activation of microglia within 
the white matter of spinal cords from TDP-Q331K mice at age 10 months in comparison to 
6 months. 
In comparison to the activation of microglia, changes in GFAP reactivity were less obvious 
between TDP-Q331K mice and NTg. Visual inspection shows GFAP reactivity within NTg 
mice to be most prominent within the white matter, with less consistent astrocyte presence 
within the grey matter. In comparison, GFAP reactivity within TDP-Q331K indicates 
astrocytes to be distributed more uniformly within the grey matter of TDP-Q331K mice, 
suggesting a recruitment of these cells to the grey matter. Indeed, quantitative examination 
of GFAP area suggests little change across the entire thoracic cord region of TDP-Q331K 
mice in comparison to NTg. Small increases in GFAP area were observed across total (13%) 
and white matter (7%) regions. However, in support of a greater astrocyte presence within 
the grey matter of TDP-Q331K mice, GFAP area was found to be increased by 31% in 
comparison to NTg mice, although this difference did not achieve statistical significance. 
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Overall, these data support a global activation of glial cells within the thoracic cord of TDP-
Q331K mice. This is most prominently observed for microglia which demonstrate 
progressively increased reactivity as the disease progresses, a feature that is most apparent 
within the white matter of thoracic cord.  
5.2.1.1.3 Glial reactivity within the thoracic cord of SOD1-G93A mice at 90 days 
The predominant focus on lumbar regions of the spinal cord in murine models expressing 
SOD1 has led to extensive characterisation of glial activation within these regions and is 
often the principal region for investigation. This is due to the bias of pathology caused by 
SOD1 mutations to be focussed predominantly towards the lower motor neurons of the 
spinal cord. However, it has been recognised that such mutations cause impairments of the 
autonomic nervous system in mice expressing mutant SOD1. This feature is associated with 
the degeneration of preganglionic sympathetic motor neurons within the thoracic cord 
(Kandinov et al., 2013; Kandinov et al., 2011). As such, the activation of glia within the 
thoracic cord was expected, but for the purposes of this study evidence of glial reactivity 
within thoracic cord would support the prevalence of glial activation throughout the spinal 
cord of SOD1-G93A mice. 
As performed for TDP-Q331K mice, the activation of microglia and astrocytes were 
evaluated by assessing Iba-1 and GFAP reactivity. For the assessment of mice at 90 days, 
sections of thoracic cord were obtained from 5 NTg mice and 6 SOD1-G93A mice.  
As displayed in figure 5.2.7, Iba-1 reactivity demonstrates an aggressive and widespread 
increase across the entire thoracic cord of SOD1-G93A samples. This is in comparison to the 
homogeneous distribution of ramified microglia observed for NTg animals. In particular, 
increased Iba-1 reactivity can be seen in dorsal and lateral regions of the thoracic cord white 
matter (representative images are shown in Figure 5.2.9). Highly reactive Iba-1 cells can be 
observed in multiple regions across the cord. However, it should be noted that, in 
comparison to the Iba-1 reactivity observed in TDP-Q331K mice, Iba-1 reactivity within the 
dorsal white matter was not consistently observed for every section of SOD1-G93A mice. A 
further contrast to that observed in TDP-Q331K and also NTg mice, is that Iba-1 reactivity 
within the thoracic cord of SOD1-G93A mice demonstrates increased reactivity and 
microglial numbers within the ventral horn (Figure 5.2.8) and also within the medioventral 
pole of the white matter. However, the magnitude of this was observed to fluctuate between 
different sections of thoracic cord obtained from the same animal.   
In line with these observations, quantitative evaluation shows Iba-1 area to be significantly 
increased by 44% across the entire thoracic cord sections of SOD1-G93A mice in 
comparison to NTg. This increase arises from the significant increases in both white matter  
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Figure 5.2.7. Glial reactivity within the thoracic cord of NTg and SOD1-G93A mice at 90 days. Iba-1 (red) and 
GFAP (green) reactivity were used to identify microglia and astrocytes, respectively, in thoracic cord of NTg (A) 
and SOD1-G93A (B) mice at 90 days of age. White dashed line in a and d distinguish Dorsal and Ventral regions 
of thoracic cord. Higher magnification of dorsal region in b and e; higher magnification of ventral region in c and 
f. White dashed box in B, b,c and f used to highlight regions of Iba-1 and GFAP reactivity in thoracic cord of SOD1-
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significant increase of Iba-1 area in Total (**, mean difference = 0.438, p = 0.008), White Matter (**, mean 
difference = 0.525, p = 0.003) and grey matter (*, mean difference = 0.332, p = 0.04) regions of thoracic cord for 
SOD1-G93A mice in comparison to NTg. D) Quantitative assessment of GFAP presence demonstrates significant 
increase of GFAP area in grey matter (*, mean difference = 0.382, p = 0.041). NTg N = 5 (female); SOD1-G93A N 




























Figure 5.2.8. Iba-1 reactivity in the ventral horn of a female NTg (A) and SOD1-G93A (B) mouse at 90 days. 






























Figure 5.2.9. Iba-1 reactivity in the lateral white matter of a female NTg (A) and SOD1-G93A (B) mouse at 90 











(53%) and grey matter (33%) regions of SOD1-G93A sections, relative to that observed for 
NTg animals. GFAP reactivity also supports the activation of astrocytes within the thoracic 
cord of SOD1-G93A mice. The most obvious change, in comparison to NTg mice, is the 
increased GFAP reactivity within the grey matter of the thoracic cord. Whilst increases can 
be observed in dorsal regions, the increased GFAP reactivity within the grey matter of SOD1-
G93A mice is most clearly apparent within the ventral horn of thoracic cord and also extends 
from the anterior tip of the ventral horn along the efferent axonal tracts that arise from 
resident motor neurons. Indeed, quantitative evaluation of GFAP area supports the most 
obvious differences between NTg and SOD1-G93A mice to exist within the grey matter. 
Evaluation of GFAP reactivity across the entire thoracic cord section demonstrated a 16% 
increase within sections of SOD1-G93A mice, although this was not considered a statistically 
significant change from NTg samples. However, whilst reactivity in the white matter of 
SOD1-G93A mice is very similar to NTg (demonstrating an increase of 6%), GFAP reactivity 
within the grey matter is significantly increased by 38% in comparison to NTg animals. 
 5.2.1.1.4 Glial reactivity within the thoracic cord of SOD1-G93A mice at 120 days 
To further extend the evidence of glial activation within thoracic cord, Iba-1 and GFAP 
reactivity was also evaluated at 120 days for 4 NTg and 4 SOD1-G93A mice (Figure 5.2.10).   
Iba-1 reactivity demonstrated the widespread presence of microglial cells with increased 
reactivity and a morphology consistent with an activated phenotype, in sections obtained 
from SOD1-G93A mice. These features were most prominent within the grey matter, lateral 
and ventral regions of the white matter (figures 5.2.11 and 5.2.12). As was detailed for mice 
at 90 days, the prevalence of reactivity within the mediodorsal regions of white matter was 
less consistent between sections of the same animal. Indeed, in comparison to the grey 
matter, lateral and ventral regions of white matter, the Iba-1 reactivity observed within the 
mediodorsal white matter of the sections analysed from SOD1-G93A mice suggests a much 
lower prevalence of microglial activation within this area. 
In support of the most prevalent difference in Iba-1 reactivity between SOD1-G93A and NTg 
mice to reside within the white matter, quantitative evaluations of Iba-1 area demonstrated 
a significant increase of 88% within the white matter of SOD1-G93A mice. This contributed 
to a significant increase of Iba-1 area across the entire thoracic cord region of 44%. An 
increase of 37% in Iba-1 area was also observed within the grey matter of SOD1-G93A mice, 
in comparison to NTg. Whilst this did not achieve statistical significance (p = 0.058), this 
does support an increased microglia activation within the grey matter of SOD1-G93A mice 
at 120 days.  
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Figure 5.2.10. Glial reactivity within thoracic cord of NTg and SOD1-G93A mice at 120 days. Iba-1 (red) and GFAP 
(green) reactivity were used to identify microglia and astrocytes, respectively, in thoracic cord of NTg (A) and 
SOD1-G93A (B) mice at 120 days of age. White dashed line in a and d distinguish Dorsal and Ventral regions of 
thoracic cord. Higher magnification of dorsal region in b and e; higher magnification of ventral region in c and f. 
White dashed box in B, f used to highlight regions of GFAP reactivity in thoracic cord of SOD1-G93A that is 
distinct to NTg. Scale bars = 200µm.  C) Iba-1 Area of total (*, Mean difference = 0.441, p = 0.015 ) and White 
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mice in comparison to NTg. Iba-1 area in grey matter is also increased but does not achieve statistical 
significance (#, mean difference = 0.375, p = 0.058). D) GFAP area of total (**, mean difference = 0.554 , p = 
0.007) and grey matter (**, mean difference = 1.062, p = 0.001) regions is significantly increased within thoracic 
cord of SOD1-G93A mice in comparison to NTg. GFAP area is also increased within white matter region of SOD1-
G93A mice, but to a lower degree that does not achieve statistical significance (#, mean difference = 0.266 , p = 




























Figure 5.2.11. Iba-1 reactivity in the ventral horn of a female NTg (A) and SOD1-G93A (B) mouse at 120 days. 



































Figure 5.2.12. Iba-1 reactivity in the lateral white matter of a female NTg (A) and SOD1-G93A (B) mouse at 120 






 GFAP reactivity within the thoracic cord of SOD1-G93A mice also supported the prevalent 
activation of astrocytes. As demonstrated for SOD1-G93A mice at 90 days, a notable increase 
of GFAP reactivity was observed within the grey matter of thoracic cord at 120 days. This 
increase of GFAP reactivity appeared to predominate within the ventral, rather than dorsal 
regions of the grey matter. In addition, reactivity within the white matter also appeared 
more prominent than that observed at 90 days. This was supported by quantitative 
evaluation of GFAP area within the thoracic cord of SOD1-G93A mice, in which a significant 
increase of 106% and 55% were observed across the grey matter and total area, 
respectively, in comparison to NTg sections. A 27% increase was also observed for the white 
matter of SOD1-G93A sections in comparison to NTg, however this did not achieve 
statistical significance (p = 0.074). 
5.2.1.2 Xcr1 and Xcl1 expression in the spinal cord of ALS mouse models 
Based on the above evidence of consistent and extensive activation of microglia and 
astrocytes, spinal cord samples of SOD1-G93A and TDP-Q331K mice provided samples in 
which there was prevalent neuroinflammation. Evaluation of Xcr1 and Xcl1 expression 
within RNA samples collected from whole spinal cords of these mice was therefore 
performed in order to provide an insight in to the potential contribution of this chemokine 
signalling axis to the central inflammatory response generated within these two ALS mouse 
models. 
For the reported Xcr1 expression detailed here, the presence of Xcr1 mRNA has been 
evaluated using Xcr1S primers. This has been done due to the consistency of these primers 
to provide a detectable signal of Xcr1 mRNA presence by qPCR. In contrast, Xcr1L primers 
provided a less reliable detection and, as was described in chapter 3, this introduced 
difficulties for the evaluation of mRNA expression due to the confounding influence of non-
detects in providing accurate quantification of amplicon presence from qPCR investigations. 
In addition, the method of preparation of cDNA was demonstrated to reliably minimise 
contamination of RNA samples with genomic DNA, supporting the reliable detection of Xcr1 
mRNA by Xcr1S primers. 
5.2.1.2.1 Xcr1 and Xcl1 expression in the spinal cord of 6 month TDP-Q331K mice 
Xcr1 and Xcl1 expression was evaluated within total RNA samples collected from whole 
spinal cords of 6 NTg mice (3 males; 3 females) and 6 Q331K mice (3 males; 3 females) at 
both 6 months and 10 months of age (Figure 5.2.13). 
At 6 months, evaluation of Xcr1 expression demonstrated a low and consistent presence of 
Xcr1 for both male and female mice of both NTg and TDP-Q331K genotypes, suggesting no 
change in Xcr1 expression within the spinal cord of TDP-Q331K mice in comparison to age-
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matched NTg controls. In addition, no difference of Xcr1 expression was identified between 
sexes.  
Assessment of Xcl1 expression demonstrated a significant increase of expression for both 
male and female TDP-Q331K mice in comparison to their respective NTg controls. For 
males, this corresponded to a level of expression that was 2.02x that of male NTg samples. 
For females this corresponded to a level of expression that was 1.79x that of female NTg 
samples. No differences in Xcl1 expression were identified between male and female mice 
from either genotype. This suggests that at 6 months of age, Xcl1 levels are increased within 
the spinal cord of TDP-Q331K mice in comparison to NTg mice. Moreover, this feature is 
consistent between sexes. 
5.2.1.2.2 Xcr1 and Xcl1 expression in the spinal cord of 10 month TDP-Q331K mice 
In comparison to the differences observed at 6 months, Xcr1 expression was indicated to be 
higher within male than female samples at 10 months of age. For male NTg mice, this 
corresponded to a mean increase of 1.67x in comparison to females. For male Q331K mice, 
this corresponded to a mean increase of 1.82x in comparison to females. However these 
differences did not achieve statistical significance. 
Evaluation of Xcl1 expression indicated an increased expression within TDP-Q331K mice 
for both sexes. For male mice, this corresponded to an increase in Xcl1 expression that was 
1.81x that of male NTg samples. Female TDP-Q331K mice demonstrated an increase in Xcl1 
expression that was 1.68x that of NTg samples. Neither of these increases achieved 
statistical significance.  
In addition, similar to the trend observed for Xcr1 expression, Xcl1 expression also 
demonstrated a trend to be increased within RNA samples from males in comparison to 
females. This corresponded to an increase of Xcl1 expression in male NTg mice that was 
1.56x that observed in female NTg mice. Male TDP-Q331K mice demonstrated a larger 
difference in Xcl1 expression, corresponding to a mean increase of 1.73x that observed for 
female TDP-Q331K mice.  However, neither of these differences were considered 
statistically significant. 
5.2.1.2.3 Xcr1 and Xcl1 expression in the spinal cord of SOD1-G93A mice at 90 days 
Xcr1 and Xcl1 expression was also investigated within the spinal cords of 3 SOD1-G93A mice 
and 3 age-matched NTg controls. Unlike for TDP-Q331K evaluations, all of these mice were 
female. 
In comparison to NTg controls, SOD1-G93A samples were indicated to contain a lower level 





   
   
   
    
         
     
    
 
 
   
   
 
   
       
         
     
     
   
   
   
   
   
   
  
     
         
           
Figure 5.2.13. Xcr1 and Xcl1 expression in the spinal cord of TDP-Q331K and SOD1-G93A mouse models of ALS. 
Evaluation of Xcr1 expression (A, B and C) and Xcl1 expression (D, E and F) in TDP-Q331K and age-matched NTg 
controls at 6 months (A, D) and 10 months (B, E) and in SOD1-G93A mice at 90 days (C, F). Absolute levels of 
gene expression (relative to GAPDH) have been shown for clarity. No differences were observed for Xcr1 
expression under any condition. Xcl1 expression was observed to be significantly increased by TDP-Q331K mice 
at 6 months in comparison to controls for both male (*, mean difference = 2.237x 10-5 (2.02x NTg), p = 0.028) 
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expression, SOD1-G93A mice demonstrated a 2.45x increase relative to NTg controls. 
However, this difference was not considered statistically significant.  
5.2.1.3 Evaluation of Xcl1 expression in primary microglial cultures from ALS mouse models 
As performed for NTg mice in chapter 3, primary microglial cultures were prepared from 
the brains of 10 month TDP-Q331K mice and 90-100day old SOD1-G93A mice. 
Unfortunately, due to infection, one of the SOD1-G93A primary cultures had to be destroyed 
and therefore comparison presented here are made between 3 primary cell cultures 
prepared from NTg mice; 3 primary cultures from TDP-Q331K mice; and 2 primary cultures 
prepared from SOD1-G93A mice. Preliminary attempts were made for the preparation of 
microglial cultures from the spinal cords of mice, however these were unsuccessful due to 
low cells numbers decreasing cell viability and preventing the culture of sufficient cell 
numbers for downstream analysis.  
The preparations of these cells were made in order to test the capacity for primary microglia 
to express Xcl1, and to see whether the microglia obtained from ALS mouse models differed 
in this capacity, in comparison to microglia from NTg mice. Furthermore, treatment with 
LPS was performed in order to evaluate the response of Xcl1 expression by microglia from 
the different mouse genotypes to a stimulus that has been demonstrated to induce an 
inflammatory response.  
5.2.1.3.1 Purity of primary microglia cultures 
The purity of primary cultures was determined by immunocytochemical detection of Iba-1 
and GFAP within cells to provide an indication of microglial and astrocyte presence, 
respectively (Figure 5.2.14, A, B). The presence of Iba-1 positive cells did vary considerably 
between cultures obtained from TDP-Q331K and SOD1-G93A mice. For cultures prepared 
from TDP-Q331K mice, the presence of Iba-1 cells was significantly lower than that obtained 
from SOD1-G93A mice, indicating a mean microglial presence of 35% of the total cell 
number, as determined by DAPI cell counts. In comparison, microglial presence was 
indicated to account for 67% of cells from SOD1-G93A mice, a proportion that demonstrated 
very strong consistency between the two cultures used for analysis. Microglial presence was 
therefore comparable between NTg and SOD1-G93A cultures. However, the lower presence 
of Iba-1 positive cells within TDP-Q331K cultures does compromise the reliability of 
analyses from these cultures to reflect changes primarily within microglial cells. 




To evaluate the influence of disease on Xcl1 expression by primary microglia from the two 
ALS models, Xcl1 expression was quantified and compared between untreated primary 
cultures from NTg, TDP-Q331K and SOD1-G93A mice. As demonstrated in Figure 5.2.14, E, 
the expression of Xcl1 within the primary microglial cultures, although low, were indicated 
to differ between cultures from mice of different genotypes. Of particular note was the 
consistency of Xcl1 expression identified within SOD1-G93A cultures, supporting the 
consistency of cell composition within the two independent primary cultures evaluated. 
Furthermore, Xcl1 expression demonstrated a mean increase in SOD1-G93A cultures that 
was 1.93x greater than NTg cultures and 2.56x greater than TDP-Q331K cultures. Indeed, 
Xcl1 expression within TDP-Q331K cultures was slightly lower, corresponding to a mean 
expression that was 0.75x that observed for NTg cultures.  
Whilst neither of these differences were determined to be statistically significant, the 
observed Xcl1 expression in tandem with the observed Iba-1 reactivity within cultures 
provides some credence to the association of Xcl1 expression by microglia. First of all, the 
lowest mean Xcl1 expression was observed within TDP-Q331K cultures that also 
demonstrated the lowest number of Iba-1 positive cells and hence lowest microglial 
presence. Secondly, the observed consistency of Iba-1 positive cells within primary cultures 
from SOD1-G93A mice was reflected by a consistent detection of Xcl1 expression within the 
two cultures. Thirdly, the observed Iba-1 reactivity within untreated primary cultures from 
SOD1-G93A mice (Figure 5.2.14 B, control images) is indicative of cells with a higher state 
of activation than that observed from Q331K or NTg cultures. Therefore, despite having a 
slightly lower mean microglial purity than NTg cultures, this suggests that the endogenous 
activation state of microglial cells obtained from SOD1-G93A mice may contribute to the 
observed increase in expression. This suggests an association of microglia presence and 
also, potentially, the endogenous activation state of primary microglia to associate with Xcl1 
expression. Moreover, the increased Xcl1 expression observed within primary microglial 
cultures of SOD1-G93A cultures in comparison to NTg cultures is reminiscent of that 
observed for the evaluation of Xcl1 expression within whole spinal cord RNA samples from 
the two groups (Figure 5.2.13, F). 
5.2.1.3.3 Evaluation of Xcl1 expression following LPS treatment of primary microglial cultures 
from SOD1-G93A and TDP-Q331K mice 
Treatment of primary microglia with LPS was performed in order to test the capacity for 
such treatment to influence Xcl1 expression, but also to determine if the response from 
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Figure 5.2.14. Xcl1 expression in primary glial cultures of NTg, SOD1-G93A and TDP-Q331K mice. Representative 
images of primary microglial cultures obtained from 10month TDP-Q331K (A) and 90 day SOD1-G93A (B) mice 
(for NTg cultures see figure 3.2.5). Microglia and astrocytes were identified by immunocytochemical detection 
of Iba-1 (red) and GFAP (green), respectively. C) Quantification of Iba-1 positive and GFAP positive cells in 
relation to total cell number was used to estimate microglia cell purity. Cultures prepared from TDP-Q331K mice 
demonstrate a low abundance (34%) of Iba-1 positive cells in comparison to NTg (68%) and G93A (67%) 
preparations. D) LPS treatment induces an increase of Iba-1 reactivity, relative to control conditions, by a mean 
of 50%, 18% and 166% in cultures prepared from NTg, TDP-Q331K and SOD1-G93A mice, respectively. E) 
Absolute levels of Xcl1 expression, relative to internal GAPDH control, are presented for each of the primary 
microglial cultures (Control conditions) prepared from each genotype. No statistical difference was observed in 
the level of Xcl1 expression between genotypes. F) Scatter graph of Xcl1 expression vs Microglial purity of 
untreated primary microglial cultures from NTg (Black), TDP-Q331K (green) and SOD1-G93A (blue) mice. G) No 
difference in Xcl1 expression was observed for TDP-Q331K or SOD1-G93A primary microglial cultures as a 
consequence of LPS treatment in comparison to control conditions. A significant decrease was observed for Xcl1 
expression by NTg microglial cultures (*, p = 0.01) as detailed in figure 3.2.5. Comparisons between control and 
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Treatment with LPS was demonstrated to induce an inflammatory response by primary 
microglial cells, as evidenced by the morphology and increased reactivity of Iba-1 positive 
cells (Figure 5.2.14, A, B, D). However, this did vary between cultures from TDP-Q331K and  
SOD1-G93A mice. For TDP-Q331K cultures this corresponded to a mean increase in Iba-1 
reactivity of 18% by cells treated with LPS in comparison to untreated, control cells. For 
SOD1-G93A cells, this increase was particularly prominent, with Iba-1 reactivity of LPS 
treated primary cell cultures increasing by a mean of 166% in comparison to untreated 
cells. This increase was reflected by the adoption of an activated, amoeboid-like morphology 
of Iba-1 positive cells following LPS treatment. Again, this feature appeared to be more 
prominent within SOD1-G93A cultures in comparison to TDP-Q331K cultures. However, 
these observations together support the capacity of LPS treatment to induce an 
inflammatory response by microglial cells in primary culture. 
Following LPS treatment, qPCR was performed to assess the impact of the induced 
activation of primary microglial cells on Xcl1 expression. In order to provide a more 
accurate quantification of the effect of LPS treatment on Xcl1 expression, qPCR data 
obtained from untreated and LPS treated primary cultures from independent experiments 
was standardised to account for variation between replicates. In accordance with previous 
recommendations (Willems, Leyns and Vandesompele, 2008), data therefore underwent a 
log transformation and mean centering prior to comparison of normalised values between 
control and LPS treated cultures. 
As can be observed from Figure 5.2.14, G, LPS treatment had very little impact on the 
expression of Xcl1 within primary microglial cultures obtained from TDP-Q331K and SOD1-
G93A mice. Moreover, the effect of LPS treatment was inconsistent between replicates. Due 
to the variability of this effect of LPS treatment on Xcl1 expression, in comparison to 
untreated cells, the standardised data demonstrates a high variability in the relative Xcl1 
expression of LPS and untreated primary cultures from TDP-Q331K and SOD1-G93A mice. 
Consequently, there is no evidence to support the capacity for the induction of microglial 
activation by LPS treatment to affect Xcl1 expression.  
5.2.2 XCR1 expression in cervical cord of ALS patients and neurological controls 
In the absence of an antibody that was able to reliably detect Xcr1, it has not been possible 
to evaluate the presence of the Xcr1 protein within the CNS of mice. However, according to 
the success of identifying an antibody that can reliably and specifically detect human XCR1 
(Chapter 4), it was possible to evaluate XCR1 expression within the human CNS. Therefore, 
to evaluate XCR1 expression within CNS and to provide an additional insight to the impact 
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of ALS on the expression of this chemokine receptor, XCR1 expression was evaluated within 
the cervical region of spinal cords collected from sALS patients and neurological controls. 
5.2.2.1 Optimisation of HPA013169 for the detection of XCR1 within the human cervical cord 
The optimisation of the immunohistochemistry protocol for the detection of XCR1 by 
HPA013169 was performed using sections of cervical spinal cord obtained from a sALS 
patient. HPA013169 reactivity was optimised by testing a series of antibody concentrations 
between 0.5µg/ml and 4µg/ml in combination with alternative antigen retrieval conditions. 
Exemplary images from this optimisation are provided in figure 5.2.15.  
Preliminary tests demonstrated weak reactivity of HPA013169 to localise to cells located 
within the lateral and medioventral regions of cervical cord white matter. Reactivity was 
also observed within endothelial cells of blood vessels, a feature that was expected 
according to the observed reactivity described by the antibody manufacturer 
(https://www.proteinatlas.org/ENSG00000173578-XCR1/tissue/primary+data). No 
reactivity was observed within the grey matter of cervical cord. Further refinement of the 
immunohistochemistry procedure provided greater HPA013169 reactivity, which was 
observed to be greatest following microwave-induced HIER at pH6 (Figure 5.2.15, A). The 
optimised protocol was in good agreement with the recommended protocol provided by the 
manufacturer, which suggested an antibody concentration of 1:20-1:50 (10µg-4µg/ml) to 
be used following HIER at pH 6. 
The morphology of reactive cells suggested HPA013169 to localise to glial cells of the white 
matter. Figure 5.2.15 demonstrates this reactivity within the medioventral white matter, a 
region that corresponds to the ventral corticospinal tracts (VCSTs). A similar pattern of 
reactivity was also observed within the lateral regions of the cervical cord white matter (not 
shown).  The reactivity observed in VCSTs was not uniform however, with a bias of 
reactivity observed within the VCSTs of one side of the cervical cord (Figure 5.2.15, c). 
Higher magnification of this region demonstrates numerous cells to exhibit HPA013169 
reactivity within the cervical cord VCSTs of this sALS patient (Figure 5.2.15, A, d). Based on 
this evidence of HPA013169, it was decided to expand the investigation to compare 
HPA013169 reactivity within the cervical spinal cord of sALS patients and neurological 
controls. 
5.2.2.2 XCR1 presence within the cervical cord of sALS patients and neurological controls 
For comparison of XCR1 presence, HPA013169 reactivity was analysed within the cervical 
cord of 5 neurological controls and 6 sALS patients. Qualitative and quantitative assessment 
of HPA01369 reactivity was performed whilst blinded to the diagnosis of sALS or control. 
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Figure 5.2.15. Optimisation of HPA013169 (Atlas Anti-XCR1) reactivity within human cervical cord. HPA013169 
was tested at concentrations between 0.5µg/ml and 4µg/ml following HIER antigen retrieval. Representative 
images of the ventral corticospinal tracts of cervical cord treated with HPA013169 at 2µg/ml or 4µg/ml, and 
their respective negative controls, following microwave HIER in pH6 (A) or pH9 (B) buffer. Exemplary 
detection of XCR1-positive cells is highlighted by red arrows in A, d. Scale bars: Black = 200µm; Green = 50µm.  
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Figure 5.2.16. Atlas anti-XCR1 immunoreactivity within the cervical cord of Control and sALS patients. Images of Dorsal Horn, LCST and VCST of sections demonstrating HPA013169 reactivity 
in sections that were positive or negative for Corpora Amylacea (CA). CA inclusions demonstrate strong DAB reactivity (Red arrowheads) whereas HPA013169-positive cells (red arrows) are 
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Figure 5.2.17. Semi-quantitative analysis of Corpora Amylacea presence within cervical cord of ALS patients and 
controls. A) Schematic illustration of cervical cord and regions analysed. Grey = Dorsal Horn (DH); Blue = Lateral 
corticospinal tracts (LCST); Green = Ventral Corticospinal Tracts (VCST). B) Quantification of DAB positive area 
within Dorsal Horn, LSCT and VCST of control and sALS samples. Error bars = ±SD. C) Incidence of HPA013169-
positive CA within DH, LCST or VCST within Control and sALS sample sections. D) Quantification of DAB positive 
area within Dorsal Horn, LSCT and VCST that are positive or negative for the presence of CA. Error bars = ±SD. 
For N of each group see table in C. 
 
 
Presence of Corpora 
Amylacea 
 Control sALS 
DH 2/4 (50%) 5/5 (100%) 
LCST 2/5 (40%) 4/6 (66%) 
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Examination of HPA013169 reactivity within these cervical cords sections indicated XCR1 
expression at variable levels, but for all samples evaluated. HPA013169 reactivity was again 
observed to predominate within the white matter of cervical cord. However, a feature that 
was not observed for the cervical cord sections used for optimisation, was the prevalent 
reactivity which localised to corpora amylacea (CA) inclusions that were distributed among 
the lateral regions of cervical cord white matter. CA also predominated within the dorsal 
horn of several cervical cord samples. The prevalence of these inclusions varied amongst 
both control and sALS samples and were either localised to the VCSTs, Lateral Corticospinal 
Tracts (LCSTs), dorsal horn, or, to a lesser extent, mediodorsal white matter. For one 
cervical cord examined (LP094/09) however, this reactivity localised to almost the entire 
perimeter of the cervical cord.  Examples of HPA013169 reactivity within the VCST, LCST or 
Dorsal horn that exhibit the presence or absence of CA is presented in figure 5.2.16. A 
consistent feature that was observed within all sections was reactivity by blood vessels and 
also by cells resembling the morphology of astrocytes. For these cells, reactivity is observed 
at the cell soma, as indicated by the presence of counterstained nuclei. In addition, some 
cells demonstrate reactivity along processes which appear to surround an internal 
structure. 
According to these initial observations, analysis of HPA013169 reactivity was decided to 
focus on the VCSTs, LCSTs and dorsal horn of cervical cord. Within these regions, analysis 
was performed on two factors: i) the presence or absence of HPA013169 reactivity by CA 
and ii) quantitative examination of HPA013169 reactivity area.  
Following this analysis of each of the cervical cords, samples were categorised to sALS or 
control following removal of the study blind. As displayed in figure 5.2.17, B, the area of 
HPA013169 reactivity was indicated to demonstrate a high variability between samples. 
However, overall the presence of HPA013169 reactivity was indicated to be reduced in all 
3 regions of the cervical cord examined for sALS samples in comparison to neurological 
controls. 
Importantly, the presence of CA that demonstrated HPA013169 reactivity did not 
distinguish between control and sALS samples, suggesting these HPA013169-positive 
inclusions to exist within the cervical cord, independent to the diagnosis of ALS. However, 
qualitative analysis suggests the presence of CA was more prevalent in the sections of sALS 
patients than controls (figure 5.2.17, C). 
In a further attempt to investigate the correspondence of HPA013169 reactivity to the 
presence of CA, the area of DAB reactivity within each cervical cord region was categorised 
according to the presence or absence of CA (Figure 5.2.17, D). Following this classification, 
regions in which there were HPA01369-positive CA inclusions were observed to 
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demonstrate a consistent decrease in DAB area, suggesting that the presence of these 
inclusions reduced the overall area of HPA01369 reactivity. Indeed, as can be seen from 
figure 5.2.16, HPA013169 reactivity within CA-negative sections demonstrates more 
extensive HPA013169 reactivity of lower intensity than that observed in CA-positive 
sections. 
Overall, these results suggest that HPA013169 reactivity, and hence XCR1 presence, is 
consistent within the cervical cord of both sALS and control patients. Whilst the reactivity 
indicates the presence of XCR1-positive cells, the extensive HPA013169 reactivity that 
localises to CA inclusions appears to affect the quality of HPA01369 binding and hence 























In this study it was aimed to evaluate the expression of Xcr1 and its cognate ligand, Xcl1, 
within the context of a prominent neuroinflammatory response. This was based on prior 
data suggesting the expression of this chemokine signalling axis to contribute to the central 
pathophysiology following peripheral nerve injury (Bird et al., 2018) and, more recently, 
diabetic neuropathy (Zychowska et al., 2016). In order to extend this evidence, the 
expression of the human XCR1 protein has also been tested within the human cervical cord 
of healthy neurological controls and sALS patients, utilising an antibody that has been 
independently validated to exhibit specificity to the human XCR1 protein. 
5.3.1 Murine ALS models demonstrate a consistent neuroinflammatory response within the 
spinal cord 
In order to provide a valid assessment of Xcr1 and Xcl1 expression in the context of a 
prominent neuroinflammatory response, the expression of Iba-1 and GFAP within the 
thoracic cord of two murine models of ALS has been investigated to assess the activation of 
microglia and astrocytes, respectively.  
5.3.1.1 SOD-1-G93A mice demonstrate glial activation most prominently within the lateral and 
ventral regions of thoracic cord 
The use of the established SOD1-G93A mouse model was in keeping with prior reports 
demonstrating the prolific activation of microglia and astrocytes within the spinal cord of 
rodent models expressing mutant SOD1 (Gurney et al., 1994; Hall, Oostveen and Gurney, 
1998; Graber, Hickey and Harris, 2010; Joyce et al., 2015). Moreover, for the model studied 
here, the high copy number of mutant SOD1 expression exacerbates the disease phenotype 
and increases glial activation, in comparison to models expressing a lower copy number of 
the transgene or expressing an endogenous mutation within the mouse Sod1 gene (Joyce et 
al., 2015; McGoldrick et al., 2013).  
The examination of astrocyte and microglia features at 90 and 120 days provided an 
indication of the temporal changes of glial behaviour with disease progression and are 
considered to represent the symptomatic and end-stage of disease, respectively (Hall, 
Oostveen and Gurney, 1998).  Iba-1 reactivity identified the enhanced microglial reactivity 
throughout the thoracic cord, demonstrated by the consistent presence of hypertrophic and 
hyper-ramified Iba-1 positive cells. In tandem with the increased area of Iba-1 coverage, 
this is consistent with the proliferation and activation of resident microglia, a characteristic 
that has been demonstrated for these cells in the SOD1-G93A model at these time points 
(Dibaj et al., 2011) and is consistent with the analysis methods used for the identification of 
activated microglial from several pathologies (Korzhevskiy and Kirik, 2015; Beynon and 
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Walker, 2012). Moreover, the prevalence of Iba-1 reactivity that was observed to be most 
extensive within the lateral and ventral regions of white and grey matter is supportive of 
prior reports suggesting a lower microglial activation within the dorsal region of spinal cord 
for rat and mouse SOD1-G93A models (Dibaj et al., 2011; Graber, Hickey and Harris, 2010). 
This is consistent with the demonstration of the relative sparing of afferent sensory neurons 
that innervate the dorsal horn in this model (Gurney et al., 1994). Iba-1 positive aggregates 
were also observed in multiple thoracic cord regions. Observation of increased microglial 
aggregates has been described previously within a rat model expressing SOD1-G93A 
(Fendrick, Xue and Streit, 2007) and suggested to represent the formation of atypical giant 
multinucleated following microglial fusion. Subsequent analysis has also suggested that 
these formations represent the  aggregation of independent microglia that migrate to sites 
containing high concentrations of extracellular, pro-inflammatory stimuli such as SOD1 
protein aggregates (Graber, Hickey and Harris, 2010). This activation was particularly 
evident within the lateral and ventral regions of white matter, with notably high numbers 
of Iba-1 positive cells observed within the ventral horn of the grey matter. These features 
were observed to progress between 90 and 120 days and clearly illustrated the extensive 
induction of microglial activation within this mouse model.  
The activation of glia at 90 and 120 days was further evidenced by the pronounced increase 
of GFAP reactivity and coverage within the thoracic cord, indicative of astrogliosis (Philips 
and Rothstein, 2014). This feature was most evident in the medial and ventral regions of the 
grey matter, in comparison to age-matched NTg controls. The response of astrocytes during 
ALS is distinct from that of microglia in that the activation of astrocytes is associated 
exclusively with a change in phenotype and morphology of resident cells, and not with 
concomitant cellular proliferation (Philips and Rothstein, 2014). Astrocytes provide 
essential support to neurons, particularly at the level of the synapse, where the formation 
of the tripartite synapse by astrocyte processes mediates the maintenance of extracellular 
neurotransmitter levels (Schousboe, 2003). Indeed, a diminished capacity of astrocytes to 
maintain physiological glutamate is heavily implicated in the development of excitotoxic 
mechanisms that contribute to motor neuron death during ALS (Morel et al., 2013; 
Rothstein et al., 1996; Shaw and Ince, 1997). The increase of GFAP reactivity within the grey 
matter, along with the comparatively lower increases observed within the white matter is 
indicative of pathology at the level of the synapse and neuronal somas. This is supported by 
prior observations in human spinal cord that demonstrates astrogliosis particularly within 
the medial and ventral spinal cord laminae of the grey matter with little to no GFAP 
reactivity observed within the cortiospinal tracts (CSTs) (Schiffer et al., 1996) and also 
consistent with previous evidence of astrogliosis within the spinal cord of the SOD1-G93A 
model (Hall, Oostveen and Gurney, 1998).  Moreover, astrocyte activation within the spinal 
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cord of murine models of ALS is associated with disease onset (Yamanaka et al., 2008) and 
in vivo monitoring of GFAP expression has clearly illustrated the association of increased 
GFAP expression with the onset of motor neuron degeneration within these mice (Keller, 
Gravel and Kriz, 2009). Indeed, despite early reports suggesting astrocyte reactivity to 
indicate an attempt to ameliorate the toxic environment induced by activated microglia 
(Hall, Oostveen and Gurney, 1998) it has since become apparent that mutant SOD1-
expressing astrocytes are detrimental to motor neuron survival. Hence, increased GFAP 
reactivity is associated with the production of a more toxic neuronal environment, although 
the exact mechanisms of this remain unclear (Clement et al., 2003; Di Giorgio et al., 2007; 
Marchetto et al., 2008).    
Importantly, the investigation of glial reactivity in this study focussed on the thoracic cord 
of SOD1-G93A mice and provides a characterisation that diverges from the typical focus on 
the ventral horn of the lumbar spinal cord. However, pathology within this region of SOD1-
G93A mice has been demonstrated and is associated with the degeneration of motor 
neurons in the ventral horn and also of pre-ganglionic sympathetic motor neurons that are 
located within the intermediolateral nucleus found between T1 and L2 vertebral regions 
(Llewellyn-Smith, 2009; Kandinov et al., 2011; Kandinov et al., 2013). The evidence of 
microglial and GFAP reactivity therefore supports the presence of pathology within this 
region but also underscores this mouse model to provide samples of spinal cord that exibits 
prevalent neuroinflammation. 
5.3.1.2 TDP-Q331K mice demonstrate distinct patterns of microglial activation to SOD1-G93A 
mice 
In contrast to the widely characterised SOD1-G93A model, the mouse TDP-Q331K model is 
more recent and has relatively little characterisation. Following the original description of 
this model (Arnold et al., 2013) a subsequent analysis provided additional insights to the 
development of pathology by TDP-Q331K mice (Mitchell et al., 2015). From these two 
descriptions, the presence of microglia and astrocytes, according to Iba-1 and GFAP 
reactivity, was observed to increase at 10 months within the ventral horn of mice expressing 
TDP-Q331K in comparison to NTg controls (Arnold et al., 2013). Later characterisation 
provided evidence of glial activation at 2 months and 24 months, however characterisation 
of microglia was made by the detection of CD68 (Mitchell et al., 2015). At 2 months, GFAP 
reactivity demonstrated increased astrocyte presence within the ventral horn, but evidence 
of CD68 reactivity was absent for TDP-Q331K mice, as observed for NTg mice. By 24 months, 
GFAP reactivity indicated the sustained increase of astrocyte presence and activation within 
the ventral horn, however microglial presence demonstrated little changes to that observed 
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for NTg animals within the same region. Instead, CD68 reactivity was significantly increased 
within the dorsal columns, lateral and ventral tracts of the white matter of TDP-Q331K mice. 
Importantly, the genetic background of the TDP-Q331K mice investigated here 
(C57BL/6NJ) is different to that used for the original generation of the TDP-Q331K model 
(C57BL/6NCrl, Arnold et al., 2013). However, behavioural and functional measures of the 
motor phenotype of the TDP-Q331K mice investigated here have been extensively 
characterised by Dr Jodie Stephenson (Stephenson 2017). This demonstrated the 
progressive development of mild motor symptoms by TDP-Q331K mice, including the 
development of motor tremor by 10 weeks, abnormal gait by 3 months and evidence of 
increased microglial and astrocyte presence in the ventral horn by Iba-1 and GFAP 
immunohistochemistry. In conclusion, it was suggested that a plateau of symptoms was 
achieved by 10 months, but by 6 months the development of the motor phenotype was 
clearly evident. Thus, this model, despite being on a different genetic background 
demonstrated consistent functional and pathological features to that described by Arnold 
et al., 2013.  
The evidence gathered by this investigation has therefore provided a considerable 
extension to the evidence of microglial and astrocyte reactivity within the spinal cord of 
TDP-Q331K mice. In particular, it has demonstrated that the major area of microglia 
activation is located within the white matter of thoracic cord at 6 months and 10 months of 
age for TDP-Q331K mice. Interestingly, the pattern of microglia reactivity within the white 
matter of TDP-331K is distinct to that observed for SOD1-G93A mice. This is most evident 
by the prominent Iba-1 reactivity within the dorsal columns of TDP43-Q331K mice, a 
feature that is not seen for SOD1-G93A mice (Figure 5.2.4; Figure 5.2.10; Dibaj et al., 2011). 
In addition, this reactivity becomes more prevalent along the entire rostrocaudal axis of the 
thoracic cord with age (Appendix 4 vs Appendix 5). Notably, previous characterisation of 
CD68 reactivity, a marker for the presence of activated, phagocytic microglia (Graber, 
Hickey and Harris, 2010; Korzhevskiy and Kirik, 2015) did not suggest microglial activation 
within the lateral tracts by 2 months of age for TDP-Q331K mice, despite evidence of motor 
neuron loss. However, by 24 months, microglial activation within the dorsal and lateral 
tracts was prevalent (Arnold et al., 2013).  Therefore, the evidence provided here within the 
thoracic cord provides an insight of microglial activity within the lateral and dorsal regions 
of white matter during an intermediary time period to that described previously. In 
addition, it also provides an insight in to the activity of microglia during a time that mice are 
observed to achieve a phenotypic plateau (Arnold et al., 2013); Stephenson 2017). Together, 
this suggests that the predominant microglial activation within the spinal cord of TDP-
Q331K is localised to the lateral and dorsal white matter of TDP-Q331K mice.  
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Despite receiving little focus within the literature for murine ALS models (Yamanaka et al., 
2006), pathology of the lateral and dorsal white matter regions are an important 
consideration for the interpretation of pathology within murine models of ALS mice. This is 
due to these regions represents the location of descending CSTs.  Within mice, the majority 
(~80%) of CSTs are located within medial dorsal region of white matter, whilst the 
remaining ~20% are located within the lateral white matter.  These lateral corticospinal 
CSTs descend throughout the thoracic cord and have been described to extensively 
innervate both dorsal and ventral grey matter, contributing to the polysynaptic control of 
lower motor neurons along the rostrocaudal axis (Steward et al., 2004). This is in contrast 
to the prominence of the descending corticospinal tracts that exist within the dorsal lateral 
region of spinal cord in primates and humans, a region synonymous with the pathology of 
ALS. A further reason for the importance of this observed pathology is that CSTs within the 
lateral regions of mouse spinal cord have been demonstrated to degenerate in a mouse 
model expressing mutant SOD1-G85R (Yamanaka et al., 2006), whilst the dorsal column 
CSTs are observed to be spared (Song et al., 2012). Furthermore, pathology within the 
lateral white matter is also associated with significant disruption to the blood-spinal cord 
barrier. In several murine models expressing mutant SOD1 this leads to vascular leakage 
and extensive microvascular haemorrhage that is evident at presymptomatic stages, prior 
to motor neuron loss, and preceding the neurovascular inflammatory response (Zhong et 
al., 2008).  This evidence has recently been furthered to demonstrate the significant 
swelling and degeneration of axons, accompanied by prominent microglial activation, 
within the lateral CSTs of the SOD1-G93A mouse model at 90 days with a continual decline 
to 120 days (Dibaj et al., 2011). 
In addition to the evidence within dorsal and lateral CSTs of the white matter, analysis of 
microglial presence, as determined by Iba-1 area, also suggested distinct microglial 
pathology within the ventral horn grey matter TDP-Q331K mice in comparison to SOD1-
G93A mice. For TDP-Q331K mice at 10 months the microglial presence within the ventral 
horn was increased to a lower extent to that observed at 6 months, in comparison to age-
matched NTg controls. Although this evidence is confounded by the low number of animals 
used for the characterisation at 6 months, this is in line with the evidence from Mitchell 
2015. Specifically, Mitchell et al., 2015 showed that the presence of CD68 was not changed 
between NTg and TDP-Q331K mice in ventral horn by 24 months. This indicates that the 
presence of phagocytic microglia was not any different between NTg and TDP-Q331K mice, 
even at this late stage and despite the significant loss of lower motor neurons. This is in 
contrast to SOD1-G93A mice that demonstrate prevalent CD68 reactivity within the ventral 
horn (Frakes et al., 2014) and were also observed here to provoke a significant increase of 
Iba-1 reactivity within this region of thoracic cord.   
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Taken together, the evidence of Iba-1 reactivity within the white and grey matter of these 
two mouse models demonstrates qualitative differences in microglial reactivity and 
phenotype.  In conjunction with the prior description of CD68 reactivity (Frakes et al., 2014; 
Mitchell et al., 2015), the microglial reaction within the two models is distinguished by the 
adoption of phagocytic phenotype within the ventral horn of SOD1-G93A mice that is not 
seen for TDP-Q331K mice. The reason for this remains speculative, however it is intriguing 
to note that the aggregation of cytoplasmic ubiquitinated inclusions was not observed for 
TDP-Q331K mice either within motor neurons or within the neuropil (Mitchell et al., 2015). 
In contrast, ubiquitinated aggregates of SOD1 protein is prevalent in mice overexpressing 
SOD1-G93A and prevails within the neuropil before aggregation within motor neurons 
(Stieber, Gonatas and Gonatas, 2000). Therefore, this distinction in the phagocytic 
phenotype of microglia may be a consequence of the distinctive presence of aggregated 
proteins within these two models. In addition, the Iba-1 reactivity observed here suggests 
the activation of microglia within both regions of CSTs of thoracic cord for TDP-Q331K, 
whilst reactivity of Iba-1 in SOD1-G93A mice is confined to the lateral CSTs only. This 
observation is in line with reports from an independent mouse model that expresses a 
distinct mutation of the human TDP-43 protein (TDP43-A315T) in which axonal 
degeneration within both dorsal and lateral CSTs was confirmed within the lower thoracic 
cord (Wegorzewska et al., 2009). Whist focus on CST pathology in mouse models in the 
literature is less prevalent than that within the grey matter, this region highlights a 
distinctive pathophysiology of ALS related to TDP-43 or SOD1 mutations and supports the 
greater involvement of upper motor neuron degeneration, as well as degeneration in other 
cortical areas, of TDP-Q331K mice. Thus, the pathology observed within the lateral and 
dorsal CTSs of thoracic cord from TDP-Q331K mice may be more representative of the 
pathology observed in the broader human ALS population, in which microglial activation 
within the CSTs of human ALS patients demonstrates a correspondence to disease 
progression (Brettschneider et al., 2012), but is also suggestive of broader cortical 
degeneration of patients suffering from ALS associated TDP-43 mutation, as discussed in 
section 5.1. This is supported by the observation of TDP-Q331K mice to demonstrate 
symptoms that correlate with a dementia-like phenotype (Stephenson 2017).  
5.3.2 The expression of Xcl1, but not Xcr1, is upregulated within the spinal cord of ALS mouse 
models  
 A recent investigation demonstrated the expression of Xcr1 and Xcl1 proteins within the 
lumbar spinal cord of mice by western blot. Furthermore, this expression was found to be 
influenced by streptozotocin treatment - a treatment used to model diabetic neuropathy in 
mice (Zychowska et al., 2016). However, no characterisation of the respective gene 
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expression was carried out within the spinal cord. This project also aimed to evaluate Xcr1 
protein expression within the mouse CNS and evaluate this within the context of ALS 
models, but unfortunately this was not possible due to the unreliability of antibody 
specificity (Chapter 4). Consequently, the evidence of Xcr1 and Xcl1 expression has relied 
on qPCR analysis of gene expression. Of particular importance to the evidence gathered 
here, was that the evaluations of Xcr1 and Xcl1 expression were made within a mouse model 
that demonstrated the activation of microglia, due to the suggestion of these cells being the 
primary contributor of Xcl1 in the CNS of mice (Zychowska et al., 2016). As described above 
and demonstrated in section 5.2, both TDP-Q331K and SOD1-G93A mice demonstrate 
prolific activation of microglia. 
Evaluations of Xcr1 expression within the spinal cord of NTg mice was previously described 
to demonstrate low expression (Chapter 3). Here, comparisons of Xcr1 expression in the 
spinal cord of NTg mice with that of TDP-Q331K mice, at both 6 and 10 months, also 
demonstrated low expression and illustrated no change in expression between diseased 
mice and NTg controls. Comparisons of Xcr1 expression also demonstrated no changes 
between SOD1-G93A mice at 90 days with their respective controls. Together, this suggests 
that Xcr1 expression is not influenced within the spinal cord of these transgenic mice, 
despite the distinct pathophysiology that they present.  
Evaluation of Xcl1 expression however, suggested a consistent upregulation of expression 
in all transgenic mice and ages, in comparison to their NTg controls. This was only observed 
to be statistically significant however for TDP-Q331K mice at 6 months of age where a mean 
increase of 102% and 79% was observed in male and female TDP-Q331K mice, respectively. 
In addition, there was a large range of Xcl1 expression observed for male TDP-Q331K mice 
at 10 months, suggesting a potential influence of TDP-Q331K expression on Xcl1 expression 
that lacks consistency, a feature that was not observed for female mice. Interestingly, a trend 
was observed to suggest an increased expression of Xcr1 by male mice at 10 months in 
comparison to their female counterparts, irrespective of genotype. A similar trend was also 
observed for Xcl1 expression. 
Xcl1 expression may also be considered to be increased in SOD1-G93A mice at 90 days. For 
the three replicates performed, two SOD1-G93A mice demonstrated consistently elevated 
levels. However one sample demonstrated particularly low expression, a feature that was 
also observed for Xcr1 expression from the same mouse. Due to all quality control 
assessments suggesting this data to be valid the low expression could not be excluded, but 
does suggest that Xcl1 expression is elevated in SOD1-G93A mice. Moreover, the level of Xcl1 




The features of Xcr1 and Xcl1 expression therefore demonstrate several features that are 
consistent with the contribution of chemokines and, more broadly, cytokines to the immune 
response of CNS disease. Firstly, the increased expression within TDP-Q331K mice was 
most prominent at 6 months of age, whilst evaluation of expression was performed for 
SOD1-G93A mice at a time point considered to reflect the prominent onset of motor neuron 
loss (Keller, Gravel and Kriz, 2009). These time points are therefore suggestive of Xcl1 
expression to contribute to an early innate immune response, a feature for which the 
expression of Xcl1 has been suggested to be characteristic of (Moser and Loetscher, 2001). 
In addition, the innate immune response is recognised as a symptom of ALS (Phani, Re and 
Przedborski, 2012) and is suggested to continue within the SOD1-G93A mouse from the pre-
symptomatic to end-stage disease, at which point an adaptive cytotoxic response is 
suggested to prevail (Beers et al., 2008; Jara et al., 2017; Komine et al., 2018). Specific 
descriptions of the innate immune response within mice expressing TDP-43 mutations isn’t 
available, yet considering the observed increases of Iba-1 throughout the thoracic cord 
observed here and the widely documented role of microglia to contribute to the immune 
response of the CNS (Philips and Rothstein, 2014; Phani, Re and Przedborski, 2012; Lewis 
et al., 2012) it would seem plausible to recognise an innate immune response within the 
spinal cords of TDP-Q331K mice, as observed for SOD1-G93A mice.  
A second reason for the patterns of Xcr1 and Xcl1 expression to resemble features of other 
cytokines and chemokines is the effect of sex on the expression of these mediators and the 
broader immune response in general (Klein and Schwarz, 2018). The separation of analysis 
performed in this study of TDP-Q331K mice was made according to the observation that 
males demonstrated a more variable disease course than females (Stephenson 2017). 
However, several cellular components of the immune system are known to vary between 
males and females. Notably, the higher expression of Toll-like receptors, including TLR4, by 
peripheral immune cells from males is suggested to be responsible for the increased 
expression of certain chemokine and cytokines following particular immune challenges, 
such as LPS (Torcia et al., 2012; Moxley et al., 2002; Rettew and Marriott, 2007; Rettew, 
Huet and Marriott, 2009). Microglia are also suggested to exhibit sexually dimorphic 
activation patterns that are linked to the differential expression of estradiol receptors on 
the microglia obtained from female and male mice (Nissen, 2017). Further sex-based 
differences between the immune response of males and females have also been 
documented, including the suggestion of a difference of CD4+ to CD8+ T-cell ratios (Klein 
and Schwarz, 2018).  
Hence, whilst the precise reasons for the differences in Xcr1 and Xcl1 expression between 
mice as a consequence of sex and genotype are unclear, the features of these differences are 
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indicative of this chemokine signalling axis to participate in some way to the immune 
response observed in these transgenic models of ALS. However, due to the source of the 
RNA samples arising from whole spinal cords of mouse and the documented migration of 
peripheral immune cells, including dendritic cells, to the CNS parenchyma in ALS (Henkel et 
al., 2004; Henkel et al., 2006; Beers et al., 2008) further refinement to the cellular source of 
this expression is required. 
5.3.3 Xcl1 is expressed at a low level by primary adult mouse microglia and is not influenced 
as a consequence of ALS-associated mutation or LPS treatment 
A further source of evidence to the expression of Xcl1 within the CNS that arose from the 
publication by Zychowska et al., was the dramatic increase (~400 fold) of Xcl1 expression 
by primary microglia obtained from P1 rat pups as a consequence of LPS treatment for 24 
hours (Zychowska et al., 2016). In order to further investigate this possibility in mice, this 
study has replicated the method used by Zychowska et al., 2016 for the treatment of primary 
adult mouse microglia. Furthermore, the isolation of primary microglia from NTg, TDP-
Q331K and SOD1-G93A mice provided an opportunity to refine the potential cellular source 
of the observed differences of Xcl1 expression within the CNS of these mice. 
No evidence has been found to here to suggest that primary microglia obtained from adult 
mice display an increased Xcl1 expression following LPS treatment. Instead, the only 
consistent and significant difference observed was a slight decrease (~25%) in Xcl1 
expression by NTg cultures following LPS treatment. This is despite the clear activation of 
these microglia as demonstrated by quantitative and qualitative assessment of Iba-1 
reactivity suggesting across.  No differences in Xcl1 expression were observed for primary 
cell cultures prepared from TDP-Q331K mice or SOD1-G93A mice following LPS treatment. 
This is again despite the demonstrated activation of these cells, a feature that was 
particularly prominent for microglia obtained from SOD1-G93A mice and in line with the 
description of these mice to exhibit to enhanced activation state (Dibaj et al., 2011).  
The expression of Xcl1 within primary microglial cultures was also observed to be similar 
between the three genotypes examined. However, the reliability of this assessment to 
accurately reflect Xcl1 expression in microglia is confounded by the lack of these cells in 
cultures from TDP-Q331K mice. In contrast, the consistency of Iba-1 positive cells in NTg 
and SOD1-G93A does suggest a reasonable assessment of microglia within these cultures. 
Considering this, the identified similarity of Xcl1 expression, irrespective of microglial 
presence between the different cultures, suggests a negligible expression of Xcl1 expression 
by microglia from mice of all three genotypes. These results are therefore in contrast to that 
described for Xcl1 expression within primary microglia, as described by Zychowska et al., 
2016, and suggest a low expression of Xcl1 by adult mouse microglia, both in resting and 
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activated states. In addition it also suggests that, unlike other chemokines, including Ccl2, 
Ccl5, Cxcl10 and Cxcl12 (Swarup et al., 2011; Sargsyan et al., 2009; Komine et al., 2018), the 
expression of Xcl1 by microglia is not influenced by the presence of ALS-associated 
mutations, nor by the treatment of LPS.  
Exquisite profiling of microglia isolated from SOD1-G93A mice have demonstrated the 
unique phenotype adopted by these cells in vivo (Chiu et al., 2013). Furthermore, this also 
demonstrated a distinct expression profile of microglia obtained from SOD1-G93A mice in 
comparison to microglia treated with LPS (Chiu et al., 2013). Given the spectrum of 
pathology that the primary microglia cultures studies here have been subject to within the 
SOD1-G93A mice and TDP-Q331K mice and the demonstration of prominent activation 
following LPS treatment, this evidence would suggest that microglial expression of Xcl1 is 
negligible under physiological and several pathophysiological states. Moreover, it suggests 
that the differences of Xcl1 expression observed within spinal cord RNA from TDP-Q331K 
and SOD1-G93A mice does not arise as a consequence of microglial expression. 
5.3.4 HPA013169 reactivity localises to glial cells and detects the presence of Corpora 
Amylacea  
The independent validation of the Atlas HPA013169 antibody to demonstrate specificity to 
human XCR1 provided an opportunity to investigate the expression of XCR1 within the 
human CNS and extend the investigation of the expression of this chemokine receptor in 
ALS. 
Initial optimisation of HPA013169 demonstrated the antibody to detect cells within the 
lateral and ventromedial white matter of cervical cord of an sALS patient. Lateral regions of 
the cervical cord contain the axons of descending CSTs from cortical neurons, particularly 
those from upper motor neurons of the motor cortex, within the contralateral brain 
hemisphere. The ventromedial white matter, also contains CSTs although these arise from 
cortical neurons of the ipsilateral hemisphere (Charles Watson, 2009). Therefore, the 
reactivity of HPA013169 to indicate the expression of XCR1 within these regions was 
particularly interesting considering the prevalent pathology observed within these regions 
of ALS patients. Consultation with a neuropathologist suggested that HPA013169 reactivity 
localised to astrocyte cells. 
Subsequent analysis was performed in cervical cord from a cohort of Control and sALS 
patients to determine if HPA013169 reactivity exhibited specific patterns of reactivity as a 
consequence of disease. This analysis was confounded by the presence of HPA013169 
reactivity which localised to CA inclusions. These inclusions were observed for both control 
and sALS patients and exhibited a high HPA013169 reactivity. The presence of CA was also 
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demonstrated to reduce the overall area of HPA013169 reactivity, suggesting the higher 
ffinity of HPA013169 to CA inclusions was capable of inhibiting antibody binding to 
surrounding XCR1 epitopes.  
CA inclusions have been demonstrated to exist within the CNS particularly as a consequence 
of age and are more prevalent within patients suffering from neurodegenerative diseases 
including Alzheimer’s diseases, Parkinsons Disease and ALS (Pisa et al., 2016). They are 
characterised by a spherical structure that has a diameter typically between 10-50µm. The 
composition of CA has been demonstrated to contain mostly polyglucans with small 
component of protein (Sfanos et al., 2009).  The origin of these inclusions is unknown, but 
the presence of protein components including mitochondrial Heme-oxygenase 1 (Song et 
al., 2014),   ubiquitin, heat shock proteins, the anti-apoptotic protein Bcl2 (Botez and Rami, 
2001), several complement factors and other innate immune proteins such as α-defensins, 
is suggestive of cellular origins that arise as a consequence of chronic inflammation and 
subsequent cellular death (Meng et al., 2009; Singhrao et al., 1995; Sfanos et al., 2009). 
Indeed, one theory for the prevalence within patients suffering from neurodegenerative 
disease is that chronic inflammation within the CNS along with the concomitant presence of 
pathogens including numerous bacteria, virus and potentially fungi, can lead to a chronic 
inflammatory reaction to such pathogens and the aggregation of cellular and pathogenic 
products within the CNS (Meng et al., 2009; Pisa et al., 2016). 
The reactivity of HPA013169 to CA inclusions may therefore indicate significant 
aggregation of XCR1 within these inclusions. However, this can only considered a possibility 
and cannot be considered certain, due in no small part to the significant non-specific binding 
of several antibodies to CA inclusions (Auge et al., 2018). Despite this, the quantification of 
CA presence within the cervical cord of sALS and control patients, according to HPA013169 
reactivity, demonstrated a higher prevalence of these inclusions within sALS patients. This 
is in line with a recent systematic quantification of CA within the CNS and spinal cord of ALS 
and control patients (Pisa et al., 2016). 
Excluding the reactivity to CA, HPA013169 was observed to identify numerous cells within 
the white matter of cervical cord. These cells were often observed to encapsulate axonal-
like structures (Figure 5.2.16, e) and therefore in addition to their identification as 
astrocytes it is possible that these cells may also represent oligodendrocytes. This provides 
an intriguing point for further investigation of XCR1 reactivity within the CNS. Indeed 
numerous chemokine receptors have been described to be expressed by astrocytes and 
oligodendrocytes and this appears to be particularly prevalent as a consequence of 
inflammatory lesions in multiple sclerosis  and include chemokine receptor CCR2, CCR3, 
CCR5, CXCR1, CXCR2 and CXCR3 (Simpson et al., 1998; Simpson et al., 2000; Omari et al., 
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2005; Omari et al., 2006).  In line with the dogmatic principle of chemokine receptor 
function, the expression of chemokine receptors by astrocytes is associated with the 
migration of these cells to sites of injury and may also influence their capacity for 
proliferation. The importance of oligodendrocytes to the pathology of ALS is underscored 
by the prominent degeneration of descending CSTs that is characteristic of the disease. 
Moreover, oligodendrocyte pathology has begun to be appreciated in murine ALS models. 
In these models, oligodendrocytes are thought to contribute to disease by the decreased 
provision of trophic support to neurons due to decreased expression of monocarboxylate 
transporters. Oligodendrocytes and their precursors also display disrupted maturation 
which likely contributes to dysfunctional myelination of axons, particularly within the 
ventral grey and white matter of mutant SOD1 mice (Hughes et al., 2013; Nonneman, 
Robberecht and Van Den Bosch, 2014).  
However, without conformation of the cellular identity responsible for this reactivity, the 
implications of HPA013169 reactivity and hence XCR1 expression by these cells is difficult 
to comment upon. In particular, due to the documented exclusivity of XCR1 expression by 
tissue and lymphoid resident cross-presenting DCs  (Dorner et al., 2009; Bachem et al., 
2010) and the documented evidence for DC recruitment to the spinal cord of ALS patients 
(Henkel et al., 2004) the possibility of HPA013169 reactivity to reflect DCs in the spinal cord 
can also not be excluded. Unfortunately, time restrictions have not made the 
characterisation of HPA013169 reactive cells possible, however plans are underway to 
achieve this.   
5.3.5 Summary 
In this study the expression of Xcr1 and Xcl1 has been sought to be investigated within a 
model of prominent neuroinflammation. This is in line with previous evidence to 
demonstrate the expression of chemokines and their receptors within the CNS as a 
consequence of disease. Moreover, it was also sought to specifically evaluate the expression 
of Xcl1 within primary microglia according to recent suggestions suggesting the expression 
of this chemokine by these cells. This has been achieved by the utilisation of two distinct 
murine models of ALS that were demonstrated to present prolific activation of resident 
microglia and astrocytes. This has demonstrated a small but noticeable increase of Xcl1 
expression within the spinal cord of these murine models, however further repeats will be 
required to validate these differences.   
The preparation of primary microglia from SOD1-G93A and TDP-Q331K mice also 
demonstrated a lack of change to the expression of Xcl1 in comparison to NTg controls and 
also following LPS treatment. Together, this evidence supports a contribution of the class C 
chemokine receptor and its ligand to the immune response that is generated in the SOD1-
227 
 
G93A and TDP-Q331K models of ALS, however this is not contributed to by the expression 
of Xcl1 by microglia. 
In an attempt to provide further clarity to the expression of XCR1 within the CNS, we have, 
to the best of our knowledge, provided the first comparison of XCR1 presence within the 
spinal cord of neurological controls and sALS patients. Unfortunately, this evidence has 
suggested the HPA013169 antibody to also demonstrate reactivity to CA inclusions, despite 
previous validation of specificity to the XCR1 protein. This has confounded a clear 
interpretation of XCR1 presence. However, HPA013169 reactivity indicates the expression 
of XCR1 by glial cells, particularly within the white matter of cervical cord that contain the 
axons of descending corticospinal tracts. The identity of these cells has yet to be confirmed 




6.0 Conclusions and Future Work 
This project has sought to provide an insight to the emerging role of the Class C Chemokine 
Receptor, Xcr1 and its ligand, Xcl1, within the CNS (Bird et al., 2018; Zychowska et al., 2016). 
One of the primary aims of this project was to establish the presence and localisation of Xcr1 
protein within the CNS. Consequently, a significant portion of time has been used for the 
testing of antibodies to validate their specificity to Xcr1. In doing so, a reliable technique 
involving the overexpression of myc-tagged target Xcr1 and XCR1 proteins in vitro has 
shown to provide a reliable source of antigen for the testing of antibody specificity. In 
particular, the C-terminal myc tag allowed clear illustration of the antibody specificity 
through colocalisation with a validated monoclonal anti-myc antibody. This is in line with 
previous and contemporary work that has demonstrated the validity of in vitro 
characterisation of antibody specificity to GPCRs and other proteins via the transient or 
stable expression of target protein in cell culture (Grimsey et al., 2008; Skogs et al., 2017). 
Based on the evidence from this method, unfortunately it has not been possible to reliably 
evaluate the expression of Xcr1 protein within the CNS due to a lack of specificity of all 
tested antibodies. 
There is evidence to suggest that the lack of antibody reliability has made a considerable 
contribution to the lack of reproducibility in life science research. Several studies have been 
shown to base conclusions upon results that arose from non-specific binding of antibody. 
One estimate has suggested ~50% of all commercially available antibodies to be non-
specific and hence provide unreliable detection of their target protein (Baker, 2015). Along 
with others (Bordeaux et al., 2010; Skogs et al., 2017; Grimsey et al., 2008) the results from 
this study therefore provide a relatively economical and reproducible protocol that should 
be used for the in-house validation of antibodies prior to their use on test specimens.  
6.1 Does an alternative composition of Xcr1 mRNA exist? 
The investigation of Xcr1 mRNA composition has focussed on the potential for an alternative 
structure to mature Xcr1 mRNA. Use of 5’RACE provided clear evidence to support the 
existence of Xcr1 mRNA composed of both exon 1 and exon 2. However, the retention of 
intron 1 sequences remains inconclusive. A lack of clarity regarding this has arisen from the 
fact that the two potential Xcr1 ORFs that have been proposed lie in-frame within one 
another. Without clarification of the actual amino acid sequence of the Xcr1 protein, 
confirming the actual Xcr1 mRNA sequence is made problematic as the original description 
of Xcr1 protein (referred to as Xcr1S in this study, (Yoshida et al., 1998)) could theoretically 
arise from either mRNA isoform. In testing the expression of each potential isoform it was 
consistently observed that for both spleen and spinal cord tissue evaluation of RNA arising 
from exon 1 and exon 2 or exon 2 only demonstrated similar levels of expression. However, 
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it was intriguing to note that for the evaluation of RNA from mESC-derived motor neurons 
the expression of RNA containing exon 2 only was considerably higher than RNA composed 
of exon 1 and exon 2. Retrospective microarray analysis of the immortalised NSC-34 murine 
motor neuron-like cell line further supported the higher presence of RNA derived from 
exon-2 of Xcr1, in comparison to exon 1. 
Given the documented alternative splicing and the use of alternative promoters by other 
chemokine receptors such as CXCR3 (Lasagni et al., 2003) and CCR5 (Mummidi et al., 2007), 
the capacity for alternative expression of mRNA arising from Xcr1 warrants further 
investigation. In particular, the functional capacity of predicted promoter regions within 
intron 1 should be assessed. This will provide important insights in to the regulation of Xcr1 
mRNA that may prove important for translating the evidence of Xcr1 between mouse and 
human.  
 6.2 Evaluation of Xcr1 protein isoforms supports the function of the Xcr1S protein 
An essential and fundamental aspect to the investigation of any protein is to be sure of its 
identity. Since the discovery of the Xcr1 protein as the murine homologue of human XCR1, 
a considerable lack of clarity has arisen regarding the identity of the Xcr1 protein. This has 
primarily arisen from the more recent discovery of Xcr1 exon 1, and led to the prediction of 
an alternative ORF site within Xcr1 mRNA, as discussed. Consequently, two protein isoforms 
remain theoretically plausible translations of the mRNA sequence, differing by 16 amino 
acids within the N-Terminal domain. This study has provided the first direct functional 
comparison of these potential isoforms by evaluating their interaction with β-arrestin, a 
ubiquitous intracellular protein that interacts with all GPCRs. This evidence has provided 
further support to the original description of the Xcr1 protein and adds credence to the 
suggestion that the functional Xcr1 protein arises from a coding sequence residing 
exclusively within exon 2. This evidence is given further support from the observation that 
the human XCR1 ORF is also confined to a single exon (Shinkai et al., 2005). This has 
important implications for future investigations of this protein, particularly for the 
development of specific antibodies. Given the observation that the only antibody with a 
validated specificity in this study targeted the N-terminal domain of the human XCR1 
protein, defining the actual sequence of the Xcr1 N-terminal will hopefully enable the 
fruitful outcome of subsequent antibody development. 
6.3 Microglia display a low Xcl1 expression that is not induced by inflammatory stimuli 
 During the course of this project, evidence emerged to support the expression of Xcr1 and 
Xcl1 within the CNS of mice in a mouse model of diabetic neuropathy (Zychowska et al., 
2016). The authors suggested Xcr1 to be expressed by neurons of the spinal cord and the 
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expression of Xcl1 by microglia. The expression of Xcl1 was also suggested in response to 
the inflammatory stimulus, LPS. Two methodological flaws were identified for this study. 
Firstly, the antibody used for the detection of Xcr1 within the spinal cord was raised to an 
immunogen from the human XCR1 protein and had not been validated for specificity to 
mouse Xcr1. Secondly, evidence to support the expression of Xcl1 in mouse microglia arose 
from the use of primary cells obtained from rat pups (Zychowska et al., 2016). The evidence 
gathered from this project has therefore provided contrasting evidence to these suggestions 
based on i) a demonstrated lack of specificity of Abcam 188896 to mouse Xcr1 and ii) the 
observed lack of response by primary adult mouse microglial cells to express Xcl1 following 
LPS administration. The expression of Xcl1 was also not observed to be upregulated within 
a primary cell culture enriched with microglia obtained from SOD1-G93A and TDP-Q331K 
mice. This is despite the upregulated expression of Xcl1 observed within RNA collected from 
the spinal cord of these mice. Furthermore, prolific microglial activation was observed in 
these spinal cords. This evidence therefore suggests that Xcl1 is not expressed by mouse 
microglia. Conformation of Xcr1 expression by spinal cord neurons will require further 
investigation utilising a reliable antibody with a demonstrated specificity to Xcr1. 
In the process of confirming the use of mouse models that demonstrate consistent 
microglial activation, this project has identified distinct glial pathology within the spinal 
cords of SOD1-G93A and TDP-Q331K mice. This is in support of the work of others that 
demonstrate alternative sites of pathology within the spinal cord of these mouse models. 
Moreover, it supports the use of these models to provide a more comprehensive reflection 
of pathophysiology that is observed for ALS patients with distinct genetic pathogenesis. 
6.4 The expression of XCR1 by resident cells of the human CNS remains inconclusive 
In line with the ultimate objective of this project to assess the expression and potential 
function of the class C chemokine receptor and ligand within the human CNS, the expression 
of human XCR1 has been evaluated within the spinal cord of control and ALS patients by 
immunohistochemistry. This preliminary investigation has provided evidence to suggest 
the low expression of this chemokine receptor by cells of the CNS, particularly within the 
white matter of cervical cord. The observed reactivity is supported by the independent 
validation of the antibody used for XCR1 detection. Unfortunately, due to circumstances 
beyond our control, it has not been possible to clarify the identity of the cells which 
demonstrate XCR1 expression. Furthermore, the detection of XCR1 using this validated 
antibody within a wider population may be confounded by reactivity to CA bodies that often 
display the non-specific accumulation of antibody. Plans to identify the cellular identity of 





The class C chemokine receptor, XCR1, and its ligand(s) in mice and human represents a 
highly conserved chemokine signalling axis. The strong homology of this axis, from the level 
of DNA sequence to the observed physiological function, suggests a clear translational 
capacity for the observations made in mice to predict that carried out in humans. Technical 
limitations, including access to reliable antibodies, have prevented the application of 
consistent methodologies to the investigation of XCR1 and XCL1 between both mouse and 
human samples of CNS tissue. However, analysis of samples from mouse models of human 
disease has permitted the examination of prior suggestions regarding the function of Xcr1 
and Xcl1 in the CNS. This has suggested that Xcl1 is not a component of the microglial 
inflammatory response and that the current evidence of Xcr1 expression by neurons can 
only be considered preliminary.  Furthermore, this study has provided the first examination 
of XCR1 protein expression within the spinal cord of humans following the independent 
validation of antibody specificity. Preliminary results from this would further suggest that 
the current observations made by others in mice are not representative of the true 
expression pattern of Xcr1 within the CNS. 
A central ethos of this PhD project has been to provide reliable and reproducible evidence 
that will serve as a cornerstone for future investigations of this chemokine ligand and 
receptor, particularly in relation to the mouse and human homologues of XCR1. Key to this 
evidence has been the attempt to clarify the molecular identity of mRNA and protein species 
that arise from the Xcr1 gene. This study has gone some way to provide this. With further 
refinement, the techniques and tools developed here should provide a reliable 
underpinning to gain further clarity of this chemokine signalling axis and its potential role 
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> Ensembl Xcr1 gene sequence (ENSMUST00000182350.1) 
>5' Flanking sequence        
                                         | 
  cacagagtcacatatctttctttttttgtttgtttgtcttcttggggggtttttttggttttttttttttgtttgtttgtttgtttgttttgttttttgg  < 100 
  gtgtctcagtgtatagaaagaaaaaaacaaacaaacagaagaaccccccaaaaaaaccaaaaaaaaaaaacaaacaaacaaacaaacaaaacaaaaaacc 
           10        20        30        40        50        60        70        80        90  
  
  
  ttttttggttttttgagacagggtttctctgtgtagccttggctgtcctggaactcactttgtagaccaggctggccttgaactcagaaatccgctgcct  < 200 
  aaaaaaccaaaaaactctgtcccaaagagacacatcggaaccgacaggaccttgagtgaaacatctggtccgaccggaacttgagtctttaggcgacgga 
           110       120       130       140       150       160       170       180       190  
                                          
 
 
  ctgcctcccgagtgccaggattaaaagcatgcgccaccacgcccggccagagtcacgtgtcttgttgaagttggttagaccaaaagacccccaatccata  < 300 
  gacggagggctcacggtcctaattttcgtacgcggtggtgcgggccggtctcagtgcacagaacaacttcaaccaatctggttttctgggggttaggtat 
           210       220       230       240       250       260       270       280       290  
   
  gctaaacagtgttttagagctttatagtttagactagagatcatgtatacagttcatatcgaaaccaaacataaggaaacattaaaaaaaaaactttagc  < 400 
  cgatttgtcacaaaatctcgaaatatcaaatctgatctctagtacatatgtcaagtatagctttggtttgtattcctttgtaattttttttttgaaatcg 
           310       320       330       340       350       360       370       380       390  
        >Exon 1     
            | 
  tccaaaatttcattcttaatgaaggggaagtttgaggccagcctagacaatttaatagaacctttatcaagcatagggttGTTACCTACGTGAAACTCTA  < 500 
  aggttttaaagtaagaattacttccccttcaaactccggtcggatctgttaaattatcttggaaatagttcgtatcccaaCAATGGATGCACTTTGAGAT 
           410       420       430       440       450       460       470       480       490  
                          
       >Intron 1        
                                                                        | 
  GCACTGGAGGAGATCAAAGGAAGCACAAAGCGTACAGACTTGAAACCCTGACATGGACTCAGAGTCAGGTGAGTTCCTCTGCATACATTTTAAACTTATA  < 600 
  CGTGACCTCCTCTAGTTTCCTTCGTGTTTCGCATGTCTGAACTTTGGGACTGTACCTGAGTCTCAGTCCACTCAAGGAGACGTATGTAAAATTTGAATAT 
           510       520       530       540       550       560       570       580       590  
 
   
  CTTTTTTTCTTCTTTTAATAGCCAGCATCAGGGTTCTGAAACTTTGATGGTCACTGGAACCACTTAGCAGGCCAATAAACCTTAAGAGTTCCGAGGCTTG  < 700 
  GAAAAAAAGAAGAAAATTATCGGTCGTAGTCCCAAGACTTTGAAACTACCAGTGACCTTGGTGAATCGTCCGGTTATTTGGAATTCTCAAGGCTCCGAAC 
           610       620       630       640       650       660       670       680       690  
 
   
  CCTCTGAGTCTCAGATTCCTTTTATCTGAGCTTTCCCAAGGATTTGTACTTTTAGAGAAGGCAATCTAGGTACCTTTCCTTGAATAGAACAGTTATATGT  < 800 
  GGAGACTCAGAGTCTAAGGAAAATAGACTCGAAAGGGTTCCTAAACATGAAAATCTCTTCCGTTAGATCCATGGAAAGGAACTTATCTTGTCAATATACA 
           710       720       730       740       750       760       770       780       790  
 
   
  TTTCATTGCTGAAAGAAATGGAAGTGTTTGATTCCAAGTTGCTTTGTAAGTTATTATTTTTGATGGCTGAATAACTTAAAACTATAGTTTTCAGCCTAAA  < 900 
  AAAGTAACGACTTTCTTTACCTTCACAAACTAAGGTTCAACGAAACATTCAATAATAAAAACTACCGACTTATTGAATTTTGATATCAAAAGTCGGATTT 
           810       820       830       840       850       860       870       880       890  
 
   
  TTATCTCATGGGCCAAAAACTAAATTCACTCCCCTAGAGTTAAATCATGGGGATGGTAAGGATCGAGGACAATGGAAAAATGGAAGTCAAATTCCTAAAA  < 1000 
  AATAGAGTACCCGGTTTTTGATTTAAGTGAGGGGATCTCAATTTAGTACCCCTACCATTCCTAGCTCCTGTTACCTTTTTACCTTCAGTTTAAGGATTTT 
           910       920       930       940       950       960       970       980       990  
 
   
  TATGTTAACATAAAATAACTTCATTTTAAAAAATACAAGCAATTTTCTTTGTGCCAAATATGAGTGACCATGACCCAGTTCGTGGAGTCAAGTTATCCTG  < 1100 
  ATACAATTGTATTTTATTGAAGTAAAATTTTTTATGTTCGTTAAAAGAAACACGGTTTATACTCACTGGTACTGGGTCAAGCACCTCAGTTCAATAGGAC 
           1010      1020      1030      1040      1050      1060      1070      1080      1090  
 
   
  AAAGACCTGATGTACTGGGTAAAAAGATACATAATATTTTACTTTTTGAGACAAAGTCTCACATAACCCAGATTGACCTCAAATTCACTGTGTTGCTGAG  < 1200 
  TTTCTGGACTACATGACCCATTTTTCTATGTATTATAAAATGAAAAACTCTGTTTCAGAGTGTATTGGGTCTAACTGGAGTTTAAGTGACACAACGACTC 
           1110      1120      1130      1140      1150      1160      1170      1180      1190  
 
   
  GCTGGCCTTGAGCTCTTAATTCTCCTGGAATATGCCAATACATCAAGCGTTTACATGAACTTTTACAGTCACAGAACAAAAGAGTGCCATAAACTAAGGT  < 1300 
  CGACCGGAACTCGAGAATTAAGAGGACCTTATACGGTTATGTAGTTCGCAAATGTACTTGAAAATGTCAGTGTCTTGTTTTCTCACGGTATTTGATTCCA 
           1210      1220      1230      1240      1250      1260      1270      1280      1290  
 
   
  CTTGACTAAATATACGGCTGTATGTTAAGGTAGGCAGCTACAGAAGGACATAGGGGTTTTCTATACATACCTGACTGAGATGGTGTGGCCTTCTCTCAGC  < 1400 
  GAACTGATTTATATGCCGACATACAATTCCATCCGTCGATGTCTTCCTGTATCCCCAAAAGATATGTATGGACTGACTCTACCACACCGGAAGAGAGTCG 
           1310      1320      1330      1340      1350      1360      1370      1380      1390  
 
   
  ATAACAATAAATGCTCAGTCCAGGTTGAGCTATTACGTCAAATATAGATGCTAATAGAAAATGGCTATTACAACACAACAGTTAACTTTGGCTCTTATTT  < 1500 
  TATTGTTATTTACGAGTCAGGTCCAACTCGATAATGCAGTTTATATCTACGATTATCTTTTACCGATAATGTTGTGTTGTCAATTGAAACCGAGAATAAA 
           1410      1420      1430      1440      1450      1460      1470      1480      1490  
 
   
  GCAACATTCCATCTCGCCACAATCACAAAACCCTAGTAATCCAAGGACAAAGAGTCATTAGGCTCCAATACACAGAGAACTTCAGTTCACTACTTAGGGA  < 1600 
  CGTTGTAAGGTAGAGCGGTGTTAGTGTTTTGGGATCATTAGGTTCCTGTTTCTCAGTAATCCGAGGTTATGTGTCTCTTGAAGTCAAGTGATGAATCCCT 
           1510      1520      1530      1540      1550      1560      1570      1580      1590  
 
   
  ACTGGAATTTGCCACCTGTCTCCTTGGAATCCCAAGTTTTCCTAGCACAAAACAGGATTACTTCCAAATTTTCCATGAAAATGAACTGGTTTTGTGGAAA  < 1700 
  TGACCTTAAACGGTGGACAGAGGAACCTTAGGGTTCAAAAGGATCGTGTTTTGTCCTAATGAAGGTTTAAAAGGTACTTTTACTTGACCAAAACACCTTT 
           1610      1620      1630      1640      1650      1660      1670      1680      1690  
 
   
  ATCAATATCATTTTTGTTTCTAACTTGTCAAAAGCTTGTATTGAGAATGGATGTTAAACTTTGTCAAATACTTTTGTGCATTTAACAAAAAAGATAATGT  < 1800 
  TAGTTATAGTAAAAACAAAGATTGAACAGTTTTCGAACATAACTCTTACCTACAATTTGAAACAGTTTATGAAAACACGTAAATTGTTTTTTCTATTACA 
           1710      1720      1730      1740      1750      1760      1770      1780      1790  
 
   
  AGGGTTTTTTTTAATCTGTTAATAAGGTGACCTAAATTGTTTAACATTCCAATATTTATGCAACTTCACATTTCCAGGACAAACTTATTTGGTCATGTTA  < 1900 
  TCCCAAAAAAAATTAGACAATTATTCCACTGGATTTAACAAATTGTAAGGTTATAAATACGTTGAAGTGTAAAGGTCCTGTTTGAATAAACCAGTACAAT 




  TACTATGTTCTAAAATATATTACTGGGGCCAGAGAGATGGCCATGAGACAAAGGTGCTTGCTACCAAGTCTCATGACCTGAGTTCTATCCCAGGGATCCA  < 2000 
  ATGATACAAGATTTTATATAATGACCCCGGTCTCTCTACCGGTACTCTGTTTCCACGAACGATGGTTCAGAGTACTGGACTCAAGATAGGGTCCCTAGGT 





   
  CCTCGTAGAAGGAGAAAACCAACTTCTACAGGTTGTCCTCCGGCATCCAAATGCATAGCATGGCAAATATATGAGTATATACTCATAAACTCAAATAAAT  < 2100 
  GGAGCATCTTCCTCTTTTGGTTGAAGATGTCCAACAGGAGGCCGTAGGTTTACGTATCGTACCGTTTATATACTCATATATGAGTATTTGAGTTTATTTA 
           2010      2020      2030      2040      2050      2060      2070      2080      2090  
 
   
  AAATAAATAAATAAATAAATAAATAAATAAATAAATGTAATAAATATTTTAAATGTATTATTGAACTTGACTCAACCTATAATTTGGAAAGAATGTTTGT  < 2200 
  TTTATTTATTTATTTATTTATTTATTTATTTATTTACATTATTTATAAAATTTACATAATAACTTGAACTGAGTTGGATATTAAACCTTTCTTACAAACA 
           2110      2120      2130      2140      2150      2160      2170      2180      2190  
 
   
  GTTGAGATAAAGCTGTAGCTCAGCATTTATCAAAAGCTGACAAAGTTCTGGATTTATTCAGTCCCCAGCACTGAATAAATCTGGTGTGATGACACAGGCC  < 2300 
  CAACTCTATTTCGACATCGAGTCGTAAATAGTTTTCGACTGTTTCAAGACCTAAATAAGTCAGGGGTCGTGACTTATTTAGACCACACTACTGTGTCCGG 
           2210      2220      2230      2240      2250      2260      2270      2280      2290  
 
   
  TTGAATCTTAGCAGTTTCAAAGTAGAACCAGGAGGATCAGAGGCCTCAAAATCTTTGGCTTATAAAGAGGCCAGCCTGTTTCAAAAAATAAAAGAATTTT  < 2400 
  AACTTAGAATCGTCAAAGTTTCATCTTGGTCCTCCTAGTCTCCGGAGTTTTAGAAACCGAATATTTCTCCGGTCGGACAAAGTTTTTTATTTTCTTAAAA 
           2310      2320      2330      2340      2350      2360      2370      2380      2390  
 
   
  TGTATCTGTATTCATAAATAATATTAGCCCGTGGTTTTTGTTTATTGTAAATTTTTCATCTGATTTTGGAATCGTGGGTATATTTTCCTTATAAAGCAAG  < 2500 
  ACATAGACATAAGTATTTATTATAATCGGGCACCAAAAACAAATAACATTTAAAAAGTAGACTAAAACCTTAGCACCCATATAAAAGGAATATTTCGTTC 
           2410      2420      2430      2440      2450      2460      2470      2480      2490  
 
   
  TTGAAGGGGATATTTGTGTAATATTGATGTTATTTTTTCCTCAAATATTTGAGAACAATTTCTAACAGTAAGCTCTGCCTCCCTTTCAGGGGCAGCACTT  < 2600 
  AACTTCCCCTATAAACACATTATAACTACAATAAAAAAGGAGTTTATAAACTCTTGTTAAAGATTGTCATTCGAGACGGAGGGAAAGTCCCCGTCGTGAA 
           2510      2520      2530      2540      2550      2560      2570      2580      2590  
 
   
  CAAATATCAATTTAGTTCTTTCAGGTATTGCTAGCACATTTACAGTTCAAGGACAACCATTTGAGCAAGATATATGGGCGAAATATGGAACTTTCTATCT  < 2700 
  GTTTATAGTTAAATCAAGAAAGTCCATAACGATCGTGTAAATGTCAAGTTCCTGTTGGTAAACTCGTTCTATATACCCGCTTTATACCTTGAAAGATAGA 
           2610      2620      2630      2640      2650      2660      2670      2680      2690  
 
   
  TTTTTTTTCTTTCCTTTATTTATACCTCTTACTTTCTAGTACTTTTAGTTGCCCTAAACCTGGCTATCTGGTTCTTCAAAATGGAAAAAAAAATGCACTA  < 2800 
  AAAAAAAAGAAAGGAAATAAATATGGAGAATGAAAGATCATGAAAATCAACGGGATTTGGACCGATAGACCAAGAAGTTTTACCTTTTTTTTTACGTGAT 
           2710      2720      2730      2740      2750      2760      2770      2780      2790  
 
   
  TTTGTCTAGCTTATTTTATTTAACACAATAATCTCAAATTGCATCCATTTTCCAGCAAATGAGAATAAAAGTCCATTGGGTTATGCCTTAGTTACTGTTT  < 2900 
  AAACAGATCGAATAAAATAAATTGTGTTATTAGAGTTTAACGTAGGTAAAAGGTCGTTTACTCTTATTTTCAGGTAACCCAATACGGAATCAATGACAAA 
           2810      2820      2830      2840      2850      2860      2870      2880      2890  
 
   
  TGTTGCTGTGAAGAGAAACCATGATAGAGGCAACACAAAAGCATTTAATTGGGGACTTATTTGACAGTTTTAGAGAGTTAGTCCATGATCATCATGGTGG  < 3000 
  ACAACGACACTTCTCTTTGGTACTATCTCCGTTGTGTTTTCGTAAATTAACCCCTGAATAAACTGTCAAAATCTCTCAATCAGGTACTAGTAGTACCACC 
           2910      2920      2930      2940      2950      2960      2970      2980      2990  
 
   
  AAGTAGGCATGATATTGGAGTAATAACTGAGAGTTTTACATTCTGATTTACAGGCATCACTCAGGGGGGGGGGAGAGAGAGAGTCAGACAGAGACAGAGA  < 3100 
  TTCATCCGTACTATAACCTCATTATTGACTCTCAAAATGTAAGACTAAATGTCCGTAGTGAGTCCCCCCCCCCTCTCTCTCTCAGTCTGTCTCTGTCTCT 
           3010      3020      3030      3040      3050      3060      3070      3080      3090  
                                                                                                    
 
  CAGAGACAGAGAGACAGAGAGACTGGACCTAATTTGTGCTTTTGAAAACTCACACCCTACTTCCAGTGACACACCAACTCCAATAAGACCATACTTCCTA  < 3200 
  GTCTCTGTCTCTCTGTCTCTCTGACCTGGATTAAACACGAAAACTTTTGAGTGTGGGATGAAGGTCACTGTGTGGTTGAGGTTATTCTGGTATGAAGGAT 
           3110      3120      3130      3140      3150      3160      3170      3180      3190  
 
   
  ATTCTTTGAAACTCTTCCACTAACTGGTGTCTAAGCATTCAAATATAAGCATTCAAATATATGCCCCTCTGGGGCCACTCTCATTCAAACCACCACAGTA  < 3300 
  TAAGAAACTTTGAGAAGGTGATTGACCACAGATTCGTAAGTTTATATTCGTAAGTTTATATACGGGGAGACCCCGGTGAGAGTAAGTTTGGTGGTGTCAT 
           3210      3220      3230      3240      3250      3260      3270      3280      3290  
 
   
  TACAAGCCACTGTTTTTCTTTATCAATTCATCAGTTGACAGATAATTGTTGGCTTATTCTGAACAGTGTTATAAGAAACATAGATGTTCAGGTATCTCTG  < 3400 
  ATGTTCGGTGACAAAAAGAAATAGTTAAGTAGTCAACTGTCTATTAACAACCGAATAAGACTTGTCACAATATTCTTTGTATCTACAAGTCCATAGAGAC 
           3310      3320      3330      3340      3350      3360      3370      3380      3390  
 
   
  TATCATAGACTTAGAGACCTTTGGGCATATACACAGGAATGGGTCGTGTGGTAGAGGAACCTCTATAATGATTTCCATAGTGCTAAACCACTTTATATCC  < 3500 
  ATAGTATCTGAATCTCTGGAAACCCGTATATGTGTCCTTACCCAGCACACCATCTCCTTGGAGATATTACTAAAGGTATCACGATTTGGTGAAATATAGG 
           3410      3420      3430      3440      3450      3460      3470      3480      3490  
 
   
  TACAAGCAGTGATAAAGGTTCCTCTTTCCCACACCCTCACTACCATTTGTTGTTTTTATAATAACAAACCCTCTGACTTGAGGGGTAAAATATTAATATG  < 3600 
  ATGTTCGTCACTATTTCCAAGGAGAAAGGGTGTGGGAGTGATGGTAAACAACAAAAATATTATTGTTTGGGAGACTGAACTCCCCATTTTATAATTATAC 
           3510      3520      3530      3540      3550      3560      3570      3580      3590  
 
   
  GTTTTAATTTTCATTTCTTTGATCCCTAAAGATGTTAAATATTCTTTATGGTCTTGGCCATTTGCACTTCATCTTTTTGAGAACTGTCTTTCATTTCATT  < 3700 
  CAAAATTAAAAGTAAAGAAACTAGGGATTTCTACAATTTATAAGAAATACCAGAACCGGTAAACGTGAAGTAGAAAAACTCTTGACAGAAAGTAAAGTAA 
           3610      3620      3630      3640      3650      3660      3670      3680      3690  
 
   
  AGCCTATTTATTGATTGAATTGTTTGAGTTTTAAAATTTAATTACTAAAAATTCTTTGTATATCCTATTATTAATCTTCTGTCAAATGTATAACTAGCAA  < 3800 
  TCGGATAAATAACTAACTTAACAAACTCAAAATTTTAAATTAATGATTTTTAAGAAACATATAGGATAATAATTAGAAGACAGTTTACATATTGATCGTT 
           3710      3720      3730      3740      3750      3760      3770      3780      3790  
 
   
  AGATTTTTTTTCTCCCATCCTATAGACCATCTCTTCATCTGATTGCTTCCATGGCTATGCAGAGGCTTTTTAATTTCAATCTATCCCACTTATCTATTCT  < 3900 
  TCTAAAAAAAAGAGGGTAGGATATCTGGTAGAGAAGTAGACTAACGAAGGTACCGATACGTCTCCGAAAAATTAAAGTTAGATAGGGTGAATAGATAAGA 
           3810      3820      3830      3840      3850      3860      3870      3880      3890  
 
   
  
 TGTATTATTTTCTGAGCTACTGGAGTCCTTTTCTAAAAGGGCTCCTATGCCAAATCTTAAAATGTTTTCTTTATTTTTCTCTAAAATTTTCAGAAGTTCA  < 4000 
  ACATAATAAAAGACTCGATGACCTCAGGAAAAGATTTTCCCGAGGATACGGTTTAGAATTTTACAAAAGAAATAAAAAGAGATTTTAAAAGTCTTCAAGT 
           3910      3920      3930      3940      3950      3960      3970      3980      3990  
 
 
   
  TGTCATACATTAAAGTCTTTAGTCCACTTTGAACTGTTTTATATTGGAGTTTAGTTTATTTTTCTATATGTAGATAACCAGTTTTCCCAGCACAATTTGT  < 4100 
  ACAGTATGTAATTTCAGAAATCAGGTGAAACTTGACAAAATATAACCTCAAATCAAATAAAAAGATATACATCTATTGGTCAAAAGGGTCGTGTTAAACA 
257 
 
           4010      4020      4030      4040      4050      4060      4070      4080      4090  
 
   
  TGAAAAGGCTGACTTTTTAACACATATGTTTTGATATTTTTGTCAAAAATCTAGTAGGTAGCTATAGCTGTGTGGGTTCTTTATCTATCCCGCTAATCTG  < 4200 
  ACTTTTCCGACTGAAAAATTGTGTATACAAAACTATAAAAACAGTTTTTAGATCATCCATCGATATCGACACACCCAAGAAATAGATAGGGCGATTAGAC 
           4110      4120      4130      4140      4150      4160      4170      4180      4190  
 
   
  CATGTCTTTTTTTTTTTTAGTTTTTTTTAATTAGGTATTTATTTCATTTACATTTCCAATGCTATCCCAAAAATCCCCCACACGCTCCCCCACCCACTCC  < 4300 
  GTACAGAAAAAAAAAAAATCAAAAAAAATTAATCCATAAATAAAGTAAATGTAAAGGTTACGATAGGGTTTTTAGGGGGTGTGCGAGGGGGTGGGTGAGG 
           4210      4220      4230      4240      4250      4260      4270      4280      4290  
 
   
  CCTACCCACCCACTCCCACTTCTTGGCCCTGGCGTTCCCCTGTACTGAGGCATATAAAGTTTGCAAGACCAAGGGGCCTCTCTTTCCAATGATGGCCGAC  < 4400 
  GGATGGGTGGGTGAGGGTGAAGAACCGGGACCGCAAGGGGACATGACTCCGTATATTTCAAACGTTCTGGTTCCCCGGAGAGAAAGGTTACTACCGGCTG 
           4310      4320      4330      4340      4350      4360      4370      4380      4390  
 
   
  TAGGCCATCTTCTGATACATATGCAGCTAGAGACACGAGCTCTGCGGGGGGTGGGGGTACTGGTTAGTTCATATTGTTGTTCCACCTACAGGGTTGCAGA  < 4500 
  ATCCGGTAGAAGACTATGTATACGTCGATCTCTGTGCTCGAGACGCCCCCCACCCCCATGACCAATCAAGTATAACAACAAGGTGGATGTCCCAACGTCT 
           4410      4420      4430      4440      4450      4460      4470      4480      4490  
 
   
  TCTCTTTAGCTCCTTGGGTACTTTCTCTAGCTCCTTCATTGGGGGCCCTGTGATCCATCCAATAGCTGACTGTGAGCATCCACTTCTGTGTTTGCTAGGC  < 4600 
  AGAGAAATCGAGGAACCCATGAAAGAGATCGAGGAAGTAACCCCCGGGACACTAGGTAGGTTATCGACTGACACTCGTAGGTGAAGACACAAACGATCCG 
           4510      4520      4530      4540      4550      4560      4570      4580      4590  
 
   
  CCCGGCATAGTCTCACAAGAGACAGCTATATCTGGGTCCTTTCAGCAAAATCTTGCTAGTGTATGCAATGGTGTCAGCGTTTGGAAGCTGATTATGGGAT  < 4700 
  GGGCCGTATCAGAGTGTTCTCTGTCGATATAGACCCAGGAAAGTCGTTTTAGAACGATCACATACGTTACCACAGTCGCAAACCTTCGACTAATACCCTA 
           4610      4620      4630      4640      4650      4660      4670      4680      4690  
 
   
  GGATCCCCGGATATGGCAGTTTCTAGATGGTCCATCCTTTCGTCTCAGCTCCAAACTTTGTCTCTGTAACTCCTTCCATGGGTGTTTTGTTCTCAATTCT  < 4800 
  CCTAGGGGCCTATACCGTCAAAGATCTACCAGGTAGGAAAGCAGAGTCGAGGTTTGAAACAGAGACATTGAGGAAGGTACCCACAAAACAAGAGTTAAGA 
           4710      4720      4730      4740      4750      4760      4770      4780      4790  
 
   
  AAGAAGGGGCAAAGTGTCCACACTTTGGTCTTCATTCTTCTTGAGTTTCGTGTGTTTTGCAAATTGTATCTTATATCTTGGGTATTCTAAGTTTCTGGAC  < 4900 
  TTCTTCCCCGTTTCACAGGTGTGAAACCAGAAGTAAGAAGAACTCAAAGCACACAAAACGTTTAACATAGAATATAGAACCCATAAGATTCAAAGACCTG 
           4810      4820      4830      4840      4850      4860      4870      4880      4890  
 
   
  TAATATCCACTTATCAGTGAGTAAGCATGTCTTTTTTTTTTTTTTTTTTTTTTTTGCCACAACCATGATGTTTCATTATGACACAACACATTTTTTAAAT  < 5000 
  ATTATAGGTGAATAGTCACTCATTCGTACAGAAAAAAAAAAAAAAAAAAAAAAAACGGTGTTGGTACTACAAAGTAATACTGTGTTGTGTAAAAAATTTA 
           4910      4920      4930      4940      4950      4960      4970      4980      4990  
 
   
  AAAGAACAAAACAGAAAACCCTGGCTGACTTCAAACTCATGATATTCTTAACATAGTTCCCCAGTAGCCAAATCATAGGCATTTACTACCATCCCCAGCT  < 5100 
  TTTCTTGTTTTGTCTTTTGGGACCGACTGAAGTTTGAGTACTATAAGAATTGTATCAAGGGGTCATCGGTTTAGTATCCGTAAATGATGGTAGGGGTCGA 
           5010      5020      5030      5040      5050      5060      5070      5080      5090  
 
   
  TATTTCAATTATAATATCTGAGAAGCTCAGGCAATTTCTCTAATTATCTTCCTCAAAATACAAGAGTATAGAATTTTGCATTGCAGTCTTAGATGTTCAA  < 5200 
  ATAAAGTTAATATTATAGACTCTTCGAGTCCGTTAAAGAGATTAATAGAAGGAGTTTTATGTTCTCATATCTTAAAACGTAACGTCAGAATCTACAAGTT 
           5110      5120      5130      5140      5150      5160      5170      5180      5190  
 
   
  GCTTCCTGGTTTTATAATGCTGAAAAGTATTTTCACTAGACTGAACCACCACCCTCCTATCCTATGAGATTTTTTTTCAATGAAAGCCTGCTATGAAGAT  < 5300 
  CGAAGGACCAAAATATTACGACTTTTCATAAAAGTGATCTGACTTGGTGGTGGGAGGATAGGATACTCTAAAAAAAAGTTACTTTCGGACGATACTTCTA 
           5210      5220      5230      5240      5250      5260      5270      5280      5290  
 
   
  CTATGCAGTTTATGAAGAGAGAATAGAGAAAGTGATAGCCAGAAAGGGAGGGGAAAGAGAGACAGGGAAGACAAAACATTCTCTAGACATTTATTGAATG  < 5400 
  GATACGTCAAATACTTCTCTCTTATCTCTTTCACTATCGGTCTTTCCCTCCCCTTTCTCTCTGTCCCTTCTGTTTTGTAAGAGATCTGTAAATAACTTAC 
           5310      5320      5330      5340      5350      5360      5370      5380      5390  
 
   
  ACTGAACAAATGAATCTGGGAACTTGAGTCCTTTTGTAAATAAGAAACTAAGGCTCAGAAAGGTTAAAAAAATTTGCACAAGGGCACAGTAGTGGGATCC  < 5500 
  TGACTTGTTTACTTAGACCCTTGAACTCAGGAAAACATTTATTCTTTGATTCCGAGTCTTTCCAATTTTTTTAAACGTGTTCCCGTGTCATCACCCTAGG 
           5410      5420      5430      5440      5450      5460      5470      5480      5490  
 
   
  ACTTTGATTTCAAGCCTTTCGGTCTAGTTCCACTTCTCTTTTCTCCTACATCTACTGCGAGCCTATCTTAAGATTTCTCAGGGCCAGTCTACCAGGAGAA  < 5600 
  TGAAACTAAAGTTCGGAAAGCCAGATCAAGGTGAAGAGAAAAGAGGATGTAGATGACGCTCGGATAGAATTCTAAAGAGTCCCGGTCAGATGGTCCTCTT 
           5510      5520      5530      5540      5550      5560      5570      5580      5590  
 
   
  ATGGGGCTTGGGACAGATGTAAATCAATGTGTGTCCTTGGTTGAGAAAGTCTTTCTACAGGAAAAAAAAAATGTTCCTTAATGACTTTATGTAGTAGCCC  < 5700 
  TACCCCGAACCCTGTCTACATTTAGTTACACACAGGAACCAACTCTTTCAGAAAGATGTCCTTTTTTTTTTACAAGGAATTACTGAAATACATCATCGGG 
           5610      5620      5630      5640      5650      5660      5670      5680      5690  
 
   
  AATTCTCAATCTTGTTATAAATAGTTCACTAGTGGAATCTGGCCCACAGACTTTACTTTTTTGCAGCATGGATAATAATGATCCCTATTCCAACTATGTG  < 5800 
  TTAAGAGTTAGAACAATATTTATCAAGTGATCACCTTAGACCGGGTGTCTGAAATGAAAAAACGTCGTACCTATTATTACTAGGGATAAGGTTGATACAC 
           5710      5720      5730      5740      5750      5760      5770      5780      5790  
 
     >Exon 2        
                                  | 
  GATTTAAACCCAACATGTCTATCATTTCAGATGCTCTCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTATGATTATCATGATAA  < 5900 
  CTAAATTTGGGTTGTACAGATAGTAAAGTCTACGAGAGTCATAGGGACGTAGGGCGCAGGTCTACCTCAGGAGATGTCGGAAAATACTAATAGTACTATT 
           5810      5820      5830      5840      5850      5860      5870      5880      5890  
 
   
  
  ATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTTTTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCCTTGTGGGTAACAGC  < 6000 
  TAACTCAGAAGATACACTCTTGTTACAGTAGAAGAAAAGGTGGTAGAGATGGTAACAGGACATGAGAGACCATAAAGAGGAGTCGGAACACCCATTGTCG 
           5910      5920      5930      5940      5950      5960      5970      5980      5990  
 
 
  CTGGTTTTGTGGGTCTTGGTGAAGTATGAGAATCTAGAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGACCTGATGTTCTCCTGTCTAC  < 6100 
  GACCAAAACACCCAGAACCACTTCATACTCTTAGATCTCAGTGAGTGGTTATAGAAGTAGGAGTTGGACACAGAGAGTCTGGACTACAAGAGGACAGATG 
           6010      6020      6030      6040      6050      6060      6070      6080      6090  
 
   
  TGCCTGTGTTGATCTCAGCACAATGGAGTTGGTTTCTAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCCTCTACAGCAGCATCTT  < 6200 
258 
 
  ACGGACACAACTAGAGTCGTGTTACCTCAACCAAAGATCCACTGAAGAAGACGTTCAAGAAGTTGTACTAGAAGCCGTAGTCGGAGATGTCGTCGTAGAA 
           6110      6120      6130      6140      6150      6160      6170      6180      6190  
 
   
  CTTCCTTACCATCATGACCATCCACCGATACCTGTCTGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCTGCCGTGTGCTGGTGACATCA  < 6300 
  GAAGGAATGGTAGTACTGGTAGGTGGCTATGGACAGACATCACTCGGGGTAGAGATGAGACCCATAGGTATGGGAGGCGACGGCACACGACCACTGTAGT 
           6210      6220      6230      6240      6250      6260      6270      6280      6290  
 
   
  TGTGTGTGGGCAGCCAGCATCCTGTTCTCCATCCCTGATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTCTGAACATCATGGGTTCTTGG  < 6400 
  ACACACACCCGTCGGTCGTAGGACAAGAGGTAGGGACTACGACAGAAGGTGTTTCACTAGAGGAATTTAACATTTATAAGACTTGTAGTACCCAAGAACC 
           6310      6320      6330      6340      6350      6360      6370      6380      6390  
 
   
  CCTCAGTCTACCAGCACAACATCTTCTTCCTCCTCTCCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGACTTTGTTTCGCACAAGGTCCAG  < 6500 
  GGAGTCAGATGGTCGTGTTGTAGAAGAAGGAGGAGAGGTACCCTTAGTAGGATAAGACAATACATGTCTAAGAGTCCTGAAACAAAGCGTGTTCCAGGTC 
           6410      6420      6430      6440      6450      6460      6470      6480      6490  
 
 
  ACAGAGACACCGAACAGTCAGGCTCATCTTCACCGTCGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACACTCTTCCTGAAAACTGGAATC  < 6600 
  TGTCTCTGTGGCTTGTCAGTCCGAGTAGAAGTGGCAGCACCATCGTATGAAGGAGTCGACCCGAGGGATGTTGGAGTGTGAGAAGGACTTTTGACCTTAG 
           6510      6520      6530      6540      6550      6560      6570      6580      6590  
 
   
  ATCCAGCAGAGCTGTGAGAGCCTTCAGCAACTGGACATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAACCCAGTGCTTTATG  < 6700 
  TAGGTCGTCTCGACACTCTCGGAAGTCGTTGACCTGTAACGATACTAATAGACAGCGGTAAACCGGAAGAGAGTAACGACAAAGTTGGGTCACGAAATAC 
           6610      6620      6630      6640      6650      6660      6670      6680      6690  
 
   
  TCTTTGTTGGGATCAAGTTCCGCAGACACCTAAAACATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACTGTTCCCTGCTCCCCTGGTAC  < 6800 
  AGAAACAACCCTAGTTCAAGGCGTCTGTGGATTTTGTAGAGAAGGTCGTCCAGACCGACACGGCCTTCTGTAGGTCGTGACAAGGGACGAGGGGACCATG 
           6710      6720      6730      6740      6750      6760      6770      6780      6790  
 
   
  CTTTACATATGAGGGACCCTCCTTCTACTGAGAGGAGAGGATGGGCACATGGAGATGACTATGGGAGGTAAAGGAAGACAAGGAGAAGTGGATCAGGAAG  < 6900 
  GAAATGTATACTCCCTGGGAGGAAGATGACTCTCCTCTCCTACCCGTGTACCTCTACTGATACCCTCCATTTCCTTCTGTTCCTCTTCACCTAGTCCTTC 
           6810      6820      6830      6840      6850      6860      6870      6880      6890  
 
   
  GAAAATATAACTGAAGATACTACAGAGTGTGGAGGAAAGACATGATACCCATGGGGAAGTGGCTTCCAGCTGGGCAAGCCAAAGCAACACTTCGTGCACT  < 7000 
  CTTTTATATTGACTTCTATGATGTCTCACACCTCCTTTCTGTACTATGGGTACCCCTTCACCGAAGGTCGACCCGTTCGGTTTCGTTGTGAAGCACGTGA 
           6910      6920      6930      6940      6950      6960      6970      6980      6990  
 
   
  CAGTTCATCATTTATTCTCTTACTTAGACATAGATTGCTTGTTAGTGATGGTCAGAAGATCCTAAATAGAAGGATTTCTAGACTTTAGGAGGGCTTGAAG  < 7100 
  GTCAAGTAGTAAATAAGAGAATGAATCTGTATCTAACGAACAATCACTACCAGTCTTCTAGGATTTATCTTCCTAAAGATCTGAAATCCTCCCGAACTTC 
           7010      7020      7030      7040      7050      7060      7070      7080      7090  
 
   
  CTTATAGTATGTGCTAACTGTGCAGTGATGTTGCTGGTACATAGGGTTGCCCCAAACTATTTTTTTTTCACCTTGGTGATAGCTGACTCTGTGATTCTTA  < 7200 
  GAATATCATACACGATTGACACGTCACTACAACGACCATGTATCCCAACGGGGTTTGATAAAAAAAAAGTGGAACCACTATCGACTGAGACACTAAGAAT 
           7110      7120      7130      7140      7150      7160      7170      7180      7190  
 
   
  GCAGCTACAGAAAGAAAAAAAACTCTCTTCAGGACAAGAATAATCACATCTTTAAATAAGTACAGTCACAATGAAGTCTATACCATAAAATCCCACTAAA  < 7300 
  CGTCGATGTCTTTCTTTTTTTTGAGAGAAGTCCTGTTCTTATTAGTGTAGAAATTTATTCATGTCAGTGTTACTTCAGATATGGTATTTTAGGGTGATTT 
           7210      7220      7230      7240      7250      7260      7270      7280      7290  
 
   
  ATGAAGATGGTTCTGAGCCGGGTGTGGTGGCGCATGCCTTTAATCCCAGCACTCAGGAGGCAGAGACAGGCAGATTTCTGAGTTTGAGGCCAGCCTGGTC  < 7400 
  TACTTCTACCAAGACTCGGCCCACACCACCGCGTACGGAAATTAGGGTCGTGAGTCCTCCGTCTCTGTCCGTCTAAAGACTCAAACTCCGGTCGGACCAG 
           7310      7320      7330      7340      7350      7360      7370      7380      7390  
 
   
  TACAGAGTGAGTTCCAGGACAGCCAGGGCTACACAGAGAAACCCTGTCTTGAAAAACAAAACAAAACAAAACAAAACAAAACAAAAAAACAACAACAACA  < 7500 
  ATGTCTCACTCAAGGTCCTGTCGGTCCCGATGTGTCTCTTTGGGACAGAACTTTTTGTTTTGTTTTGTTTTGTTTTGTTTTGTTTTTTTGTTGTTGTTGT 
           7410      7420      7430      7440      7450      7460      7470      7480      7490  
 
   
  AAGATGGTTCCATATTCTGGCAACAGCTGCTAACACATAAGCTGGCTTTTAAATATTTAGCTCATAACTGAAAGAAAAAATACAATATGTGCTACTGTCT  < 7600 
  TTCTACCAAGGTATAAGACCGTTGTCGACGATTGTGTATTCGACCGAAAATTTATAAATCGAGTATTGACTTTCTTTTTTATGTTATACACGATGACAGA 
           7510      7520      7530      7540      7550      7560      7570      7580      7590  
 
   
  GCACTAAGTAATTATTTGGACAATACAAAGATGAATAGGATATTGCTGCTAACTTTCAGTTGACACCAATCCATCCAAGAAGGTCCAGATAAGAAAAGTC  < 7700 
  CGTGATTCATTAATAAACCTGTTATGTTTCTACTTATCCTATAACGACGATTGAAAGTCAACTGTGGTTAGGTAGGTTCTTCCAGGTCTATTCTTTTCAG 
           7610      7620      7630      7640      7650      7660      7670      7680      7690  
 
   
  CACTTAACAGAGGCATTCAGGTTGAATATTCCTGTCATTTCATCTCTTCCAGATTGAGAGAAAGATGACTTCCTTACATGTGGATAATAATGCCAGCATT  < 7800 
  GTGAATTGTCTCCGTAAGTCCAACTTATAAGGACAGTAAAGTAGAGAAGGTCTAACTCTCTTTCTACTGAAGGAATGTACACCTATTATTACGGTCGTAA 
           7710      7720      7730      7740      7750      7760      7770      7780      7790  
 
   
  CCCCTCTTAACCATTCTCCAGAGCTAAATTCTCCTCATGCACCACATTCCCTTTCGCAGAGCCAGGTCCCGTGGATTCTGCCTTCCCAACATCTCTCCAG  < 7900 
  GGGGAGAATTGGTAAGAGGTCTCGATTTAAGAGGAGTACGTGGTGTAAGGGAAAGCGTCTCGGTCCAGGGCACCTAAGACGGAAGGGTTGTAGAGAGGTC 
           7810      7820      7830      7840      7850      7860      7870      7880      7890  
 
   
  
  CTTATGAGCACATACCCTTGACTTCATCTTTATAGTGCCCTCTGTTCCATAGTATCTTCCTTTTGCTTCTATTTTTCCTCTGTTACATCTTCCTCCTTCA  < 8000 
  GAATACTCGTGTATGGGAACTGAAGTAGAAATATCACGGGAGACAAGGTATCATAGAAGGAAAACGAAGATAAAAAGGAGACAATGTAGAAGGAGGAAGT 
           7910      7920      7930      7940      7950      7960      7970      7980      7990  
 
 
  GGAAGCTGCCTGCCTGAGATTTATCTTTTATTTTACAGCTCCTCTGCCTAGAGTCTGTCTTTGACGCTTTAATAAAATTGTCCTCAAGCTCCCTTCTGAG  < 8100 
  CCTTCGACGGACGGACTCTAAATAGAAAATAAAATGTCGAGGAGACGGATCTCAGACAGAAACTGCGAAATTATTTTAACAGGAGTTCGAGGGAAGACTC 
           8010      8020      8030      8040      8050      8060      8070      8080      8090  
 
   
  TTACTTCTTAAATTCTTTTATTAATAAAACTAGTAACACAAAAGAGGGCCCAGATTTCCCTGGTAATATAAGGTTACTCCATCAGAATGCTCCAGAATTT  < 8200 
  AATGAAGAATTTAAGAAAATAATTATTTTGATCATTGTGTTTTCTCCCGGGTCTAAAGGGACCATTATATTCCAATGAGGTAGTCTTACGAGGTCTTAAA 
           8110      8120      8130      8140      8150      8160      8170      8180      8190  
 
   
  CAGGTAACATTATTACCTTTGGGGCAGTTTAGACTGTTATATCTGCATCCAGGGCCAAAGACAGAACTCAGATCCTGTTCTTTCAACCAAAAATAAATAC  < 8300 
259 
 
  GTCCATTGTAATAATGGAAACCCCGTCAAATCTGACAATATAGACGTAGGTCCCGGTTTCTGTCTTGAGTCTAGGACAAGAAAGTTGGTTTTTATTTATG 
           8210      8220      8230      8240      8250      8260      8270      8280      8290  
 
   
  ATAAAAACATATAACAGTAGACTTTAAAGAATTAATGAAAAAATTAAAAGACATAAAATAGTTATGGATTACCCAGAAGAAGTAACTTTCAAGTGGATAG  < 8400 
  TATTTTTGTATATTGTCATCTGAAATTTCTTAATTACTTTTTTAATTTTCTGTATTTTATCAATACCTAATGGGTCTTCTTCATTGAAAGTTCACCTATC 
           8310      8320      8330      8340      8350      8360      8370      8380      8390  
 
   
  AGGGATGGCTCAGCAGTTAAGAGCACTGGCTACTCCTCCAGAGGGCCTAAATTCAGTTCCCAAAGCCCACATGGTATCTCCCAACCATTTTAACTGCAGT  < 8500 
  TCCCTACCGAGTCGTCAATTCTCGTGACCGATGAGGAGGTCTCCCGGATTTAAGTCAAGGGTTTCGGGTGTACCATAGAGGGTTGGTAAAATTGACGTCA 
           8410      8420      8430      8440      8450      8460      8470      8480      8490  
 
   
  TCCAAGGGAATCCATTGCCCTCTTCTGGCCTCCTTTCCTTTGTACACGAAGATGAACATTTCATATATCTTACAATGTGTCGGTTAGAGATCCCTCGGGC  < 8600 
  AGGTTCCCTTAGGTAACGGGAGAAGACCGGAGGAAAGGAAACATGTGCTTCTACTTGTAAAGTATATAGAATGTTACACAGCCAATCTCTAGGGAGCCCG 
           8510      8520      8530      8540      8550      8560      8570      8580      8590  
 
   
  ACCTTACACTTCATCCTAGTTTATATCTCTGCCCATTAGCCAGGTGGGCTTGAAATTCCTTTTCTTCTAAAAGCCTCAATTTCATCTTTGAAGTTCAGAA  < 8700 
  TGGAATGTGAAGTAGGATCAAATATAGAGACGGGTAATCGGTCCACCCGAACTTTAAGGAAAAGAAGATTTTCGGAGTTAAAGTAGAAACTTCAAGTCTT 
           8610      8620      8630      8640      8650      8660      8670      8680      8690  
 
   
  ATGAACCCTACCTATAGCACAGAGCTGTGTTGAGTTTTAAACATAACATTATATAGGCTTTTGGTTAGGGTATGACATATTAGGTTTTTAATATATACAA  < 8800 
  TACTTGGGATGGATATCGTGTCTCGACACAACTCAAAATTTGTATTGTAATATATCCGAAAACCAATCCCATACTGTATAATCCAAAAATTATATATGTT 
           8710      8720      8730      8740      8750      8760      8770      8780      8790  
 
   
  TAATCTACTGCACAATATTTTGGTCAATGTTGGACCACATATCACTGTGCTCCCTTAAGACTAAATCATCTAGTGATGTCATAGTCATCTTAATTTATCT  < 8900 
  ATTAGATGACGTGTTATAAAACCAGTTACAACCTGGTGTATAGTGACACGAGGGAATTCTGATTTAGTAGATCACTACAGTATCAGTAGAATTAAATAGA 
           8810      8820      8830      8840      8850      8860      8870      8880      8890  
 
   
  AACTATACTCCAGATGAATTGTCTATGAAATTCTCAAAATACATCATTGCCCTTAAATAACCCATGATTGCTTGAGACCTGTCTTCCTCTTCTCTGTAAA  < 9000 
  TTGATATGAGGTCTACTTAACAGATACTTTAAGAGTTTTATGTAGTAACGGGAATTTATTGGGTACTAACGAACTCTGGACAGAAGGAGAAGAGACATTT 
           8910      8920      8930      8940      8950      8960      8970      8980      8990  
 
   
  TTTATTTGGGATCTAAGTTTCAAACAAGGGTGTTTGAAATCCCTTTTGTGGGAACAGGACTGAGGATGGGCATTTAGAGGCGACAGAGTCACGTGACAAC  < 9100 
  AAATAAACCCTAGATTCAAAGTTTGTTCCCACAAACTTTAGGGAAAACACCCTTGTCCTGACTCCTACCCGTAAATCTCCGCTGTCTCAGTGCACTGTTG 
           9010      9020      9030      9040      9050      9060      9070      9080      9090  
 
   
  TCCTGGTAAATAAAGCTCCAGAGATCAGTATCAGTGTGCAGATCTGCATTTATTGCCAAGCACATAAGCTTATATACAGTATTTGAGCCAATCCCAAGCC  < 9200 
  AGGACCATTTATTTCGAGGTCTCTAGTCATAGTCACACGTCTAGACGTAAATAACGGTTCGTGTATTCGAATATATGTCATAAACTCGGTTAGGGTTCGG 
           9110      9120      9130      9140      9150      9160      9170      9180      9190  
 
   
  CCTAAATCCTTGGCCAAGCATAACTTACTACATCTCACCATATCCCAATAAAAGCTGTGACTGATGAGGTAACTCAGAGAGAAGGGGTGTGGCGAGCATT  < 9300 
  GGATTTAGGAACCGGTTCGTATTGAATGATGTAGAGTGGTATAGGGTTATTTTCGACACTGACTACTCCATTGAGTCTCTCTTCCCCACACCGCTCGTAA 
           9210      9220      9230      9240      9250      9260      9270      9280      9290  
 
   
  GTCACCTGTAGGGACTTTTGTGAAGACTCAGAAGCAGCCACTGTCTTGACCTTAGTTCCTTTTTGCTGTCTCACTGGTGTCCCGGGAGCCATCTTAGATC  < 9400 
  CAGTGGACATCCCTGAAAACACTTCTGAGTCTTCGTCGGTGACAGAACTGGAATCAAGGAAAAACGACAGAGTGACCACAGGGCCCTCGGTAGAATCTAG 
           9310      9320      9330      9340      9350      9360      9370      9380      9390  
 
   
  TGACACCATGTACAGCAGATCAGGACTCTGTGGCACAGTGCTCTCCACCCCACATATTCCTTCACAAGGTTGTCTTCCACATGCCTCACACTCTCAATCT  < 9500 
  ACTGTGGTACATGTCGTCTAGTCCTGAGACACCGTGTCACGAGAGGTGGGGTGTATAAGGAAGTGTTCCAACAGAAGGTGTACGGAGTGTGAGAGTTAGA 
           9410      9420      9430      9440      9450      9460      9470      9480      9490  
 
   
  TAACATCCCAAAGCTGTTCAGGCTGTAGTCAGAGCAAGTTTTTCTTAGTTCACTCTATTGATAAATCTTTATTTCTGATGTCATTTCCTCCCACTTCTTC  < 9600 
  ATTGTAGGGTTTCGACAAGTCCGACATCAGTCTCGTTCAAAAAGAATCAAGTGAGATAACTATTTAGAAATAAAGACTACAGTAAAGGAGGGTGAAGAAG 
           9510      9520      9530      9540      9550      9560      9570      9580      9590  
 
   
  CCTTTTTTTTGTTTTCCTTTGTTAACAGAAAGGGGAATCATTTCTCTTCGTGAGGTTTTTTTTATCCTCATCCACAAACTGACAACTCCATCAAGTTAAT  < 9700 
  GGAAAAAAAACAAAAGGAAACAATTGTCTTTCCCCTTAGTAAAGAGAAGCACTCCAAAAAAAATAGGAGTAGGTGTTTGACTGTTGAGGTAGTTCAATTA 
           9610      9620      9630      9640      9650      9660      9670      9680      9690  
 
   
  ATGTTGTCTCATATACCTCCAGTATAAAATATGAAATTAACTTAAAAGATTTCTTTTCCTTCCTGTATGAATTTATCCTGAGAACCTGGAATGCTGAAGT  < 9800 
  TACAACAGAGTATATGGAGGTCATATTTTATACTTTAATTGAATTTTCTAAAGAAAAGGAAGGACATACTTAAATAGGACTCTTGGACCTTACGACTTCA 
           9710      9720      9730      9740      9750      9760      9770      9780      9790  
 
   
  CTGGCAGATGCCACTATTAGCTAAGTCCTGTAAGGTACACAAGCATTTCTAGCTAACATGATGAAAATAAGGCAGTGTGAGGAGCCAGCCAGAGCTAAGA  < 9900 
  GACCGTCTACGGTGATAATCGATTCAGGACATTCCATGTGTTCGTAAAGATCGATTGTACTACTTTTATTCCGTCACACTCCTCGGTCGGTCTCGATTCT 
           9810      9820      9830      9840      9850      9860      9870      9880      9890  
 
   
  
 
  AGCGAACCTAATCATGGGCTGACATTCCTATGTACTGTCCCCTGTCTTTAGCATGTTCATCCATACTGGACTTGGAATGCAGTGTTCTATTGCACCAGGC  < 10000 
  TCGCTTGGATTAGTACCCGACTGTAAGGATACATGACAGGGGACAGAAATCGTACAAGTAGGTATGACCTGAACCTTACGTCACAAGATAACGTGGTCCG 
           9910      9920      9930      9940      9950      9960      9970      9980      9990  
 
 
   
  TTCAGGGTGCTTTGCAACTCAGCAACAAGCAAACACGGGACTGAGGAAGCTAAGCATGGTAGTTCTTTAGCACATATTTTCAAACACTGTTTTTTAAGTG  < 10100 
  AAGTCCCACGAAACGTTGAGTCGTTGTTCGTTTGTGCCCTGACTCCTTCGATTCGTACCATCAAGAAATCGTGTATAAAAGTTTGTGACAAAAAATTCAC 
           10010     10020     10030     10040     10050     10060     10070     10080     10090  
 
   
  TCTGTTAATGAGGGGGAAACAAAAACTGAGAACTTAGGTCCAGCAGTACATACTAAGTTCATTTTTTTTTAGCTTCATAAATAAAACGTAATAGT  < 10195 
  AGACAATTACTCCCCCTTTGTTTTTGACTCTTGAATCCAGGTCGTCATGTATGATTCAAGTAAAAAAAAATCGAAGTATTTATTTTGCATTATCA 







Appendix 1. Xcr1 gene sequence containing 5’ flanking region, exon 1, intron 1 and exon 2. Sequence obtained 





RC221929           1 AACAAAATATTAACGCTTACAATTTCCATTCGCCATTCAGGCTGCGCAAC     50 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929          51 TGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC    100 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         101 GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTT    150 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         151 CCCAGTCACGACGTTGTAAAACGACGGCCAGTGCCAAGCTGATCTATACA    200 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         201 TTGAATCAATATTGGCAATTAGCCATATTAGTCATTGGTTATATAGCATA    250 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         251 AATCAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATA    300 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         301 TGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGA    350 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         351 TTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG    400 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         401 CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTG    450 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         451 GCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTT    500 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         501 CCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTA    550 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         551 TTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAA    600 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         601 GTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTAT    650 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         651 GCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGT    700 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         701 ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATG    750 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         751 GGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATT    800 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         801 GACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAA    850 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         851 ATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC    900 
262 
 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         901 GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAATTTT    950 
                                                                        
RC221929seq        1 --------------------------------------------------      0 
 
RC221929         951 GTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATC----    996 
                                                                        
RC221929seq        1 ----------------------------------------------NNNN      4 
 
RC221929         997 -----------CGGTACCGAGGAGATCTGCCGCCGCGATCGCCATGGAGT   1035 
                                ||||||||||||||||||||||||||||||||||||||| 
RC221929seq        5 NNNNNNNNGNNCGGTACCGAGGAGATCTGCCGCCGCGATCGCCATGGAGT     54 
 
RC221929        1036 CCTCAGGCAACCCAGAGAGCACCACCTTTTTTTACTATGACCTTCAGAGC   1085 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq       55 CCTCAGGCAACCCAGAGAGCACCACCTTTTTTTACTATGACCTTCAGAGC    104 
 
RC221929        1086 CAGCCGTGTGAGAACCAGGCCTGGGTCTTTGCTACCCTCGCCACCACTGT   1135 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      105 CAGCCGTGTGAGAACCAGGCCTGGGTCTTTGCTACCCTCGCCACCACTGT    154 
 
RC221929        1136 CCTATACTGCCTGGTGTTTCTCCTCAGCCTAGTGGGCAACAGCCTGGTCC   1185 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      155 CCTATACTGCCTGGTGTTTCTCCTCAGCCTAGTGGGCAACAGCCTGGTCC    204 
 
RC221929        1186 TGTGGGTCCTGGTGAAGTATGAGAGCCTGGAGTCCCTCACCAACATCTTC   1235 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      205 TGTGGGTCCTGGTGAAGTATGAGAGCCTGGAGTCCCTCACCAACATCTTC    254 
 
RC221929        1236 ATCCTCAACCTGTGCCTCTCAGACCTGGTGTTCGCCTGCTTGTTGCCTGT   1285 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      255 ATCCTCAACCTGTGCCTCTCAGACCTGGTGTTCGCCTGCTTGTTGCCTGT    304 
 
RC221929        1286 GTGGATCTCCCCATACCACTGGGGCTGGGTGCTGGGAGACTTCCTCTGCA   1335 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      305 GTGGATCTCCCCATACCACTGGGGCTGGGTGCTGGGAGACTTCCTCTGCA    354 
 
RC221929        1336 AACTCCTCAATATGATCTTCTCCATCAGCCTCTACAGCAGCAGCTTCTTC   1385 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      355 AACTCCTCAATATGATCTTCTCCATCAGCCTCTACAGCAGCAGCTTCTTC    404 
 
RC221929        1386 CTGACCATCATGACCATCCACCGCTACCTGTCGGTAGTGAGCCCCCTCTC   1435 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      405 CTGACCATCATGACCATCCACCGCTACCTGTCGGTAGTGAGCCCCCTCTC    454 
 
RC221929        1436 CACCCTGCGCGTCCCCACCCTCCGCTGCCGGGTGCTGGTGACCATGGCTG   1485 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      455 CACCCTGCGCGTCCCCACCCTCCGCTGCCGGGTGCTGGTGACCATGGCTG    504 
 
RC221929        1486 TGTGGGTAGCCAGCATCCTGTCCTCCATCCTCGACACCATCTTCCACAAG   1535 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      505 TGTGGGTAGCCAGCATCCTGTCCTCCATCCTCGACACCATCTTCCACAAG    554 
 
RC221929        1536 GTGCTTTCTTCGGGCTGTGATTATTCCGAACTCACGTGGTACCTCACCTC   1585 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      555 GTGCTTTCTTCGGGCTGTGATTATTCCGAACTCACGTGGTACCTCACCTC    604 
 
RC221929        1586 CGTCTACCAGCACAACCTCTTCTTCCTGCTGTCCCTGGGGATTATCCTGT   1635 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      605 CGTCTACCAGCACAACCTCTTCTTCCTGCTGTCCCTGGGGATTATCCTGT    654 
 
RC221929        1636 TCTGCTACGTGGAGATCCTCAGGACCCTGTTCCGCTCACGCTCCAAGCGG   1685 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      655 TCTGCTACGTGGAGATCCTCAGGACCCTGTTCCGCTCACGCTCCAAGCGG    704 
 
RC221929        1686 CGCCACCGCACGGTCAAGCTCATCTTCGCCATCGTGGTGGCCTACTTCCT   1735 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




RC221929        1736 CAGCTGGGGTCCCTACAACTTCACCCTGTTTCTGCAGACGCTGTTTCGGA   1785 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      755 CAGCTGGGGTCCCTACAACTTCACCCTGTTTCTGCAGACGCTGTTTCGGA    804 
 
RC221929        1786 CCCAGATCATCCGGAGCTGCGAGGCCAAACAGCAGCTAGAATACGCCCTG   1835 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      805 CCCAGATCATCCGGAGCTGCGAGGCCAAACAGCAGCTAGAATACGCCCTG    854 
 
RC221929        1836 CTCATCTGCCGCAACCTCGCCTTCTCCCACTGCTGCTTTAACCCGGTGCT   1885 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      855 CTCATCTGCCGCAACCTCGCCTTCTCCCACTGCTGCTTTAACCCGGTGCT    904 
 
RC221929        1886 CTATGTCTTCGTGGGGGTCAAGTTCCGCACACACCTGAAACATGTTCTCC   1935 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      905 CTATGTCTTCGTGGGGGTCAAGTTCCGCACACACCTGAAACATGTTCTCC    954 
 
RC221929        1936 GGCAGTTCTGGTTCTGCCGGCTGCAGGCACCCAGCCCAGCCTCGATCCCC   1985 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq      955 GGCAGTTCTGGTTCTGCCGGCTGCAGGCACCCAGCCCAGCCTCGATCCCC   1004 
 
RC221929        1986 CACTCCCCTGGTGCCTTCGCCTATGAGGGCGCCTCCTTCTACACGCGTAC   2035 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq     1005 CACTCCCCTGGTGCCTTCGCCTATGAGGGCGCCTCCTTCTACACGCGTAC   1054 
 
RC221929        2036 GCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATG   2085 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
RC221929seq     1055 GCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATG   1104 
 
RC221929        2086 ATATCCTGGATTACAAGGATGACGACGATAAGGTTTAAACGGCCGGCCGC   2135 
                     ||||||||||||||||||||||||||||||||||                     
RC221929seq     1105 ATATCCTGGATTACAAGGATGACGACGATAAGTTNNNN------------   1132 
 
RC221929        2136 GGTCATAGCTGTTTCCTGAACAGATCCCGGGTGGCATCCCTGTGACCCCT   2185 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2186 CCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGC   2235 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2236 CTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTT   2285 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2286 CTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTG   2335 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2336 GGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGT   2385 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2386 GCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGC   2435 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2436 GATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGA   2485 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2486 CCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATA   2535 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2536 TTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTG   2585 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2586 GCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTG   2635 
264 
 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2636 TCCTTCTGATTTTAAAATAACTATACCAGCAGGAGGACGTCCAGACACAG   2685 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2686 CATAGGCTACCTGGCCATGCCCAACCGGTGGGACATTTGAGTTGCTTGCT   2735 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2736 TGGCACTGTCCTCTCATGCGTTGGGTCCACTCAGTAGATGCCTGTTGAAT   2785 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2786 TGGGTACGCGGCCAGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAAT   2835 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2836 ACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAA   2885 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2886 AAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTT   2935 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2936 TTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAG   2985 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        2986 TCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCC   3035 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3036 CTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGA   3085 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3086 TACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTC   3135 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3136 ACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCT   3185 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3186 GTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAAC   3235 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3236 TATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGC   3285 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3286 AGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAG   3335 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3336 AGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTT   3385 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3386 GGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAG   3435 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3436 CTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTT   3485 
                                                                        




RC221929        3486 GCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTG   3535 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3536 ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGG   3585 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3586 GATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAA   3635 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3636 ATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAACCTGAG   3685 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3686 GCTATGGCAGGGCCTGCCGCCCCGACGTTGGCTGCGAGCCCTGGGCCTTC   3735 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3736 ACCCGAACTTGGGGGGTGGGGTGGGGAAAAGGAAGAAACGCGGGCGTATT   3785 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3786 GGCCCCAATGGGGTCTCGGTGGGGTATCGACAGAGTGCCAGCCCTGGGAC   3835 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3836 CGAACCCCGCGTTTATGAACAAACGACCCAACACCGTGCGTTTTATTCTG   3885 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3886 TCTTTTTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTCTCCTTCC   3935 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3936 GTGTTTCAGTTAGCCTCCCCCTAGGGTGGGCGAAGAACTCCAGCATGAGA   3985 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        3986 TCCCCGCGCTGGAGGATCATCCAGCCGGCGTCCCGGAAAACGATTCCGAA   4035 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4036 GCCCAACCTTTCATAGAAGGCGGCGGTGGAATCGAAATCTCGTGATGGCA   4085 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4086 GGTTGGGCGTCGCTTGGTCGGTCATTTCGAACCCCAGAGTCCCGCTCAGA   4135 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4136 AGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATCGGGAGCG   4185 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4186 GCGATACCGTAAAGCACGAGGAAGCGGTCAGCCCATTCGCCGCCAAGCTC   4235 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4236 TTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGATCCGCCA   4285 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4286 CACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACC   4335 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4336 ATGATATTCGGCAAGCAGGCATCGCCATGGGTCACGACGAGATCCTCGCC   4385 
266 
 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4386 GTCGGGCATGCTCGCCTTGAGCCTGGCGAACAGTTCGGCTGGCGCGAGCC   4435 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4436 CCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACCGGCTTCCATC   4485 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4486 CGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCGAATGGGCA   4535 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4536 GGTAGCCGGATCAAGCGTATGCAGCCGCCGCATTGCATCAGCCATGATGG   4585 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4586 ATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCCGGC   4635 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4636 ACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAACGTCGAG   4685 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4686 CACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGCCGCGCTG   4735 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4736 CCTCGTCTTGCAGTTCATTCAGGGCACCGGACAGGTCGGTCTTGACAAAA   4785 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4786 AGAACCGGGCGCCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCA   4835 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4836 GCCGATTGTCTGTTGTGCCCAGTCATAGCCGAATAGCCTCTCCACCCAAG   4885 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4886 CGGCCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCGAAACGAT   4935 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4936 CCTCATCCTGTCTCTTGATCGATCTTTGCAAAAGCCTAGGCCTCCAAAAA   4985 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        4986 AGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGCCTCGGCC   5035 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5036 TCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAATGGGCGGA   5085 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5086 ACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGGACTATGG   5135 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5136 TTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGCTGGGGAG   5185 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5186 CCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCATGCTTTG   5235 
                                                                        




RC221929        5236 CATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCTAACTGAC   5285 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5286 ACACATTCCACAGCTGGTTCTTTCCGCCTCAGGACTCTTCCTTTTTCAAT   5335 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5336 ATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTT   5385 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5386 GAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCG   5435 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5436 AAAAGTGCCACCTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTG   5485 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5486 TGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCC   5535 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5536 GCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCC   5585 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5586 CCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTT   5635 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5636 TACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTCACGTAGT   5685 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5686 GGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCAC   5735 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5736 GTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTA   5785 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5786 TCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTAT   5835 
                                                                        
RC221929seq     1133 --------------------------------------------------   1132 
 
RC221929        5836 TGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTT   5880 
                                                                   
RC221929seq     1133 ---------------------------------------------   1132 
 
Appendix 2. Alignment of sequenced region of RC221929 to complete plasmid sequence. RC221929 was amplified 
by E.Coli transformation. Plasmids were isolated and sequenced as described in section 5.2.2. Start and stop 







Predicted          1 AACAAAATATTAACGCTTACAATTTCCATTCGCCATTCAGGCTGCGCAAC     50 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted         51 TGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGC    100 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        101 GAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTT    150 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        151 CCCAGTCACGACGTTGTAAAACGACGGCCAGTGCCAAGCTGATCTATACA    200 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        201 TTGAATCAATATTGGCAATTAGCCATATTAGTCATTGGTTATATAGCATA    250 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        251 AATCAATATTGGCTATTGGCCATTGCATACGTTGTATCTATATCATAATA    300 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        301 TGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGA    350 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        351 TTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAG    400 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        401 CCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTG    450 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        451 GCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTT    500 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        501 CCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTA    550 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        551 TTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAA    600 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        601 GTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTAT    650 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        651 GCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGT    700 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        701 ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATG    750 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        751 GGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATT    800 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        801 GACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAA    850 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        851 ATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTGTAC    900 
                                                                        
MR225748Seq        1 --------------------------------------------------      0 
 
Predicted        901 GGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGAATTTT    950 
                                                                        




Predicted        951 GTAATACGACTCACTATAGGGCGGCCGGGAATTCGTCGACTGGATCCGGT   1000 
                                                                   |||| 
MR225748Seq        1 ----------------------------------------------CGGT      4 
 
Predicted       1001 ACCGAGGAGATCTGCCGCCGCGATCGCCATGGACTCAGAGTCAGATGCTC   1050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq        5 ACCGAGGAGATCTGCCGCCGCGATCGCCATGGACTCAGAGTCAGATGCTC     54 
 
Predicted       1051 TCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTAT   1100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq       55 TCAGTATCCCTGCATCCCGCGTCCAGATGGAGTCCTCTACAGCCTTTTAT    104 
 
Predicted       1101 GATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTT   1150 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      105 GATTATCATGATAAATTGAGTCTTCTATGTGAGAACAATGTCATCTTCTT    154 
 
Predicted       1151 TTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCC   1200 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      155 TTCCACCATCTCTACCATTGTCCTGTACTCTCTGGTATTTCTCCTCAGCC    204 
 
Predicted       1201 TTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAGAATCTA   1250 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      205 TTGTGGGTAACAGCCTGGTTTTGTGGGTCTTGGTGAAGTATGAGAATCTA    254 
 
Predicted       1251 GAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGACCTGAT   1300 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      255 GAGTCACTCACCAATATCTTCATCCTCAACCTGTGTCTCTCAGACCTGAT    304 
 
Predicted       1301 GTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTTGGTTTC   1350 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      305 GTTCTCCTGTCTACTGCCTGTGTTGATCTCAGCACAATGGAGTTGGTTTC    354 
 
Predicted       1351 TAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCCTC   1400 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      355 TAGGTGACTTCTTCTGCAAGTTCTTCAACATGATCTTCGGCATCAGCCTC    404 
 
Predicted       1401 TACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATACCTGTC   1450 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      405 TACAGCAGCATCTTCTTCCTTACCATCATGACCATCCACCGATACCTGTC    454 
 
Predicted       1451 TGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCTGCCGTG   1500 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      455 TGTAGTGAGCCCCATCTCTACTCTGGGTATCCATACCCTCCGCTGCCGTG    504 
 
Predicted       1501 TGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCCATCCCT   1550 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      505 TGCTGGTGACATCATGTGTGTGGGCAGCCAGCATCCTGTTCTCCATCCCT    554 
 
Predicted       1551 GATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTCTGAACA   1600 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      555 GATGCTGTCTTCCACAAAGTGATCTCCTTAAATTGTAAATATTCTGAACA    604 
 
Predicted       1601 TCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCCTCCTCT   1650 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      605 TCATGGGTTCTTGGCCTCAGTCTACCAGCACAACATCTTCTTCCTCCTCT    654 
 
Predicted       1651 CCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGACTTTGTTT   1700 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      655 CCATGGGAATCATCCTATTCTGTTATGTACAGATTCTCAGGACTTTGTTT    704 
 
Predicted       1701 CGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTTCACCGT   1750 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      705 CGCACAAGGTCCAGACAGAGACACCGAACAGTCAGGCTCATCTTCACCGT    754 
 
Predicted       1751 CGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACACTCTTCC   1800 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      755 CGTGGTAGCATACTTCCTCAGCTGGGCTCCCTACAACCTCACACTCTTCC    804 
 
Predicted       1801 TGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAACTGGAC   1850 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      805 TGAAAACTGGAATCATCCAGCAGAGCTGTGAGAGCCTTCAGCAACTGGAC    854 
 
Predicted       1851 ATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAA   1900 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      855 ATTGCTATGATTATCTGTCGCCATTTGGCCTTCTCTCATTGCTGTTTCAA    904 
 
Predicted       1901 CCCAGTGCTTTATGTCTTTGTTGGGATCAAGTTCCGCAGACACCTAAAAC   1950 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 




Predicted       1951 ATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACTGTTCCC   2000 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq      955 ATCTCTTCCAGCAGGTCTGGCTGTGCCGGAAGACATCCAGCACTGTTCCC   1004 
 
Predicted       2001 TGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACACGCGTAC   2050 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq     1005 TGCTCCCCTGGTACCTTTACATATGAGGGACCCTCCTTCTACACGCGTAC   1054 
 
Predicted       2051 GCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATG   2100 
                     |||||||||||||||||||||||||||||||||||||||||||||||||| 
MR225748Seq     1055 GCGGCCGCTCGAGCAGAAACTCATCTCAGAAGAGGATCTGGCAGCAAATG   1104 
 
Predicted       2101 ATATCCTGGATTACAAGGATGACGACGATAAGGTTTAAA-------CGGC   2143 
                     ||||||||||||||||||||||||||||||||||||..|       .    
MR225748Seq     1105 ATATCCTGGATTACAAGGATGACGACGATAAGGTTTNNANNNNNNNN---   1151 
 
Predicted       2144 CGGCCGCGGTCATAGCTGTTTCCTGAACAGATCCCGGGTGGCATCCCTGT   2193 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2194 GACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCC   2243 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2244 CACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGG   2293 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2294 TGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGG   2343 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2344 CAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAG   2393 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2394 CTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGG   2443 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2444 TTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCA   2493 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2494 TGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTT   2543 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2544 CACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACC   2593 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2594 CACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCC   2643 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2644 TTCCCTGTCCTTCTGATTTTAAAATAACTATACCAGCAGGAGGACGTCCA   2693 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2694 GACACAGCATAGGCTACCTGGCCATGCCCAACCGGTGGGACATTTGAGTT   2743 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2744 GCTTGCTTGGCACTGTCCTCTCATGCGTTGGGTCCACTCAGTAGATGCCT   2793 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2794 GTTGAATTGGGTACGCGGCCAGCGGCGAGCGGTATCAGCTCACTCAAAGG   2843 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2844 CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATG   2893 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2894 TGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCT   2943 
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MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2944 GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGAC   2993 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       2994 GCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCG   3043 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3044 TTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCT   3093 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3094 TACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTC   3143 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3144 ATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAG   3193 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3194 CTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATC   3243 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3244 CGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCAC   3293 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3294 TGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGT   3343 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3344 GCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAAC   3393 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3394 AGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAG   3443 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3444 TTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTT   3493 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3494 TTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGA   3543 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3544 TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCAC   3593 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3594 GTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATC   3643 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3644 CTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTA   3693 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3694 ACCTGAGGCTATGGCAGGGCCTGCCGCCCCGACGTTGGCTGCGAGCCCTG   3743 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3744 GGCCTTCACCCGAACTTGGGGGGTGGGGTGGGGAAAAGGAAGAAACGCGG   3793 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3794 GCGTATTGGCCCCAATGGGGTCTCGGTGGGGTATCGACAGAGTGCCAGCC   3843 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3844 CTGGGACCGAACCCCGCGTTTATGAACAAACGACCCAACACCGTGCGTTT   3893 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3894 TATTCTGTCTTTTTATTGCCGTCATAGCGCGGGTTCCTTCCGGTATTGTC   3943 
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MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3944 TCCTTCCGTGTTTCAGTTAGCCTCCCCCTAGGGTGGGCGAAGAACTCCAG   3993 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       3994 CATGAGATCCCCGCGCTGGAGGATCATCCAGCCGGCGTCCCGGAAAACGA   4043 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4044 TTCCGAAGCCCAACCTTTCATAGAAGGCGGCGGTGGAATCGAAATCTCGT   4093 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4094 GATGGCAGGTTGGGCGTCGCTTGGTCGGTCATTTCGAACCCCAGAGTCCC   4143 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4144 GCTCAGAAGAACTCGTCAAGAAGGCGATAGAAGGCGATGCGCTGCGAATC   4193 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4194 GGGAGCGGCGATACCGTAAAGCACGAGGAAGCGGTCAGCCCATTCGCCGC   4243 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4244 CAAGCTCTTCAGCAATATCACGGGTAGCCAACGCTATGTCCTGATAGCGA   4293 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4294 TCCGCCACACCCAGCCGGCCACAGTCGATGAATCCAGAAAAGCGGCCATT   4343 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4344 TTCCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTCACGACGAGAT   4393 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4394 CCTCGCCGTCGGGCATGCTCGCCTTGAGCCTGGCGAACAGTTCGGCTGGC   4443 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4444 GCGAGCCCCTGATGCTCTTCGTCCAGATCATCCTGATCGACAAGACCGGC   4493 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4494 TTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTCGA   4543 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4544 ATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGCATTGCATCAGCC   4593 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4594 ATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTG   4643 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4644 CCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGTGACAA   4693 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4694 CGTCGAGCACAGCTGCGCAAGGAACGCCCGTCGTGGCCAGCCACGATAGC   4743 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4744 CGCGCTGCCTCGTCTTGCAGTTCATTCAGGGCACCGGACAGGTCGGTCTT   4793 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4794 GACAAAAAGAACCGGGCGCCCCTGCGCTGACAGCCGGAACACGGCGGCAT   4843 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4844 CAGAGCAGCCGATTGTCTGTTGTGCCCAGTCATAGCCGAATAGCCTCTCC   4893 
                                                                        




Predicted       4894 ACCCAAGCGGCCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCG   4943 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4944 AAACGATCCTCATCCTGTCTCTTGATCGATCTTTGCAAAAGCCTAGGCCT   4993 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       4994 CCAAAAAAGCCTCCTCACTACTTCTGGAATAGCTCAGAGGCCGAGGCGGC   5043 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5044 CTCGGCCTCTGCATAAATAAAAAAAATTAGTCAGCCATGGGGCGGAGAAT   5093 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5094 GGGCGGAACTGGGCGGAGTTAGGGGCGGGATGGGCGGAGTTAGGGGCGGG   5143 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5144 ACTATGGTTGCTGACTAATTGAGATGCATGCTTTGCATACTTCTGCCTGC   5193 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5194 TGGGGAGCCTGGGGACTTTCCACACCTGGTTGCTGACTAATTGAGATGCA   5243 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5244 TGCTTTGCATACTTCTGCCTGCTGGGGAGCCTGGGGACTTTCCACACCCT   5293 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5294 AACTGACACACATTCCACAGCTGGTTCTTTCCGCCTCAGGACTCTTCCTT   5343 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5344 TTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATA   5393 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5394 CATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACAT   5443 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5444 TTCCCCGAAAAGTGCCACCTGACGCGCCCTGTAGCGGCGCATTAAGCGCG   5493 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5494 GCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCT   5543 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5544 AGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCG   5593 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5594 GCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTT   5643 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5644 AGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTC   5693 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5694 ACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGG   5743 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5744 AGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTC   5793 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5794 AACCCTATCTCGGTCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTC   5843 
                                                                        
MR225748Seq     1152 --------------------------------------------------   1151 
 
Predicted       5844 GGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATT   5893 
                                                                        




Predicted       5894 TT   5895 
                        




Appendix 3. Alignment of sequenced region of MR225748 to complete plasmid sequence. MR225748 was 
amplified by E.Coli transformation. Plasmids were isolated and sequenced as described in section 5.2.2. Start 





           
           






           
            
Appendix 4. Iba-1 reactivity along the rostrocaudal axis of the thoracic cord of a 6 month female TDP-Q331K 
mouse. 30µm sections were made along the collected thoracic cord samples. Sections are numbered in 
ascending order from the most rostral to most caudal segment. Images presented represent sections at 
intervals of approximately 450-540µm and are estimated to originate between levels T7 and T13. 
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Appendix 5. Iba-1 reactivity along the rostrocaudal axis of the thoracic cord of a 10 month female TDP-Q331K 
mouse. 30µm sections were made along the collected thoracic cord samples. Sections are numbered in 
ascending order from the most rostral to most caudal segment. Images presented represent sections at 
intervals of approximately 450-540µm and are estimated to originate between levels T7 and T13. 
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Appendix 6. Iba-1 reactivity along the rostrocaudal axis of the thoracic cord of a 10 month female NTg mouse. 
30µm sections were made along the collected thoracic cord samples. Sections are numbered in ascending 
order from the most rostral to most caudal segment. Images presented represent sections at intervals of 
approximately 450-540µm and are estimated to originate between levels T7 and T13. 
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Appendix 7. Evaluation of TMEM119 in primary microglial cultures obtained from NTg, TDP-Q331K and SOD1-
G93A mice following LPS treatment. LPS treatment results in the consistent decrease of TMEM119 expression 
within primary microglial cultures, irrespective of genotype. This decrease was considered significant for the 
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